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Abstract 
 
Enteric (typhoid) fever is a life-threatening disease caused by the Salmonella 
enterica subspecies enterica serovars Typhi (S. Typhi) and Paratyphi A, B, and C (S. 
Paratyphi A, B, and C). The disease still causes major public health problems in 
low- and middle-income countries, principally in Asia and Africa. The increasing 
frequency of multi-drug resistant (MDR) and extended-drug resistant isolates (XDR) 
of S. Typhi and an increasing incidence of S. Paratyphi A mean that the international 
dynamics of enteric fever are changing. These changes add urgency to the demand 
for more efficient enteric fever control campaigns. The aim of this thesis was to 
assess control measures for enteric fever in Vietnam and to develop techniques that 
can be used as further control methods. I firstly systemically reviewed retrospective 
information regarding enteric fever in Vietnam and combined these data with data 
on economic development. This investigation revealed that national economic 
growth, the provision of improved quality drinking water, and better sanitation were 
likely the greatest contributors to the decline and ultimate elimination of enteric 
fever in Vietnam. My work then evaluated the serodiagnostic potential of a panel of 
novel S. Typhi protein antigens and the Vi capsular polysaccharide (Vi) in a group 
of patients with febrile diseases in Bangladesh. These data demonstrated the utility 
of serology for typhoid diagnostics when exploiting a combination of Vi and at least 
one protein antigen. I then assessed the acquisition of antibody against typhoid toxin 
during natural S. Typhi and S. Paratyphi A infections and measured the capability of 
these antibodies to neutralise the toxin. The data provided supporting evidence for 
generating an antitoxin treatment for enteric fever (caused by both S. Typhi and S. 
Paratyphi A), and potentially encourages the use of typhoid toxin in vaccine 
formulations. Within the scope of searching for vaccine novel candidates, my work 
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further identified a panel of immunogenic antigens shared between S. Typhi and S. 
Paratyphi A that can stimulate an antibody response which can instigate bactericidal 
killing during natural infection. Finally, by exploiting the unique immunological 
profiles of S. Typhi carriers (cytokines and antibody), I developed a method of 
identifying S. Typhi carriers and estimating the prevalence of S. Typhi carriage in a 
typhoid endemic population. My findings will potentially lead to the development of 
novel enteric fever control strategies. I conclude that improved case detection and 
widespread vaccination campaigns using polyvalent Salmonella vaccines should be 
initiated for reducing the burden of enteric fever in endemic areas. 
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Chapter 1 Introduction 
1.1 Introduction to enteric fever 
Typhoid fever (typhoid) is thought to be one of the oldest human diseases for which 
there are written records, and probably caused the plague of Athens in 430 B.C. 1, 
but the disease was not clearly distinguished from rickettsial disease (typhus) until 
the mid-nineteenth century. The name “typhoid” implies a “typhus-like” condition 
and  ‘typhus” is derived from the Greek word for cloud, associated with the fact that 
typhoid/typhus patients have a clouded brain as they can be delirious 2. Typhoid is a 
systemic life-threatening human disease caused by the bacterium Salmonella 
enterica subspecies enterica serovar Typhi (S. Typhi) 3. Paratyphoid, caused by the 
Salmonella enterica subspecies enterica serovars Paratyphi A, B, and C (S. 
Paratyphi A etc.) is a disease that is clinically indistinguishable from typhoid 4, 
collectively typhoid and paratyphoid are referred to as enteric fever. The various 
Salmonella serovars that cause enteric fever are distantly related to one another, 
have arisen to cause a similar infection through convergent evolution 5,6 and are 
referred to as “typhoidal salmonellae” 7. The organisms that cause enteric infections 
are transmitted via contaminated food or water. Consequently, enteric fever remains 
a substantial public health issue in large cities and rural populations that have poor 
sanitation and limited access to safe water 8–10. Therefore, the vast majority of 
enteric fever cases now occur in countries in south-central Asia, southeast Asia and 
Africa 11.  
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 1.2 Salmonella Typhi and Salmonella Paratyphi A 
1.2.1 Taxonomy 
S. Typhi and S. Paratyphi A are in the large bacterial genus Salmonella, which falls 
within the largest Gram-negative bacterial family, the Enterobacteriaceae. Current 
classification segregates the genus Salmonella into two species, Salmonella enterica 
and Salmonella bongori 12. Salmonella enterica (S. enterica) is comprised of six 
subspecies: enterica (I), salamae (II), arizonae (IIIa), diarizonae (IIIb) houtenae (IV), 
and indica (VI). These six subspecies are further divided into approximately 2,500 
different serovars based on their O (lipopolysaccharide) and H (flagella) antigens; S. 
Typhi and S. Paratyphi A are found with majority of other Salmonella in subspecies 
enterica 12.  
 
1.2.2 Bacteriology of Salmonella Typhi and Salmonella Paratyphi A 
When S. Typhi or S. Paratyphi A are isolated from clinical specimens they form 
smooth, round colonies on nutrient agar. On Kligler iron agar they can be primarily 
identified by the characteristic biochemical pattern of producing acid without gas, 
and are moderate H2S producers on an alkaline slant 3. The general method for 
identifying Salmonella in clinical microbiology laboratories is serotyping following 
the Kauffmann-White scheme. Salmonella serotyping is performed by assessing 
antibody agglutination reactions with the bacterial surface structures, which includes 
the O-antigen (somatic, lipopolysaccharide) and H-antigen (flagella). According to 
the Kauffmann-White scheme, S. Typhi belongs to serogroup O9 or group D (type 
O9 and 12), while S. Paratyphi A belongs to into serogroup O2 or group A (type O1, 
O2 and O12). In addition, S. Typhi identification is also confirmed by the 
serological demonstration of the Vi (virulence) capsular polysaccharide. 
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S. Typhi and S. Paratyphi A are exclusively human restricted pathogens 13. They 
have evolved convergently to possess many shared characteristics, consequently 
their pathological and epidemiological lifestyles are highly comparable 4,14. The 
course of disease associated with infection by these two typhoidal Salmonella 
serovars are largely indistinguishable, yet they differ substantially from the disease 
caused by the non-typhoidal Salmonella serovars 14. Notably, the establishment of a 
chronic infection in the human gallbladder is another feature shared between the two 
serovars that differs from the non-typhoidal Salmonella serovars 15. Transmission of 
S. Typhi and S. Paratyphi A occurs via the faecal-oral route, which arises mainly 
through the consumption of contaminated water and food. Furthermore, S. Typhi 
and S. Paratyphi A infections can also be spread via person to person to cause 
epidemics 16. A further shared characteristic between S. Typhi and S. Paratyphi A is 
that they are clonal, and the populations of both organisms are monophyletic 17. 
Individual genomes of S. Typhi and S. Paratyphi A are highly conserved and have 
limited evidence of recombination and horizontal gene transfer 17,18. 
 
1.2.3 Enteric fever 
1.2.3.1 The clinical features of enteric fever 
A common misconception is that S. Paratyphi A causes a less severe disease with 
fewer complications than S. Typhi 12; however, in the largest comparison of 
infections caused by both S. Typhi and S. Paratyphi A to date, the clinical features of 
both organisms were indistinguishable in terms of clinical presentation, duration, 
and outcome 4. Enteric fever has a well-studied disease progression in both natural 
infection and human challenge. The first disease symptoms appear 8 to 14 days 
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(range 3-60 days) after ingestion of the bacteria 3, which marks the onset of the 
major period of bacteraemia. The temperature progressively rises and is maintained 
at 39 to 40oC by the second week of disease. Typical symptoms include prolonged 
fever and malaise. Enteric fever is also accompanied by various symptoms in the 
acute phase such as flu-like discomfort (chills and frontal headache), anorexia, 
nausea, dry cough, and bowel pain. Some patients may also have a coated tongue, 
hepatomegaly, and splenomegaly 16. Several immunologic symptoms such as 
leukopenia, and neurological complications can also be commonly observed 16. The 
clinical presentation and disease severity of enteric fever can widely vary due to 
several factors including the length of illness prior to receiving appropriate 
treatment, the virulence and antimicrobial susceptibility profile of the infecting 
organism, appropriate antimicrobial therapy, the age of the patient, previous 
exposure, vaccination profile, inoculum, and other host factors (i.e. AIDS or other 
immune suppression) 19–24. The occurrence of minor complications and severe 
complications can also vary greatly and can be dependent on the medical care in the 
healthcare facility in which the patient is admitted. Neuropsychiatric manifestations 
can also occur in enteric fever, again the prevalence of such complications is highly 
variable depending on the study and may arise in 5% to 84% of typhoid patients 25–28 
at the acute phase or after the initial fever has subsided 29. Other complications have 
been reported, such as gastrointestinal bleeding and intestinal perforation, which are 
often associated with poor outcome, including death 30. 
 
More recently (the end of the last century onwards), severe and fatal typhoid has 
been substantially reduced to <1% in most places where effective antimicrobial 
treatments are available 31. Notably, these figures ranged from 7 to 26% of all 
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hospitalized cases prior to the introduction of antimicrobials 13,31. Severe enteric 
fever has been reported to occur in very young children and elderly, and patients not 
receiving adequate antimicrobial therapy 22,32. A study conducted in Vietnam during 
1993 to 1995 and 1997 to 1999 reported that severe typhoid was associated with 
increasing age and intermediate susceptibility to ciprofloxacin but not MDR 
phenotype 23. Symptomatic disease relapse can occur in both antimicrobial treated 
and untreated patients at a rate of 5 to 10% of all cases. However, relapse appears to 
occur at a lower rate in patients with susceptible infections treated with newer 
generation antimicrobials including second generation fluoroquinolones (1.5%) or 
third generation cephalosporins (5%) in comparison to those treated with traditional 
first line drugs (chloramphenicol, trimethoprim-sulfamethoxazole, and ampicillin) 
33–38. Isolated organisms from relapse cases typically have the same antimicrobial 
susceptibility pattern as the ones identified from the original episode. The organisms 
causing relapse can be discriminated from those causing reinfection by molecular 
typing 39. 
 
1.2.3.2 The treatment of enteric fever and antimicrobial resistance 
Enteric fever patients in endemic areas are not always treated in hospital, rather they 
self-manage at home with oral antimicrobials and may be followed-up regularly for 
complications 40,41. Generally, only a small number of enteric fever patients are 
hospitalized, limited to those with more severe symptoms. For these patients, it is 
critical they are clinically managed to prevent serious complications and death. Such 
provisions include the timely administration of effective antimicrobials, good 
nursing care, the maintenance of appropriate nutrition and hydration. Even though 
the use of appropriate antimicrobials has been proven to be the most effective 
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therapy to reduce mortality, complications, and duration of the illness 3, the selection 
of antimicrobial is not always straight forward. The choice of drugs in endemic areas 
is based on a variety of important principles such as their availability, efficacy, and 
cost 42.   
 
The emergence of antimicrobial resistant enteric fever infections has become a 
major concern in many endemic areas 32,43–49. Until the mid-1970s, chloramphenicol 
was the chief first-line drug for enteric fever treatment. Chloramphenicol resistant 
outbreaks of S. Typhi arose in Mexico and India in the 1970s 49. In the following 
years outbreaks occurred in Pakistan, India, and Bangladesh, and the organisms had 
acquired a multi-drug resistance (MDR) plasmid which induced resistance to the 
three primary antimicrobials (ampicillin, chloramphenicol, and co-trimoxazole) 50,51. 
The introduction of fluoroquinolones became essential after the failure of 
chloramphenicol and the emergence of MDR organisms. However, reports of S. 
Typhi and S. Paratyphi A that are resistant to nalidixic acid and exhibit reduced 
susceptibility to fluoroquinolones in different parts of Asia have become more 
prevalent 43,46,50. These organisms became associated with rising frequencies of 
fluoroquinolone treatment failure 33,52–54. Effective alternative antimicrobials for 
treating S. Typhi and S. Paratyphi A with reduced susceptibility to fluoroquinolones 
include the third generation cephalosporins (i.e. ceftriaxone, cefixime, cefotaxime, 
and cefoperazone) and the macrolide azithromycin 52,55–61. Alternatively, the original 
first line drugs (ampicillin, chloramphenicol, and co-trimoxazole) can still be used 
effectively in regions where the circulating organisms remain susceptible to these 
antimicrobials. Regarding the treatment of carriage, some reports have indicated a 
prolonged course of the same antimicrobials used for acute infections 62,63. However, 
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various antimicrobial regimes have been suggested to treat typhoid carriage yet none 
have been demonstrated to be completely effective in the eradication of the chronic 
colonized pathogens 64–66. 
 
1.3 The epidemiology of typhoid fever 
The epidemiology of enteric fever changed substantially in the twentieth century, 
facilitated by regional population growth and delivery of clean water and better 
sanitation systems 67. Historically, enteric fever caused by S. Typhi had been largely 
considered more common than S. Paratyphi A. However, disease caused by S. 
Paratyphi A has become increasing prevalent in many low- and middle-income 
countries (LMICs) in south and southeast Asia 68–70. An increased incidence of S. 
Paratyphi A enteric fever has been reported in India, Pakistan, China, Nepal, and 
Cambodia 69,71,72. An annual increase of S. Paratyphi A enteric fever was reported in 
a 10-year surveillance study of blood cultures in Kathmandu, Nepal; the overall 
incidence rate of S. Typhi enteric fever remained unchanged 73.  
 
The global estimate of enteric fever disease burden is often adjusted for the poor 
sensitivity (50 to 60% 74) of blood culture 67,75 and/or water-related risk 76. 
Accordingly, with adjustment for poor sensitivity of blood culture, in 2000, S. Typhi 
was estimated to cause 21.6 million new cases and 216,500 deaths globally per year 
(crude estimate of 10.8 million cases); the equivalent figure for S. Paratyphi A was 
adjusted to an estimate of 5.4 million cases 67. Ten years later (in 2010), for the same 
adjustment method, the global burden of S. Typhi disease was of 26.7 million cases 
(crude estimate, 13.5 million cases) 75. However, the global burden of enteric fever 
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in 2010 was estimated to be lower, with 11.9 million cases and 129,000 deaths 
annually when adjusted for water-related risk and using data from LMICs 76. 
 
The most recent systemic review on the global burden of enteric fever in 2017 
provided estimates of 14.3 million episodes of enteric fever of which typhoid was 
responsible for 76.3% of all cases 77. Enteric fever in non-endemic areas in 
developed countries is rare, but unvaccinated travellers visiting areas where enteric 
fever is endemic are at risk of contracting the disease. There are approximately 400 
reported cases of enteric fever in the United States and the United Kingdom 
annually, the majority of these are associated with a recent travel history to south 
Asia 78,79. 
 
1.3.1 Enteric fever in Asia 
The majority of epidemiological studies for enteric fever have been performed in 
Asia; therefore, Asia is considered the main global hub for enteric fever. More than 
90% of the reported morbidity and mortality associated with enteric fever in 2000 
occurred in Asia 80. In this year, the incidence of S. Typhi associated enteric fever in 
Asia was estimated to be 394.2/100,000 population 67. Despite the common 
circulation of MDR organisms and the emergence of fluoroquinolone resistance in 
many parts of Asia, there has been an encouraging reduction in the burden of enteric 
fever across Asia; this is particularly valid in locations where there have been 
improvements in clean supply and sanitation. A decline of 72 to 6.2% of S. Typhi 
positive blood cultures over 15 years from 1998-2004 was reported in the south of 
Vietnam 81. 
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1.3.2 Enteric fever in Africa 
Enteric fever has become recognized as a major cause of febrile disease in many 
parts of Africa over the last decade despite the fact that the disease burden is 
probably under-estimated because of an overlap with the symptoms of malaria 82. A 
community acquired bloodstream infection study conducted in Nigeria in 2008 and 
2009 found that 55% of children with a fever receiving a blood culture were 
confirmed to have S. Typhi, but were clinically diagnosed with malaria 83. S. Typhi 
was responsible for 9.9% of all culture positive bloodstream infections across Africa 
during 1984 - 2006 82. Notably, a fever study conducted in Zanzibar found that S. 
Typhi comprised 58% of all bacterial pathogens isolated from bloodstream 
infections (March 2009 till December 2010) 84. This isolation rate was considered 
high and may reveal typhoid incidence that are as comparably high as those recorded 
in regions in Asia. Moreover, the systemic review on global burden of enteric fever 
in 2010 reported that the highest incidence rate was in sub-Saharan Africa 
(724.6/100,000 people) 75. 
 
1. 4 Enteric fever risk factors  
Risk factors for contracting enteric fever include drinking contaminated water, 
consuming food prepared outside the home, and poor housing with inadequate 
personal hygiene. The transmission of S. Typhi could be also associated with contact 
with a recently infected individual who may be shedding infectious organisms 85,86. 
Other reported risk factors for S. Typhi infection include flies, laboratory accidents, 
unsterile medical instruments, and oral-anal intercourse 13.  
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The vast majority of enteric fever cases occur in school-age children (5-16 years) 
and young adults 87,88. However, in some settings, typhoid fever is also highly 
prevalent in children <5 years of age 89. Additionally, outbreaks of enteric fever 
involving all age groups can occur in the rapidly expanding conurbations of Asia, 
where sanatory conditions and a lack of hygiene permit the transmission of the 
organisms 3.  
 
The health status of the individual is also an important factor for enteric fever 
susceptibility. A case-control study conducted over a period of one year in an urban 
area in India reported that enteric fever cases were associated with the detection of 
anti–Helicobacter pylori antibodies; the presence of anti–Helicobacter pylori 
antibodies was associated with enteric fever with an adjusted odds ratio of 2.03 
(1.02–4.01) 24. This observation supported a report on vaccinees immunized with the 
live oral vaccine CVD 908-htrA; individuals infected with H. pylori had 
significantly elevated S. Typhi-specific IgG LPS than those uninfected with H. 
pylori 90.  
 
There have been only a modest number of studies regarding the influence of human 
genetic factors on the variation of enteric fever in terms of incidence and disease 
severity, this is in spite of the enormous number of genetic associations found in 
mice with respect to Salmonella susceptibility. From the studies that have been 
performed, very few human genetic factors have been found to contribute to enteric 
fever susceptibility. In the studies that have identified genetic factors associated with 
susceptibility to enteric fever, genes involved in the immune response to disease 
appear to be pivotal. Human major histocompatibility complex (MHC) class II and 
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III genes were found to associate with S. Typhi enteric fever investigated on patients 
from two geographic locations in the south of Vietnam 19. Accordingly, HLA-
DRB1*0301/6/8, HLA-DQB1*0201-3, and TNFA*2(-308) were associated with 
susceptibility to typhoid fever, while HLA-DRB1*04, HLA-DQB1*0401/2, and 
TNFA*1(-308) appeared to be associated with disease protection 19. A genome-wide 
association study from the same author conducted with a large collection of 432 
cases and 2,011 controls from Vietnam, which was replicated with a collection from 
a Nepali cohort and a second independent collection from Vietnam, confirmed their 
role as  protective factor against enteric fever for HLA-DRB1*04:05 91. Toll-like 
receptors (TLRs) mediate the innate immune responses to bacterial pathogens; 
TLR5 is stimulated by bacterial flagellin, whilst TLR4 is triggered by LPS. Genetic 
variation within TLR4 was found to be potentially protective for enteric fever in a 
Vietnamese population 92, polymorphisms within the genes encoding TLR5 were 
found not to play a significant role in TLR-stimulated innate immune responses to S. 
Typhi infection 93. A more recent genome-wide association study conducted in a 
Vietnamese population found that raised VAC14 (a phosphoinositide-regulating 
protein) expression increased plasma membrane cholesterol, which assisted 
Salmonella invasion, resulting in increased susceptibility to enteric fever 94. The 
cystic fibrosis transmembrane conductance regulator (CFTR) is the affected protein 
in cystic fibrosis (CF) expressed on the intestinal mucosa. S. Typhi uses CFTR to 
invade intestinal epithelial cells 95. A study conducted in a typhoid endemic area in 
Indonesia genotyped two highly polymorphic markers in CFTR and the most 
common CF mutation, showed an association between genotypes in CFTR and 
susceptibility to typhoid fever (OR=2.6) 96.  
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1.5 Virulence factors of Salmonella Typhi and Salmonella Paratyphi A  
There is approximately 10% difference in the gene content of S. Typhi and S. 
Typhimurium; approximately 480 genes are unique to S. Typhimurium 97 and >600 
genes are unique to S. Typhi 98. Much of this variation makes those two 
comparatively closely related bacteria induce two distinct infectious diseases in 
humans 99. The genetic differences found in S. Typhi include plasmids, 
pathogenicity islands, and the formation of pseudogenes. A combination of these 
factors contribute to the distinct disease S. Typhi causes 97,99–101. 
 
1.5.1 Plasmids  
A global analysis of S. Typhi isolates revealed that the S. Typhi population is highly 
clonal with limited genomic variation 18,102. Accordingly, this serovar seldom caries 
plasmids and the self-transmissible IncH1 group is the only commonly found 
plasmid in S. Typhi 103. The IncH1 plasmid is associated with an MDR phenotype 
and commonly carries the AMR genes cat, dhfr7, dhfr14, sul1, and blaTEM-1 104. The 
presence of these IncH1 plasmids has been associated with disease severity and 
fatality 105.  
 
Plasmid pSLT, is a self-transmissible virulence plasmid, harboured by the majority 
of S. Typhimurium isolates, which contains the spv operon 106. The spv locus has 
been found to facilitate serum resistance in S. Typhimurium and also enhance the 
ability of the organism to adhere, colonize, survive, and replicate in host cells 107,108. 
This plasmid (and operon) is notably absent from S. Typhi. However, a recent study 
found a homologue of the spv operon locus with 99.8% sequence identity on an 
alternative plasmid (pRST98) in S. Typhi 109. This plasmid was isolated from S. Typhi 
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associated with an outbreak in China in the 1980s 110. AMR genes (ampicillin, 
chloramphenicol, carbenicillin, cephalosporin, gentamicin, kanamycin, neomycin, 
streptomycin, sulphonamide, trimethoprim and tetracycline) and virulence genes 
were located on pRST98, making it a hybrid resistance-virulence plasmid 110. In vitro 
studies of pRST98 found that the presence of this plasmid impairs the dendritic cell 
response to infection 110, enhances intracellular bacterial growth 109, and impairs the 
autophagic flux in infected macrophages 111.  
 
Lastly, pBSSB1, a linear plasmid, was described in S. Typhi isolates from Indonesia 
and was found to carry the fljBz66 gene. The product of the fljBz66 gene is an 
alternative flagellin antigen known as H:z66. The association between the presence 
of this plasmid and pathogenesis of S. Typhi still remains largely unknown 112.  
 
1.5.2 Salmonella pathogenicity islands (SPIs) 
The virulence-associated genes in Salmonella genomes are typically clustered 
together in pathogenicity islands. Among known 21 Salmonella pathogenicity 
islands (SPIs), only one SPI-14 is specific for S. Typhimurium and S. Typhi possess 
17 SPIs, 11 are shared between S. Typhi and S. Typhimurium (1-6, 9, 11, 12, 13, and 
16), four (SPI-7, -15, -17, -18) are unique to S. Typhi 97. SPI-1 and SPI-2 are well 
described and each encodes a type three secretion system (TTSS) 97. Over 40 
effector proteins are associated with these two TTSSs and are secreted through the 
needle complex to manipulate the host cell during infection. The SPI-1 TTSS 
secretes effectors, which assist extracellular Salmonella to invade nonphagocytic 
host cells (such as M cells) and induce pro-inflammatory activation 113. A recent 
study comparing the bile responses of S. Typhi and S. Typhimurium revealed that 
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upon exposure to bile there is significant up-regulation of SPI-1 genes in S. Typhi 
but not S. Typhimurium 114. Alternatively, whilst the SPI-2 TTSS is crucial for the 
proliferation of S. Typhimurium within the macrophage Salmonella-containing 
vacuole (SCV) 115, S. Typhi does not rely on SPI-2 TTSS to survive in human 
macrophages 116.  
 
1.5.3 Flagella and fimbriae 
Flagellum is a complex structure that consists chiefly of the flagella filament, of 
which the major constituent is polymerized flagellin. Flagella enable bacterial 
motility and are an essential antigen that triggers innate immune responses 117. 
Expression of S. Typhi flagellin has been demonstrated to be partially down 
regulated by TviA, (a transcriptional regulator associated with the viaB locus on 
SPI-7 in S. Typhi; notably this regulator is generally absent in Salmonella serovars 
that cause gastroenteritis) 118 during invasion of intestinal epithelial cells 119. This 
down regulation subsequently enables S. Typhi to subvert the innate immune system 
by limiting inflammasome activation in infected phagocytes. As previously 
mentioned, under an experimental culture conditions supplemented with 3% bile, S. 
Typhi but not S. Typhimurium up-regulates SPI-1 gene expression and flagellin 
production 114. This observation may explain the contribution of the flagellar 
filament to S. Typhi biofilm formation on gallstones 120.  
 
For S. Typhi to initiate an infection it requires to colonise the host and needs to 
adhere to cells, which is assisted by various adhesins 121. Fimbriae and pili are 
important adhesion factors for S. Typhi. These virulence factors are employed by S. 
Typhi for its various cellular interactions during infection and host colonization 122. 
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The stg operon, one of the six fimbriae operons that are found in S. Typhi but not S. 
Typhimurium, has been recently demonstrated to be involved in cellular invasion 
and epithelial cell disruption in vitro 122. Furthermore, the stg operon was found to 
aid S. Typhi in preferentially targeting enterocytes than M cells, which facilitates S. 
Typhi to eludes the innate immune system by bypassing the Peyer’s patches 123.   
 
1.5.4 The Vi capsular polysaccharide 
S. Typhi is capsulated by the Vi (virulence) polysaccharide, which is 
indistinguishable from those found in S. Paratyphi C and some strains of S. Dublin 
and Citrobacter freundii 118. The Vi capsular polysaccharide is a homopolymer of α-
1,4(2-deoxy)-2-N-acetyl-3-O-acetylgalacturonic acid, which does not contain free 
hydroxyl groups 118. Vi was first purified from a fresh culture of S. Typhi in 1943 
and has been studied extensively. The ViaB locus, which is located on SPI-7, is a 
cluster of 10 genes which are responsible for regulation (tviA), biosynthesis 
(tviBCDE) and export (vexABCDE) of the Vi capsule 118. Despite the isolation of Vi-
negative S. Typhi variants 124,125, these organisms are rare, which suggests that this 
antigen is a vital characteristic of the organism 126. As an enteric pathogen, after 
entering the gastrointestinal tract, S. Typhi experiences a range of harsh 
environmental conditions, including raised temperature, low pH and high pH, 
reduced oxygen abundance, poor nutrition, and mixed osmolarity 127. Notably, 
osmolarity is one of the principal factors that regulates the production of Vi through 
tviA 128–130.  
 
Several facts support the non-essential role of Vi for pathogenicity including the 
isolation of Vi-negative S. Typhi variants from blood 131, and the ability of other Vi 
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negative Salmonella serovars to cause enteric fever 4. However, Vi is largely 
considered as a crucial virulence factor for S. Typhi. Various experimental studies 
have highlighted the importance of Vi in S. Typhi; these include: i) the lethal dose of 
S. Typhi is reduced by 50% when mice are infected with Vi negative organisms, 
compared to Vi positive organisms 132, ii) Vi deficient S. Typhi is less virulent than 
Vi positive S. Typhi in human volunteers 132, iii) Vi assists serum resistance to non-
Vi antibodies, prevents complement deposition, and phagocytic opsonization 133. 
Furthermore, clinical evidence suggesting Vi is an essential S. Typhi virulence factor 
includes: i) clinical S. Typhi from typhoid patients are predominantly Vi-positive 
13,133; ii) licensed Vi subunit vaccines have been widely demonstrated to confer 
comparable protective efficacy to the licensed live oral attenuated S. Typhi vaccines 
134,135. 
 
1.5.5 Typhoid toxin 
Amongst the most interesting loci among the genomic regions unique to S. Typhi 
compared to S. Typhimurium is the one encoding typhoid toxin, the CdtB-islet. This 
small region comprises of genes encoding three components of typhoid toxin 
including CdtB (cytolethal distending toxin B serving nuclease activity), pltA (ADP-
ribosyltransferase homologous to the S1 subunit of the pertussis toxin), and pltB 
(another pertussis like toxin) as well as other two proteins encoding genes 
responsible for its secretion and transportation. Typhoid toxin is an A2B5 toxin 
composing 2 active subunits linked by a disulfide bridge (CdtB and PltA) and five 
binding subunits (pentameric pltB). Of note, the toxin is only secreted when S. 
Typhi is intracellular and inside a Salmonella-containing vacuole (SCV) 136. 
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The discovery of the typhoid toxin has added greater insight into the ability of S. 
Typhi and S. Paratyphi A to induce typhoid fever in humans 137. Typhoid toxin has 
been shown in experimental animals to be important for orchestrating the clinical 
symptoms associated with acute typhoid 138. Further evidence for the role of typhoid 
toxin during acute typhoid fever is the fact that both the S. Typhi and the S. 
Paratyphi A genome harbour almost identical copies of the toxin encoding genes 139. 
Typhoid toxin has also been proposed to be a key factor for persistent asymptomatic 
infection 140,141, a complex process in which the infecting pathogen can avoid 
clearance from the gallbladder. Furthermore, new research has revealed why S. 
Typhi and S. Paratyphi A do not cause typhoid fever in any other species. The 
precise binding of subunit pltB to Neu5Ac-terminated glycans exclusively expressed 
on human cells, which contrasts to the Neu5Gc-terminal glycan expressed on cells in 
other mammals, has added new insight into the host specificity of typhoidal 
Salmonella 142 (C57Bl/6 mice naturally expresses Neu5Ac 142). Typhoid toxin 
targets not only the infected cells but also immune cells 143. The toxin has been 
demonstrated to target neutrophils, lymphocytes, monocytes, and macrophages, 
which assists S. Typhi in manipulating the immune response, which may result in 
persisting an infection 136,143,144. Of note, in mice injected with toxin circulating 
neutrophils were almost completely withdrawn 136, contributing to obstructing 
neutrophil recruitment during typhoid acute phase 143.  
 
1.5.6 Pseudogenes 
Host-restricted pathogens have normally evolved from a broad host pathogen via 
horizontal acquisition of foreign genes or/and by inactivation of functional genes 
(reductive evolution) 145,146. Genes that encode extraneous functions in a determined 
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niche accumulate mutations and eventually lose function. Additionally, to escalate 
fitness, genes encoding functions no longer harmonious with a specific lifestyle are 
selectively inactivated 101,147. The S. Typhi genome contains approximately 5% 
pseudogenes in comparison to 1% in S. Typhimurium 97, which are usually related to 
increased virulence in S. Typhi 100 or host-specificity 148. 
 
Sif and Ssej are two SPI-2 TTSS effectors required for the intracellular proliferation 
of S. Typhimurium 149,150; sif has followed a differential evolutionary route in 
nontyphoidal Salmonella 151 and ssej is a pseudogene in S. Typhi. The loss of ssej in 
S. Typhi results in elevated cytotoxicity and reduced intracellular proliferation of S. 
Typhi inside cultured epithelial cells, which influences serovar adaptation during 
systemic infection 152. SopD2, a known SPI-1 TTSS effector, which is expressed 
under SPI-1 inducing conditions in S. Typhimurium, is also a pseudogene in S. 
Typhi. The complementation of a functional sopD2 gene into S. Typhi interferes 
with proliferation within human epithelial cells and decreases cellular permeability, 
leading to less cytotoxicity in the host cells 153. Inactivation of sopD2 is another 
example proposing that gene pseudogenization is vital for facilitating S. Typhi to 
cause systemic infection. Several other S. Typhi pseudogenes, such as sopA and 
sopE2 100, marT 101, sptP 154 all contribute to the serovar adaptation and aid systemic 
infection. 
 
1.6 The pathogenesis of enteric fever 
S. Typhi and S. Paratyphi A begin to induce their infection in immunocompetent 
human’s individual after ingestion. After crossing the intestinal mucosal barrier, 
they arrive at the lymphoid follicles, encountering non-phagocytic immune cells and 
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macrophages in which the bacteria have to survive and replicate (S. Typhi is a 
facultative intracellular pathogen of macrophages). The survival inside cells aids in 
the bacteria continuing its dissemination to distant sites 99. To achieve successful 
systemic dissemination, S. Typhi and S. Paratyphi A have to possess specific 
strategies to invade particular cells and survive the insults of the highly sophisticated 
innate and adaptive immune systems. Our knowledge regarding the pathogenesis of 
enteric fever is largely derived from our understanding of S. Typhimurium in murine 
models. However, accumulative studies have shown that the behaviour of S. 
Typhimurium and S. Typhi are not comparable and S. Typhimurium virulence genes 
may not be as relevant in S. Typhi 100,154. Recently, a humanized mice model has 
been reported to be capable of studying the pathogenesis of S. Typhi 155–157. These 
models complemented immunocompromised mice, who were not able to generate 
antibody or T cells, with human induced pluripotent stem (iPS) cells. The human iPS 
cell engrafted mice were demonstrated to be susceptible to S. Typhi infection and 
even able to show the different immune responses when infected with wild type or 
mutant S. Typhi 155–157. Another mouse model for studying typhoid is based using 
TLR-11 knockouts 158. Intestinal TLR-11 in mice recognizes of Salmonella flagellin 
and tlr11-/- mice were found to be susceptible to S. Typhi when administered orally 
158. In the 1960s, the University of Maryland conducted human challenge model 
studies, which are acknowledged to be one of the key events that improved our 
understanding the pathogenesis of S. Typhi 159–161. More recently, the Oxford 
Vaccine Group (OVG) has established another controlled human infection of wild 
type S. Typhi. These studies provided data on the correlation between the pre-
challenge immunological status and the subsequent clinical outcome. Furthermore, 
this model delivered detailed kinetics and characteristics of innate as well as 
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adaptive immunological responses following infection with wild type S. Typhi 162–
169.  
 
1.6.1 Salmonella Typhi survives the innate immune system 
1.6.1.1 Observing facts indicating a distinct pathogenesis 
NTS induce a rapid onset of infection after 12-72 hours of incubation period; the 
typhoidal Salmonella serovars tend to initial enteric fever 8-14 days after entering a 
human body. While diarrhoea is considered the main symptom of NTS infections it 
occurs infrequently (33%) of the enteric fever patients 14,170. Histopathology of 
biopsies of the upper small intestine from typhoid patients is typically dominated by 
mononuclear cell infiltrates and neutrophils are scarce 171. Additionally, enteric fever 
has a long period of clinical symptoms and is a systemic infection while 
gastroenteritis has a short course of presentation and the infection is limited to the 
intestine and mesenteric lymph nodes 14,170. Collectively, these different clinical 
manifestations represent distinct mechanisms of pathogenesis that assist the 
typhoidal Salmonella serovars in evading the innate immune defensive system, 
enabling them to cause systemic infections.  
 
1.6.1.2 Salmonella Typhi immune evasion 
On the process of S. Typhi invading epithelial cells and surviving the phagocytes, 
the bacteria senses the osmolarity changes of the approaching environments and 
alters its virulence expression through tviA, the first gene of viaB locus. TviA is 
induced to express at low osmolarity condition and positively regulates genes 
encoding the Vi capsular polysaccharide and negatively regulates genes encoding 
flagellin and T3SS-1 (Figure 1.1) 129,130. Consequently, prior to entering the 
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intestinal mucosa (high osmolarity; >=0.3 M NaCl) S. Typhi is non-capsulated, 
motile (flagellated) and invasive however it is capsulated, non-flagellated and does 
not express TTSS-1 when residing into the intestinal epithelial cells (low osmolarity; 
~0.15 M NaCl) 118,130. These regulations of tviA minimize the alertness of the host 
immune defence resulting in neutrophil recruitment failure 130. Neutrophils are one 
of the important factors the hosts possess to limit dissemination of S. Typhimurium  
infection in humans 172. To perform their phagocytosis function, neutrophils must 
migrate to the sites of the detected threats. S. Typhi performs several ways to 
obstruct neutrophil migration.  
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Figure 1.1 Immune evasion during typhoid fever (Redrawn and adapted from Keestra-Gounder, 2015 173) 
Comparison of mucosal responses elicited by Salmonella Typhimurium and Typhi. A) Injection of T3SS1effector proteins by S. Typhimurium into intestinal epithelial cells activates the 
nucleotide-binding oligomerization domain containing 1 (NOD1)–NOD2 signalling pathway, thereby increasing neutrophil recruitment. The O-antigen chains of lipopolysaccharide (LPS) 
trigger the alternative pathway of complement cascade, which consequently promotes neutrophil chemotaxis, opsonophagocytosis and the generation of an oxidative burst. Anaphylatoxins 
produced during complement activation escalate cytokine production, which additionally accelerates recruitment of neutrophils into the threated sites. S. Typhimurium flagellin stimulates Toll-
like receptor 5 (TLR5), which activates CD4+T cell responses to the antigen in the intestinal mucosa. B) Induction of tviA expression by low osmolarity when the S. Typhi enters the intestinal 
mucosa, which induces to express Vi capsular polysaccharide and represses the expression of T3SS1 and flagella. Vi capsule obstructs the activation of complement by the S. Typhi O-antigen, 
which attenuates neutrophil recruitment, neutrophil chemotaxis, opsonophagocytosis and the ability of neutrophils to generate an oxidative burst. Repression of T3SS1 expression prevents the 
NOD1–NOD2 signalling pathway, which further reduces neutrophil recruitment. The impairment of flagellum expression blunts the development of CD4+T cell responses against flagellin. S. 
Typhi exploits these mechanisms to prevents activation of a number of pattern recognition receptors that assist the host responses against non-typhoidal Salmonella (NTS) serovars. C3b, 
complement component 3 fragment b 173.  
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The physical outmost structure of S. Typhi, Vi, obstructs the generation of downstream 
signals that stimulate the host to recruit neutrophils to the site of infection. The structure 
of Vi prevents deposition of C3b (by the alternative pathway and limited to early time 
points after infection), which is the first complement deposition of the complement 
cascade activation 173,174,175 (Figure 1.1). By prevention of C3b deposition, S. Typhi is 
able to escape the opsonophagocytic activity by neutrophils 175. The complement 
cascade is blocked, which leads to a lack of C5a deposition. Therefore, neutrophil 
chemotaxis does not occur, resulting in S. Typhi not being cleared by neutrophils. S. 
Typhi, unlike NTS serovars, does not have long O-antigen chains, which allows the Vi 
capsule to shield the LPS 176. Further, the absence of C5a also lessens the recognition of 
the lipid A fragments of the pathogen LPS to TLR4, which reduces the cytokine 
response to provoke neutrophils recruitment to the site of infection 177–179. A lack of 
interaction of C5a and its receptors inhibits neutrophils to generate an oxidative burst 
which is seen during S. Typhimurium infection 173,180. Therefore, Vi permits S. Typhi to 
be virtually ‘‘invisible’’ to neutrophils 181. However, give that S. Paratyphi A lacks Vi, 
there must be multiple alternative strategies for typhoidal Salmonella serovars  to evade 
the host innate immune system 182.   
 
S. Typhi does not evoke the innate immune system as it blocks activation of TLR5 
(absent flagella) and NOD1-2, and NLRC4 (absent TTSS-1 effectors) 173,174 (Figure 
1.1). Down regulation of flagellin expression reduces TLR5-dependent responses in the 
intestinal epithelial cells 183. This impairment contributes to an inhibition of 
inflammasome activation in macrophages in the early phase of infection 119, this also 
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obstructs the  maturation of CD4+ T cells against flagellin in the intestinal mucosa and 
the mesenteric lymph nodes 184. S. Typhimurium pathogenesis experiments have shown 
that upon entry into epithelial cells, virulence effectors secreted by TTSS-1 activate NF-
ĸB through the NOD1-2 signalling pathway, which leads to expression of IL8, an 
important cytokine that regulates inflammation in the gut 185 (Figure 1.1). Therefore, by 
rapidly suppressing TTSS-1 after successfully being internalized into intestinal 
epithelial cells, S. Typhi limits early inflammatory responses 186. Alternatively, through 
suppression of TTSS-1, S. Typhi impairs the capacity of macrophages to detect 
pathogen-induced processes leading to a reduction in the release of intracellular bacteria 
through pyroptosis 187. By reducing pyroptotic macrophage cell death, S. Typhi can 
persist in protected intracellular niches, while avoiding being up-taken and killed by 
neutrophils 119.  
 
Peyer’s patches (PPs) are lymphoid follicles comprised of an arrangement of immune 
cells, such as B cell follicles, T cells, macrophages, dendritic cells, and other antigen-
presenting cells. PPs play a crucial role in secretion of immunoglobin A during 
Salmonella infection 188. The whole patch is overlaid by microfold cells (M cells) which 
has been assumed to be the main entrance for S. Typhi during invasion 188. In vitro 
Salmonella infection experiments have demonstrated that sidestepping the PPs 
dramatically reduces mucosal immune responses against Salmonella 189,190. More recent 
research has revealed that although S. Typhi can adhere and invade M cells, the 
organisms preferentially invades enterocytes, which is facilitated by fimbriae operon stg 
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123,191. By avoiding the traditional route of Salmonella invasion (M cells), S. Typhi has 
an additional approach to prevent triggering the innate immune system.  
 
1.6.2 Adaptive immunity to Salmonella Typhi infection 
Our current knowledge of the adaptive host immune response to enteric fever mostly 
originates from S. Typhi infections rather than from S. Paratyphi A infections. In fact, 
our understanding of the adaptive host immune responses to S. Paratyphi A has only 
been acquired through natural infection while S. Typhi has been studied in natural 
infection, experimental challenge (controlled human infection model) and vaccination 
192. Both S. Typhi and S. Paratyphi A are facultative intracellular bacteria 193, therefore 
immunity against infection should involve both humoral immunity (antibody) and cell 
mediated immunity (CMI). Even though the precise contribution of each adaptive 
immune response aspect remains largely unknown, antibodies are predicted to be 
involved in host protection against extracellular bacteria, while CMI is relevant for the 
intracellular organisms 192 (Figure 1.2). 
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Figure 1.2 Simplified diagram of immunity to Salmonella Typhi in humans (Redrawn 
and adapted from Marcelo B. Sztein, 2014 192) 
Immunity to S. Typhi involves multiple factors including various antigen-presenting cells (e.g., 
macrophages, dendritic cells, B cells) and effector cells (e.g., various effector and regulatory T-cell 
subsets, B cells, NK, and MAIT cells). APC, antigen-presenting cells; ASC, antibody secreting cells; DC, 
dendritic cells; CD8, CD8+ T-cells; CD4, CD4+ T-cells; MAIT, mucosal associated invariant T-cells; 
MO, macrophages; NK, natural killer cells; PMN, polymorphonuclear neutrophil; TM, memory T-cells; 
TCM , central memory T-cells; TEM, effector memory T-cells; TEMRA, effector memory expressing 
CD45RA T-cells; Treg, regulatory T-cells; HLA, human leukocytes antigen; HLA-I, HLA class I; HLA-
II, HLA class II; BCR, B cell receptor; TCR,T-cell receptor; MR1, HLA-I non-classical (b) molecule 
MR1; Ig, immunoglobulin. 
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1.6.2.1 Humoral immunity 
There have been numerous studies on serum antibody responses to S. Typhi following 
natural infection, immunization, and human controlled infections recently. Several 
classes of antibodies such as IgG, IgM, and IgA (including SIgA in the intestinal fluid) 
against classical antigens such as O antigen, H antigen, Vi, and heat-shock proteins 
(GroEL, etc.), have been extensively examined in serum from acute and convalescent 
typhoid patients 194–200. While there are studies showing a correlation between elevated 
anti S. Typhi-specific antibodies and mounting protective immune responses, 
susceptibility to S. Typhi infection has also been suggested within individuals with 
rising levels of S. Typhi-specific antibodies 132,198,201,202. Therefore, the protective roles 
of antibodies to these antigens in protection against typhoid infection is conflicting and 
fragmentary 192.  
 
The role of anti-O-antibody in immune protection has been suggested from field studies 
of Ty21a vaccine, where raised anti-O-IgG was associated with protection when the 
vaccine is in the enteric-coated capsule formulation 203. In the recent human controlled 
infection model, the concentration of pre-challenge anti-H and anti-Vi antibodies did 
not correlate with subsequent protection from development of typhoid 204. In the same 
challenge study, IgG, IgM, and IgA against LPS and H antigens (but not Vi) were 
detected in the participants that developed typhoid. However, the Vi polysaccharide 
vaccine achieves comparable levels of protection to those of the oral live attenuated 
Ty21a vaccine 205. Evidence for the efficacy of Vi polysaccharide vaccine suggests that 
high anti-Vi antibodies are protective against typhoid. Notably, for the Vi-rEPA 
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conjugate vaccine, a concentration of serum anti-Vi antibodies of 1.4–2.0 µg/ml has 
been documented to be protective 206. Additionally, the majority of chronic S. Typhi 
carriers, especially in endemic areas, have high levels of serum anti Vi-IgG 207. 
However, there have been very few reports on S. Typhi specific antibody function 
following S. Typhi infection. 
 
In typhoid infection, B cells do not only serve as antibody secreting cells (ASCs), they 
also act as excellent antigen presenting cells (APCs) following the bacteria being 
internalized 208–216. The serum S. Typhi specific ASCs peak at ~7–10 days after antigen 
encounter, before they home to the original mucosal sites for local antibody secretion 
159,217–223. The extended circulation of these particular cells in peripheral blood can be 
observed with prolonged exposure to these antigens 224. Furthermore, the concentration 
of serum S. Typhi specific antibodies were observed to be elevated in correspondence 
with an increase in S. Typhi specific ASCs, which are thought to have been stimulated 
by antigen encounters at the mucosal surface; antibody titres to specific antigens were 
undetectable when the count of ASCs was low 225.  
 
1.6.2.2 Cell mediated immunity (CMI) 
Cell mediated immunity (CMI), has been clinically observed to play an important role 
in the host defence against Salmonella infection 192. Individuals that are deficient in 
IFN-γ, IL-12, and IL-23 are more susceptible to Salmonella infections, including S. 
Typhi and S. Paratyphi A 226–228. Further, it has been demonstrated that in a Vietnamese 
population, variations within HLA-DRB1, HLA-DQB1 alleles and the tumour necrosis 
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factor TNF-α gene were significantly associated with being resistant or susceptible to 
typhoid fever 229. Studies in S. Typhi and S. Paratyphi A infected patients in Nepal 230, 
in Indonesia 231 and Israeli travellers to Nepal 232 found the serum pro-inflammatory 
(including IL-6, IL-8, IL-15, TNF-α and IFN-γ) and anti-inflammatory 
cytokines/mediators (including IL-10, TNF-α receptor (TNF-R) p55 and TNF-R p75) 
were significantly elevated during the acute phase of infection. Comparable patterns of 
pro-inflammatory cytokines in S. Typhi and S. Paratyphi A infections proposes that host 
immunity might be evoked by similar mechanisms in these patients 192. Suppressive and 
pro-inflammatory responses always act in concert together to induce effective immune 
responses, which is thought to be vital for establishing a balanced immune response 
against S. Typhi infection 192.  
 
CMI response to S. Typhi infection involves largely CD4+ and CD8+ T cells. A range of 
pro-inflammatory cytokines including INF-γ generated by S. Typhi specific CD4+ and 
CD8+ T cells have been reported following immunization 233214,234,235212. However, 
immune response through CD4+ or CD8+ T cells is dependent on the triggering antigen 
192; S. Typhi soluble antigens appear to better at activating the response of CD4+ T cells 
while S. Typhi infected cells are more likely to stimulate CD8+ T cells 209,212,214,236. The 
relationship between CMI and humoral immunity is not clear, and the correlation 
between those two types of adaptive immunity appear to vary from individual to 
individual following immunization with live attenuated S. Typhi 212,237. This observation 
suggests that multiple immunological elements as well as the influence of host factors 
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(i.e. genetics, microbiome composition) determine the development and dominance of 
CMI and/or humoral immunity 192. 
 
1.6.3 Host specificity 
Salmonella enterica serovars can commonly cause infections in a broad-range of 
vertebrate hosts including humans, while some serovars are host restricted, causing 
disease in a limited range of host species 238. Only S. Typhi and S. Paratyphi A (and S. 
Paratyphi B and C) are adapted to be exclusive human pathogens. The current theory 
into this is that host specificity arises through two pathways, which contribute to the 
process by which S. Typhi/S. Paratyphi A are unable to thrive in other environments. 
Firstly, non-typhoidal Salmonella can effectively counter cell-intrinsic host defense 
mechanisms that restrict intracellular pathogen replication by targeting a Rab GTPase 
239. Rab GTPases, with more than 60 members, are global regulators of all steps of 
membrane budding in eukaryotic cells 240,241. Rab32 is abundant in many different cell 
types and is required for killing S. Typhi in mouse macrophages 242. Rab32 is recruited 
into the SCV and apparently delivers an antimicrobial agent (an unknown factor) to 
limit Salmonella replication. S. Typhimurium challenges this by secreting two TTSS 
effector proteins to block the host defensive Rab32-pathway in two converging 
mechanisms. One of the effector proteins (GgtE) is a protease, which can recognize and 
efficiently cleave Rab32 242,243. The other effector (SopD2) works as a GAP (GTPase-
activating proteins, enzymes that alter post-translational modification) directly 
inhibiting Rab32-dependent pathway 239. However, S. Typhi, not able to survive in 
mouse macrophages 244, does not possess ggtE; sopD2 is a pseudogene 98,153. These 
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factors suggest that within the human host these two proteins are not under selective 
pressure to be maintained, otherwise this restriction pathway would not function in 
humans.   
 
The loss of GgtE and SopD2 are not exclusively responsible for the host specificity of S. 
Typhi. Experimental evidence found that chimpanzee are permissive for S. Typhi, and 
replication of the infecting bacteria occurs at an equivalent level to those observed in 
humans 245. However, ‘typical’ typhoid symptoms do not develop during S. Typhi 
infection in chimpanzees, suggesting that pathogen restriction does not solely determine 
host specificity of S. Typhi. Typhoid toxin is now considered to be central for classic 
acute symptoms of typhoid fever 136. As described previously, the pentameric binding 
subunit PltB of typhoid toxin specifically binds to a receptor, which is predominantly 
expressed on human cells but not in other mammals 142. The selective binding of PltB to 
its specific receptor expressed on the inside of the SCVs assists the toxin in being 
packaged into vesicle carriers which transport the toxin to the extracellular milieu 246. 
After being trafficked to extracellular environment, typhoid toxin targets new cells 
expressing compatible receptors to intoxicate them. The target cells are neutrophils, 
lymphocytes, and even brain endothelial cells 247,143. These two known evolutionary 
mechanisms, to prevent S. Typhi surviving in a non-permissive host and toxin binding 
to Neu5Ac-terminal glycans begin to explain the host specificity of S. Typhi. 
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1.7 Carriage 
Chronic S. Typhi asymptomatic carriers have been documented for more than a century 
since the story of Typhoid Mary was reported. Mary Mallon was a New York cook who 
apparently transmitted typhoid to at least 51 people 248. Approximately 2-5 per cent of 
the enteric fever cases in the typhoid endemic regions, are thought to become chronic 
carriers 76,249. However, up to quarter of chronic carriers never experience an episode of 
acute enteric fever 170. Chronic carriers are those who experience (or not) enteric fever 
and fail to clear the pathogens within one year of disease recovery 250. The 
establishment of chronic carriage follows an acute infection and is associated with older 
age, being female, and having gallstones or an abnormality of the gallbladder 170,250. 
Gallstones alone used to be considered the permissive niche for the bacteria to colonize 
and persist in the chronic stage 251. S. Typhi may colonize the gallbladder and attach to 
gallstone surfaces during the acute phase of infection. The primary attachment to 
gallstones requires outer-membrane protein C (OmpC) followed by a specific 
interaction between flagellin and cholesterol 120. Subsequently, the attaching bacteria 
form a biofilm surrounding the gallstones, the process is facilitated by the bacterial exo-
polysaccharide 252. Free bacteria breaking from the biofilm matrix would enter the bile 
duct and access the small intestine before being shed in the faeces 251. Invasion of 
gallbladder epithelium is an alternative mechanism by which S. Typhi establishes 
colonization in the gallbladder 253. According to this hypothesis, intracellular S. Typhi 
replicate in epithelial cells and these cells follow a natural epithelial regeneration 
process. During this process, epithelial cells containing S. Typhi would be naturally 
expelled into the gallbladder lumen by the neighbouring cells 185. Released bacteria 
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could invade new gallbladder epithelial cells or be washed back into the intestinal tract 
120,185. 
 
The public health concern of Salmonella carriage is the shedding of viable bacteria, 
which causes new infection episodes in the community and facilitates disease 
transmission. Alternatively, individuals who have chronic irritation of their gallbladder 
because of persistent inflammation, abnormality or harbouring gallstones have been 
observed to be more likely to develop gallbladder carcinoma 254. Furthermore, the 
carriage of S. Typhi significantly increases the risk of gallbladder carcinoma in these 
individuals 255. More recent work has suggested that the biofilm formation plays a 
significant role in constantly secreting bacterial substances, which includes genotoxins 
and free radicals. These elements may subsequently induce DNA damage and mutations 
in gallbladder tissue 256. 
 
The prospective detection of chronic Salmonella carriers is a crucial step for preventing 
local enteric fever transmission 257 as well as beneficial to individuals at an awareness of 
the pathogens they are carrying 254. However, the major challenge in identifying enteric 
chronic carriers is the fact that they are asymptomatic and may never have suffered from 
acute typhoid. Several attempts have been made to diagnose enteric carriers, which 
include sequential faecal culture 258, bile/gallstone bacterial detection after 
cholecystectomy 250, serological testing of raised anti-Vi antibody 259, or the detection of 
metabolite markers of enteric chronic carriers 257. However, for routine diagnosis, none 
of these methods are routinely applied 257. 
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Various antimicrobial regimes have been applied to treat typhoid carriers yet none have 
been demonstrated to be wholly effective in eradiation of pathogens 64–66. Treatment 
failure might be associated with the biofilm formation, which prevents antimicrobial 
penetration or the development of pore-forming-bacterial subpopulations which are 
highly protected 260. In the case of severe inflammation of the gallbladder, having a 
gallbladder removed (cholecystectomy) has a carriage cure rate of 85% 261. However, 
persistence may still remain 262 because of the other chronic colonized foci in the biliary 
tree, mesenteric lymph nodes, liver, or bone marrow 263. 
 
1.8 The diagnosis of enteric fever 
The infected individuals and organisms associated with acute, convalescent, and 
asymptomatic carriage during enteric fever have different physiological characteristics 
264. There are various phases that an enteric fever diagnostic can be useful, these include 
clinical management (acute phase), disease tracking (convalescence and chronic 
carriage), and epidemiology (acute and convalescence) 264. Therefore, the development 
of an enteric diagnostic should consider tests targeting different samples, exploiting 
different methods so that each test can be aimed at a specific purpose 264. For the 
purpose of diagnosing acute enteric infections, the requirements include high 
specificity, sensitivity (as high as 100% as recommended by WHO 265) low cost, and a 
short duration. Numerous novel approaches using leading-edge technologies, newly 
developed or tailored from other fields, tried to address these objectives such as 
detecting metabolites biomarkers of chronic typhoid carriage 257 and identifying 
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Salmonella-specific IgA responses in lymphocyte culture supernatant (TPTest) 266,267. 
Yet they are still restricted to research laboratories and are not promptly developed into 
simple, rapid diagnostic tests (RDTs) in most resource-limited laboratories 264,265.  
 
1.8.1 Blood culture and nucleic acid detection  
Microbiological culture is still considered as gold standard for enteric diagnosis because 
isolation of the causative agents from blood, bone marrow, rose spots or other sterile 
specimens is the most definite proof of enteric fever 264. Bacterial isolation allows for 
subsequent whole-genome sequencing characterization of the circulating organisms and 
including their antimicrobial resistance genes 265. Microbiological culture enables 
antimicrobial susceptibility testing on the isolated organisms, which can direct 
appropriate therapy 264. Despite its absolute specificity, microbiological isolation 
(except from bone marrow) only has approximately 40 to 60% sensitivity 268–271. 
Following infection trafficking, the typhoidal Salmonella serovars are presumably 
viable in various tissues, including blood. However, these pathogens may only be 
trafficked in blood for a short window, which is major factor limiting their detection in 
blood specimens 265. Additional factors that limit the sensitivity of blood culture is that 
the quantity of the bacteria in blood, as low as <1 CFU/ml 272, and many patients self-
treat with antimicrobials prior to accessing a healthcare facility 40,273. A further 
possibility is that S. Typhi is a fastidious pathogen, which is too delicate to survive the 
harsh environmental change from blood to culturing media 265.  
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Nucleic acid amplification is largely considered to have most of the same difficulties for 
diagnosis as encountered with blood culture. S. Typhi and S. Paratyphi A PCR-based 
assays require only a small number of the bacteria in the clinical specimens and short 
time from laboratorial bench to results. The technique can also overcome the issue of 
dead or non-culturable bacteria as the result of antimicrobial pre-treatment. Multiple 
approaches of PCR-based assays ranging from conventional to real-time, monoplex to 
multiplex, have been developed to amplify the serovars’ specific sequences including 
coding or putative genes 264. The majority of the assays target the fliC gene, and have 
variable sensitivities and specificities 274–281. Some of these methods claim the assays 
have 100% specificities and >90% sensitivity 278,280,282, others report much more modest 
figures of 38 to 42% sensitivity 281. In general, none of the PCR-based assays are used 
as a common enteric fever diagnostic tool across laboratories, which is evidence for the 
limited potential of these assays in the field 265. The physical presence of the bacteria at 
low number in blood makes the required volume of blood even not feasible for a highly 
sensitive test. A novel method, which is termed “the selective target DNA enrichment 
method” (STEM), exploiting micrococcal nuclease added to ox bile to lyse human 
blood cells for subsequent enzymatic cleavage of the contaminating human DNA 283. S. 
Typhi and S. Paratyphi A are not affected as they are bile-resistant and intact cells are 
collected by centrifugation and then subjected to PCR targeting fliC-d and fliC-a 
respectively 283,284. The sensitivity of this approach was found to be 103 fold greater in 
comparison to non-pretreated PCR because human DNA is mostly eliminated 283,284.  
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1.8.2 Serological diagnostic tests 
The Widal test was developed in 1896 and was the first typhoid diagnostic. It is a visual 
test, which monitors agglutinating antibodies in blood of individuals with suspected 
enteric fever. The test targets the polysaccharide (LPS; O) and flagella (H) antigens of 
S. Typhi 285. However, many of the surface antigens of S. Typhi, including O and H, are 
highly conserved with other members of the Enterobacteriaceae. The obvious problem 
of the specificity of the test is that people accumulate antibodies which are cross-
reactive with S. Typhi as they age 265.  
 
ELISAs have also been applied to diagnose enteric fever and have again targeted Vi, 
liposaccharide (LPS; O), flagella (H) antigens and other outer-membrane proteins. It is 
understandable that the ELISAs detecting antibodies against O and H antigens have 
poor specificities and unimproved sensitivities in comparison to the Widal 264. ELISA 
detecting antibody against Vi (anti-Vi IgG) may be a more suitable method for 
identifying chronic carriers 259 rather than those with acute infection (anti-Vi IgM) 264. 
 
Knowledge derived from developing serological assays for enteric fever has been 
applied to generate rapid diagnostic tests (RDTs). Currently available enteric fever 
RDTs are available in different formats and include immunodot, latex agglutination, dip 
stick, or lateral flow, which all detect IgM or IgG against S. Typhi antigens in blood 
(mostly) or other suitable specimens 286. Overall, RDTs contribute some improvement 
over the Widal test for diagnosing enteric fever, yet still remain modest specificity and 
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sensitivity. Therefore, RDTs are not considered as a reliable approach for the diagnosis 
of enteric fever in endemic settings 264. 
 
1.9 Enteric fever vaccines 
Enteric fever occurs only in humans, making it a disease that can technically be 
eradicated 182. Indeed, enteric fever has all but been eliminated from several countries in 
Southeast Asia where it was the most common cause of hospitalized febrile disease 20-
30 years ago 81,287. The elimination of typhoid in these areas is generally attributed to 
extensive improvements in sanitation rather than local immunization. However, for 
various political and economic reasons such improvements of national infrastructures 
cannot be promptly achieved in regions where enteric fever is currently endemic. 
Additionally, the treatment of enteric fever has encountered a major concern in the 
growing rates of AMR 265. Collectively, such a situation makes it essential for the 
community to consider en masse immunization programmes targeting high-risk 
populations to minimize enteric fever where the disease is still common.     
   
1.9.1 Inactivated whole cell typhoid vaccines 
The first typhoid vaccines introduced in the 1890s were the inactivated whole cell S. 
Typhi (heat-killed, phenol-preserved) which were parentally delivered 288. In the 1960s, 
large-scale, randomized, controlled field trials implementing these vaccines was 
sponsored by the World Health Organization (WHO). These vaccines were found to be 
immunogenic with efficacies of 60 to 80%, thus conferring considerable protection 
against typhoid 192,289. However, because of their excessive immunogenic reactions 
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(adverse fever and malaise) these vaccines were rarely used in high-risk populations in 
endemic regions and are no longer manufactured 289. 
 
1.9.2 First generation of live attenuated typhoid vaccines and Vi subunit typhoid 
vaccines 
Historically, the interest in developing typhoid vaccines faded soon after it was 
discovered that chloramphenicol treated enteric fever very effectively 290. An 
efficacious typhoid vaccine generation attracted scientist’s attention again in the 1970s, 
when chloramphenicol-resistant S. Typhi started to be isolated and caused several 
epidemics in Mexico and India 49. The oral live attenuated S. Typhi vaccine strain 
Ty21a and parenteral purified Vi vaccine were licensed in the 1980s-1990s.  
 
The oral live attenuated S. Typhi vaccine is comprised of the strain S. Typhi Ty21a, 
which was generated in the early 1970s by random chemical mutagenesis 291,292. The 
key mutations that make Ty21a attenuated and safe for use in a vaccine are multiple 
mutations in galactose metabolism leading to galE deficiency 292. Other spontaneous 
mutations attenuate the organism further include Vi, auxo-trophy for isoleucine and 
valine, and a mutation precluding H2S utilization 291. Ty21a also has mutations in the 
rpoS gene, which was inherited from the wild-type parental strain Ty2 293. These 
mutations together limit the ability of Ty21a to survive starvation and different stress 
conditions. Ty21a was demonstrated to be only shed limitedly, which reduces the 
environmental risk 294, a substantial benefit of a good oral vaccine. This oral live 
attenuated typhoid vaccine is licensed for children aged >6 years, providing 60-80% 
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efficacy, with 5-7 years lasting protection after three to four spaced doses 295–297. Ty21a 
vaccine has also been shown to induce herd immunity 296. Studies of immunological 
responses post immunization of Ty21a vaccine have dispensed much of our knowledge 
on the pathogenesis of S. Typhi 298–301,301–303. 
 
Parenteral subunit Vi polysaccharide vaccines were developed using non-denatured 
purified Vi capsular polysaccharide of S. Typhi. The Vi polysaccharide vaccine is 
administered as a single dose and confers protection of 55 to 72% in children aged >2 
years for a period of 3 years 304,305. The immunological induction of the vaccine 
stimulates neither mucosal immunity nor T cells because the vaccine is parenteral and 
Vi is a non-protein T-cell-independent antigen 118. However, Vi vaccine has been 
demonstrated to induce herd immunity 306. 
 
1.9.3 Conjugate Vi typhoid vaccines 
The conjugation of the S. Typhi Vi polysaccharide and a protein carrier converts Vi, a 
T-cell-independent antigen, into a T-cell-dependent antigen. Therefore, conjugate Vi 
typhoid vaccines are able to induce the immune system to involve T helper cells, 
establishing immunological memory 295. There are a number of candidates for this novel 
approach under development. One of the most well-known conjugates is the Vi O-
Acetyl Pectin-rEPA conjugate vaccine of which the protein carrier is the non-toxic 
recombinant Pseudomonas aeruginosa exotoxin A (rEPA). This vaccine has been shown 
to be safe and immunogenic. A randomized controlled phase III field trial evaluated its 
efficacy of ~90% in children aged 2-5 years over 46 months of follow-up 
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134,170,206,307,308. Vi-conjugated to CRM197 309 have been demonstrated to be safe and 
immunogenic in adults and teenagers 310,311. Another conjugate has Vi linked to 
diphtheria toxoid 312 which has been licensed in India but peer review on its safety and 
immunogenicity has just been reported in a phase I trial in Filipino adults and children 
(aged 2-45 years) 313. A relatively new Vi conjugate vaccine named Typbar-TCV™, 
developed by an Indian company (Bharat biotech), is a conjugate of Vi polysaccharide 
to tetanus toxoid, which is safe to administer to infants older than 6 months 314. This 
vaccine has been licensed and is now WHO prequalified, the vaccine is currently being 
rolled out across South Asia and endemic parts of sub-Saharan Africa. The potential 
emergence of multi-drug resistant Vi negative S. Typhi variants may result in an 
increased incidence of typhoid fever caused by Vi negative S. Typhi if Vi subunit 
vaccines or conjugate Vi vaccines are generally implemented 124,125. Consequently, Vi 
subunit vaccines or conjugate Vi vaccines will be no longer effective in the regions they 
are most expected to work 192. New alternatives instead of the approach of using Vi as 
the main antigen stimulating the immune system have been considered. These include, 
among others, conjugates of S. Typhi and S. Paratyphi A LPS to carrier proteins or 
Salmonella proteins (e.g., flagellin, porins) to extend the generation of immunity to 
other relevant specific antigens.  
 
1.9.4 Novel attenuated live Salmonella Typhi strains 
Even though live attenuated Ty21a vaccine is well tolerated and efficacious, it requires 
at least 3 doses to achieve optimal immunogenicity. Engineering new attenuated strains 
that are as safe as Ty21a and immunogenic requiring a single dose is sought to improve 
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public health at regions where typhoid fever is endemic 315. The aim of developing a 
new generation of attenuated strain candidates was to attenuate S. Typhi by mutating 
known virulence genes. There have been several candidate mutants generated (mostly 
using the same parent strain as Ty21a; Ty2) and some of them have been tested in 
humans. Many of the engineered organisms generated promising primary 
immunological data for further evaluation 316. Strain M01ZH09 was a targeted mutant 
of aroC and structural protein ssaV in pathogenicity island 2 (SPI-2), which helps 
bacteria survive the intracellular oxidative burst. The mutated organism cannot 
efficiently spread out of the cell and cause systemic infection 233,317. This strain was 
tested in humans and several clinical trials demonstrating a good safety profile and an 
ability to induce immune responses in children 233,318,319. M01ZH09 strain was recently 
evaluated for protective efficacy after a single dose by direct challenge of susceptible 
volunteers 168. Even though a single-dose of M01ZH09 did not succeed to provide 
substantial protection, there have been numerous of publications on the humoral and 
CMI responses to S. Typhi induced through this challenge 168,220,233,318,319. Strain Ty800 
was a phO/phQ virulence regulon mutant, which prevents the bacteria surviving inside 
macrophages 315. There are also other candidates of which the targeted attenuations rely 
solely on mutating the synthesis of aromatic amino acids (aroC and aroD) or in 
combination with a mutation in heat-shock proteins (htrA). Strains CVD906 and 
CVD908 contain mutations in the two aro genes only and are generated from two 
different parental strains (ISP1820 and Ty2, respectively) 320. Results from two phase I 
trials reported that CVD908 could induce appropriate immune responses 320,321 but also 
evoked a self-limiting vaccine bacteraemia 4-8 days after vaccination in 50% of 
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volunteers who received a low dose (5x107) and 100% of volunteers who received a 
high dose (5x108)  321. The vaccine bacteraemia associated with CVD908 prevented it 
being tested in larger populations and efforts were sought to further attenuate the 
organism 316. Strain CVD908-htrA was designed on from CVD908 and had an 
additional defined mutation in its heat-shock protein (htrA) 217. This candidate has been 
evaluated in phase I and II clinical trials and was demonstrated to be safe and able to 
induce humoral and CMI responses 221. However, none of the candidates described 
(strain M01ZH09, Ty800, CVD906, CVD908, CVD908-htrA) could stimulate serum 
anti-Vi antibody. Strain CVD909 was engineered from CVD908-htrA and harboured a 
strong promoter (Ptac’ instead of PtviA), which ensures the constitutive expression of Vi 
322. However, when volunteers were immunized with one or two doses of CVD909, 
serum anti-Vi IgG antibody was not detected despite anti-Vi antibody-secreting cells 
being identified in the majority of the volunteers 219,322.. 
 
1.9.4 Paratyphoid vaccines 
The first S. Paratyphi vaccines, produced over a century ago, were a component of the 
killed whole-cell parenteral typhoid vaccines 299. The vaccines consisted of heat-
inactivated and phenol-preserved S. Typhi, S. Paratyphi A, and S. Paratyphi B (TAB 
vaccine)299. However, their manufacture was discontinued because this vaccine was 
highly reactogenic 323. Currently, there is no commercially available S. Paratyphi A 
vaccine. The current approach to S. Paratyphi A vaccine development follows two main 
strategies, which are O-specific polysaccharide (O:2) conjugates and live attenuated S. 
Paratyphi A strains. Monovalent S. Paratyphi A and bivalent S. Paratyphi A/S. Typhi 
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conjugate vaccines are under different stages of development 323. The O:2 tetanus toxoid 
conjugate (O:2-TT) vaccine candidate, developed by the US National Institutes of 
Health (NIH), was demonstrated to be safe and immunogenic after the first dose at 
phase II trials, yet did not show an antibody boosting response after a second dose 324. 
Another S. Paratyphi A vaccine candidate, developed by the GSK Vaccines Institute for 
Global Health, O:2 conjugated to CRM197. This conjugate was generated in an attempt 
to combine this with Vi-CRM197 in a bivalent formulation targeting both S. Typhi and 
S. Paratyphi A. The O:2-CRM197 conjugate has been shown to induce strong serum 
bactericidal activity against S. Paratyphi A and to be immunogenic when solely 
delivered or as a component of the bivalent formulation 325. Another alternative 
conjugate candidate for immunizing against S. Paratyphi A is O:2-DT, yet the data from 
the clinical testing of this vaccine has not been released 326. Regarding oral live 
attenuated vaccines against S. Paratyphi A, CVD1902 is a S. Paratyphi A strain 
harbouring two independently attenuating mutations in guaBA and clpX 327. A single 
dose of this candidate was demonstrated, in phase I trial, to be well tolerated and 
immunogenic. A bivalent vaccine combining CVD1902 and CVD909 against both S. 
Typhi and S. Paratyphi A is the ultimate aim. 
 
Lastly, there has been substantial attention in investigating live-vector vaccines using 
attenuated S. Typhi strains 328. Multiple clinical trials have been conducted to examine 
the immunogenicity of the foreign antigens carried by an S. Typhi vector 329–332. Even 
though the immune responses against the engineered S. Typhi foreign antigens are 
modest, current technologies promise great potential to improve the immunogenicity of 
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such vaccines 328. This approach (using S. Typhi as vector) may also be an important 
avenue of development for a vaccine targeting both S. Typhi and S. Paratyphi A 192.  
 
1.10 Aims 
Enteric fever is a life-threatening disease causing major public health problems in 
LMICs. Further, the emergence of multi-drug resistant variants of S. Typhi and S. 
Paratyphi A in south Asia is making antimicrobial treatment for enteric fever 
progressively complicated. Potential control measures include improving the quality of 
drinking water supplies, education in better hygiene practices, better case detection, and 
widespread vaccination campaigns. Because the disease only occurs in humans and is 
faecal-orally transmitted, the former interventions are likely the most effective measures 
for enteric fever elimination. However, they cannot be promptly realized in the endemic 
areas. For example, Kathmandu (Nepal) and Chittagong (Bangladesh), have many of the 
typical issues in an endemic enteric fever region. Low quality infrastructure, including 
water supply and sanitary systems, appears to be ideal for the sustained transmission of 
these enteric pathogens, and are unlikely to be improved over the coming years. 
Therefore, improved diagnostic tests to assess disease burden and to subsequently 
manage the disease cases are a priority. In addition, mass immunization campaigns of 
safe, efficacious vaccines are another crucial arm for the rational control of enteric fever 
in these areas. Accordingly, a better understanding of the host immune responses 
against S. Typhi and S. Paratyphi A during infection, after infection and during chronic 
carriage is now essential. Alternatively, in a different setting in Vietnam, enteric fever 
was once a major problem in the 1990s, but the country has successfully controlled the 
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disease for the last decade or more. The model for controlling typhoid fever in Vietnam 
should be an exemplar for other settings where enteric fever is still a burden. However, 
the foundations leading to the elimination of the disease in this country has not been 
systemically reviewed and remains to be elucidated. 
 
In order to address these issues, the aims of my thesis are: 
 
1. To review the retrospective data and information regarding enteric fever in 
Vietnam and to combine this information with the country’s economic 
development. The aim was to evaluate the greatest contribution for the decline 
and ultimate elimination of enteric fever in Vietnam in the last decade. 
 
2. To measure the acute antibody responses against a range of recently identified S. 
Typhi protein antigens for the purpose of typhoid fever diagnosis in a cohort of 
Bangladeshi patients with febrile disease.  
 
3. To assess the longitudinal dynamics of antibody against typhoid toxin in a 
cohort of enteric fever patients in Kathmandu, Nepal. 
 
4. To identify immunogenic antigens that are targeted during bactericidal activity 
using a newly constructed S. Typhi transposon mutant library and assess the 
longitudinal dynamics of antibody against these identified antigens. 
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5. To estimate the prevalence of S. Typhi carriage in a typhoid endemic population 
(Kathmandu, Nepal) by exploiting their unique immunological profile. 
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Chapter 2 Materials and Methods 
 
2.1 Study sites and settings and ethics 
2.1.1 Chittagong Medical College Hospital in Chittagong, Bangladesh 
Plasma samples used in Chapter 4 were collected at Chittagong Medical College 
Hospital (CMCH), Chittagong, Bangladesh. CMCH is a regional teaching hospital in 
the city of Chittagong, and co-located with the Chittagong Medical College, serving 
Chittagong and surrounding provinces 333. The capacity of CMCH is of 1,000 inpatient 
beds admitting 600,000 patients (500,000 adults and 100,000 children) annually and 
sees > 5,000 outpatients daily. Chittagong is the second largest city in Bangladesh, with 
a of 2.1 million. It is positioned in South-eastern Bangladesh and has a tropical wet 
climate which has cool and dry winters from December and February 334.  
 
The study conducted at CMCH followed the principles expressed in the Declaration of 
Helsinki. The Bangladesh National Research Ethical Committee (BMRC/NREC/2010- 
2013/1543), the Chittagong Medical College Hospital Ethical Committee, the Oxford 
Tropical Research Ethics Committee (OXTREC 53-09) gave ethical approval for the 
study. Informed written or thumbprint consent was taken from the subject, their parent 
or caretaker for all enrolees. 
 
Patients particiated in this study was recruited by Prof Chrisopher Parry and plasma 
seperation was performed by the nurses of CMCH, Chittagong, Bangladesh. 
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2.1.2 Patan Hospital in Kathmandu, Nepal 
The majority of plasma samples in my study, which are used in Chapters 5, 6, and 7 
originated from enteric fever studies conducted in Patan Hospital in Kathmandu, Nepal. 
The majority of patients are from the Kathmandu Valley and Lalitpur area. Patan 
Hospital has 318 beds with the occupancy rate about 85% admitting 16,000 inpatients 
annually. Kathmandu is the capital city of Nepal having a population of 1.5 million. The 
city is located at an altitude of 1,300m having four typical seasons of which the hot wet 
season is from June to August and is reported to have the greatest burden of enteric 
infections.  
 
The plasma samples used in my study were collected from a clinical trial that received 
ethical approval from the Nepal Health Research Council, Kathmandu, Nepal and the 
Oxford Tropical Research Ethics Committee, Oxford, UK.  The study was conducted 
according to the principles expressed in the Declaration of Helsinki. The trial was 
registered as ISRCTN63006567 (www.controlled-trials.com). Written informed consent 
was taken from the subject, their parent or guardian of enrolee under 18 years of age. 
 
The patient recruiment data, blood cultures, bile cultures, and plasma samples utilised in 
my work were from enteric fever studies conducted at Patan Hospital, Kathmandu, 
Nepal. The work providing these samples was performed by doctors, nurses and 
microbiologists based at this hospital. 
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2.2 Bacterial identification and plasma preparation 
2.2.1 Blood culture 
Enteric infections were definitively diagnosed by blood culture. Blood (1-2mL for 
children; 5-12mL for adults) was taken within 24 hours of admission prior to 
antimicrobial therapy was started in hospital. For blood culture in CMCH, blood 
samples were inoculated into an adult or paediatric BactAlert® blood culture bottle and 
incubated aerobically in a BactAlert® automated system (bioMérieux, Marcy l’Etoile, 
France) at 37°C for 5 days. For blood culture in Patan Hospital, blood samples were 
inoculated into a sterile bottle containing tryptone soya broth and sodium polyanethol 
sulfonate, up to a total volume of 50mL. The broth of bottles that were positive was 
subcultured onto blood, chocolate and MacConkey agar. Suspected Salmonella colonies 
were identified using standard biochemical tests and serotype-specific antisera (Murex 
Biotech, Dartford, England). 
 
2.2.2 Bile culture 
Bile collected from all patients undergoing cholecystectomy or laparotomy surgery 
between June 2007 and October 2010 was submitted for culture. Selenite F broth and 
Peptone broth individually were prepared as an equal volume as the bile sample and 
made the bile inoculated mixture. The broth was incubated at 37oC overnight, then 
subcultured onto MacConkey agar and Xylose Lysine Deoxycholate (XLD) agar 
incubated at 37oC overnight. Cultured Gram-negative bacteria were identified by 
standard microbiological methods and API20E (BioMerieux, Inc). Potential S. Typhi 
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and S. Paratyphi A isolates were confirmed by slide agglutination by specific antisera 
(Murex Biotech, Biotech, England). 
 
2.2.3 Plasma preparation 
Blood samples were collected in EDTA K3 (Golden Vac) containing 10% EDTA. 
Plasma and pellet were separated by centrifuging at 3,000rpm for 3 minutes and plasma 
aliquoted into cryovials and stored at -20oC. 
 
2.3 Plasma samples and bacterial isolates 
2.3.1 Plasma samples for Chapter 4  
Plasma samples used in Chapter 4 originated from a study conducted in Chittagong 
Medical College Hospital, Chittagong, Bangladesh 335 aiming to compare the accuracy 
of three rapid diagnostic tests for typhoid fever; the Life Assay Test-itTM Typhoid IgM 
(Life Assay Diagnostics (Pty), Cape Town, South Africa), the SD Bioline test (Standard 
Diagnostics Inc., Gyeonggi, Korea), and the CTK Biotech Onsite Typhoid IgG/IgM 
Combo Rapid-test cassette (CTK Biotech, Inc., San Diego, CA, USA). Briefly, adults 
and children (>6 months) consecutively admitted from January to June 2012 to the adult 
and paediatric wards at CMCH with an axillary temperature of ³38oC up to 48 h after 
admission and history of fever for <2 weeks were eligible for the inclusion in the study. 
The plasma collection for this was from patients with confirmed typhoid fever (n=32, 16 
cases confirmed by blood culture, 13 cases confirmed by PCR and 3 cases confirmed by 
both blood culture and PCR), other confirmed infections (n=17) and undiagnosed febrile 
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disease (n=244). Further, there were 40 plasma samples collected from among the 
hospital staff as negative controls. 
 
2.3.2 Plasma samples for Chapter 5, 6, 7  
2.3.2.1 Plasma samples for investigations of acute and convalescent febrile diseases  
Plasma samples used for longitudinal assessment originated from an open-label, 
randomized, controlled trial, comparing Gatifloxacin and Ofloxacin for the treatment of 
uncomplicated enteric fever, conducted at Patan Hospital. The trial was registered as 
ISRCTN63006567 (www.controlled-trials.com). Briefly, patients were randomly 
assigned to treatment for 7 days with either ofloxacin (200mg or 400mg tablets, 
National Healthcare Pvt. Ltd., Nepal) at 20mg per kg per day in two divided oral doses 
or gatifloxacin (400mg tablets, Square Pharmaceutical Limited, Bangladesh) at 10mg 
per kg once daily. Blood from all patients were sampled on the day of enrolment and 
day 8, 28 (month 1) and 90 (month 3) post enrolment. Blood samples were directly 
subjected to culture or to plasma preparation. Number of plasma samples collected at 
day 1, day 8, month 1, month 3 from S. Typhi confirmed patients were 152, 148, 148, 
81; from S. Paratyphi A confirmed patients were 68, 67, 66, 52; from unidentified 
febrile patients were 316, 316, 266, 177, respectively.  
 
2.3.2.2 Plasma samples for investigations of asymptomatic chronic enteric fever  
Patients admitted to the surgical department of Patan Hospital for open cholecystectomy 
or laparotomy surgery for symptomatic cholelithiasis, between June 2007 to October 
2010, were enrolled after giving written informed consent. Blood samples were 
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collected and plasma samples were prepared as described in section 2.2.3. Forty-six 
blood samples including 10 from patients having confirmed S. Typhi, 6 from patients 
having confirmed S. Paratyphi A, and 30 from patients that were bile culture negative 
(cholecystectomy controls) were used. 
 
2.3.2.3 Plasma bank  
The plasma bank was collected from patients visiting Patan Hospital Emergency 
Department from January 2010 to September 2010. The bank consisted of 733 plasma 
samples collected from an age group spanning from 2 months to 65 years of age. The 
distribution of the plasma bank was 28±2 samples for each year of age from 0 (2 
months) to 30 years; 9±1 samples for each year of age from 31 to 60 years old; and 
finally, 4±1 samples for each year of age from 61 to 65 years old. Community 
population was collected from 49 afebrile adults living within Kathmandu valley. 
 
2.3.3 Bacterial isolates 
The bacterial isolates used for genetic manipulation in Chapter 6 were S. Typhi AS252, 
identified in Ho Chi Minh city, Vietnam in 1999, and S. Paratyphi A 01TY546, 
identified in Kathmandu, Nepal in 2010.  
 
2.4 Protein purification 
I selected 18 S. Typhi antigens that gave a differential serodiagnostic signal using 
protein microarray screening 336 for further expression and purification (Table 2.1). The 
coding sequences of the selected genes, excluding trans-membrane domains were PCR 
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amplified from CT18 genomic DNA and cloned into the 5’NcoI and 3’NotI restriction 
sites of pET28b(þ) vector (Novagen, UK) for further His-Tag purification. E. coli 
DH5a were transformed with the plasmid constructs for stable storage and E. coli 
BL21(DE3)pLysS (Promega, WI, USA) were used for expression and purification 
(Table 2.1)
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Table 2.1 Plasmid constructs of Salmonella Typhi antigens generated for protein expression 
 
  
Target 
(CT18) 
Construct 
name 
5'RE Ty2 nomenclature and 
Coding sequence 
3'RE Forward primer Reverse primer bp aa kDa 
STY4190 pEK90 NcoI 3904 (Typhi) aa25-495 NotI catg ccatgg gt 
GATGCGCTCCAGCCCGATC 
gcatgagc gcggccgc 
CTGTGCCGCCGGTGTTTCC 
1413 471 52.6 
STY3208 pEK91 NcoI 2970 (Typhi) aa1-279 NotI catg ccatgg gt 
ATGGCAGCTAACGGAGAAAATAATCC 
gcatgagc gcggccgc 
CCAGGTCTTACCTATTTTAAATTCCC 
837 279 30.5 
STY1767 pEK92 NcoI 1224 (Typhi) aa21-154 NotI catg ccatgg gt 
GCACCGGCGCCAAATGCCAG 
gcatgagc gcggccgc 
AATTCGCCGTGCCTGCCAGAAG 
402 134 15.1 
STY1703 pEK93 NcoI 1285 (Typhi) aa1-124 NotI catg ccatgg gt 
ATGCGTATTACCAAAGTTGAGGG 
gcatgagc gcggccgc 
TTCGCTATTCTTAACATAGAATATCTC 
372 124 14.1 
STY1522 pEK94 NcoI 1459 (Typhi) aa25-363 NotI catg ccatgg gt 
TGCACAACCCTTGCTATTCAGGATAAAC 
gcatgagc gcggccgc 
TCCTTTGACGTTGATTTTCTCGAACAC 
1017 339 37.6 
STY1886 pEK95 NcoI 1111 (Typhi) aa28-269 NotI catg ccatgg gt 
AAAGTTATGACCTGGAATCTTCAGGG 
gcatgagc gcggccgc 
ACAGCTTCGTGCCAAAAAGGCTAC 
726 242 26.4 
STY1498 pEK96 NcoI 1477 (Typhi) aa203-305 NotI catg ccatgg gt 
GGCGTGATTGAAGGGAAATTGATTCc 
gcatgagc gcggccgc 
GACGTCAGGAACCTCGAAAAGCG 
309 103 11.5 
STY3375 pEK99 NcoI 3116 (Typhi) aa1-118 NotI catg ccatgg gt 
ATGGCGTCCACATATCGCAC 
gcatgagc gcggccgc 
CTCTTGTGGATCGACTGGC 
354 118 13.8 
STY1372 pEK100 NcoI 1594 (Typhi) aa27-74 NotI catg ccatgg gt 
AGCAACCGCGCCGGTCGG 
gcatgagc gcggccgc 
GCGCTCTCTCCAGTTCGGATG 
144 48 5.7 
STY1612 pEK101 NcoI 1376 (Typhi) aa30-108 NotI catg ccatgg gt 
AGTAAAACAGAAGAACGCCAGGC 
gcatgagc gcggccgc 
TTGACCTCCGGTATTGCGGTAC 
237 79 9.2 
STY0357 pEK102 NcoI 2538 (Typhi) aa20-246 NotI catg ccatgg gt 
GGTTTGCTGAGCAGCAGCAGC 
gcatgagc gcggccgc 
TTTTGCCTCGGAGAGCGTATAATTTG 
681 227 25.8 
STY4539 pEK103 NcoI 4239 (Typhi) aa20-414 NotI catg ccatgg gt 
CAGCAGACCTCCACCCAAACC 
gcatgagc gcggccgc 
CGACCGGTCAGCCGGTTTATC 
1185 395 41.9 
STY0452 pEK104 NcoI 2449 (Typhi) aa22-179 NotI catg ccatgg gt 
CCGCAGAGCGAAGTTCGC 
gcatgagc gcggccgc 
TTGATTAACAGGCTGAATATCATGG 
474 158 17.2 
STY0796 pEK105 NcoI 2126 (Typhi) aa27-262 NotI catg ccatgg gt 
CAGGCGCCAATCAGTAGTGTC 
gcatgagc gcggccgc 
CATCGCGTTAAGACGCTTCTGC 
708 236 25.4 
STY0065 pEK106 NcoI 0058 (Typhi) aa33-79 NotI catg ccatgg gt 
GGTATGTCTGCCGTGATTACTC 
gcatgagc gcggccgc 
AGCGTTAAGGCGGTGATGGTG 
138 46 4.9 
STY3093 pEK107 NcoI 2864 (Typhi) aa1-118 NotI catg ccatgg gt 
ATGTTTTTGACGTACATTTCATTTCagg 
gcatgagc gcggccgc 
CTGGCCTTTGGCGTTAATTTTAC 
354 118 13.6 
STY1086 pEK108 PciI 1855 (Typhi) aa20-178 NotI catg acatgt ta 
GGAGAAAATAAAAGCTATTATCAGCTC 
gcatgagc gcggccgc 
AGCGGCCGCTTCCTGACTC 
477 159 17.4 
STY3765 pEK109 NcoI 3515 (Typhi) aa1-518 NotI catg ccatgg gt 
ATGAAAGTAAAACTGCTTGCTGCC 
gcatgagc gcggccgc 
CTTCTTCACATCCGCAACACG 
1554 518 55.5 
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For protein expression, E. coli BL21(DE3)pLysS harbouring unique plasmid constructs 
(pEK90 - pEK109) containing the genes of interest were inoculated into LB broth 
containing 100mg/L kanamycin (Sigma, MO, USA), and incubated at 37oC overnight. 
Overnight cultures were diluted (1:100) into LB broth (100mg/L kanamycin) and 
incubated at 37oC with agitation until optical density (OD at 600nm) of 0.5. Expression 
of the exogenous proteins was induced by the addition of isopropyl-b-D-thiogalactoside 
(IPTG) (Sigma Aldrich, UK), to a final concentration of 0.1mM. Bacterial cells were 
harvested by centrifuging (5000xg at 4oC for 10 minutes) after 3 hours of incubation at 
24oC. 
 
For soluble proteins, bacterial pellets were resuspended in 50mM phosphate buffer 
(pH8) containing 300mM NaCl and 10mM imidazole. After sonication, cell debris and 
the membrane fragment were pelleted by centrifugation at 16,000xg at 4oC for 30 
minutes. Supernatants were filtered through a 0.45nm membrane before being rocked at 
4oC with nickel coated agarose beads (Ni-NTA, Invitrogen) for 2 hours. Protein bound 
Ni-NTA beads were loaded into gravity flow columns (Qiagen, Germany) and washed 
with 20 mM imidazole in phosphate buffer. Proteins were eluted with 250mM 
imidazole in phosphate buffer. For insoluble proteins a denaturing protocol was 
performed by firstly incubating the bacterial cells in an 8M urea (pH7.8) solution 
containing 20mM sodium phosphate and 500mM NaCl. Proteins were eluted with 4M 
Urea (pH3) in a solution containing 20mM Sodium Phosphate buffer and 500mM NaCl. 
Proteins were renatured after purification in 50mM Sodium Phosphate solution and 
500mM NaCl. 
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2.5 Enzyme-linked immunosorbent assays (ELISA) 
ELISAs to detect antigen specific antibodies, classes IgM or IgG, in human plasma 
samples were performed as described previously 337,338. Briefly, 96 well flat-bottom 
ELISA plates (Nunc 2404, Thermo Scientific) were coated overnight with 100mL per 
well of the various antigens (final concentrations; 7µg/mL of protein antigens, 15µg/mL 
for O2 antigen, 1µg/mL for the STY1498, STY1479, Vi and typhoid toxoid antigen in 
50mM Carbonate Bicarbonate buffer). Coated plates were washed and blocked with 5% 
milk solution in PBS. After 2 hours of blocking, plates were washed and incubated with 
100mL (per well) of a 1:200 dilution of plasma at ambient temperature for 2 hours. 
Plates were washed again and incubated with 100mL per well of alkaline phosphatase-
conjugated anti-human IgM at ambient temperature for 1 hour. The final ELISA plates 
were developed using p-Nitro- phenyl phosphate (SigmaFAST N1891, Sigma Aldrich, 
UK) substrate for 30 minutes at ambient temperature and the final absorbance was read 
at dual wavelengths (405nm and 490nm) using an automated microplate reader 
(Biorad). End point positive absorbance results were defined as optical densities (OD) 
greater than the absorbance obtained for the blank control wells plus four times the 
standard deviation. Three wells of culture S. Typhi positive plasma were run as control 
for every 96-well plate for each antigen. The results of each ELISA plate were accepted 
only if the OD values of the controls were within the range of their known values 
plus/minus two standard deviations of the blank wells. Every sample (plasma or positive 
control or blank control) was measured in triplicate (in three individual wells). 
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2.5.1 ELISAs specific for Chapter 4 
ELISAs to detect antibodies (IgM)  against purified antigens and anti Vi polysaccharide 
(provided by Novartis vaccines for Global Health, Siena, Italy which were purified as 
described elsewhere 309,325) in human plasma were performed as described in section 
2.5. Of the 18 protein antigens I aimed to purify, I was initially able to express and 
purify 12 (Table 2.2). All these 12 proteins were used as the antigens for the ELISA 
performed in Chapter 4. I was additionally able to purify protein HylE (STY1498) for 
later experiments described in Chapter 6.  
 
For the purpose of the experiments in Chapter 4, I used plasma from patients with 
confirmed enteric fever (n=32), other confirmed infections (n=17), and afebrile controls 
(n=40). ELISAs were performed on plasma from 243 patients with undiagnosed febrile 
disease using the most specific antigens. 
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Table 2.2 Salmonella Typhi antigens expressed for serological testing in Chapter 4 
Gene ID 
Number a 
Isotype detected 
using array b 
Gene name Amino acid identity S. Typhi 
CT18/S. Paratyphi A AKU_12601 
Annotation 
STY0452 IgM yajI 163/165 (98%) Putative lipoprotein- Prokaryotic homologue of protein DJ-1 
STY0796 IgM ybgF 260/262 (99%) Putative exported protein - Tol/pal system protein 
STY1086 IgM - 187/187 (100%)  Putative lipoprotein 
STY1372 IgM pspB 74/74 (100%) Phage shock protein B 
STY1612 IgM - Absent Putative membrane protein - prophage assocaited 
STY4539 IgM pilL Absent Putative exported protein - type IV pili 
STY1522 IgG - 292/296 (99%) Putative secreted protein - Choloylglycine secreted homologue 
STY1703  IgG ssaP 123/124 (99%) Putative secreted protein - T3SS 
STY1767 IgG nlpC 48/140 (34%) Putative lipoprotein - Endopeptidase 
STY1886 IgG cdtB 268/269 (99%) Cytolethal distending toxin subunit B homologue  
STY3208 IgG - 277/279 (99%) Hypothetical protein - Unknown function 
STY4190 IgG yhjJ 190/192 (99.0%) Putative Zinc-protease 
 
a) Reference Parkhill et al. 2001 339 
b) Reference Liang et al. 2013 340 
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2.5.2 ELISAs specific for Chapter 5 
ELISAs to detect IgM and IgG in human plasma samples against various antigens (Vi, 
O2, or typhoid toxin) were performed as described as section 2.5. The Vi and O2 
antigens were provided by Novartis vaccines for Global Health (Siena, Italy), which 
were purified as described previously 309,325. Typhoid toxin was provided by Professor 
Jorge Galan (Department of Microbial Pathogenesis, Yale University School of 
Medicine, New Haven, CT, USA), which was generated by mutating its catalytic 
subunits PltAE133A and CdtBH160Q. The overexpression and purification of typhoid 
toxoid were as described previously 136.   
 
For the purpose of experiments in Chapter 5, a collection of plasma samples from 220 
enrolees with culture confirmed enteric fever (152 with S. Typhi infection and 68 with 
S. Paratyphi A infection) longitudinally sampled for up to 90 days was analysed. 
Additionally plasma samples from 316 febrile patients with clinical symptoms of 
typhoid but were blood culture negative, 49 plasma samples from healthy afebrile 
individuals living in the same population, and 733 plasma samples collected from the 
plasma bank were used for measuring background antibody concentrations in the 
population 337. The plasma samples and tests performed in Chapter 5 are summarised in 
Table 2.3. 
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Table 2.3 Plasma samples and ELISA tests detecting IgM and IgG performed in Chapter 5 
Samples Anti-toxoid IgM Anti-toxoid IgG Anti Vi IgG & 
anti O2 IgG 
S. Typhi confirmed (Day 1, Day 8, Month 1, Month 3) 152, 148, 148, 81 152, 148, 148, 81 0 
S. Paratyphi A confirmed (Day 1, Day 8, Month 1, Month 3) 68, 67, 66, 52 68, 67, 66, 52 0 
Unidentified febrile (Day 1, Day 8, Month 1, Month 3) 316, 316, 266, 177 316, 316, 266, 177 0 
Afebrile community Control (AF) 49 49 
 
Serum bank (SB) 0 733 733 
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2.5.3 ELISA specific for Chapter 6  
ELISAs to detect IgG in human plasma samples against various antigens (STY0796, 
STY1086, STY1372, STY1498, O2, Vi) were performed as described as in section 2.5 
using the same set of human plasma samples as used in Chapter 5 (section 2.5.2, Table 
2.3).  
 
2.5.4 ELISAs specific for Chapter 7  
ELISAs to detect specific IgG against antigens listed in Table 2.4 were performed as 
described in section 2.5. A collection of plasma samples collected from 148 patients 
with culture confirmed acute typhoid fever on day 8 after admission and from patients 
undergoing cholecystectomy which included 10 culture confirmed S. Typhi carriers and 
30 cholecystectomy controls were used in this chapter. Additionally, 733 plasma 
samples from the plasma bank were used for measuring background antibody 
concentrations in the population 337. The plasma samples and tests performed in Chapter 
7 are summarised in Table 2.4.  
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Table 2.4 Plasma samples and ELISAs detecting antibody IgG performed in Chapter 7 
Samples Anti -
STY1479  
Anti-
toxoid  
Other 
antigens* 
Anti-Vi  
S. Typhi carriage 10 10 10 10 
Cholecystectomy control 30 30 30 30 
S. Typhi acute (Day 8) 148 148 148 148 
Serum bank (SB) year 1-19 351 351 0 351 
Serum bank (SB) year 20-65  382 382 0 382 
 
*Other antigens included STY0452, STY0796, STY1086, STY1372, STY1498, STY1522, STY1612, 
STY1703, STY1767, STY3208, STY4190, STY4539  
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2.6 Typhoid toxin neutralization 
Plasma samples at all four different time points of four patients in every group of 
confirmed S. Typhi, confirmed S. Paratyphi A and undiagnosed febrile disease were 
selected randomly with respect to their seroconversion status. Eight community controls 
were also selected for the neutralization assay. Toxin neutralization assays were 
performed by examining the ability of the different plasma samples to block the DNA 
damage response induced by typhoid toxin in cultured epithelial cells 341. Briefly, 
human Henle-407 epithelial cells were seeded onto 12-well plates at a concentration of 
2.5 x 104 cells per well and incubated at 37°C overnight in a tissue culture incubator. 
Purified typhoid toxin (6nM in 20µl of PBS) was incubated with 1µl of the different 
plasma samples for 30 minutes at room temperature and applied to the cultured cells, 
and further incubated for 68 hours at 37°C CO2 in tissue culture incubator. Cells, were 
then washed, trypsinized, and processed for cell cycle analysis as previously described 
136. 
The toxin neutralization experiments were performed in the laboratory of Professor 
Jorge Galan, Yale University School of Medicine, New Haven, CT, USA. 
 
2.7 S. Typhi transposon mutant library preparation 
2.7.1 Competent cell preparation 
The S. Typhi transposon mutant library was generated with a clinical S. Typhi isolate 
AS252. Therefore, to get the starting materials for the library preparation, S. Typhi 
isolates AS252 was subjected to competent cell preparation. Pre-warmed LB broth was 
inoculated with a suitable volume of overnight AS252 bacterial culture at a proportion 
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of 100:1 and horizontally agitated at 37oC, ~180rpm, until early exponential phase (OD 
at 600nm ~ 0.3 - 0.4). The bacterial culture was cooled on ice and harvested by 
centrifuged at 4oC at 4,000rpm for 10 minutes using a temperature-controlled centrifuge 
(Eppendorf, Hamburg, Germany). The supernatant was discarded and the cells were re-
suspended in a half of the initial volume of chilled (0 – 8oC) 10% glycerol. This 
procedure for harvesting and re-suspending cells was repeated twice with an increasing 
centrifugation speed (9,000rpm) before cells being re-suspended in 0.5mL of (0 – 8oC) 
10% glycerol and centrifuged at 6,000rpm for 1 minute. The supernatants were 
discarded and the cells were suspended in 1/1000 x volume of 10% glycerol (i.e., if 
starting culture was 400mL then re-suspended in 400µl). The competent cells were kept 
on ice if to be used immediately or stored at -80oC for later use; 60µl of cell suspension 
was used for one electro-transformation. This procedure was also used for competent 
cell preparation in section 2.9.3. 
 
2.7.2 High frequency electrotransformation of Salmonella Typhi 
The Tn5 transposon was constructed from the EZ-Tn5 < R6Kgori/KAN-2> (Epicentre 
Biotechnologies) flanked with T7 and SP6 promoters at each end, respectively, and 
with R6Kgori deleted 342. The plasmid was named in house as pTnTMDH5(del)oriR6K 
(Figure 2.1). Other materials comprised of Phosphorylation Kit (T4 Polynucleotide 
Kinase – Biolabs), Transposomes Preparation Kit (Mu/EZ-Tn5 transposase). 
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Figure 2.1 Plasmid pTnTMDH5(del)oriR6K 
Map of plasmid used for genetic manipulation of S. Typhi and S. Paratyphi A  
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2.7.2.1 Plasmid digestion 
This step was included to avoid grown kanamycin resistant strains that contained an 
intact original plasmid, therefore guaranteeing all of the recovered organism had a Tn5 
insertion. A plasmid digestion reaction was set up in a 10µl volume, consisting of 2.5µl 
of pTnTMDH5(del)oriR6K (10ng/mL), 1µl of 10X NEB4 buffer, 5.5µl water, 0.5µl 
MspAI1 restriction enzyme and 1µl BSA. The mixture was incubated at 37oC for 2 
hours. 
 
2.7.2.2 Transposon amplification 
The transposon was amplified using specific oligonucleotides  
(5’-CTGTCTCTTATACACATCTC CCT and 5’-CTGTCTCTTATACACATCTCTTC) 
with the proofreading DNA polymerase, Pfu Ultra Fusion II, (Stratagene). The reactions 
were established in a stock of ten and equally distributed into ten wells prior to the 
thermal cycling to assure homologous amplicon production. Ten reactions were 
established in 200µl mixture of 20µl 10X buffer, 2µl deoxyribonucleotide triphosphates 
(dNTPs, 10mM), 2µl digested plasmid, 0.4µl Primer (forward and reverse, 100nM), 
171µl water and 4µl Pfu (Ultra fusion II). The thermal cycling was: 95oC for 90 
seconds followed by 30 cycles of denaturation at 95oC for 10 seconds, annealing at 
58oC for 20 seconds and elongation at 72oC for 20 seconds, then 72oC for 3 minutes. 
 
2.7.2.3 Phosphorylation 
The Tn5 amplicons were phosphorylated to obtain Pi-5’ terminus products, which were 
able to forms transposomes in the later step. The Tn5 amplicons were purified using 
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Quick-Start PCR purification kit (Qiagen) following the manufacture procedure before 
being subjected to phosphorylation. The phosphorylation reaction was established in 
80µl total consisting of 70µl purified Tn5 amplicons (approximately 50µg/ml), 8µl 10X 
T4 buffer, 1µl ATP (75mM, Roche) and 1µl T4 Polynucleotide Kinase (Biolabs). The 
mixture was incubated at 37oC for 30 – 45 minutes and inactivated at 65oC for 20 
minutes. 
 
2.7.2.4 Phenol:chloroform extraction and precipitation 
The phosphorylated Tn5 amplicons were purified from proteins (T4 nucleotide kinase) 
and other chemicals in the phosphorylation reaction for the transposome preparation 
step. The extraction reaction included 2 volumes of phosphorylated Tn5 amplicons with 
1 volume of phenol:chloroform. The mixture was mixed well and separated by 
centrifugation at 4oC at 13,000rpm for 10 minutes, and the supernatant was kept. The 
DNA containing supernatant was precipitated in a 30µl reaction including 10µl 
supernatant, 1µl NaOAc 3M pH7.5 and 19µl absolute Ethanol. The mixture was mixed 
well and centrifuged at 4oC at 13,000rpm for 10 minutes. The supernatant step was 
discarded and the pellet was rinsed twice with 200µl 70% Ethanol. The pellet (pure 
phosphorylated Tn5) was eluted in 10µl TE (pH7.5). The pure phosphorylated Tn5 was 
stored at -20oC. 
 
2.7.2.5 Transposome preparation 
Transposome preparation was always performed in 2 parallel reactions with (Tn5+) and 
without (Tn5-) EZ-Tn5 Transposase for the purpose of monitoring the downstream 
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activity of Tn5. The Tn5+ reaction included 2µl pure phosphorylated Tn5 DNA 
(~70µg/ml in TE pH7.5), 4µl EZ-Tn5 Transposase, 2µl 100% glycerol and 0µl 50% 
glycerol. Accordingly, the Tn5- reaction included 2µl pure phosphorylated Tn5 
(~70µg/ml in TE pH 7.5), 0µl EZ-Tn5 Transposase, 2µl 100% glycerol and 4µl 50% 
glycerol. The solutions were mixed well and incubated at room temperature for 30 
minutes.  
 
2.7.2.6 Electrotransformation 
Sixty microliters of competent cells were mixed with 0.2mL of transposomes and stored 
on ice for at least 10 minutes. The cells were then electrotransformed in a 1mm 
electrode gap cuvette using a Bio-Rad GenePulser II setting to 1.8 kV, 25 mF, and 200 
W. Cells were immediately recovered in 1mL of SOC medium (Invitrogen) and 
incubated at 37°C for 2 hours then spread on LB agar containing kanamycin 
(25mg/mL). After overnight incubation at 37°C, kanamycin resistant colonies were 
resuspended in sterilized 10% glycerol using a bacteriological spreader. This procedure 
was also used for electrotransformation in section 2.9.1.3. Typically, one batch of 
mutants (one day mutant generating) included 10 electrotransformations generating 
approximately 3x105 mutants.  
 
2.8 Serum (plasma) bactericidal assays (SBAs) 
2.8.1 Reagents 
Phosphate Buffer Saline-Calcium Chloride (PBS-CaCl2) was prepared by mixing buffer 
A (100mL of 0.9mM CaCl2.2H2O) into buffer B (100mL of 10X PBS, Sigma Aldrich) 
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and filling up to 1,000mL with double distilled water. Buffer was filtered by 0.2µm 
sterile membrane and stored at 4oC. SBA Diluting Buffer (prepared on ice before 
performing the experiment) was prepared by adding BSA (bovine serum albumin, 
Sigma Aldrich) into an appropriate volume of PBS-CaCl2 (according to the volume of 
samples) to obtain a final concentration of 0.1% BSA in PBS-CaCl2. Bentonite (Sigma 
Aldrich) was freshly prepared daily by rinsing three times with 1mL saline (10mg/mL 
NaCl) for every 10mg of bentonite (centrifuge at 2,500rpm, 20 minutes, 4oC). Bentonite 
was used at a concentration of 1mg for every 100µl plasma.  
 
2.8.2 Human complement 
SBAs were performed using human complement because baby rabbit complement 
(BRC) was found to be too toxic for S. Typhi; the natural killing rate of S. Typhi with 
BRC was >80%. For these purposes, blood was collected in silica-bead-colleting-tubes 
(not EDTA) as S. Typhi was found to be susceptible to EDTA. Blood donated from a 
volunteer whose plasma was demonstrated to be negative for Vi, anti-toxoid, and anti-
YncE antibody) was centrifuged at 4,000rpm for 10 minutes. The raw complement 
containing plasma was aliquoted into smaller volumes and stored at -80oC.  
 
Plasma containing complement still carries several elements (lysozymes) which are able 
to kill or inhibit the survival of bacteria. Therefore, the raw complement containing 
plasma was treated with bentonite in order to minimize any components that may be 
harmful to bacteria. Accordingly, a certain volume of raw complement containing 
plasma was mixed with a corresponding amount of rinsed bentonite and incubated at 
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37oC for 10 minutes on the day of use. The mixture was centrifuged at 2,500rpm at 
20oC for 10 minutes. The bentonite-treated-complement containing plasma 
(supernatant) was distributed into two equal volumes. The first was kept on ice and used 
as active complement. The second was inactivated at 56oC for 30 minutes and used as 
in-active complement.  
 
2.8.3 Bacterial preparation 
Bacteria (S. Typhi AS252/S. Paratyphi A 01TY546) in early log phase were used for the 
SBA experiment. Bacterial growth was initiated with a beginning suspension of 0.05 
OD600 and horizontally agitated at ~180rpm at 37oC until an OD600 of 0.1. The bacterial 
solution was diluted in LB broth to obtain a concentration of approximately 1.2 x 106 
CFU/mL (ranged 1-2 x106 CFU/mL).  
 
2.8.4 Toxicity testing 
Treated complement (or plasma samples after inactivation at 56oC for 30 minutes) was 
examining its toxicity for S. Typhi (wildtype parent strain, pool of transposon mutant 
library and single gene knocked out mutant strain) and S. Paratyphi A (wildtype parent 
strain, single gene knocked out mutant strain) where appropriate. The procedure for the 
toxicity testing was as described for full SBA assay (section 2.8.5) but including only 
treated complement (or treated plasma), diluting buffer and S. Typhi/S. Paratyphi A. A 
control assay was also performed with in-activated treated complement. An acceptable 
killing rate was deemed to be <30% in comparison to the control. 
 
72 
 
2.8.5 Serum (plasma) bactericidal assays (SBA) performance 
All tested clinical plasma samples (or immunized mice plasma samples) were heated at 
56oC for 30 minutes before being subjected to SBAs to inactivate the complement 
components in the plasma. The dilution of plasma samples will be specified where 
appropriate. SBAs were performed in a 96-well plate (Thermo Scientific; individual 
SBA was prepared in a single well consisting of 18.5µl SBA diluting buffer, 12.5µl 
diluted plasma samples, 6.5µl active complement and 12.5µl diluted bacteria 
suspension. Parallel SBAs were performed using the same procedure but with in-active 
complement. Further, each SBA was performed in triplicate in three individual wells. 
The initial number of bacteria challenged in the assay was monitored by plating 7µl of 
the mixture onto LB plates, which were incubated at 37oC overnight. Colonies were 
enumerated (X) and calculated back to the total numbers of a whole well as 50X/7. The 
remaining volume of the mixture was incubated at 37oC and gently agitated for 90 
minutes. The numbers of bacteria were again enumerated (Y) by plating 7µl of the 
mixture on LB plates, which were incubated at 37oC overnight. The total number of 
colonies was calculated by Z=43Y/7. There were ZA and ZI which represent the number 
of bacteria after 90 minutes being challenged in a well, with Active or In-active 
complement, respectively. Therefore, for a specific plasma sample, the killing rate was 
calculated as 1-(ZA/ZI). The killing rate could be calculated on the average number or 
the total number of the triplicate.  
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2.8.6 Bactericidal assays specific for Chapter 6 
2.8.6.1 Bactericidal assays on Salmonella Typhi transposon mutant library 
The S. Typhi transposon mutant library consisted of approximately 5x105 individual 
colonies. Therefore, the number of unique insertion sites across the whole S. Typhi 
genome was predicted to be 2x105, (2/5 the obtained mutant colonies), which was 
approximately twice as high as the rate of unique insertion sites over the number of the 
mutant library obtained from previous transposon mutant library of the S. Typhi Ty2-
derived CVD908-htrA (2x105 unique insertion sites over 10x105 mutant colonies) 343. 
To challenge every mutant (carrying unique insertion site) at least 10 times, 2x106 
bacteria of the library required to be screened. The final bacterial concentration in SBA 
was approximately 1.5x104 CFU/reaction of 50µl (3x105 CFU/mL), which was 1:4 
diluted from the bacterial concentration prior SBA (see section 2.8.3 and 2.8.5). 
Consequently, to challenge every mutant at least 10 times, 133 reactions needed to be 
performed (133x1.5x104 ~ 2x106). However, as the SBAs were performed in 96-well 
plates, I performed the challenge assay on two complete 96-well plates, which resulted 
in every mutant (carrying unique insertion site) being challenged approximately 14 
times.  
 
Every plasma pool (see section 2.8.6.1.2) collected from each of the four time points 
post admission was subjected to the SBA using the S. Typhi transposon mutant library 
on two full 96-well plates (2 plates x 4 time points ~8plates). The experiment was 
performed in parallel with control experiments where the same pool of plasma was 
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assayed on wildtype parent strain of the transposon mutant library (10 wells for every 
pool of plasma).  
 
2.8.6.1.1 Harvesting colonies recovered from bactericidal assays 
The recovered colonies from the bactericidal assays using the transposon mutant library 
(individually for each time point) were scraped using sterile glass slides and suspended 
in PBS in a 50mL tube. The suspended bacteria were subjected to extraction of total 
genomic DNA (Wizard Kit, Promega). Purified nucleic acid was stored at -20oC until 
being sent to be Wellcome Sanger Institute (Hinxton, Cambridge, UK) for sequencing 
using their Transposon Directed-Insertion Site Sequencing (TraDIS) protocol. The 
original transposon mutant library was TraDIS simultaneously.  
 
2.8.6.1.2 Titrating the plasma samples for bactericidal assays 
A plasma pool (at every time point) used to challenge S. Typhi transposon mutant 
library was required to be diluted to the optimum concentration to kill/inhibit the 
growth of S. Typhi wildtype parent strain during the bactericidal assay. Accordingly, 
plasma samples from six patients that had been pre-tested for their bactericidal activity 
to S. Typhi wildtype parent strain were diluted with PBS to obtain dilutions as listed in 
Table 2.5.  
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Table 2.5 Working dilutions of plasma prior to SBA challenging the S. Typhi 
transposon mutant library  
Patient ID Dilution       
 Day 1 Day 8 Month 1  Month 3 
01TY305 1:50 1:25 1:25 1:25 
01TY311 1:100 1:25 1:25 1:50 
01TY447 1:50 1:75 1:50 1:25 
01TY473 1:25 1:37.5 1:12.5 1:37.5 
01TY405 1:25 1:50 1:25 1:25 
01TY410 1:37.5 1:37.5 1:37.5 1:25 
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2.8.6.2 Bactericidal assays on Salmonella Typhi and Salmonella Paratyphi A 
mutants 
Thirteen S. Typhi antigens including six antigens were recognised by both the protein 
array and TraDIS (STY1372, STY1498_hylE, STY1612, STY1767_nlpc, STY3208, 
STY4190_yhjJ,) and other seven antigens (STY0452, STY0796, STY1086, STY1522, 
STY1703, STY1886, STY4539) were purified following the procedure as described in 
section 2.4. These thirteen proteins (and STY1479_yncE, the Vi polysaccharide and 
PBS) were used to immunised female C57BL/6 mice (3 for each antigen). Mice were 
immunised subcutaneously at a dose of 100µg per mouse per antigen and adjuvanted 
with labile toxin. Mice were boosted on day 7 and day 21 with the same dose and killed 
by cardiac puncture under terminal anaesthesia on day 28. Blood was drained using a 
ventricular bleed immediately and separated into cells and plasma by centrifugation at 
16g for 5 minutes.     
 
Individual pairs of S. Typhi AS252/S. Paratyphi A 01TY546 wildtype (WT) and the 
specific isogenic descendant mutant (dMT) were challenged by bactericidal assay 
(following the same procedure as described in section 2.8.5) using plasma extracted 
from mice that had been immunized with the specific antigen. All fifteen plasma 
samples from the immunised mice were used to challenge S. Typhi, while only four 
plasma samples (STY0796, STY1086, STY1372, and STY1498) were used to challenge 
S. Paratyphi A. The dilution of immunised mice plasma was 1:12.5. Control bactericidal 
assays were performed with plasma from unimmunized mice. The rate of bacterial 
killing calculated as described in section 2.8.5; the presented killing rates were 
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magnitudes of the killing rate of antigen-immunised mice plasma (WT strain and an 
isogenic dMT strain individually) subtracted by killing rate of the control mice plasma 
(WT strain and an isogenic dMT strain individually). 
 
The immunization of mice was performed by Dr Simon Clare at Wellcome Sanger 
Institute, Cambridge, UK. Protein STY1479_yncE was provided by Professor Edward 
T. Ryan, Harvard University, USA. Vi polysaccharide was provided by Novartis 
Vaccines for Global Health. 
 
2.8.7 Bactericidal assay for Chapter 7 
Plasma bactericidal assays (SBA) in Chapter 7 were performed using S. Typhi AS252. I 
used a collection of plasma samples collected from 4 patients with culture confirmed 
acute typhoid fever on day 8 after admission, from 3 culture confirmed S. Typhi 
carriers, and from 4 cholecystectomy controls. Additionally, plasma collected from 5 
samples from the plasma bank that were indicative of typhoid carriage and 7 samples 
from the plasma bank that had a profile not associated with carriage were also assayed. 
Bactericidal activity to S. Typhi of any plasma sample was examining via 2-fold serial 
dilutions starting from 1:100 (to 1:12,800) of plasma. 
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2.9 Direct homologous recombination for Chapter 6 
2.9.1 Primer design 
Primers for bacterial mutagenesis were designed using Artemis (The Wellcome Trust 
Sanger Institute, UK), for site-specific recombination. The designed primers targeted 
the candidate loci and were 40-50bp in length with a GC content of 40-50%. Eighteen 
pairs of primers were constructed for site-specific mutagenesis. Forward primers were 
tagged with ’TGTGTAGGCTGGAGCTGCTTCG’ and reverse primers were tagged 
with ‘CATATGAATATCCTCCTTA’. These 19- to 22- nucleotide extensions are 
homologous to regions adjacent to the antimicrobial resistance gene in the pKD4 
plasmid for site-specific mutagenesis. Further, primers were also designed to check 
successful homologous recombination. The designed primer sets were synthesised by 
Sigma and are shown in Table 2.6.  
 
79 
 
Table 2.6 Primer design for gene knock-outs in Salmonella Typhi and Salmonella Paratyphi A 
Primer ID Sequence String Position Length GC% 
STY0452-F acgctccgccagaacgtttattgattaacaggctgaatatcatggatgcgTGTGTAGGCTGGAGCTGCTTCG 460891..460940 50 46 
STY0452-R actaccattacgctatcggaccacgaaggaaatgatcgacatgacaagacgCATATGAATATCCTCCTTA complement 461437..461487 51 47 
STY0452-R-check gaaacaaaatgggcaatgcatacggcgtcctgaccagatgatttagg complement 461573..461619 46 47 
STY0796-F tgagcagtaacttcagacatcacctgttgagtctgtcgttactggttggcTGTGTAGGCTGGAGCTGCTTCG 792520..792569 50 48 
STY0796-R aatatcccgtggcaacggcggcatatattactgatttcagatttgagcgcCATATGAATATCCTCCTTA complement 793396..793445 50 46 
STY0796-R-check tgagtttgatgttaaattagtgggtcgtgcaggattcgaacctgcgacc complement 793516..793564 49 47 
SPA1993_STY0796-F tgagcagtaacttcagacatcacctgttgagtctgtcgttactggttggcTGTGTAGGCTGGAGCTGCTTCG complement 2067828..2067877     50 48 
SPA1993_STY0796-R aatatcccgtggcaacggcggcatatattactgatttcagatttgagcgcCATATGAATATCCTCCTTA 2066952..2067001     50 46 
SPA1993_STY0796-Fcheck gcggcttacgctaagaaccgtcgcgctgtactggtttactaagagaattg complement 2067880..2067929     50 50 
STY1086-F ataaaagctattatcagctcccgatagcgcaaagcggtgtgcaaagcaccTGTGTAGGCTGGAGCTGCTTCG 1065926..1065975 50 48 
STY1086-R tggatcgcccgtcaatgcgcaaaattcacaccaatgtcatatttgtgagcCATATGAATATCCTCCTTA complement 1066544..1066593 50 46 
STY1086-R-check ctcgtttttgtctcctcatgcctcgtttccctcatatttgtatctggtgg complement 1066648..1066697 50 46 
SPA1019_STY1086-F ataaaagctattatcagctcccgatagcgcaaagcggtgtgcaaagcaccTGTGTAGGCTGGAGCTGCTTCG complement 1836571..1836620     50 48 
SPA1019_STY1086-R cttttatctcagggaaggcgctttatctcatctgcgatagcggctgcttcCATATGAATATCCTCCTTA 1836113..1836162     50 50 
SPA1019_STY1086-Fcheck gaaaaaatggctagtcgtgataatggcgttctggctggcgtcatgtagctcc complement 1836631..1836682     52  50 
STY1372-F ggccatcccgttaaccatttttgtgttgtttgtgttaccgatttggctgtggTGTGTAGGCTGGAGCTGCTTCG 1328119..1328170  52 46 
STY1372-R tctctccagttcggatgctctgcatcaagaatatcttccagcgcctgaatgcCATATGAATATCCTCCTTA complement 1328268..1328319 52 50 
STY1372-R-check ggtaaaaaacgccagcccaaagaaaatcgacagcacgaccagaatacg complement 1328437..1328484 48 47 
SPA1195_STY1372-F ggccatcccgttaaccatttttgtgttgtttgtgttaccgatttggctgtggTGTGTAGGCTGGAGCTGCTTCG 1328119..1328170  52 46 
SPA1195_STY1372-R tctctccagttcggatgctctgcatcaagaatatcttccagcgcctgaatgcCATATGAATATCCTCCTTA complement 1328268..1328319 52 50 
SPA1195_STY1372-R-check ggtaaaaaacgccagcccaaagaaaatcgacagcacgaccagaatacg complement 1328437..1328484 48 47 
STY1498-F atgtatcagacgtcaggaacctcgaaaagcgtcttcttaccgtgtctttgttggTGTGTAGGCTGGAGCTGCTTCG                                         1455050..1455103  54  46.3 
STY1498-R aatatttgcagaacaaactgtagaggtagttaaaagcgcgatcgaaaccgcagatggCATATGAATATCCTCCTTA.     complement              1455902..1455958 57 42.1 
STY1498-Rcheck ctcaaactgttgatcaggtatcgaaatttgtgcccggtaccg complement.             1456312..1456353   42  47.7 
SPA1306_STY1498-F aaaagagttaagccgttttaaacaggagtactcgcaggaagcttctTGTGTAGGCTGGAGCTGCTTCG complement 1381576..1381620   45 42.22 
SPA1306_STY1498-R tattcattacaggtgttaatcattttctttgcagctccttttagtaCATATGAATATCCTCCTTA 1381338..1381383 46 30.43 
SPA1306_STY1498-Rcheck actttcgatcaaatcatccagaaagcaaaagccgggtgcccggtat   1381073..1381118 46 47.83 
STY1522-F gaccaggttttatagttgatatcattgtagccgcgcaccatcatctcaccTGTGTAGGCTGGAGCTGCTTCG 1478652..1478701 50 46 
STY1522-R tttcatgggcgtacgctggaatatatgcaggatttaccctcatggttaacCATATGAATATCCTCCTTA complement 1479522..1479571 50 44 
STY1522-R-check tggtcacacggataacgcgtttcatgttagttcgctgtgtttaactctcc complement 1479806..1479855 50 46 
STY1612-Fe ttgaattctggacggtagtgagttttctgctcaccttcatggggtttgtggTGTGTAGGCTGGAGCTGCTTCG 1549221..1549271 51 47 
STY1612-Re acttccagtttgttataaagcgcgtccagtttggcctcaatgactgtctggCATATGAATATCCTCCTTA complement 1549450..1549500 51 47 
STY1612-R-check tctccagatcaaccattttacggtcagccagataatccagttcg complement 1549686..1549729 44 45 
STY1703-F atctccagggaaattatataccccatatgcagcaactgagactccagcTGTGTAGGCTGGAGCTGCTTCG 1629028..1629075   48 46 
STY1703-R aacgtatggactttgaacaactcatgcaccaggcattacccattggtgCATATGAATATCCTCCTTA complement 1629254..1629301 48 46 
STY1703-R-check tggataagaaacaacaaatggccggactattcactcaggcgcagagc complement 1629502..1629548 47 48 
STY1767-F ccagtcactacggacggaaacagacgtaacttcagatactaattgaagcgTGTGTAGGCTGGAGCTGCTTCG 1689925..1689974  50 46 
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STY1767-R catgcgtttttggcttcttgttatcacagcattgttcctggcaggatgcCATATGAATATCCTCCTTA complement 1690620..1690668 49 47 
STY1767-R-check tttatgtcaggcaggaattgcgattgtgatgagtagccacgatctgaacc complement 1690911..1690960 50 46 
STY1886-F ctgcgctaatatcagtgactacaaagttatgacctggaatcttcagggctcttcagcTGTGTAGGCTGGAGCTGCTTCG 1785447..1785503 57 45 
STY1886-R ttcgtgccaaaaaggctacgggataatgatcagaagcgagttgtggattacgCATATGAATATCCTCCTTA complement 1786138..1786189 52 46 
STY1886-R-check tgatacaggtagtcatgaatgattgccgctttggcatattcaccatccgg complement 1786444..1786493 50 46 
STY3208-F atttcagtgaatcgacggcaatattaaatgacggaccaacaacccattcggTGTGTAGGCTGGAGCTGCTTCG 3073414..3073464 52 43 
STY3208-R tgcaatggcagctaacggagaaaataatcccagtaatctattaggtgcaccCATATGAATATCCTCCTTA complement 3074103..3074153 51 43 
STY3208-R-check tgttctgctcctgcgtaccgattagcgactaccagtaatttactgattcg complement 3074647..3074696 50 46 
STY4190-F attaccaggattgttgatcaggggttcacatgcagggcacaaaaattcgTGTGTAGGCTGGAGCTGCTTCG 4053338..4053386 49 44 
STY4190-R gaaccatgatttcatcccacgtcgcctttaacgccttcatattaaattccggCATATGAATATCCTCCTTA complement 4054732..4054783 52 44 
STY4190-R-check ttccggcagtaaaactgccgaaagagaaagtgatagacaccactg complement 4055057..4055101 45 47 
STY4539-F tcaaccagctcatcgatattactatgccagggcaactggttaactcagtcTGTGTAGGCTGGAGCTGCTTCG 4408732..4408781 50 46 
STY4539-R ccgtctcaaagttgcctttaaataccaacggtgcgtcaatgcggtaatccCATATGAATATCCTCCTTA reverse 
complement 
4409600..4409649 50 48 
STY4539-Fcheck ttacggtcatccacgggatttttcatgaacacacaagcgcttttctgcct   4408494..4408543 50 46 
STY4294-F (ompR-F) ttataagattctggtggttgatgacgatatgcgtctgcgggcgctactggTGTGTAGGCTGGAGCTGCTTCG 4170277..4170326 50 50 
STY4294-R (ompR-R) gtcaacctcttcacccttcgccgtgaccataatgatcggcattggattacCATATGAATATCCTCCTTA complement 4170486..4170535 50 51 
STY4294-Fcheck (ompR-
Fcheck) 
ttgcgcacacggggtataacgtgatcgtcccgacagaataaataatgggg   4170068..4170117 50 50 
 
STY and SPA are prefix of a CDS on the S. Typhi genome CT18 and S. Paratyphi A genome ATCC9150, respectively 
F: Forward primer 
R: Reverse primer 
F-check: Checking primer on the same genome string as forward primer, using the same reverse primer of the selected locus 
R-check: Checking primer on the same genome string as reverse primer, using the same forward primer of the selected locus 
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2.9.2 Amplification of the pKD4 KanR gene cassette  
Amplification of a 1,749 bp length KanR gene cassette in pkD4 was performed in ten 
reactions. A stock of 200µl PCR reaction mixture containing 20µl 10X buffer, 4µl 
dNTPs (10mM), 0.8µl Primer (forward and reverse primers shown in Table 2.6, 10nM), 
5µl of Pfu polymerase (Aligent, US) and 1µl of purified DNA plasmid pKD4 was 
generated. The thermal cycling conditions were: denaturation at 95°C for 90 seconds 
followed by 30 cycles of denaturation at 95°C for 30 seconds, annealing at 55°C for 20 
seconds and elongation at 72°C for 2 minutes. A 10-minute elongation was added after 
the final cycle. PCR amplicons were visualised using Ultraviolet (UV) transilluminator 
(Bio-Rad) with the Quantity One (Bio-Rad) imagining software on 1% agarose gel 
(Bio-Rad) after staining with 1% Nancy (Sigma). PCR amplicons were purified using 
Quick-Start PCR purification kit (Qiagen) for electrotransformation.   
 
2.9.3 Homologous recombination (site-specific mutagenesis) 
Homologous recombination was performed using S. Typhi strain AS252 (or S. 
Paratyphi A 01TY546), which was firstly transformed with plasmid psim18. Competent 
cell preparation and electrotransformation were performed as described in sections 2.7.1 
and 2.7.2.6, respectively. However, the selection for psim18 plasmid was hygromycin 
and the psim18-electrotransformed S. Typhi cells were recovered and incubated at 30oC 
until being harvested (psim18 plasmid is maintained at 30oC). Psim18 plasmid carries 
an operon encoding recombinase (induced at 42oC) which facilitates recombination. 
Therefore, S. Typhi (or S. Paratyphi A) carrying psim18 could accept purified PCR 
amplicons (section 2.9.1.2) for recombineering (the pKD4 KanR gene cassette).  
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Competent cell preparations of S. Typhi (or S. Paratyphi A) carrying psim18 were 
handled as described in section 2.7.1 with the additional step of recombinase induction. 
Accordingly, when the bacterial growth was in early exponential phase (OD at 600nm 
~0.3 - 0.4) the recombinase was induced by incubation at 42oC in a water bath for 15 
minutes before being transferred onto ice and ready for subsequent washes. S. Typhi (or 
S. Paratyphi A) carrying psim18 was electrotransformed with a piece of nucleotide 
sequence generated from section 2.9.1.2 using the same procedure as described in 
section 2.7.2.6.   
 
2.9.4 Examination the successful recombination 
Site-specific mutants were examined by colony PCR. The amplification conditions were 
as described in section 2.7.2.2, except template material was bacteria scraped directly 
from the mutant colonies. To verify the newly recombineering sequences at the target 
locus, the sequences flanking the target locus (at the 5’ end or 3’ end) were sequenced. 
The flanking sequence of the pkD4 KanR cassette was amplified using specific primers 
(Table 2.6) and the amplification condition as described in section 2.7.2.2. PCR 
amplicons were purified using Quick-Start PCR purification kit (Qiagen) and Sanger 
sequenced. Each 10µl of the amplification reaction contained 1µl of purified amplicon, 
2µl of 10X buffer (Applied Biosystems, California, US), 1µl of Bigdye (Applied 
Biosystems), 0.3µl of either forward primer with paired reverse checking primer (or 
forward checking primer paired with reverse primer) (Table 2.6) and 5.7 µl of water. 
PCR reactions were cycled at 95°C for 2 minutes followed by 30 cycles of 95°C for 10 
83 
 
seconds, 55°C for 5 seconds and 60°C for 4 minutes. Ten minutes at 72°C was added at 
the end. The whole volume of amplified products was precipitated on ice with 1µl of 
3M Sodium Acetate (NaOAc) (Sigma), 1µl of Ethylenediaminetetraacetic acid (EDTA) 
(Prolabo, Pennsylvania, US) and 35µl of 100% ethanol (Merck). The mixture was 
vortexed and centrifuged at 4°C at 14,000rpm for 15 minutes, and supernatant was 
discarded. The pellet was washed twice with 500µl of 70% ethanol by centrifugation 
and the supernatant was discarded. Samples were air-dried, removed from ice and re-
suspended with 10µl of Hidi (Applied Biosystems). The sequences were analysed using 
an Applied Biosystems genetic analyser, sequences were aligned in Artemis against the 
S. Typhi CT18 (or S. Paratyphi A ATCC9150) genome and the pKD4 plasmid sequence 
to confirm homologous recombination. 
 
2.10 Cytokine measurement 
A collection of plasma samples including 10 from S. Typhi carriers, 17 from age-
matched cholecystectomy controls, 89 from aged-matched S. Typhi acute enteric fever 
(Day 8 after admission) were submitted to measure eight pro-inflammatory cytokines 
(IL-1, IL-2, IL-5, IL-6, IL-12, IL-13, TNF-alpha and Interferon (IFN)-gamma) and two 
anti-inflammatory cytokines (IL-4 and IL-10) using Precision Pro (Bio-plex). The 
performance followed the recommendations of the manufacture. Briefly, a pre-wet filter 
plate was loaded with diluted beads (50µl per well) and washed twice with wash buffer 
(100µl per well) using a washing station. Prepared (diluted) standards and samples were 
added into separate wells (50µl per well). The plate was wrapped, agitated at 1,100rpm 
for 30 seconds then maintained at 300rpm for 30 minutes in the dark, then washed 3 
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times with wash buffer. Prepared detection antibody was added (25µl per well). The 
plate was sealed and agitated at 300rpm for 30 minutes in the dark. Ready Streptavidin-
PE (50µl per well) was added and the plate was sealed, incubated and washed as 
previous steps. Cytokine bound beads were diluted in assay buffer (150µl per well). The 
plate was sealed again and rigorously mixed at 1,100 rpm for 30 seconds, unsealed and 
read immediately on the Bio-plex system.   
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2.11 Data analysis 
All analysis were performed using R software (version 3.3.1; R Foundation for 
Statistical Computing) 344. All confidence intervals (CIs) are reported 2-sided at the 
95% intervals; all significance testing was performed 2-sided with a significance level 
of r value ≤0.05. 
 
2.11.1 Data analysis for Chapter 4  
A geometric mean optical density was calculated to summarize the IgM response to the 
S. Typhi antigens in each arm of validation group including the negative reference 
population samples (afebrile controls and other confirmed febrile infections) and the 
positive reference population (febrile patients with confirmed S. Typhi). The Wilcoxon 
signed-rank test was used to test the null hypothesis; no difference in optical densities 
between the patient groups. Spearman’s rho was used to investigate potential 
correlations between IgM antibody responses against the various antigens. Receiver 
operating characteristic (ROC) curves were used to determine the optimal cut-off and 
the specificity and sensitivity of the various antigens. A performance estimation of more 
than one antigen combination was evaluated using Support Vector Machine (SVM). 
SVM is a supervised learning model that analyses data for classification and regression 
analysis using a training and testing data set. All analyses were performed with R 
software (version 3.3.1; R Foundation for Statistical Computing). All confidence 
intervals (CIs) are reported 2-sided at the 95% intervals; all other significant tests were 
performed 2-sided with a significance level of r value <0.05. 
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The SVM was performed with assistance from Mr. Tran Tuan Anh (Enteric Infections 
Group, OUCRU, Vietnam) in order to identify combinations of antigens that could 
diagnose acute typhoid fever.   
 
2.11.2 Data analysis for Chapter 5  
A geometric mean of EU was calculated to summarize the antibody responses (IgM and 
IgG) where appropriate against typhoid toxin, Vi and O2 antigen in patient group, the 
community controls, and the plasma bank. The Wilcoxon signed-rank test and 
Wilcoxon matched-pairs signed-rank test were used to test the null hypothesis that there 
was no difference in EU between groups and between time points, respectively. The 
classification of enteric fever cases from unidentified febrile patients was evaluated 
using SVM.  
 
For assessing diagnostic classification, the acute antibody profile of anti-toxin IgM 
alone or combined with anti-Vi IgM and anti-O2 IgM from patients with a confirmed S. 
Typhi or S. Paratyphi A infection was used as positive control; the same profile from 
febrile patients with an unknown pathogen was used as the negative control. Significant 
diagnostic associations were calculated by Castro and Azevedo 345 approach where the 
entire longitudinal antibody profile, individually, was discretized into breaks 346. The 
significant dynamic patterns were then statistically calculated using a hidden Markov 
model and binomial distribution (insignificant patterns were not used for later 
calculation). Sero-conversion was considered when a significant pattern showed 
antibody titre of any later time points elevated at least one break in comparison to the 
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baseline antibody titre. A mixed effect model was utilized for longitudinal typhoid toxin 
IgG profile 347,348. K-mean clustering was employed for the association between  anti-
toxin IgG versus anti-Vi IgG and anti-toxin IgG versus anti-O2 IgG 349,350.  
 
The mixed effect model and K-mean clustering were performed with assistance from 
Mr. Tran Tuan Anh. 
 
2.11.3 Data analysis for Chapter 6  
2.11.3.1 TraDIS library analysis 
Approximately 2 million reads per sample were generated. Illumina FASTQ files 
containing 50 base pairs reads were parsed for 100% identity to the transposon. The 
tags were stripped from the resulting reads and mapped back onto S. Typhi CT18 (Acc. 
No. AL513382_ using SMALT-0.7.2) and the precise insertion site of the transposon 
was determined as described previously 343,351,352. Briefly, for each gene (CDS) the 
insertion index, the number of insertions in each gene divided by the total gene length, 
was calculated by excluding 10% of the 3’ end of gene, which could be functional 
despite having an insertion. To determine the genes required for serum sensitivity, the 
input transposon library was compared to the serum challenged library (output) and 
significant differences in insertion counts were expressed as Log2Fold-Change 352 and r 
values were corrected for multiple testing using the Benjamini-Hochberg method. Only 
genes (CDSs) with a r value (Q value) of <0.1 (a hypothetical 10% false discovery rate 
[FDR]) and an absolute log fold change (logFC) of >2 were considered significant. 
However, for a higher specificity, I only selected genes (CDSs) with a r value <10-5. 
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The candidate gene collections were classified according to functional classes based on 
the Sanger Institute classification system (http://www.sanger.ac.uk) 98 (Table 2.7). 
Additionally the gene collections were also categorised into various biological 
pathways using the KEGG pathways 417. 
 
The primary analysis on the sequencing data to define the collection of genes that have 
logFC>2 and with a r value <0.05 was performed by Dr Christine Boinett (Enteric 
Infections Group, OUCRU, Vietnam). 
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Table 2.7 Salmonella Typhi gene functional classification scheme 
1.A Degradation 1.D.4 Aromatic Amino Acid 1.G.9 Riboflavin 4.A.2 Transport Cations 
1.A.1 Degradation of carbohydrate 1.D.5 Histidine 1.H Fatty acid biosynthesis 4.A.3 Transport Carbohydrates, organic acids, alcohols 
1.A.2 Degradation of amino acids 1.D.6 Pyruvate Family 2 Broad regulatory function 4.A.5 Transport Anions 
1.B Energy metabolism 1.E Polyamine synthesis 3.A Macromolecule synthesis/modification 4.A.6 Transport Other 
1.B.1 Glycolysis 1.F Nucleotide biosynthesis 3.A.10 Polysaccharides - (cytoplasmic) 4.B Chaperones 
1.B.10 Glyoxylate Bypass 1.F.1 Purine ribonucleotide biosynthesis 3.A.11 Phospholipids 4.C Cell division 
1.B.2 Pyruvate dehydrogenase 1.F.2 Pyrimidine ribonucleic 3.A.2 Ribosomal proteins - synthesis, modification 4.D Chemotaxis and mobility 
1.B.3 Tricarboxylic acid cycle 1.F.3 2'-Deoxyribonucleotide metabolism 3.A.3 Ribosomes - maturation and modification 4.G Detoxification 
1.B.5.b Non-oxydative branch 1.F.4 Salvage of nucleosides and nucleotides 3.A.5 Amino acyl tRNA synthesis; tRNA modification 4.H Cell Killing 
1.B.6 Entner-Doudoroff pathway 1.F.5 Miscellaneous 3.A.7 DNA - replication, repair, restriction/modification 4.I Pathogenicity 
1.B.7.a Aerobic Respiration 1.G Biosynthesis of cofactors, carriers 3.A.8 Protein translation and modification 5.A IS element, Phage related 
1.B.7.b Anaerobic Respiration 1.G.1 Biotin 3.A.9 RNA synthesis, modification 5.B Colicin-related function 
1.B.7.c Electron Transport 1.G.10 Thioredoxin 3.B Macromolecule degradation 5.D Drug/Analogue sensitivity 
1.B.8 Fermentation 1.G.11 Menaquinone 3.B.1 Degradation of RNA 5.F Adaptions and atypical conditions 
1.B.9 ATP-proton motive force 1.G.12 Heme and porphyrin 3.B.2 Degradation of DNA 5.H Hypothetical protein 
1.C Central intermediary metabolism 1.G.13 Cobalamin 3.B.3 Degradation of proteins, peptides, glycoproteins 5.I Unknown 
1.C.2 Gluconeogenesis 1.G.14 Iron uptake and storage 3.B.4 Degradations of polysaccharides 
 
1.C.3 Sugar-nucleotide biosynthesis, conversions 1.G.2 Folic Acid 3.C Cell envelope 
 
1.C.4 Amino sugars 1.G.3 Lipoate 3.C.1 Membranes lipoprotein 
 
1.C.5 Sulphur Metabolism 1.G.4 Molybdopterin 3.C.2 Surface polysaccharides & antigens 
 
1.D Amino Acid Biosynthesis 1.G.5 Pentothenate 3.C.3 Surface structure 
 
1.D.1 Glutamate Family 1.G.6 Pyridoxine 3.C.4 Murein sacculus, peptidoglycan 
 
1.D.2 Aspartate Family 1.G.7 Pyridine nucleotide 4.A Transport/binding proteins 
 
1.D.3 Serine Family 1.G.8 Thiamine 4.A.1 Transport amino acid and amines 
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2.11.3.2 Testing the difference in killing rates between the wild type parent strain 
and mutant descendant strain 
The null hypothesis was that there was no difference in killing rates between wild type 
parent strain and mutant descendant strain after being challenged with plasma from the 
antigen immunised animals. The null hypothesis was tested using Wilcoxon signed-rank 
test.  
 
2.11.3.3 Testing the difference in titres of antibody IgG against a certain antigen 
among assessing groups and among time points 
A geometric mean of EU was calculated to summarize the antibody IgG responses 
against S. Typhi antigens in patient groups and afebrile controls. The null hypothesis 
that there was no difference in EU between groups and between time points was tested 
using Wilcoxon signed-rank test and Wilcoxon matched-pairs signed-rank test, 
respectively. Correlation between each pair of anti-antigen antibody was calculated 
using Spearman’s rho Test. 
 
2.11.4 Data analysis for Chapter 7  
2.11.4.1 Testing for significant difference in cytokine and IgG concentration and 
the bactericidal capacity of plasma samples 
The null hypothesis that there was no difference in cytokine level (pg/ml), antibody IgG 
measurement (OD), or bactericidal capability (killing rate %) between groups was tested 
using Wilcoxon signed-rank test.  
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2.11.4.2 Principal component analysis (PCA) for cytokine measurement among 
patient groups 
Data generated from the measurements of pro-inflammatory (and anti-inflammatory) 
cytokines was visualised by a PCA plot. The whole set of data was produced from 10 
cytokine values of each individual from every group of patients. Therefore, the whole 
set of data was originally on 10 dimensions, which is impossible to manually analyse. 
PCA analysis reduces the number of data dimensions to 2 in order to simplify the way 
to interpret the data. PCA was performed using R software (version 3.3.1; R Foundation 
for Statistical Computing). 
 
2.11.4.3 Estimating the prevalence of Salmonella Typhi carriage in Kathmandu 
The IgG antibody against three antigens (YncE, toxoid, and Vi) generated from S. Typhi 
carriers and cholecystectomy controls were individually tested for a best fit model using 
Akaike Information Criterion estimator. The log-normal model was found to best fit the 
data. For each antigen, density for distribution was estimated to construct the log-
normal model. The estimated values of density corresponding to IgG antibody titre from 
the models were used to calculate global/combined odds of being S. Typhi carriers 
(pseudo likelihood of being S. Typhi carriers). The global odds were subsequently used 
to construct a ROC curve to assess the sensitivity and specificity for classification of S. 
Typhi carriers from cholecystectomy controls. The global odd thresholds of being a S. 
Typhi carrier, corresponding with different compromises of sensitivity and specificity, 
were used to estimate the prevalence of S. Typhi carriers in the anonymous individuals 
from the plasma bank of 20≤ aged ≤65 years. The obtained prevalence of S. Typhi 
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carrier was then extrapolated to estimate the total number of S. Typhi carriers in 
Kathmandu within the age group of 20≤ aged ≤65 years, taking proximal population 
figures from the 2011 government census (Table 2.8).  
 
The statistical estimation of S. Typhi carriage prevalence in Kathmandu was performed 
with assistance from Dr Thibaut Jombart (London School of Hygiene and Tropical 
Medicine). 
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Table 2.8 Kathmandu valley year 2011 government census 
Age group Number of people  Percent 
0-4         111,600  6.4 
5-9         137,162  7.9 
10-14         165,679  9.5 
15-19         202,174  11.6 
20-24         233,794  13.4 
25-29         202,417  11.6 
30-34         162,746  9.3 
35-39         134,021  7.7 
40-44         106,558  6.1 
45-49           78,678  4.5 
50-54           60,754  3.5 
55-59           43,354  2.5 
60-64           34,946  2 
65-69           25,950  1.5 
70-74           18,205  1 
75-79           13,220  0.8 
80-84             7,482  0.4 
85-89             3,660  0.2 
90-94             1,314  0.1 
95+                526  0 
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Chapter 3 The Control of Typhoid in Vietnam 
 
3.1 Introduction 
Typhoid fever, the disease caused by Salmonella enterica serovar Typhi (S. Typhi), 
is a diminishing public health problem in Vietnam 81. However, the disease remains 
an ongoing public health issue in other parts of South and Southeast Asia 353–355, and 
an enhanced understanding of disease estimates and the influence of antimicrobial 
resistance (AMR) on disease presentation are needed to better control this disease 
across the region. Furthermore, insights into the trends of typhoid and factors that 
directly impinge on disease incidence are important for allocating resources for 
reducing the burden of disease 356. Currently, Vietnam represents an exemplar Asian 
country that has all but eliminated this once common infection, and there is probably 
much to be learnt from the control of typhoid in Vietnam. However how reduction 
in typhoid was precisely achieved is unclear and providing a roadmap for typhoid 
reduction in similar settings is largely dependent on good historical quantitative 
data. 
 
3.2 Typhoid fever incidence in Vietnam 
Typhoid fever has likely been endemic in Vietnam for some time, although 
historical incidence data for this common cause of febrile disease from across 
Southeast Asia before the reunification of Vietnam in 1975 is scarce. Notified 
typhoid fever cases reported to the pre-reunification government of South Vietnam 
showed a generally increasing trend from 2.05 cases per 100,000 people annually in 
1957 to 10.02 cases per 100,000 people annually in 1966 (Figure 3.1) 357. Health 
care provisions, and water and sanitation infrastructure in South Vietnam during this 
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time period were generally poor, which likely contributed to the increasing rates of 
typhoid fever and other infectious diseases during this period, which were frequently 
observed in military personnel returning back to the United States 358. By contrast, a 
report suggests that the pre-reunification government in North Vietnam prioritized 
health care access and began mass vaccination campaigns against typhoid fever and 
other communicable diseases as early as 1954, although reliable incidence data from 
North Vietnam during this period are not available 359.  
 
The best and most accurate recent estimates of typhoid incidence in Vietnam were 
calculated during the International Vaccine Institute’s (IVI) Diseases of the Most 
Impoverished (DOMI) program, which was conducted between 1999 and 2003 360. 
The annual incidence of typhoid fever in Hue, in central Vietnam, in 2002-2004 was 
estimated to be 21.3/100,000 person years and 24.2/100,000 person years in children 
aged 5-15 in years (Figure 3.1). This programme went on to conduct various 
epidemiological investigations and vaccine studies the same location 361,362. In 
addition, the National Institute of Epidemiology (NIHE) in Hanoi conducted further 
nationwide surveillance around the same period of time as the DOMI study. The 
average number of typhoid cases in Vietnam across the country in all ages was 
estimated to be 11,696, corresponding with an average national incidence rate of 
14.7/100,000 population per year 363. During this period (1999 to 2003) two out of 
the 63 provinces of Vietnam (Soc Trang in the south and Dien Bien in the north) 
were estimated to have particularly high incidences (>100/100,000 population per 
year) (Figure 3.2A); a further 18 were estimated to have a medium incidence 
(>10<100/100,000 population per year). The propensity of the disease was 
understood to arise in children, with an estimated incidence of 36.6/100,000 
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population aged <15 years per year 363. Lastly, in 1998, Lin and others 87 estimated a 
population incidence of 198/100,000 population in Dong Thap province in the 
Mekong Delta, equating with a crude incidence of 930/100,00 people (Figure 3.1).  
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Figure 3.1 Historic crude estimates of typhoid fever incidence in Vietnam 
Histogram showing the estimated crude incidences (on a log scale) of typhoid fever in Vietnam from government records (GR) and subnational incidence 
estimates available from Ochiai et al. (aggregated estimated from 2002-2004 with 2003 as the midpoint from Hue province in people aged 5-18 years) and 
Lin et al. (aggregated estimated from 1997-2000 with 1998 as the midpoint from Dong Thap province) 41,360. 
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Figure 3.2 (A) Map of Vietnam showing estimated disease incidences and 
provinces implemented Vi immunization 
A) North orientated map of Vietnam showing the estimated incidence of typhoid fever in 
Vietnam from government data between 1999 and 2003. Provinces with high, medium, low 
incidence are highlighted by shading (see key). 
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Figure 3.2 (B) Map of Vietnam showing estimated disease incidences and provinces 
implemented Vi immunization  
B) North orientated map of Vietnam showing the 35 provinces in Vietnam in 2005 that were 
incorporated into the national typhoid Vi immunization campaign; blue shading (see key). 
Maps are reproduced from Cuong N. Typhoid Vaccine Used in Vietnam and its Impact. In: 
Consultation on Typhoid Vaccine Introduction and Typhoid Surveillance 363. 
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3.3 Typhoid trends in Ho Chi Minh City 
Routine blood culture data from the Hospital for Tropical Diseases (HTD) in Ho Chi 
Minh City (HCMC) in the south of Vietnam between 1994 and 2014 highlights a 
major reduction in the prevalence (and absolute number) of positive blood cultures 
for S. Typhi over time (Figure 3.3)81. HTD is a sentinel infectious disease hospital 
that serves as a primary and secondary facility for the surrounding local population 
in HCMC and a tertiary referral centre for 17 provinces in the south of the country, 
and, therefore, has catchment population of approximately 40 million people. The 
highest rates of positive blood cultures for S. Typhi at HTD were recorded in 1995 
and 1998, when the proportion of positive blood cultures for S. Typhi was 14.5% 
and 12.8% (of all blood cultures taken), respectively. In the late 1990s this figure 
began to show an annual decline; 5% S. Typhi blood culture positivity rate of all 
blood cultures taken in 1999. After the turn of the millennium the number of culture 
positive cases of typhoid fever at HTD continued to decrease annually, with the 
prevalence of S. Typhi-positive blood cultures not rising higher than 1 per cent from 
2005 onwards. Therefore, in the absence of contemporary (and accurate incidence) 
data, if we extrapolate these trends we can surmise that presently the incidence of 
enteric fever in Vietnam is probably exceptionally low (<10/100,000 population per 
year), and there has been a remarkable and sustained decline in the prevalence of S. 
Typhi-positive blood cultures in HTD and other health care facilities across the 
country.  
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Figure 3.3 The decline in Salmonella Typhi positive blood cultures in a sentinel infectious disease hospital in Ho Chi Minh City 
Plot showing the proportion of total blood cultures taken from which Salmonella Typhi was isolated between 1993 and 2015 at the Hospital for Tropical 
Diseases in Ho Chi Minh City, with a LOESS curve. The total number of blood cultures taken and the number from which Salmonella Typhi were isolated are 
shown at the base of the figure.    
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In a pattern similar to those observed in parts of sub-Saharan Africa (but not in the 
same magnitude), there has been a replacement of “classical” community-acquired 
pathogens in bloodstream infections (such as S. Typhi) with those more commonly 
associated with HIV infection and the current international epidemic of AMR 
bacteria 364. Specifically, assorted fungal pathogens, multi-drug resistant (MDR) 
non-Salmonella Gram-negative bacteria, and non-typhoidal Salmonella (NTS) now 
dominate the bloodstream infection landscape in Vietnam 81,365,366. Paratyphoid 
fever, which is associated with the various pathovars of Salmonella Paratyphi (S. 
Paratyphi A, B, and C), has been reported to be increasing in prevalence in parts of 
Asia 367. This surge is specifically associated with S. Paratyphi A; however, the 
isolation of this organism is rare in Vietnam (and across Southeast Asia) and is 
generally limited to extended sporadic outbreaks, as recently observed in 
neighbouring Cambodia 368. A study conducted at HTD cultured less than 7 S. 
Paratyphi A isolates per year between 1998 and 2008, this subsequently declined to 
zero from 2008 81. However, in 1990, Global Burden of Disease estimated incidence 
of paratyphoid to be 81/100,000 population; this was estimated to be 40/100,000 in 
2016 70.  
  
3.4 Antimicrobial susceptibility 
Traditionally, Vietnam has been a global hotspot for MDR S. Typhi, which is 
defined as resistance against the first-line antimicrobials, ampicillin, 
chloramphenicol, and trimethoprim-sulphamethoxazole 369. These latter days, first-
line regimes were commonly prescribed in the community and in health care 
settings for the treatment of typhoid fever, and many non-specific febrile diseases, in 
Vietnam in the 1980s and early 1990s. The first notable spike of MDR S. Typhi in 
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Vietnam arose in the early 1990’s, correlating with a major peak in S. Typhi-
positive blood cultures at HTD in HCMC 370. This MDR phenotype in S. Typhi was 
associated with an incH1 plasmid backbone 103, which has been consistently 
identified within S. Typhi isolated in Vietnam and coupled with organisms 
belonging to a specific phylogenetic group known as haplotype 58 (H58) 371, now 
designated genotype 4.3.1 372. These organisms, with this same MDR phenotype, 
were described as still circulating in high numbers in the Mekong Delta region, 
some 150 km away from HCMC, in 2004 and 2005 373.  
 
Salmonella enterica serovar Typhi belonging to genotype 4.3.1 are also commonly 
associated with a mutation (S83F) in the DNA gyrase gene gyrA, catalysing 
resistance against nalidixic acid and reduced susceptibility against the second-
generation fluoroquinolones, ciprofloxacin, and ofloxacin 374,375. Variants with this 
specific gyrA mutation began to emerge in Vietnam in the early 1990s 376, shortly 
after the introduction of quinolones for the treatment of non-specific febrile diseases 
when the first-line treatments became less effective at inducing defervescence. The 
secondary peak in S. Typhi cases in routine blood culture data from HTD was 
associated with the emergence of organisms exhibiting resistance against nalidixic 
acid and reduced susceptibility against fluoroquinolones 81,377. These organisms, 
specifically genotype 4.3.1 S. Typhi with an S83F mutation in gyrA, have since 
become the most prevalent variant in Vietnam 373, reflecting the pattern of the 
molecular epidemiology of S. Typhi across much of Asia 375. Current information 
regarding the AMR profiles of the extant S. Typhi population in Vietnam are 
limited, but our unpublished data suggests that MDR strains have all but 
disappeared in the southern part of the country and S. Typhi with an S83F and 
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reduced susceptibility to fluoroquinolones continue to circulate. Notably, despite the 
sustained use and availability of fluoroquinolones in Vietnam for various bacterial 
infections there has not yet been the emergence of S. Typhi exhibiting resistance 
against ciprofloxacin and ofloxacin, as has been observed elsewhere in Asia 378.   
  
3.5 Vaccination campaigns 
The Vietnamese government recognized the public health issue of typhoid fever in 
the 1990s and initiated several vaccine campaigns with internationally manufactured 
vaccines in an attempt to protect the most vulnerable groups within the population, 
most commonly children 379. Further, NIHE in Hanoi was pioneering in instigating 
locally manufactured Vi Polysaccharide vaccine and distributing it as control 
measure through the public health network. However, despite a Vi conjugate 
vaccine and a new oral attenuated typhoid vaccine being trialled in Vietnam for the 
first time these were never introduced as public health interventions 319,380. All the 
national typhoid Vi vaccine programs conducted between 1997 and 2012 were 
executed as school-based campaigns, immunizing children between the ages of three 
and 10 years. Between 1997 and 2003 the Vietnamese government immunized more 
than 4,000,000 children aged three to five years with TYPHIM Vi polysaccharide, 
manufactured by Aventis Pasteur. After manufacturing their own Vi polysaccharide 
vaccine through the Institute of Vaccines and Medical Biologicals/DaLat Pasteur 
Vaccine Company (IVAC/DAVAC), the Vietnamese public health system 
administered more than 2,000,000 additional does to children aged five to ten years 
(2004-2010), and latterly children aged three to five years (2011-2012). At the peak 
of these Vi vaccine campaigns in 2005 (1,200,000 doses), children were being 
immunized in 35 different provinces across the country (Figure 3.2B) 363. The 
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coverage rate of these campaigns was high, with greater than 90 per cent of the 
target population receiving a Vi vaccine between 1999 and 2010. Population based 
data assessing the direct effect (i.e. without additional sanitation covariates) of these 
immunization programmes on typhoid incidence are unavailable, but a there was a 
substantial decrease in the incidence of typhoid fever across the country between 
1997 and 2007, most notably in the northwest of the country and Mekong River 
Delta in the South 363, which were covered extensively by the immunization 
program (Figure 3.2) 363. 
 
3.6 Contextual factors that may have influenced typhoid fever incidence 
Being of low socioeconomic status is a major risk factor for contracting typhoid 
fever 337. Vietnam has been through an unprecedented period of economic 
development since the mid 1990s, which has had a substantial knock-on effect on 
the reduction of poverty and poverty-associated communicable diseases 381. 
Between 1998 and 2014 Vietnam’s Gross Domestic Product (GDP) increased from 
$27 billion to $86 billion, and the Gross National Income (GNI) per capita increased 
from $360 to $1,890 over the same time period 382. These figures correlate with a 
reduction in national poverty (poverty headcount ratio at $1.90 a day declining from 
34.8 percent in 1998 to 3.2 per cent in 2012) (Figure 3.4) and a waning in typhoid 
fever incidence, but overlap with the period of the national immunization 
campaigns. In addition, multiple contextual factors are considered to have had an 
effect on the incidence of typhoid fever. Typhoid fever is associated with poor water 
quality and evidence of the organism in water supplies can be measured using 
molecular methods 383. Consequently, water, sanitation, and hygiene (WASH) 
conditions are one of the major factors in assessing disease control. Sub-national 
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data on water and sanitation extracted from Multiple Indicator Cluster Surveys 
(MICS) in Vietnam show that the fraction of the population in the southeast of 
Vietnam with access to improved sanitation facilities (means of excreta disposal that 
decrease human contact with faeces) increased from only 42% in 1995, to 93.6% in 
2014 384. Furthermore, the proportion of the south-eastern population of Vietnam 
with improved water sources (as per MICS standards; water piped into homes or 
yard, public taps, standpipes, protected wells, or springs) rose from 93.6% in 2006 
to a peak of 98.4% in 2011 384. Correspondingly, data from the World Bank shows 
that there was a steady increase in the proportion of the Vietnamese population with 
access to improved sources of drinking water between 1998 (74.5 per cent of the 
population) and 2014 (96.4 per cent of the population) 385. Similarly, there was an 
increase in the proportion of the population with access to improved sanitation 
facilities, including flush and slab latrines, over the same period; 49.5 per cent of the 
population in 1998 to 76.3 per cent of the population in 2012 385.  
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Figure 3.4 The reduction of poverty and improvements in sanitation in Vietnam 
(data from World Bank 385) 
Plots showing; the proportion of the Vietnamese population living on <$1.90 a day (black 
triangles), the proportion of the Vietnamese rural population with improved sanitation 
(black circles), and the proportion of the Vietnamese urban population with improved 
sanitation (white circles) from 1994 to 2013. 
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3.7 Knowledge gaps 
All available data suggests that the trend of typhoid fever incidence began to exhibit 
a steep decline in Vietnam from 1999 onwards. Therefore, the outstanding questions 
regarding the dramatic reduction in typhoid fever in Vietnam are: to what extent did 
immunization play a role in reducing typhoid fever? and how much influence did 
economic growth have on improving living standards to reduce all waterborne 
diseases, including typhoid fever? Given the paucity of data regarding the 
longitudinal incidences of typhoid fever (and other waterborne diseases) in Vietnam, 
disaggregating the independent effect of these differing approaches is a major 
challenge. Furthermore, dissimilar demographics, disease epidemiology, and disease 
incidence across the provinces of Vietnam make it impractical to assess the overall 
impact of a specific intervention in any given location. The data that are available 
are inconclusive and limited by disease time trends from a single tertiary referral 
hospital in HCMC. As a result, these data do not provide insight into regional 
differences in typhoid fever reduction across Vietnam or characterize the current 
national burden. Furthermore, there is no systematic data regarding intestinal 
perforation (although this has been described in the southern provinces of Vietnam 
386), other severe disease presentations 23, or typhoid associated mortality. As a 
result, it is impossible to directly assess any trends associated with these severe 
outcomes.  
 
Regardless of the precise role of any single intervention, the reduction and virtual 
elimination of typhoid fever in Vietnam, largely driven by strong political will, as 
evidenced by sanitation improvements, better health care, and immunization 
campaigns, should be considered a major public health success. However, this 
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success story does not quite replicate into a blueprint in how typhoid fever should be 
controlled across Asia, that is, what worked in Vietnam may not work in precisely 
the same way in other locations. It is likely that the various vaccination campaigns 
that have taken place in Vietnam over the last 15 years have contributed to the 
observed decreasing trend in typhoid fever, but their effect is difficult to assess. 
However, the immunization campaigns were conducted in children in selected 
provinces, and these individuals received a single dose of the Vi polysaccharide 
vaccine. This vaccine only provides limited efficacy in the first year after 
immunization and there is a rapid decline in antibody titre two years after receiving 
the vaccine 387,388; herd protection remains variable. Therefore, I conclude that 
economic development, improved access to clean water supplies, better sanitation, 
and a reduction in poverty probably played the greatest combined role in reducing 
the incidence of typhoid in Vietnam. Quantifying the precise contribution of these in 
reduction of typhoid is again problematic, and there are multiple additional factors 
that should also be considered that may confound these interactions. It is, however, 
worth stating that S. Typhi appears to profoundly sensitive to improvements in 
sanitation, which reduces human exposure to the organism, thus, lessening disease 
incidence and person-to-person transmission.  
 
3.8 Conclusions 
The reduction of typhoid fever in Vietnam has been remarkable, and has been 
largely driven by economic development and improved living standards for the 
population. Immunization has probably had some impact on disease reduction, but 
the use of an imperfect vaccine may only provide limited respite in disease 
transmission without required improvements in WASH. Better-designed WASH 
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intervention studies with disease endpoints and systematic incidence data are 
required to glean a greater understanding of the precise contextual factors that 
impact on typhoid fever incidence. 
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Chapter 4 An evaluation of purified Salmonella Typhi protein 
antigens for the serological diagnosis of acute typhoid fever 
 
4.1 Introduction 
Typhoid occurs only in humans, making it a disease that can technically be 
eradicated 182. Indeed, typhoid has all but been eliminated from several countries in 
Southeast Asia where it was the most common cause of hospitalized febrile disease 
20-30 years ago 81,287. Elimination in these areas is generally attributed to extensive 
improvements in sanitation rather than widespread immunization schemes. The lack 
of data regarding the long-term impact of mass immunization for typhoid and the 
performance of licensed vaccines have hindered immunization as a sustainable 
typhoid control and elimination strategy. Future considerations for rational control 
measures for typhoid will rely on more accurately assessing disease burden, which 
requires a reliable diagnostic approach 389.  
 
All commonly used typhoid diagnostics perform poorly and are a roadblock for 
disease control efforts 390,391. Currently, the only reliable method for the 
identification of febrile individuals with typhoid is the culture of a causative 
organism from a biological specimen 391,392. However, this procedure is restricted to 
laboratories with adequate equipment and microbiology training, and the method 
has a limited sensitivity due to low concentrations of organisms in the peripheral 
circulation 281,393,394. Low bacterial loads have a similar impact on other methods 
that rely on detecting the presence of the infecting organisms, such as antigen 
detection or nucleic acid amplification. These methods are often reported to be 
highly sensitive, but have unrealistic performances; pre-treatment with 
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antimicrobials is likely to compound this issue further 281,390. New typhoid 
diagnostics are a necessity and various approaches have been evaluated, including 
measurement of innate immune responses 164,395, antibody in lymphocyte 
supernatants 222,396, and the identification of metabolomic signatures 397. However, 
these advances are still restricted to research laboratories and are not yet ready to be 
developed into simple, rapid diagnostic tests (RDTs).  
 
I previously exploited a protein microarray to identify a multitude of immunogenic 
S. Typhi protein antigens to which an antibody response was generated during the 
early stages of typhoid 340. With the aim of validating antigens that could be used in 
a diagnostic assay I expressed and purified several of these potentially 
serodiagnostic S. Typhi antigens and investigated their diagnostic performance in a 
cohort of febrile Bangladeshi patients.   
 
4.2 Results 
4.2.1 Acute IgM antibody responses against Salmonella Typhi antigens 
Of the 18 protein antigens targeted, 12 of them were successfully purified (Table 
2.2). ELISAs were independently performed employing the purified protein antigens 
and the Vi polysaccharide to detect IgM in the plasma of 40 afebrile control 
subjects, 17 febrile individuals with a confirmed infection other than typhoid, and 32 
individuals with either blood culture or PCR (or both) confirmed typhoid infections 
(n=89 samples). IgM against all twelve of the purified S. Typhi proteins and the Vi 
polysaccharide were measured in all of the 89 samples subjected to ELISA. IgM 
titres from each of the antigens individually were compared to assess the 
performance of the antigens and to identify potential correlations between the 
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serological targets. I found that early IgM responses against the majority of the 
novel S. Typhi protein antigens, with the exception of STY1522 (rho<0.7, r<0.05, 
Spearman’s correlation coefficient test), were highly correlated with one other 
(rho>0.8). Notably, the collerations between IgM response to the protein antigens 
and to the Vi polysaccharide were relatively weaker (rho<0.8) than those between 
two protein antigens (Figure 4.1). 
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Figure 4.1 Spearman correlation among antigen-induced antibodies  
The names of the various antigens and histograms showing the distribution of IgM antibody 
against these antigens are presented on the diagonal. Scatterplots below the diagonal 
represent the correlation of IgM measurements of the two antigens on a right angle to the 
plots. The numerals above the diagonal depict the Spearman correlation coefficient (rho) 
values of the mirrored plots. OD values of each antigen-induced antibody are presented to 
the side of the corresponding scatterplots. 
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4.2.2 The diagnostic potential of IgM against Salmonella Typhi antigens 
IgM against all twelve of the protein antigens and the Vi polysaccharide was 
significantly elevated in the plasma of the typhoid patients in comparison with the 
afebrile controls (r<0.05, Wilcoxon signed-rank test) (Figure 4.2). Furthermore, 
there was a significant differentiation in the plasma IgM measurements between the 
typhoid patients and those with a febrile disease with an alternative confirmed 
aetiology with all antigens (r <0.05, Wilcoxon signed-rank test) with the exception 
of STY1522.  
 
By assessing raw antibody measurements, I surmised that the best performing 
antigens, with respect to differentiating between the patient groups were STY4539, 
STY1886, and Vi (Figure 4.2). The mean IgM responses (OD values) in the afebrile 
controls, the other confirmed infections and the typhoid infections were 0.29, 0.27, 
and 0.42 (against STY4539), 0.17, 0.18, and 0.25 (against STY1886), and 0.22, 
0.21, and 0.35 (against Vi), respectively. This segregation between the patient 
groups was highly significant, resulting in r-values of 0.0001 and 0.003 for IgM 
against STY4539; <0.0001 and 0.004 for IgM against STY1886; and 0.0001 and 
0.0001 for IgM against Vi, between afebrile controls and typhoid infections and 
between other febrile diseases and typhoid infections, respectively (Wilcoxon 
signed-rank test). 
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Figure 4.2 IgM responses against Salmonella Typhi antigens in a Bangladeshi cohort of febrile patients and controls 
Boxplots showing IgM measurements (optical density) in plasma from afebrile controls (orange), febrile patients with an infection other than typhoid fever (purple), and 
confirmed typhoid patients (red). Dark horizontal lines represent the mean IgM measurement, with the box representing the 25th and 75th percentiles, whiskers represent the 
5th and 95th percentiles; outliers are represented by dots. A) Boxplots of antibody responses against (from left to right) STY0452, STY0769, STY1086, STY1372, STY1522, 
STY1612, STY1703, STY1767, STY3208, STY4190, STY1886, STY4539 and Vi. All mean antibody measurements were statistically significant between the afebrile 
controls and typhoid infections and between other infections and typhoid infections (r< 0.05 Wilcoxon signed rank test), with the exception of STY1522. 
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4.2.3 Sensitivity and specificity of the serodiagnostic antigens 
To further assess the IgM responses against the various S. Typhi antigens for the 
purposes of diagnostic sensitivities and specificities were calculated using a 
validation group incorporating two positive reference groups and a negative 
reference group for additional statistical power. The negative reference group 
(n=57) was the combination of data from the afebrile controls (n=40) and from those 
with a confirmed diagnosis other than typhoid (n=17 cases). The assay results were 
validated independently with two sets of positive reference data; these were a 
combination of blood culture confirmed S. Typhi along with those with a positive 
PCR amplification result for S. Typhi from blood (n=32), and the blood culture 
confirmed S. Typhi patients (n=19). 
 
The IgM responses against each of the antigens generated a continuous data set that 
was used to generate ROC curves to optimize the index cut-off value. The defined 
cut-off values of the thirteen antigens corresponded with a range of sensitivities 
ranging from 0.50 to 0.84 and specificities between 0.58 and 0.84; areas under the 
ROC curve (AUC) ranged from 0.7 to 0.85. When used alone, none of the antigens 
demonstrated a sensitivity or specificity >0.8. As predicted, Vi, STY4359, and 
STY1886 were the three antigens with the greatest serodiagnostic capacity in 
discriminating typhoid cases from afebrile controls and other infections. The 
sensitivities and specificities for identifying typhoid patients by IgM titres were 
0.68, 0.8 (Vi); 0.62: 0.82 (STY4539); and 0.62; 0.82 (STY1886) respectively. 
Correspondingly, the AUCs were 0.84 (95%CI: 0.71, 0.96), 0.77 (95%CI: 0.61, 
0.92), and 0.77 (95%CI: 0.62, 0.91). 
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I next employed SVM to identify combinations of two or more antigens across all 
13 antigens to increase overall sensitivity and specificity. Using confirmed S. Typhi 
infection by blood culture or PCR as the positive reference (n=32), I found 11 
combinations of two to four antigens that gave sensitivities from 0.81 to 0.84, 
specificities from 0.81 to 0.86, and AUCs from 0.87 to 0.89 (Figure 4.3). I 
additionally identified 17 combinations of two to four antigens when using the 
positive reference as culture confirmed S. Typhi only (n=19), obtaining sensitivities 
from 0.84 to 0.89, specificities from 0.88 to 0.94, and AUCs from 0.86 to 0.91 
(Figure 4.3). 
 
For the positive reference sets, IgM against Vi contributed to all of the 
combinations, while STY1703, STY1886, and STY4539 were present in more than 
half of the combinations. The remaining nine antigens contributed to at least one 
combination that gave sensitivities and specificities >0.8. These results 
demonstrated that, in the majority of examples, a combination of up to four antigens 
was directly associated with an increased performance of the IgM serology. 
However, the best performing antigens for the identification of typhoid patients by 
IgM were Vi in combination with either STY1703 or STY1886. Some 
representative combinations are presented in Table 4.1 and Table 4.2. 
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Figure 4.3 Assessing the sensitivity and specificity of IgM against Salmonella Typhi antigens for the diagnosis of typhoid fever 
Receiver operating characteristic (ROC) curves summarizing the antibody responses against antigen combinations for the diagnosis of typhoid. The x-axis 
displays the false positivity rate (1-Specificity) and the y-axis displays true positive rate (Sensitivity). The performance of two, three and four antigens are 
shown by the red, green, and blue lines, respectively. A) ROC curve produced when the positive references are typhoid cases confirmed by blood culture and 
PCR amplification (n=32). B) ROC curve produced when the positive references are typhoid cases confirmed by blood culture only (n= 19). 
100  
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Table 4.1 The sensitivity and specificity of using multiple antigens for typhoid diagnosis using blood culture and PCR positive patients as 
positive reference group (n=32) 
Antigen combinations STY1703 & Vi STY4539 & STY1703 & 
Vi 
STY4539 & STY1703 & STY1886 & 
Vi 
Specificity  0.86 0.86 0.86 
Sensitivity  0.81 0.84 0.84 
Number positive with undiagnosed febrile disease 
(n=226) 
135 (59%) 134 (59%) 134 (59%) 
Number positive with clinically suspected typhoid 
(n=18) 16 (88%) 16 (88%) 16 (88%) 
AUC (95%CI) 0.865 (0.782, 0.947)  0.863 (0.779, 0.947) 0.866 (0.783, 0.949) 
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Table 4.2 The sensitivity and specificity of using multiple antigens for typhoid diagnosis using blood culture positive patients only as positive 
reference group (n=19) 
Antigen combinations STY1886 & Vi STY4190 & STY1886 & Vi STY4539 & STY4190 & STY1886 
& Vi 
Specificity  0.88 0.89 0.88 
Sensitivity  0.84 0.84 0.89 
Number positive with undiagnosed febrile disease 
(n=226) 119 (52%) 78 (34%) 71 (31%) 
Number positive with clinically suspected typhoid 
(n=18) 
15 (83%) 13 (72%) 13 (72%) 
AUC (95%CI) 0.859 (0.746, 0.972) 0.891 (0.791, 0.991) 0.912 (0.81, 1.014)  
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4.2.4 Identifying typhoid cases in patients with undiagnosed febrile disease 
In this Bangladeshi cohort there were 226 patients with febrile disease without 
laboratory confirmed aetiology and 18 with clinically suspected typhoid that were 
negative by blood culture and PCR amplification. I aimed to estimate the proportion 
of patients in this population who may have typhoid by applying the SVM cut-offs 
and combining the IgM titres against two S. Typhi antigens. I performed two 
independent analyses; the first combined IgM titres against STY1703 and Vi using a 
combination of culture confirmed S. Typhi and positive PCR amplification for S. 
Typhi from blood as the positive reference group (Figure 4.4 and Table 4.2). Using 
these criteria, I found that 135/226 (59%) of the undiagnosed febrile patient group 
and 16/18 (88%) with clinically suspected typhoid had IgM titres indicative of 
typhoid. Using more stringent criteria (blood culture confirmed patients) as the 
positive reference and a combination of IgM against Vi and STY1886 I found that 
119/226 (52%) febrile cases and 15/18 (83%) clinically suspected typhoid, 
respectively, had a profile indicative of typhoid (Figure 4.4).  
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Figure 4.4 Detecting febrile patients with an IgM profile indicative of typhoid fever 
Hyperplane plots predicting the number of undiagnosed febrile patients that have an IgM measurement indicative of typhoid fever. The orange points 
represent the negative controls, which includes afebrile controls and patients with other infections. The red points represent typhoid cases confirmed by blood 
culture or PCR. Yellow points are febrile patients with an IgM profile indicative of not having typhoid fever, whilst the green points are febrile patients 
defined as having a typhoid infection using pre-defined hyperplane IgM profile. A) Plot where hyperplane was defined using the positive reference as the 
typhoid cases confirmed by blood culture or PCR (n=32); the selected combination of antigens was STY1703 and Vi. B) Plot where hyperplane was defined 
using the positive reference as the typhoid cases confirmed by blood culture only (n=19); the selected combination of antigens was STY1886 and Vi.  
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4.3 Discussion 
Typhoid is caused by a human restricted pathogen that is transmitted faecal-orally. 
Consequently, improving the quality of drinking water supplies and education in 
better hygiene practices are likely the most effective measures for typhoid 
elimination. However, these interventions cannot be promptly realized in the 
endemic areas of Africa and South Asia. Therefore, the short-term control of 
typhoid is dependent on large vaccination programmes and appropriate treatment, 
both of which, for differing reasons, rely on better case detection. The fact that there 
is not currently a typhoid diagnostic assay with a high degree of sensitivity or 
specificity limits disease burden assessments 80,398, and may result in patients being 
misdiagnosed and receiving sub-optimal therapy 399. Furthermore, with the global 
increase in S. Typhi associated with reduced susceptibility and resistance against the 
fluoroquinolones and other antimicrobials 378,400, the demand for typhoid diagnostics 
are now greater than ever 401,402.   
 
There are a paucity of data arising from studies on humans with typhoid that have 
measured the immunological response to S. Typhi specific antigens 182. Studies that 
have been performed have found significant interferon-γ (IFN-γ) responses in cells 
stimulated with various antigens including fimbriae and outer membrane proteins 
using polymorphonuclear cells from the blood of typhoid patients 403. Further, when 
whole blood from typhoid patients is stimulated with S. Typhi lipopolysaccharide, 
tumour necrosis factor α (TNF-α) release is lower during active typhoid than after 
antimicrobial treatment, indicating a short immune modulation effect, which may be 
induced by the Vi polysaccharide 404. Antigen arrays and other probing techniques 
have being used successfully to interrogate the antibody repertoire during early 
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infection 340,405–407, and have detected antibody responses to several novel, and 
potentially organism specific, antigens that may be able to distinguish typhoid 
patients from controls 340. Using this “screening data” I rationally selected several S. 
Typhi protein antigens and aimed to investigate if early immunological diagnostic 
signals could be detected in the plasma of febrile patients.  
 
My study focused on a well-defined patient group from Bangladesh, who were 
enrolled for the primary focus of studying typhoid diagnostics. Whilst the patient 
numbers with typhoid in this group were relatively modest, the clinical and 
laboratory criteria for patients with febrile disease were consistent and have been 
previously assessed with commercial serological tests for typhoid 335. I noted that 
the IgM response against the twelve purified S. Typhi protein antigens were stable 
and well correlated; the IgM responses in comparison to Vi correlated less 
consistently. These data confirm my original antigen screening data and suggest that 
these antigens are immunogenic and induce an antibody response early in infection. 
Given the poor performance of commercial RDTs 267,408, my data signify that the 
early detection of IgM against more specific S. Typhi protein antigens may be a 
more specific and sensitive approach for developing a RDT for typhoid.  
 
Indistinguishable clinical features and the lack of a reliable gold standard test 
complicate typhoid diagnosis. Here, the IgM response against all 12 antigens was 
significantly higher in typhoid patients than both afebrile controls and patients with 
febrile diseases other than typhoid. Furthermore, through inference from the AUC 
under the ROC curve I was able to identify the best three performing antigens, 
which were encoded by STY4539 (PilL) and STY1886 (CdtB) in combination with 
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the Vi polysaccharide. PilL is a putative exported protein and a component of the 
type IV pili encoded adjacent to the genes encoding Vi on SPI-7 409,410. The PilL 
protein is induced following uptake by human derived macrophages 411, and the type 
IV pili to which it is associated facilitates entry into epithelial cells 412. CdtB, 
encoded by STY1886, is one of the two A sub-units of typhoid toxin, an AB type 
toxin 137. Typhoid toxin is a virulence-associated factor of S. Typhi, which is 
thought to be associated with the early symptoms of typhoid 139. I confirm that this 
component of typhoid toxin is immunogenic and may be an important biomarker of 
acute typhoid 340,413. Whilst these three virulence factors (PilL, CdtB, and Vi) were 
not sufficient in themselves to produce a reproducibly high (>0.8) degree of 
sensitivity and specificity for typhoid diagnosis, I gained additional power by 
combining data from >1 antigen using an SVM model. The IgM responses against 
Vi in combination with either PilL or CdtB were found to generate the highest 
degree of sensitivity and specificity. Seemingly, a combination of the differing IgM 
responses against polysaccharide and a protein compensates for a lower affinity to 
one of the antigens. Furthermore, I was able to estimate the proportion of the 
population that may have typhoid by imposing cut-offs from the typhoid confirmed 
patients onto the population with undiagnosed febrile diseases. These data did not 
generate a precise cut-off; therefore, my data suggest that typhoid diagnostics are 
not an exact science and my data should be interpreted with caution. These methods 
warrant further investigation in additional cohorts, but it suggests a substantial 
burden of undiagnosed febrile disease is associated with S. Typhi in this setting. 
 
This study has limitations. The sample size was relatively small; I aimed to rectify 
this by including a subset of patients that appear to have S. Typhi DNA in their 
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bloodstream but were culture negative 89. Using this combination of methods as a 
gold standard I was able to increase the diagnostic power of the assays. A further 
limitation is that this study was conducted in a single healthcare location over a 
limited time period. Whilst my data provide some confidence that these serological 
assays may be of utility for typhoid diagnostics, these methods should to be 
validated in additional cohorts. However, there remains a challenge in identifying 
typhoid patients that have a sterile blood culture; a combination of novel 
approaches, such as metabolomics and/or functional genomics 395,397, in a febrile 
disease cohort may add further insight into this important patient group. 
 
In conclusion, I have investigated the serological diagnostic potential of S. Typhi 
protein antigens and the Vi polysaccharide in a group of patients with febrile 
diseases in Bangladesh. My novel data show that serology may have some utility for 
typhoid diagnostics and a combination of antigens improves the diagnostic potential. 
My assays give high levels of sensitivity and specificity, but require further 
assessment in differing patient populations. 
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Chapter 5 Acute and longitudinal humoral immune responses to 
typhoid toxin after natural infections with Salmonella Typhi and 
Salmonella Paratyphi A 
 
5.1 Introduction  
The discovery of typhoid toxin has added greater insights into the ability of S. Typhi 
and S. Paratyphi A to induce typhoid fever in humans 137. Typhoid toxin has been 
shown in experimental animals to be important for orchestrating the clinical 
symptoms associated with acute typhoid 138. However, the role of typhoid toxin in 
the pathogenesis of typhoid fever during human infection has not, as yet, been 
determined. A component of typhoid toxin (CdtB; the active subunit) has been 
shown to elicit an acute IgM response in collection of plasma collected from a well-
defined group of febrile patients in Bangladesh, raising the possibility of using the 
early immune response against this subunit of typhoid toxin for disease diagnosis 
414.  
 
Here, I aimed to measure the natural humoral immune response against typhoid 
toxin in a group of patients diagnosed with enteric fever to assess the potential of 
using these responses for diagnosis, and to provide a potential framework for the 
development of novel therapeutic and prevention strategies. More specifically, I 
assessed the acute and longitudinal antibody responses against typhoid toxin in a 
cohort of patients infected with S. Typhi and S. Paratyphi A in Nepal, and evaluated 
the toxin neutralizing capacity of acute and convalescent plasma from patients with 
enteric fever. 
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5.2 Results 
5.2.1 Longitudinal acute and convalescent anti-toxin IgM responses 
ELISAs detecting anti-toxin IgM antibodies (anti-toxin IgM) were performed on a 
collection of longitudinal plasma samples (up to three-months post presentation) 
from afebrile community controls (n=49), febrile individuals with an undetermined 
pathogen (culture negative patients, n=316), and patients with culture confirmed 
enteric fever (S. Typhi, n=152 and S. Paratyphi A, n=68) (Figure 5.1).  
 
Overall, these data demonstrated that the concentration of anti-toxin IgM in plasma 
from community controls was significantly lower than in plasma samples from the 
three patient groups (r<0.05, Wilcoxon signed-rank test). Notably, the concentration 
of anti-toxin IgM in plasma from the febrile patients with an undetermined pathogen 
was longitudinally greater than the afebrile community controls; this difference in 
antibody titres was not significantly different between any of the four sampling 
points. In S. Typhi and S. Paratyphi A infected patients, the concentration of anti-
toxin IgM in plasma peaked at Day 8 (r<0.05, Wilcoxon matched-pairs signed-rank 
test) and declined steadily until the three-month sampling point. At three months 
post-infection, anti-toxin IgM titres were significantly lower than those observed on 
Day 8 (r<0.05, Wilcoxon matched-pairs signed-rank test) and were comparable to 
the baseline measurements recorded on Day 1 (r>0.05, Wilcoxon matched-pairs 
signed-rank test) (Figure 5.1A).  
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Figure 5.1 Acute and convalescent IgM response to typhoid toxin. 
Boxplots showing the IgM antibody response against toxin (log10 EU) up to three months after a febrile disease with A) an undetermined pathogen, B) S. 
Paratyphi A and C) S. Typhi. Dark horizontal lines represent the mean, with the box representing the 25th and 75th percentiles, whiskers represent the 5th and 
95th percentiles; outliers are represented by dots. The dashed lines across the boxes represent the trend of the data throughout different time points and the 
shaded area around trend is 95% confidence interval. The solid/dashed lines above boxes define significantly different distributions (r <=0.05) or not 
(r>0.05). AC: afebrile controls, D1: Day 1, D8: Day 8, M1: Month 1, M3: Month 3.  
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The acute anti-toxin IgM responses from patients infected with S. Typhi and S. 
Paratyphi A were indistinguishable. Therefore, as a potential approach for 
diagnosing enteric fever, I compared the acute anti-toxin IgM profiles from patients 
with S. Typhi and S. Paratyphi A infections to those from the febrile patients with an 
undetermined pathogen. I found that the best compromise between specificity and 
sensitivity of using anti-toxin IgM titres (alone on day 8 of sampling) for diagnosing 
enteric fever were 56% and 68%, respectively.  
 
Observing that the specificity and sensitivity were relatively modest, I aimed to 
improve the classification using additional serological data. I hypothesized that the 
acute IgM antibody profile against the Vi antigen (anti-Vi IgM) and the O2 antigen 
(anti-O2 IgM) (the classical surface antigens of S. Typhi and S. Paratyphi A, 
respectively) may compensate for the limited performed of anti-toxin IgM to 
diagnose enteric fever. To test this hypothesis, I additionally measured anti-Vi IgM 
and anti-O2 IgM in plasma samples from the enteric fever patients and the culture 
negative patients. The acute antibody profiles against toxin, Vi, and O2 were 
combined in an attempt to better discriminate culture positive enteric fever cases. 
The resulting specificity and sensitivity of a combination of anti-toxin IgM, anti-Vi 
IgM, and anti-O2 IgM titres for diagnosing enteric fever on Day 8 of sampling, in 
comparison to blood culture using an SVM were 81% and 80%, respectively. 
 
5.2.2 Longitudinal acute and convalescent anti-toxin IgG responses 
I next performed ELISAs to detect anti-typhoid toxin IgG antibodies (anti-toxin 
IgG) in the corresponding collection of patient plasma samples. Overall, the median 
anti-toxin IgG concentration in the community controls was comparable to the 
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longitudinal samples taken from the febrile patients with an undetermined pathogen 
(Figure 5.2A), and those with culture confirmed S. Typhi and S. Paratyphi A on the 
day of admission (r>0.05 for all comparisons, Wilcoxon signed-rank test) (Figure 
5.2B&C). There was however a significant difference in anti-toxin IgG 
concentrations over the three-month sampling period in the enteric fever patients 
(r<0.05, Wilcoxon matched-pairs signed-rank test). Initially, the anti-toxin IgG 
responses in patients with S. Typhi and S. Paratyphi A were comparable, increasing 
between Day 1 and Day 8 and increasing again between Day 8 and Month 1 (r<0.05 
for both comparisons, Wilcoxon matched-pairs signed-rank test). However, anti-
toxin IgG in plasma from the S. Paratyphi A patients declined after Month 1, 
plateauing to a Day 8 equivalent concentration at the three-month time point (Figure 
5.2B).  
 
The S. Typhi patients exhibited a differing anti-toxin IgG response, increasing from 
Day 8 to Month 1, and increasing again to the three-month time point (r<0.05, 
Wilcoxon matched-pairs signed-rank test) (Figure 5.2C). In total, 19% of the 
significant patterns of the longitudinal antibody profiles in the febrile patients with 
an undetermined pathogen exhibited sero-conversion against typhoid toxin, the 
equivalent proportion in those with S. Typhi or S. Paratyphi A was 80%.  
  
 133 
 
 
Figure 5.2 Acute and convalescent IgG response to typhoid toxin 
Boxplots showing the IgG antibody response against toxin (log10 EU) up to three months after a febrile disease with A) an undetermined pathogen, B) S. 
Paratyphi A, and C) S. Typhi. Dark horizontal lines represent the mean, with the box representing the 25th and 75th percentiles, whiskers represent the 5th and 
95th percentiles; outliers are represented by dots. The dashed lines across the boxes represent the trend of the data throughout different time points and the 
shaded area around trend is 95% confidence interval. The solid/dashed lines above boxes define significantly different distributions (r<=0.05) or not 
(r>0.05). AC: afebrile controls, D1: Day 1, D8: Day 8, M1: Month 1, M3: Month 3.  
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To better disaggregate the dynamics of anti-toxin IgG in the various patient groups, 
I fitted the longitudinal serological data using mixed effects model. The resulting 
patterns from the mixed effects model confirmed my observations of longitudinal 
anti-toxin IgG dynamics. The anti-toxin IgG trend line in the community controls 
and febrile patients with an undetermined pathogen were low, horizontal, and 
substantially divergent from those of the S. Typhi and S. Paratyphi A culture 
confirmed patients (Figure 5.3). However, anti-toxin IgG in the S. Typhi and S. 
Paratyphi A patients increased between Day 1 and Day 28; anti-toxin IgG 
subsequently decreased in the S. Paratyphi A patients and continued to increase in 
the S. Typhi patients at three-months post infection.    
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Figure 5.3 The longitudinal dynamics of IgG response against typhoid toxin.  
Mixed effects model using the anti-toxin IgG data from the afebrile control (AC, orange) for 
generating trends of anti-toxin IgG of those with an undetermined pathogen (UF, green), S. 
Paratyphi A (SPA, blue) and S. Typhi (ST, red) culture confirmed patients throughout 90 
days of observation.  
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5.2.3 Anti-toxin and anti-Vi polysaccharide IgG responses in the general Nepali 
population 
Aiming to examine the association between the humoral response to typhoid toxin 
and the Vi capsular antigen, I measured anti-toxin IgG and anti-Vi IgG antibodies in 
a cross-sectional plasma bank from afebrile Nepali individuals. Antibody titres 
against these two antigens were plotted and could be grouped into three distinct 
serological populations using K-means clustering (Figure 5.4A). The majority of 
individual plasma samples (669/733, 91.2%) exhibited a high correlation (rho>0.85, 
r<0.05, Spearman’s correlation coefficient test) between anti-toxin IgG and anti-Vi 
IgG. The remaining data points (64/733, 8.8%) were skewed towards higher 
concentrations of anti-toxin IgG.  
 
To assess potential exposures to S. Typhi in individuals in the plasma bank samples 
I considered the correlation between anti-toxin IgG and anti-Vi IgG titres within 
each of the three serological defined populations. The longest anti-toxin IgG 
responses for which I had data were in acute typhoid patients three-months post 
presentation, therefore any inference of S. Typhi exposure in the plasma bank was 
made on the assumption that it occurred within the three-month pre-sampling 
period.  
 
In population one (532/733, 72.5%) (Figure 5.4A, red circles), anti-toxin IgG and 
anti-Vi IgG were proximal to the root of both axes, suggesting that individuals in 
this cluster did not have an antibody response indicative of recent S. Typhi 
exposure. In contrast, high concentrations of anti-toxin IgG and anti-Vi IgG in 
population two (137/733, 18.7%) (Figure 5.4A, green triangles) was indicative of S. 
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Typhi exposure within the proceeding three months. The profile in population three 
(64/733, 8.8%) (Figure 5.4A, pink checked boxes and green squares and blue 
crosses) contained those with lower anti-Vi IgG than those in population two and 
higher anti-toxin IgG than in population one. 
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Figure 5.4 Correlations between antibody IgG responses to typhoid toxin and Vi and O2 antigens.  
The associations between IgG response against typhoid toxin and Vi (A); or typhoid toxin and O2 (B) in a Nepali plasma bank visualized by scatter plots. A) 
Every sample in the plasma bank was grouped into one of three population clusters by K-mean clustering method, these were population one of low anti-toxin 
IgG/low anti-Vi IgG (532/733, 72.5%, red circles), population two of high anti-toxin IgG/ high anti-Vi IgG (137/733, 18.7%, green triangles), and population 
three of high anti-toxin IgG/low anti-Vi IgG (64/733, 8.8%, pink checked boxes and green squares and blue crosses). B) Individuals in figure A are presented 
in relation with their values of anti-O2 IgG, which reveals 75% (48/64, pink checked boxes) of population three having anti-O2 IgG > 75th percentile, 14% 
(9/64, blue crosses) of population three having 50th percentiles <anti-O2 IgG< 75th percentiles and 11% (7/64, green squares) of population three having anti-
O2 IgG < 50th percentiles.   
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I next hypothesized that the disparity between anti-toxin IgG and anti-Vi IgG in 
population three (high anti-toxin IgG/low anti-Vi IgG) was associated with S. 
Paratyphi A infection. To test the hypothesis, I additionally measured anti-O2 IgG in 
the plasma bank. I found that 48/64 (75%) of individuals who had high anti-toxin 
IgG/low anti-Vi IgG, had anti-O2 IgG concentrations in the 75th percentiles of the 
anti-O2 IgG concentrations in the plasma bank. Overall, the anti-O2 IgG titres 
exhibited a low degree of correlation (rho~0.5, r<0.05, Spearman’s correlation 
coefficient test) against anti-toxin IgG titres (Figure 5.4B). The location of the 48 
individuals with high anti-toxin IgG, low anti-Vi IgG, and high anti-O2 IgG (Figure 
5.4B, pink checked boxes) were within the group with the highest levels of both 
anti-toxin IgG and anti-O2 IgG (Figure 5.4B). This observation suggested that S. 
Paratyphi A exposure may contribute to at least 75% of serological population 3, 
which was equivalent to 6.5% (48/733) of the entire serum bank and indicative of a 
lower incidence of infection than S. Typhi. 
 
5.2.4 Neutralization of typhoid toxin with acute and convalescent patient 
plasma  
My work demonstrated that a substantial longitudinal antibody response against 
typhoid toxin is mounted during and after infection with both S. Typhi and S. 
Paratyphi A. To assess if these anti-typhoid toxin antibody responses had any 
functional a toxin neutralization assay was performed. The neutralization assays 
were conducted on longitudinal plasma samples from four seroconverting 
participants (according to significant patterns) from each of the patient groups (S. 
Typhi confirmed, S. Paratyphi A confirmed, and febrile patients with an 
undetermined pathogen); eight afebrile community plasma samples were added as a 
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control. I could identify a robust toxin-neutralizing activity in all samples assayed 
that were obtained at Day 28 or longer after the onset of symptoms. In some 
patients, toxin neutralizing activity was detected as early as 8 days after infection 
(Figure 5.5A-D). A potential correlation between plasma neutralization capacity and 
anti-toxin IgG was visualized by plotting the inversion of cells arrested in phase 
G2M against anti toxin IgG concentration (Figure 5.6). We observed a good 
correlation (rho~0.85, r<0.05, Spearman’s correlation coefficient test) between anti- 
toxin IgG and neutralization for plasma samples in which the anti-toxin IgG was 
<100 EU. However, there was no such correlation between anti toxin IgG and 
neutralization for plasma samples in which the anti-toxin IgG was ³100 EU. This 
segregation in the capacity of human plasma to neutralize typhoid toxin suggests a 
saturation effect. The maximum neutralization ability of toxin-specific antibodies 
was reached at approximately 100 EU, whereby the amount of inoculated typhoid 
toxin was presumably all neutralized.  
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Figure 5.5 The ability of human plasma from typhoid patients to neutralize typhoid toxin  
Toxin neutralization was performed by examining the ability of different plasma samples to block the DNA damage response induced by typhoid toxin in 
cultured epithelial cells, which was figured by the number of arrested cells in the G2M phase of cell cycle in the intoxication experiment. Plots A-D represent 
the percentage of arrested cells at G2M phase of cell cycle. Right Y-axis was constructed by log scale of anti-toxin IgG in ELISA Unit of the plasma samples 
in community (A), and in undefined febrile (B), S. Paratyphi A (C) and S. Typhi (D) patients. Values of the right Y-axis are shown in solid lines. Left Y-axis 
was constructed by log scale of the percentage of arrested cells at G2M phase of cell cycle. Values of the left Y-axis are shown in dashed lines.   
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Figure 5.6 Association between toxin neutralization ability and anti-toxin IgG concentration  
Y-axis was constructed by Inversion of log scale of the percentage of arrested cells at G2M phase of cell cycle (IG2M). The Spearman’s 
correlation (rho) between the level of antibodies and IG2M reached to 0.85 (r<0.01) when antibody titre was less than100 EU and rho 
approached to zero when the level of antibody exceeded 100 EU. 
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5.3 Discussion  
Typhoid is still a life-threatening disease, especially in endemic parts of Africa and 
South Asia where the poverty compounds the modest circumstance of current 
typhoid diagnosis and treatment 76. Better case detection is a principal aspect that 
should be considered for combating typhoid, followed by the need for an 
alternative/assistant therapy for typhoid treatment because of the sharp rise in 
reduced susceptibility and resistance to fluoroquinolone and other antimicrobials 
among S. Typhi and S. Paratyphi A strains globally 43,46,50. The recent discovery of 
typhoid toxin and the various studies on its activities have revealed its potential for 
both diagnosis and treatment 139,415. However, the experiments determining the 
function of typhoid toxin were performed either in vitro with human cell lines or in 
non-human primates (chimpanzee); therefore, we need further data and functional 
evaluation in human, the actual species where typhoid arises. The activite subunit of 
typhoid toxin (cdtB) was recently assessed for the first time for its ability to classify 
typhoid patients and generated some promising results as an application for 
diagnosis 333. Conducting additional investigations using longitudinal samples from 
typhoid patients (>200 enteric patients and >300 patients with undefined febrile 
disease) I investigated the acute and longitudinal immunological responses to 
typhoid toxin; the resulting data suggests that antibody against typhoid toxin is 
functional and may be suitable as a future approach for typhoid treatment. 
 
Typhoid toxin is a virulence factor which is thought to be highly associated with 
early symptoms of typhoid 138. I found that acute anti-toxin IgM responses were 
comparable between patients infected with S. Paratyphi A and S. Typhi. Notably, 
these antibody titres were significantly different and generally greater degree than 
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those for febrile patients with an unidentified pathogen. The possibility of having 
culture negative typhoid cases in the undiagnosed febrile patient group, which I used 
as the control for our classification, might have led to the reduction in specificity 
and sensitivity compared to those in the earlier study on acute immune response to 
CdtB 333. I obtained better discrimination for S. Typhi infected cases when anti-CdtB 
IgM profile was combined with anti-Vi IgM 333.This result may be a consequence of  
recompense for weakness of the induced IgM between polysaccharides and proteins 
333. Seemingly, I achieved a better typhoid case classification when combining acute 
antibody responses against typhoid toxin with Vi and O2.  
 
Given that the typhoid toxin is shared between S. Typhi and S. Paratyphi A (and limited 
other Salmonella serovars) it appears that this may be a prime candidate for a diagnostic 
marker. The data suggests that the majority of patients have an early and prolonged IgG 
antibody response when infected with either S. Typhi and S. Paratyphi A. Consequently, 
these data are encouraging and suggest that any early IgG response may be suitable marker 
for the serological detection of enteric fever. The data presented here need to be replicated 
in additional cohorts and the utility of this approach should be tested in comparison to other 
diagnostic methods and the gold standard of blood culture.  
 
The time duration for samples from patients was three months, which made this 
study a valuable insight into the longitudinal, long-term antibody responses to 
typhoid toxin. The trends of longitudinal response to typhoid toxin were marginally 
different between S. Paratyphi A and S. Typhi patients, providing better recognition 
for S. Typhi over S. Paratyphi A. The different distribution of the immunological 
responses against typhoid toxin between S. Paratyphi A and S. Typhi patients at 
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three months post onset of disease suggests longer term immunity to typhoid toxin 
in the later patient group. This observation also suggests that S. Typhi may have a 
distinctive ability for using the toxin as a key virulence factor, despite the toxin and 
its supportive proteins encoded by both S. Typhi and S. Paratyphi A. All of the 
experimental studies on typhoid toxin, including the data presented here, have been 
performed by using typhoid toxin purified from S. Typhi, which may have left 
specific signatures that make it better recognized by the immune system in those 
infected with S. Typhi than S. Paratyphi A. 
 
An examination into the serum bank revealed that anti-toxin IgG correlated well 
with anti-Vi IgG (in the majority of the serum bank) but to lesser degree with anti-
O2 IgG. Vi and O2 have been traditionally used to serologically detect S. Typhi and 
S. Paratyphi A, respectively 264. The inclusion of anti-O2 IgG in addition to anti-
toxin IgG and anti-Vi IgG on the serum bank samples provided evidence that anti-
toxin IgG is preferable over Vi and O2 for detecting typhoid exposures. A potential 
downstream application of these data may be for estimating disease burden in 
locations with endemic typhoid for epidemiologic surveillance. This approach is 
ideal at it provides a specific tool that can detect exposure to either of the causative 
agents of enteric fever. 
 
In this chapter I not only confirmed typhoid toxin as an immunogenic antigen of S. 
Typhi and S. Paratyphi A but also demonstrated the toxin-induced antibody is 
capable of neutralizing toxin. Because typhoid toxin has been demonstrated to be 
responsible for the death-dealing clinical symptoms of the disease 138, my results are 
a significant step towards targeting typhoid toxin as a specific therapeutic through 
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monoclonal antibodies. Further, deactivated typhoid toxin could be considered as a 
component of enteric bivalent vaccines directing both S. Typhi and S. Paratyphi A.  
 
My study may have generated a higher specificity and sensitivity to detect typhoid 
patients using anti-toxin IgM if classification was performed in a group of febrile 
patients with a confirmed diagnosis of other (non-Salmonella) pathogens. Therefore, 
using typhoid toxin for the purpose of developing a serological diagnostic test needs 
further investigation. While these data describe the antibody response dynamics to 
typhoid toxin up to three months after the onset of presentation, it would have 
delivered more insight for the enteric fever immunity if I had had access to 
additional samples collected at more prolonged time points.  
 
In conclusion, I have assessed the acute and convalescent humoral immunity 
responses to typhoid toxin in a longitudinal plasma collection of Nepali people. My 
informative data offers supportive evidence for generating an antitoxin approach for 
enteric fever (caused by both S. Typhi and S. Paratyphi A) treatment. Furthermore, 
my work creates the foundation to support further to use typhoid toxin in diagnosis 
of enteric fever and in vaccine formulations against enteric fever. 
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Chapter 6 Insights into the immunogenicity of Salmonella Typhi 
protein antigens 
 
6.1 Introduction 
Increasing antimicrobial resistance in S. Typhi and S. Paratyphi A infections in 
endemic areas suggest that bivalent vaccine may be a more sustainable approach for 
enteric fever control 416. Conjugate vaccines for enteric fever have been shown to be 
as safe and more efficacious than traditional unconjugated polysaccharide subunit 
vaccines 135. The commonly used carrier proteins (e.g., rEPA, diphtheria toxoid, 
tetanus toxoid, and CRM197) convert polysaccharides (S. Typhi Vi or S. Paratyphi A 
O-specific polysaccharide) into T-cell inducers, but the polysaccharide antigens that 
would be used in these vaccines are heterologous between serovars. A homologous 
S. Typhi/S. Paratyphi A protein antigen that can be conjugated to S. Typhi Vi 
capsular and/or S. Paratyphi A O antigen polysaccharide may enhance a cross-
reactive protective immune response. Consequently, this approach may induce 
greater efficacy than existing heterologous conjugate vaccines 314, but this approach 
has not been progressed or tested in humans 314. Therefore, a conjugate vaccine 
containing the Vi antigen or the S. Paratyphi A O antigen polysaccharide linked to a 
homologous protein antigen that can induce protection that is shared between the 
two serovars is an appealing concept to generate a bivalent vaccine against both 
forms of enteric fever. However, there are little data regarding the immunogenicity 
of S. Typhi and S. Paratyphi A protein antigens during natural infection.  
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Aiming to generate more insight into immunogenic repertoire of S. Typhi protein 
antigens, here I challenged a S. Typhi transposon mutant library with longitudinally 
plasma samples collected from enteric fever patients after the onset of infection to 
identify mutants that were able to survive serum bactericidal activity. I subsequently 
performed transposon directed-insertion site sequencing (TraDIS) on the surviving 
mutants to identify the specific proteins antigens that mediate antibody killing. To 
validate the resulting TraDIS data I sub-selected a smaller collection of TraDIS-
identified S. Typhi antigens to assess their ability of inducing antibody mediated 
killing. Four of these antigens were able to induce bactericidal activity of both S. 
Typhi and S. Paratyphi A. I next aimed to describe the dynamics of the antibody 
response against these immunogenic antigens by measuring acute and convalescent 
antibody (IgG) against this selection of S. Typhi antigens in a cohort of typhoid and 
paratyphoid patients in Nepal. I identified a number of antigens that had sustained 
antibody response and that could induce bactericidal activity; thereby, suggesting 
their utility in a pan-enteric fever vaccine. 
 
6.2 Results 
6.2.1 TnTMDH5 mutant library 
A mutant library consisting of approximately 500,000 mutants was generated using 
a Tn5-derived transposon using a clinical H58 S. Typhi isolate (AS252). The library 
was explored using short-read sequenced using transposon-specific primers 
(transposon directed-insertion site sequencing, TraDIS) to identify all the specific 
insertions. The recovered sequences determined that the TraDIS transposon library 
contained 202,982 unique insertion sites, resulting (on average) of a single insertion 
every 25bp of the genome (genome~4,800,000bp) (see input library in Table 6.1). 
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The insertion index, which equates to the number of unique insertion sites of any 
given gene divided by the gene length, had binomial distribution across the genome. 
This was comparable to a previously generated S. Typhi TraDIS library in the 
attenuated S. Typhi Ty2-derived strain CVD908-htrA 343.   
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Table 6.1 General information of TraDIS post typhoid plasma challenges 
 
Pool of mutants/  
Time of plasma 
collection  
Total reads Reads mapped 
to CT18 (%) 
Unique insertion 
site 
No of genes having 
Log2FC>2, r value<10-5 
Input 2,312,856 93.8 202,982   
Output Day 1 2,535,040 93.54 8,219 292 
Output Day 8 3,480,955 93.81 5,913 614 
Output Month 1 2,793,832 93.82 37,197 81 
Output Month 3 2,731,170 93.22 13,905 204 
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6.2.2 Bactericidal assay against the TnTMDH5 mutant library 
6.2.2.1 Salmonella Typhi antigens as a target for antibody mediated killing 
The generated transposon mutant library was subjected to challenge with plasma 
collected from enteric fever patients at different time points during clinical disease: 
Day 1, Day 8, Month 1, and Month 3 after presentation of illness (named Day 1, 
Day 8, Month 1, and Month 3 from this point forward). The library was challenged 
with plasma for 90 minutes and then plated on LB agar plates overnight, persisting 
bacteria were subjected to DNA extraction the following day. This procedure 
allowed the growth of the mutants that were resistant to the bactericidal activity of 
plasma from enteric fever patients, whilst eliminating or inhibiting susceptible 
mutants. This process was performed in parallel with equivalent experiments where 
the same pool of plasma at each time point was inoculated onto the wildtype parent 
S. Typhi to act as a control. This control was performed to ensure that the 
experimental dilution of pooled plasma was capable of killing 100% of the wildtype 
organisms. Therefore, any mutants that were resistant to bactericidal challenge were 
likely to be generated as a result of them lacking the specific target antigen.  
 
The plasma samples were collected from patients participated in a clinical trial 
comparing two fluoroquinolone antimicrobials for the treatment of enteric fever. 
Therefore, there may be a concern of residual antimicrobials in the plasma samples 
which may affect the results of the bactericidal assays. However, the resulting data 
(presented below) suggest these antimicrobials did not interfere with the bactericidal 
activity because mutations were not identified in the site these antimicrobials are 
active.  
 
 152 
The recovery rates (the proportion of organisms at each time point) of the 
transposon mutant library post plasma challenges are shown in Table 6.2 and the 
numbers of recovered sequences are shown in Table 6.1. The sequences of the 
plasma-challenged output transposon libraries were compared to those of the input 
transposon library at each time point to identify the loci encoding antigens required 
for antibody mediated killing. Essentially, the interruption of genes with a 
transposon insertion generated a set of clones that could survive the challenge with 
plasma from typhoid patients. This process enriched specific genes in the output 
pool in comparison to the input pool. Genes that were significantly increased in the 
output pool (Log2Fold-Change >=2 and r value <10-5) were considered to be 
relevant for further investigation.  
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Table 6.2 The bacterial recovery rate of TraDIS post challenge with typhoid plasma 
Time of plasma 
collecting 
% Bacterial recovery compared to control 
 
Wild-Type S. Typhi  Transposon mutant S. Typhi 
Day 1 0% 0.05% 
Day 8 0% 0.01% 
Month 1 0% 0.28% 
Month 3 0% 0.06% 
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6.2.2.1.1 Molecular functional classes and KEGG pathways 
After challenging the transposon mutant library with Day 1, Day 8, Month 1 and 
Month 3 typhoid patient plasma, I identified 292, 614, 81, and 204 candidate 
mutants that respectively survived the challenge at the specified significance level 
(L2FC>=2 and r value <10-5) (Appendix A). The candidate gene collections 
identified at Day 1, Day 8, Month 1 and Month 3 were classified according to 
previously assigned functional classes (Table 2.7).  
 
The most common and shared molecular functional classes identified in the output 
pools at the various time points were genes involved in cell envelope, 
transport/binding proteins, pathogenicity, broad regulatory proteins, and genes 
encoding a large quantity of unknown and hypothetical proteins (Figure 6.1). These 
candidate genes were also categorised into various biological pathways using the 
KEGG pathways system 417 (Figure 6.2). The majority of identified pathways were 
shared between two, three, or all four of the time points. The most prominent 
biological pathways identified were involved in infection (sty05132), quorum 
sensing (sty02024), bacterial chemotaxis (sty02030), flagella assembly (sty02040), 
peptidoglycan biosynthesis (sty00550), lipopolysaccharide biosynthesis (sty00540), 
bacterial secretion (sty03070), purine metabolism (sty00230), and two-component 
regulation (sty02020). Additionally, the gene pool at each time point also identified 
specific biological pathways that may reflect the different phases of bacterial 
infection. Of note, the specific biological pathways identified on Day 8 and Month 3 
were siderophore biosynthesis (sty01053), and fatty acid metabolism/ biosynthesis/ 
degradation (sty01212/ sty00061/ sty00071), respectively.  
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Figure 6.1 Functional classification of Salmonella Typhi genes identified following 
typhoid plasma challenge of the Salmonella Typhi transposon mutant library  
Functional classes are indicated on the outer most circle. Four circles from the middle 
represent 20 – 40 – 60 – 70 per cent of the cumulative percentage of functional classes over 
four time points. Purple, blue, green and red blocks are representatives of Month 3, Month 
1, Day 8, Day 1 respectively. 
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Figure 6.2 Shared KEGG pathways of Salmonella Typhi genes identified following 
typhoid plasma challenge of the Salmonella Typhi transposon mutant library 
KEGG pathways fitted for identified genes from Day 1 (red oval), Day 8 (green oval), 
Month 1 (blue oval) and Month 3 (purple oval). The number of specific or shared pathways 
among time points are indicated by a number in a corresponding division.  
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6.2.2.1.2 Candidate genes 
Approximately 20 – 25% of all identified genes at each time point encoded either 
hypothetical or unknown proteins, opening great potential for further investigation. 
However, several groups of genes, which have been previously studied, were 
identified at specific time points or at all time points. Flagellar associated genes 117 
such as fliHKNMT, flgG, and the torque-generating machinery, motA, and genes 
associated with invasion and the SPI-1&2 type III secretion systems, such as invA, 
invF, pagC, prgh, spaM, sigD, sipB, sseB, sspH2, stpA were also identified 418–423. 
Notably, these key loci (and others as described in Appendix A) were detected at all 
four time points. Genes required for bacterial adherence to the host cells as well as 
those involved in bacterial motility, such as fimbriae (17 genes in total, including 
fimF, fimW, fimbrial subunits bcfA, steF, fimbrial chaperons steC, stbB, and 
stgB,123,424) and type IV pilus (4 genes, pilABCT, 425,426) (Appendix A), were 
enriched at Day 1 and Day 8. Genes associated with the synthesis and export of 
siderophores (STY0631, STY0637, STY0639, STY0641) 427–429 and genes 
involving in Vi capsular polysaccharide synthesis, tviABCDE and vexABE 118, were 
detected at Day 8 but not the remaining time points (Appendix A).  
 
The gene pools of the mutants recovered from the typhoid plasma challenges 
revealed some overlap with the gene pools previously detected using a protein 
microarray that detected immunogenic antigens 336. This overlap encompassed 46 
genes over the four time points: Day 1, 9 genes; Day 8, 23 genes; Month 1, 3 genes; 
and Month 3, 11 genes (Table 6.3). Notably, 6 genes out of this overlap were also 
identified as having diagnostic potential in Chapter 4 333; these genes were 
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STY3208, STY1372 (Day 1), STY1767_nlpc, STY4190_yhjJ (Day 8) and 
STY1612, STY1498_hylE (Month 3).  
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Table 6.3 Genes identified by protein array* and by TraDIS following typhoid plasma challenges of the Salmonella Typhi transposon  
mutant library 
GeneID_CT18 GeneID_ ATCC9150 Gene name Description Antibody class** Time 
STY1372 SPA1195 pspB phage shock protein B IgM D1 
STY3008 SPA2743 sipB pathogenicity island 1 effector protein IgG D1 
STY2595 SPA0500 dedD DedD protein IgG D1 
STY0332 SPA2464 safA probable lipoprotein IgG D1 
STY2259 SPA0817 pduT putative propanediol utilization protein PduT IgG D1 
STY1871 NA - putative heat shock protein IgG/IgM D1 
STY3208 SPA2920 - hypothetical protein IgG D1 
STY3684 NA - phage lysis regulatory protein, LysB family IgG/IgM D1 
STY1767  SPA1500 nlpc putative lipoprotein IgG D8 
STY4190  SPA3469 yhjJ putative zinc-protease precursor IgG D8 
STY4519 SPA4136 phoN nonspecific acid phosphatase precursor IgG D8 
STY3970 SPA3658 ibpB/hslS heat shock protein B IgG D8 
STY2467 NA sspH2 secreted effector protein IgG D8 
STY2894 SPA2633 iroN TonB-dependent outer membrane siderophore receptor  IgG D8 
STY4023 SPA3613 mgtB Magnesium transport ATPase, P-type 2 IgG D8 
STY0231 SPA0215 htrA protease DO precursor; heat shock protein HtrA IgG D8 
STY1384 SPA1205 mppA periplasmic murein peptide-binding protein MppA IgG D8 
STY2179 SPA0899 fliH flagellar assembly protein FliH IgG D8 
STY3958 SPA3670 yhjA probable cytochrome c peroxidase IgG D8 
STY3969 SPA3659 hslT heat shock protein A IgG D8 
STY4260 SPA0206 ggt putative minor fimbrial subunit; putative adhesin IgG D8 
STY4721 SPA4181 hflC HflC protein IgG D8 
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GeneID_CT18 GeneID_ ATCC9150 Gene name Description Antibody class** Time 
STY3765 SPA3947 - hypothetical protein IgG D8 
STY4570 NA traB TraB pilus assembly family protein IgG/IgM D8 
STY3837 SPA3881 - putative lipoprotein IgG D8 
STY0294 SPA2496 - ClpB-like protein IgG D8 
STY1368 SPA1191 sapB peptide transport system permease protein SapB IgG/IgM M1 
STY1498 SPA1306 hlyE haemolysin HlyE IgG M3 
STY0793 SPA1996 tolA tolA protein IgG M3 
STY0107 SPA0093 surA survival protein SurA precursor IgG M3 
STY3252 SPA2962 pilT Type II secretion, ATP-binding, protein IgG M3 
STY3178 SPA2898 - conserved hypothetical protein IgG/IgM M3 
STY1444 SPA1249 - putative glycolate oxidase IgG M3 
STY1612 NA - putative membrane protein IgG/IgM M3 
STY0303 SPA2484 - probable lipoprotein IgG M3 
STY4745 SPA4206 yjfY conserved hypothetical protein IgM D1 
STY0065 SPA0057 oadG oxaloacetate decarboxylase gamma chain IgM D8 
STY3969 SPA3659 hslT heat shock protein A IgM D8 
STY4260 SPA0206 ggt putative minor fimbrial subunit; putative adhesin IgM D8 
STY3093 SPA2820 - hypothetical protein IgM D8 
STY3671 NA - possible lipoprotein IgM D8 
STY2368 SPA*** - Putative membrane protein IgM M1 
STY0788 SPA2001 ybgT putative membrane protein IgM M1 
STY0682 SPA2102 tatE sec-independent protein translocase protein TatE IgM M3 
STY1969 SPA1034 - putative exported protein IgM M3 
STY4599 SPA2554 - hypothetical protein IgM M3 
*Protein array 336 
**Antibody classes immune-recognised by the protein array 
***STY2368 is a conserved protein among Salmonella enterica. It is a small protein (38 aa) on Salmonella Paratyphi A ATCC_9150 genome, 100% matched 
to STY2368 but is not annotated. 
NA. not available on S. Paratyphi A genome 
D1: Day 1; D8: Day 8; M1: Month 1; M3: Month 3  
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6.2.3 Antibody-dependent complement-mediated killing by mice plasma 
immunised with Salmonella Typhi antigens  
6.2.3.1 Plasma directed Salmonella Typhi killing 
I aimed to validate the TraDIS data by investigating a selection of six candidate 
genes (STY3208, STY1372, STY1767_nlpc, STY4190_yhjJ, STY1612, and 
STY1498_hylE) that were identified by protein microarray and TraDIS. I aimed to 
assess if IgG against the selected antigens was functional for inducing specific 
bactericidal activity against S. Typhi. I hypothesized that plasma from animals 
immunised with specific antigens is capable of reducing or restricting the growth of 
a wild type S. Typhi. Further, I hypothesised that mutants lacking the specific gene 
encoding the target antigen (dMT) would not be subjected to the same bactericidal 
activity. I additionally extended this experiment to the other antigens that I 
evaluated for diagnostics (STY0452, STY0796, STY1086, STY1522, STY1703, 
STY1886, STY4539) and to other S. Typhi antigens known to be antigenic 
(STY1479_yncE, Vi).  
 
To test the above hypothesis, C57BL mice were independently immunized with 
these 14 protein antigens, the Vi polysaccharide antigens and PBS. Plasma from 
each of the mice immunized with the specific antigens were used to challenge the 
WT S. Typhi and the corresponding isogenic dMT mutant. Plasma from mice 
immunised with PBS was used as a control for bactericidal assay. Plasma from mice 
immunised with PBS demonstrated some intrinsic bactericidal activity against the 
wild type strain and each of the mutants, this killing activity was comparable 
between the wild type and mutants and ranged from 0% to 4% (data not shown). 
This correction factor was used for each antigen to control for the effect of intrinsic 
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bactericidal activity. The results of the bactericidal assays with plasma from all 15 
antigen immunisations could be categorized into three groups (Figure 6.3). The first 
group (n=5) contained the plasma from the mice immunised with STY0796, 
STY1086, STY1372, STY1498 and Vi. All could induce bactericidal killing with 
WT S. Typhi but not (or low level) to the paired dMT (i.e. an isogenic organism 
lacking the gene encoding the target protein). The second group (n=4) contained the 
plasma from the mice immunised with STY1612, STY1703, STY1767, and 
STY3208 failed to induce bactericidal activity to both the WT and the paired dMT. 
Finally, the third group (n=6) contained plasma from the mice immunised with 
STY0452, STY1479, STY1522, STY1886, STY4190 and STY4539. These plasma 
samples showed a comparable degree of bactericidal activity between WT and dMT 
or exhibited no bactericidal activity against the dMT but low level killing against the 
WT.  
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Figure 6.3 Bactericidal activity of immunised mice plasma on Salmonella Typhi and Salmonella Paratyphi A  
Bacteria was challenged by mice plasma immunised with selected antigen-immunised individually. Killing rates, for a wild type parent strain (WT) in orange 
and for a descendant mutant strain (dMT) in green, were calculated as (1- ratio (number of SBA active_complement recovered colonies /SBA inactive_complement 
recovered colonies) x100%. The first group shows good bactericidal activity of S. Typhi (STY) and S. Paratyphi A (SPA) challenged by mice plasma 
immunised with four protein antigens (STY0796, STY1086, STY1372, STY1498) and Vi polysaccharide. The second group does not show any bactericidal 
killing to either WT or dMT S. Typhi challenged by mice plasma immunised with four antigens (STY1612, STY1703, STY1767, STY3208). The third group 
includes results of S. Typhi challenged by mice plasma immunised with six antigens (STY0452, STY1479, STY1522, STY1886, STY4190 and STY4539), 
which showed some degree of bactericidal activity to both WT and dMT.   
0
25
50
75
100
ST
Y0
796
SP
A1
993
_S
TY
079
6
ST
Y1
086
SP
A1
019
_S
TY
108
6
ST
Y1
372
SP
A1
195
_S
TY
137
2
ST
Y1
498
SP
A1
306
_S
TY
149
8
ST
Y4
294
_V
i
ST
Y1
612
ST
Y1
703
ST
Y1
767
ST
Y3
208
ST
Y0
452
ST
Y1
479
ST
Y1
522
ST
Y1
886
ST
Y4
190
ST
Y4
539
 
Ki
lli
ng
 ra
te
 (%
)
 164 
6.2.3.2 Salmonella Paratyphi A killing 
The aim of this series of experiment was to identify shared S. Typhi and S. Paratyphi 
A protein antigens that are immunogenic and able to be targeted by bactericidal 
activity. Consequently, I performed a comparable series of bactericidal assays 
challenging S. Paratyphi A as opposed to S. Typhi. I selected the plasma immunised 
with four antigens (STY0796, STY1086, STY1372, and STY1498) belonging to 
group one (Figure 6.3) as these plasma samples induced bactericidal activity against 
WT S. Typhi, but this was diminished or removed with the isogenic mutants. These 
plasma samples were used in a bactericidal assay against a wild type S. Paratyphi A 
and a corresponding mutant for each of the antigens. The results were consistent 
between S. Paratyphi A and S. Typhi (Figure 6.3). Briefly, plasma from mice 
immunized with STY0796, STY1086, STY1372 and STY1498 could induce killing 
against both WT S. Paratyphi A and S. Typhi, but this was diminished or completely 
removed against a mutant lacking the target antigen.  
 
6.2.4 Salmonella Typhi specific antibody dynamics in enteric fever patients  
Aiming to extend the data generated from the SBA experiment, I investigated the 
dynamics of specific antibody responses to the four antigens (STY0796, STY1086, 
STY1372, and STY1498), that could induce killing to S. Typhi and S. Paratyphi A, 
during natural enteric fever infections. I compared these antibody responses to those 
induced by STY1886, Vi and O2. ELISAs were independently performed to detect 
IgG antibodies against these 7 S. Typhi/S. Paratyphi A antigens on a collection of 
longitudinal plasma samples (up to three-months post presentation/admission) from 
enteric fever patients with culture confirmed S. Typhi and S. Paratyphi A infections 
(S. Typhi, n=152 and S. Paratyphi A, n=68). The same assays were performed on 
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plasma from febrile patients with an undetermined pathogen (n=316), and 
community controls (n=49).  
 
The data generated from this series of ELISAs revealed that antibody could be 
detected longitudinal against all the selected antigens. Therefore, I firstly examined 
if there was a correlation between anti-antigen antibodies in plasma samples from 
different patient groups and the controls (Figure 6.4). Except for the anti-STY1498 
antibody, the antibody responses against the remaining anti-antigen antibodies were 
well correlated to one another in all groups (control and patients); the value of rho 
was >= 0.7 (r<0.05, Spearman’s correlation coefficient test). Conversely, the 
antibody responses against the two polysaccharide antigens (Vi, O2) correlated 
poorly with the protein antigens and to one another.  
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Figure 6.4 Correlation between antibody responses to various Salmonella antigens 
Spearman correlation among antigen-induced antibodies in (A) febrile controls unidentified 
pathogen febrile patients (B), S. Paratyphi A confirmed patients (C) and S. Typhi confirmed 
patients (D). The names of the various antigens and histograms showing the distribution of 
the antibody IgG against such antigens are presented on the diagonal. Scatterplots below the 
diagonal represent the correlation of IgG measurements of the two antigens on a right angle 
to the plots. The numerals above the diagonal depict the Spearman correlation coefficient 
(rho) values of the mirrored plots. OD values of each antigen-induced antibody are 
presented on side of the corresponding scatterplots. 
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Notably, more than 50% and 40% of patient population infected with S. Typhi or S. 
Paratyphi A, respectively, had detectable IgG against all antigens on Day 8 and 
Month 1. These responses were elevated by at least 15% in comparison to those 
measured on Day 1 (Figure 6.5). Conversely, those with afebrile controls and 
undetermined pathogen febrile patients did not elaborate a comparative antibody 
response.  
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Figure 6.5 Anti-antigen IgG measurements at threshold of 15% elevation in 
comparison to those measured on Day 1  
Vertical axis represents the percentage of patient population having at least 15% elevation 
of IgG measurements in comparison to those measured on Day 1. Different shapes represent 
different time points; circles for Day 8, triangles for Month 1 and squares for Month 3. 
Colours indicate groups of patients; green for unidentified febrile patients, blue for S. 
Paratyphi A infected patients and red for S. Typhi infected patients. Blue and red dashed 
lines were constructed at 43% and 50%, respectively, of the vertical axis measurement unit. 
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On the day of admission, the concentrations of anti-antigen IgG in plasma from the 
three patient groups were found to be at a comparable level in plasma samples from 
afebrile community controls (r>0.05, Wilcoxon signed-rank test), this was true for 
all antigens (Figure 6.6). However, the general dynamic patterns of longitudinal 
anti-antigen IgG in plasma samples of three patient groups was different. Firstly, in 
the group of febrile patients with an unidentified pathogen (Figure 6.6A), the IgG 
response induced by the majority of the antigens (except STY1498) were 
longitudinally comparable to the baseline measurements recorded on Day 1 (r>0.01, 
Wilcoxon matched-pairs signed-rank test). Secondly, in the S. Paratyphi A 
confirmed patients (Figure 6.6B), in comparison to those at Day 1, the induced 
antibody IgG significantly increased at Day 8 (STY1498 and O2, r<0.05, Wilcoxon 
matched-pairs signed-rank test) or gradually increased achieving a statistically 
significant difference at Month 1 (STY0796, STY1086, STY1372, r<0.05, 
Wilcoxon matched-pairs signed-rank test); both trends were consistent until Month 
3. Alternatively, IgG antibody against Vi was not significantly elevated over the 
reference/baseline measurements at any time point of sampling (r>0.05, Wilcoxon 
matched-pairs signed-rank test). Thirdly, in the S. Typhi confirmed patients (Figure 
6.6C), the anti-antigen IgG concentrations in plasma samples (for all antigens, 
individually) were significantly elevated at Day 8, in comparison to those at Day 1, 
(r<0.05, Wilcoxon matched-pairs signed-rank test) and remained consistently high 
until Month 1. This was true of all antigens with the exception of IgG against O2 
polysaccharide which declined substantially after Month 1 (r<0.05, Wilcoxon 
matched-pairs signed-rank test), plateauing to the concentration of Day 1 at Month 3 
(r>0.05, Wilcoxon matched-pairs signed-rank test) (Figure 7.6C). Notably, antibody 
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against the other antigens was maintained at a stable and comparable level as those 
measured on day 8 until the end of the observation (STY0796, STY1498 and Vi, 
r<0.05, Wilcoxon matched-pairs signed-rank test). Some IgG titres even rose again 
after Month 1 and significant differences between Day 8 at Month 3 titres were 
observed for STY1086 and STY1372 (r<0.05, Wilcoxon matched-pairs signed-rank 
test) (Figure 6.6C).   
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Figure 6.6 Longitudinal IgG responses against Salmonella Typhi/Salmonella Paratyphi A antigens in a Nepali cohort of febrile patients and 
controls 
Three panels of boxplots showing IgG measurements (log10 of ELISA Unit) in plasma from febrile patients with an unidentified pathogen (A panel in green), 
S. Paratyphi A infected patients (B panel in blue) and confirmed S. Typhi infected patients (C panel in red). Every group of five boxplots presents IgG 
responses against a specific antigen, with the first box is the IgG measurement in the afebrile controls (orange), the 2nd to 5th boxes are the IgG measurement 
in the patient groups on Day 1, Day 8, Month 1 and Month 3, respectively. Antibody responses against STY0796, STY1086, STY1372, STY1498, O2 and Vi 
are displayed from left to right. Dark horizontal lines represent the mean IgG measurement, with the box representing the 25th and 75th percentiles, whiskers 
represent the 5th and 95th percentiles; outliers are represented by dots.   
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6.3 Discussion 
The current licensed vaccines against S. Typhi are likely to play an important role in 
the decline of typhoid worldwide 430; however, they do not confer protection against 
S. Paratyphi A 323. Furthermore, paratyphoid vaccine development is lagging behind 
the increase of reported paratyphoid cases 323. Focussing on development of a mono-
valent vaccine for either of the typhoidal Salmonella serovars does not convey the 
real need for enteric fever control campaigns. Bi-valent vaccines against both S. 
Typhi and S. Paratyphi A would be a valuable public health tool to address this life-
threating disease more broadly 416. The novel strategy of using a homologous 
protein carrier between serovars for the bi-valent conjugate vaccines should become 
a priority 431, which may enhance the immune response against the targeted 
pathogens leading to extra effectiveness over conjugates using a heterologous carrier 
314. 
 
The stimulation and prolongation of a protective antibody response of an 
immunogenic candidate antigen is crucial for the development of a successful 
vaccine. However, a more informed understanding of the host immune responses 
against S. Typhi/ S. Paratyphi A has proved challenging as these two typhoidal 
serovars are restricted human pathogens. Therefore, the antigens provoking a 
potentially host protective immune responses have been largely uninvestigated. The 
immunogenicity of a small number of S. Typhimurium and S. Typhi antigens, such 
as Fim C_S 432, outer membrane adhesion protein T2544 433,434, and OmpS1&2 435, 
have been studied in mouse models and extrapolated to typhoid infection in humans. 
However, the antigens that found to be immunogenic in murine models may not 
adequately recapitulate in S. Typhi natural infection 436. Some studies have 
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investigated in vitro stimulation to human immune cells that were collected from 
post Ty21a immunized vaccinees by S. Typhi protein antigens such as SifA, OmpC, 
FliC, GroEL 437. Other studies investigating the immunogenicity of S. Typhi 
antigens for vaccine potential based on the antigen-antibody recognition within 
natural human S. Typhi infected sera have also been implemented 336,438413. Yet, 
these studies stopped after confirming the presence of these antigen-antibody 
complexes in the typhoid patient plasma (differed from in healthy control plasma) 
without any investigation of their function. As S. Typhi and S. Paratyphi A are 
facultative intracellular bacteria, humoral and cell-mediated immunities 
harmoniously orchestrate the duty of eradicating extracellular bacteria and bacteria-
infected cells 439. Antibody-dependent complement-mediated killing (bactericidal 
activity) is one of two operative attributes (antibody-dependent phagocyte-mediated 
killing or opsonophagocytic activity is the other) of serum antibodies that have been 
recorded for estimation of protection potential of bacterial vaccines including for 
typhoid 431,440–442.  
 
My study performed a series of experiments to generate extensive information on 
the induction and function of antigen specific antibody (direct S. Typhi/ S. Paratyphi 
A killing) over time, after the original point of infection. The primary screening for 
immunogenic S. Typhi antigens were longitudinal plasma bactericidal activity, 
which delivered a unique data that provides fundamental data for future research on 
novel immunogenic antigens that may contribute to vaccine development. The most 
common and shared (between time points) molecular functions of the target 
antibody response were cell envelope, pathogenesis, quorum sensing, bacterial 
chemotaxis, and previously characterised genes involved in flagella biosynthesis. 
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These targets were identified throughout the course of investigation; confirming that 
functional and long-lasting antibodies are induced by antigens involved in the 
bacteria communicating with each other, the surrounding environment, and with the 
host. Additionally, fimbriae and pili are amongst the earliest virulence factors that 
bacteria exploit during infection, these were also found to induce specific and 
functional antibodies at early time points.  
 
Fatty acids are a vital component of a bacterial cell, and especially important for 
inner and outer membrane structures 443. My data suggested that even though the 
fatty acid component of the outer membrane appears to stimulate specific antibody 
production in the convalescent phase of infection the antibodies are functional and 
last until at least Month 3 post presentation. Siderophores are small ferric iron 
binding molecules secreted by microorganisms in response to iron stressing 
conditions 429. As soon as entering the oxygen-rich environment (like peripheral 
blood), where ferrous iron is oxidized and turns into an insoluble form, 
microorganisms excrete siderophores to acquire and solubilize ferric iron 429. In a 
pathogenic context, siderophores are a principal virulence factor that not only 
facilitate the infecting organism to grow but also disrupts iron homeostasis in the 
organelles of host cells 429. The fact that genes involved in the siderophore 
manufacturing processes were specifically recognised by antibody in Day 8 plasma 
highlights the role of these structures during the early pathogenesis of S. Typhi in 
human blood. The window that S. Typhi is likely to be present in blood (an oxygen-
rich environment) after successfully translocating through the barrier of intestinal 
ECs and replicating in macrophages is likely to be short and at least 48 hours (the 
time it takes to produce an antibody response) before the Day 8 sampling point. 
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Genes associated with the capsular polysaccharide Vi was only found in the gene 
pool produced after challenge with Day 8 plasma, while Vi polysaccharide vaccines 
confer protection for at least 3 years 444. Therefore, to decipher the complete 
underlying mechanisms which foster the protective efficacy of the Vi 
polysaccharide vaccines requires more investigation. 
  
A validation of the TraDIS data revealed that four antigens (excluding Vi 
polysaccharide) STY0796, STY1086, STY1372, and STY1498 and their equivalent 
antigens of S. Paratyphi A could induce antibody specific bactericidal activity, 
which stimulated strong and selective antibody-dependent complement-mediated 
killing. Additionally, bactericidal activity of anti Vi containing plasma to Vi+ and 
Vi- S. Typhi reconfirmed previous findings that prevention of Vi capsular to 
complement-medicated killing can be overcome by specific anti Vi antibody 133. 
Further, the acquisition of natural antibody IgG against STY0796 (SPA1993), 
STY1086 (SPA1016), STY1372 (SPA1195) and especially STY1498 (SPA1306), in 
patients infected with S. Typhi and S. Paratyphi A, demonstrated these antigens are 
able to induce longitudinally specific antibody in both S. Typhi and S. Paratyphi A 
infections. Previously, I identified 3 S. Typhi antigens (STY0796, STY1086 and 
STY1372) that were promising for the serological diagnosis of typhoid (Chapter 4) 
333. STY1498, which encodes HylE is an important S. Typhi virulence factor 445–447. 
HlyE (also known as ClyA or SheA), which exists in both S. Typhi and S. Paratyphi 
A, is a haemolysin pore-forming toxin which accumulates in the periplasmic space 
of the bacterial membrane 448. This protein was found to have diagnostic potential 
by immunoaffinity proteomic-based technology (IPT) 413 and on a protein array 336. 
Further, its diagnostic discrimination has been evaluated among typhoid patients, 
 176 
other infections, and healthy controls in children in Africa 449. My data suggests that 
an immunogenic, inactivated form of HlyE may also act as a S. Typhi/S. Paratyphi 
A vaccine candidate. 
 
The work in this chapter study would have been more sequential if all immunogenic 
antigens identified by the protein array and the TraDIS (Table 6.3) could have been 
validated and investigated for their ability to induce longitudinal IgG. Expanding the 
validation of the TraDIS results is current being performed in my research group 
and we aim to develop this work further into vaccinology. Further, a more expansive 
understanding of the antibody response to these antigens in different cohorts in 
different locations will be essential for understanding their utility and reproducibility 
in other settings.   
 
In conclusion, the work presented in this chapter provides a unique set of data on S. 
Typhi antigens that can induce an antibody response and are capable of directing 
bactericidal killing during natural infections. Additionally, a subset of these antigens 
has been further validated in vitro and will add valuable information to the 
development of new generation of conjugate vaccines against enteric fever.   
  
 177 
Chapter 7 Estimating the burden of typhoid carriers in a typhoid endemic 
city in Asia 
 
7.1 Introduction 
The principal agent of typhoid fever is S. Typhi, which has highly complex 
pathogenesis. Briefly, after being ingested, S. Typhi is translocated through the wall 
of the small intestine and disseminates in low concentrations throughout the body in 
the reticuloendothelial system via the blood, bone marrow, and liver. A further 
characteristic of S. Typhi is the ability of the organism to enter an asymptomatic 
carrier state, which is thought to be vital for geographical dispersal, maintenance of 
a diverse bacterial population, and disease transmission 250. During asymptomatic 
carriage, organisms can be sustained for long periods (potentially decades) within 
the gallbladder or other internal organs/tissues (e.g. gallbladder and bone marrow) 
and are intermittently shed in faeces. Therefore, typhoid carriers, such as the 
notorious “Typhoid Mary” Mallon and Mr. N the Milker 450, are assumed to be the 
longer-term reservoirs of infection, and carriers are thought to pose a substantial risk 
to public health 250. Due to the stealth-like nature of typhoid carriage the 
mechanisms and precise epidemiological role of S. Typhi carriage in humans are 
poorly defined and the challenge of prospectively detecting carriers is a key 
objective for regional typhoid elimination.  
 
Aiming to assess the frequency of S. Typhi carriers in a high transmission setting I 
investigated a cross-sectional population who underwent cholecystectomy in a 
general hospital in Kathmandu, Nepal 15. This population had an S. Typhi carriage 
rate of 1.7%. I hypothesized that carriers have a unique immunological profile that 
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can be exploited to estimate the prevalence of carriage in a typhoid endemic 
population. To test this hypothesis, I identified carriage serological signatures using 
plasma samples from these individuals and evaluated these representative markers in 
plasma samples taken from the general population. This work provides a first-time 
serological method for estimating the prevalence of S. Typhi carriage in an endemic 
typhoid region.  
 
7.2 Results 
7.2.1 Typhoid carriers have a limited systemic inflammatory response 
Aiming to study the relation of the systemic inflammatory response to the state of S. 
Typhi asymptomatic carriage, I measured the concentration of eight pro-
inflammatory cytokines (IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, TNF-
alpha (TNF-a) and Interferon-gamma (IFN-g)) and two anti-inflammatory cytokines 
(IL-4 and IL-10) in plasma samples collected from patients undergoing 
cholecystectomy (S. Typhi positive, n=10; S. Typhi negative, n=17) and 89 acute 
typhoid patients (Day 8 after presentation). The entire data set of cytokine 
measurements were then subjected to a principal component analysis (PCA) to 
identify profiles associated with carriage. A visualization of these data identified 
discriminating profiles of these cytokines in acute typhoid patients, S. Typhi chronic 
carriers, and cholecystectomy controls (Figure 7.1).  
 
The cytokine concentrations were subsequently examined to determine if the 
profiles were significantly discriminatory between patient groups. This analysis 
found that those with S. Typhi in their gallbladder had significantly lower 
concentrations of all assayed cytokines in comparison to those with acute typhoid 
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fever (day 8 after hospital admission) (r<0.001, Wilcoxon signed-rank test), and the 
cholecystectomy controls (r<0.001, Wilcoxon signed-rank test) (Figure 7.2). 
Furthermore, I examined the ratio of INF-γ:IL-10 and TNF-α:IL-10 among the three 
groups of patients to assess whether carriage was associated with a down regulation 
of the inflammatory response and found that the S. Typhi carriers had a significantly 
lower INFγ:IL10 ratio than acute typhoid cases (r=0.02, Wilcoxon signed-rank test). 
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Figure 7.1 Visualization of cytokine profiles acquired from different groups of 
patients by Principal Component Analysis (PCA) plot 
Cytokine measurements in plasma samples from different patient groups; acute typhoid 
(blue), cholecystectomy controls (orange) and S. Typhi carriers (red), were visualised by 
PCA plot. PC1, 2: Principle component 1, 2. 
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Figure 7.2 Cytokine measurements in Salmonella Typhi carriers  
Boxplots showing cytokine measurements (pg/ml) in plasma from acute enteric fever patients (blue), cholecystectomy controls (orange), S. Typhi carriages 
(red). Every group of three boxes presents measurement of one pro-inflammatory/anti-inflammatory cytokine. Dark horizontal lines represent the mean 
cytokine measurement, with the box representing the 25th and 75th percentiles, whiskers represent the 5th and 95th percentiles; outliers are represented by dots. 
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7.2.2 Salmonella Typhi carriers have a specific serological profile 
Previous studies have shown that S. Typhi carriers elicit an elevated humoral 
immune response (i.e. higher IgG antibody titres in carriers compared to non-
carriers) against the Vi antigen and STY1479, a hypothetical DNA binding protein 
encoded within the S. Typhi genome 259,406. To validate these observations, I 
performed a series of ELISAs on the plasma samples taken from 148 patients with 
culture confirmed acute typhoid fever (day 8 after admission), 10 culture confirmed 
S. Typhi carriers, and 30 cholecystectomy controls to detect IgG against Vi (anti-Vi 
IgG) and STY1479 (anti-STY1479 IgG). I additionally measured circulatory IgG 
against additional 12 serodiagnostic proteins that I demonstrated to have utility in 
distinguishing between acute typhoid infections and asymptomatic controls 340, and 
the recently described typhoid toxin 137.  
 
I found no differential IgG responses between S. Typhi carriers and cholecystectomy 
controls for the 12 serodiagnostic acute typhoid antigens (r>0.05, Wilcoxon signed-
rank test). Conversely, I found significantly elevated IgG against Vi (r=0.05), 
STY1479 (r=0.008), and typhoid toxin (r=0.02, Wilcoxon signed-rank test) in S. 
Typhi carriers compared to the cholecystectomy controls (Figure 7.3).  
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Figure 7.3 IgG responses against different Salmonella Typhi antigens among 
patients with acute Salmonella Typhi infection, Salmonella Typhi carriages and 
cholecystectomy controls  
Boxplots showing IgG measurements (OD) in plasma from acute S. Typhi infected patients 
(blue), S. Typhi carriages (red), cholecystectomy controls (orange). Every group of three 
boxplots presents measurement of IgG against one antigen. Dark horizontal lines represent 
the mean IgG measurement, with the box representing the 25th and 75th percentiles, whiskers 
represent the 5th and 95th percentiles; outliers are represented by dots. 
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7.2.3 Estimating the prevalence of Salmonella Typhi carriage in Kathmandu 
The fact that I could identify significantly elevated anti-Vi IgG, anti-STY1479 IgG, 
and anti-toxin IgG in S. Typhi carriers suggests that the humoral immune response 
against these antigens could be exploited to identify carriers in the community. 
Therefore, I measured anti-Vi IgG, anti-STY1479 IgG, and anti-toxin IgG in an 
anonymous age-stratified (0-65years) collection of 733 plasma samples from 
asymptomatic individuals collected at the same study site and over the same time 
period as those undergoing cholecystectomies 337. The raw data for the ELISAs from 
the general population are shown in Figure 7.4. These plots suggest some utility in 
using these antigens to detect carriers, as the majority had low antibody titres but 
there were a small number of outliers with highly elevated titres. The broad range of 
antibody titres in the population may have meant some overlap between the resulting 
antibody profiles and carriers.  
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Figure 7.4 Acquisition of antibody IgG against typhoid toxoid, Vi and YncE antigens in an anonymous age-stratified (0-65 years) collection of 
plasma samples from Kathmandu 
Scatter plots showing measurement of IgG (OD) against typhoid toxoid (leftmost panel), Vi (middle panel) and YncE (rightmost panel) in plasma samples 
collected from an age-stratified population of Kathmandu. Values (in OD) of antigen-induced antibodies are presented on Y-axes and ages are presented on 
X-axes. Solid lines represent age-dependent median of the IgG measurements with 95%CI presented by shaded areas.   
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Aiming to detect S. Typhi carriers, I investigated the set of data generated from S. Typhi 
carriers and cholecystectomy controls. The antibody responses exhibited positive 
correlation between antigens with rho>0.6 (r<0.05, Spearman’s correlation coefficient 
test), which was also found in the set of data obtained from the asymptomatic individuals. 
There were, however, no precise cut-offs that could be used to perfectly differentiate 
potential carriers from non-carriers (the cholecystectomy controls). Therefore, I exploited 
log-normal model to estimate the density distribution against antibody titre for each of 
three antigens (based on the data from S. Typhi carriers and cholecystectomy controls) 
(Figure 7.5). The estimated values from these models were used to calculate the odds of 
being a S. Typhi carrier for each individual antigen. These odds were then used to 
calculate the combined/global odds of being a S. Typhi carrier based on three antigens and 
subsequently to construct a ROC curve (Figure 7.6).  
 
Using this model, the best compromise between sensitivity and specificity (expected 
specificity of 1) corresponded to a threshold global odds of S. Typhi carriers of 4.2 (Figure 
7.6), which estimated a prevalence of S. Typhi carriage, among the population of 20≤ aged 
≤65 years, of 2.6% (95%CI=1.3%-4.4%). However, with the intention of targeting the 
elimination of carriers, the spectrum of identification of S. Typhi carriage was extended 
(while preserving high specificity of >0.9), so that less cases of true S. Typhi carriage 
would be missed during the prediction process. The threshold odds were reduced to 2 and 
suggested that 14.1% (95%CI=10.7%-17.5%) of the population of 20≤ aged ≤65 years 
would need to be treated to better target elimination of carriers (Figure 7.6 and Figure 7.7).  
 
Taking the best compromise between sensitivity and specificity (expected specificity of 1), 
the rate of 2.6% was used to extrapolate the prevalence of the total number of S. Typhi 
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carriers in Kathmandu, referencing proximal population figures from the 2011 government 
census (Table 2.8). Consequently, the estimated number of S. Typhi carriers in Kathmandu 
at this time (2011) was 27,623 (95%CI;13,811-46,748) existing among the population of 
20≤ aged ≤65 years (n=1,062,458).  
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Figure 7.5 Log-normal model for density distributions of antibody IgG titres against 
different antigens in Salmonella Typhi carriers and cholecystectomy controls. 
Density distributions of antibody IgG against typhoid toxoid (top panel), Vi (middle panel), 
YncE (bottom panel) were estimated using a log-normal model. For each panel the red and 
orange curves represent the density distributions of S. Typhi carriers and cholecystectomy 
controls, respectively. Vertical red and orange bars represent the individual IgG 
measurements of 10 S. Typhi carriers and 30 cholecystectomy controls, respectively. 
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Figure 7.6 Receiver operating characteristic (ROC) curve assessing the sensitivity and 
specificity of different odd cut-offs for detecting Salmonella Typhi carriers  
The Y-axis displays the true positive rate (sensitivity) and X-axis displays the false positive 
rate (1-specificity). The coordinates of the dots represent a given combination of specificity 
and sensitivity which corresponds with an odd cut-off of being a S. Typhi carrier. The 
colour of a dot represents odd cut-offs of being a S. Typhi carrier, from 0 (navy blue) to 10 
(orange). * and ** are the odd cut-offs of 2 and 4.2, respectively, to which subsequently 
calculate the predicted prevalence of S. Typhi carriers of 14.1% and 2.6%, respectively, 
among the population of 20≤ aged ≤65 years in the plasma bank. 
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Figure 7.7 The variation of predicted prevalence of Salmonella Typhi carriers in the 
population of 20≤ aged ≤65 years in the plasma bank 
A choosen odd cut-off of being a S. Typhi carrier affects the sensitivity and specificity of 
the estimation and subsequently affects the predicted prevalence; the lower the odds cut-off  
the higher the predicted prevalence of S. Typhi carriers. The predicted prevalences (%) of S. 
Typhi carriers in the population of 20≤ aged ≤65 years in the plasma bank vary 
accordingly to the corresponding odds cut-offs. Colour represents the range of odds cut-
offs, from 2 (dark blue) to 5 (light green). * and ** are the odds cut-offs of 2 and 4.2, 
respectively, to which subsequently calculated the predicted prevalence of S. Typhi carrier 
of 14.1% and 2.6%, respectively, among the population of 20≤ aged ≤65 years in the 
plasma bank. 
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7.2.4 Plasma from Salmonella Typhi carriers efficiently induce enhanced 
complement mediated killing  
Due to the anonymous nature of the population plasma bank we were unable to 
follow up any individuals with indicative antibody responses and confirm the 
carriage and/or excretion of S. Typhi. To address this limitation, I performed a series 
of functional antibody assays, measuring the ability of plasma from S. Typhi carriers 
to induce complement mediated bactericidal activity in comparison to plasma from 
acute typhoid patients and the cholecystectomy controls.  
 
At any plasma dilution (of 2-fold serial dilution started from 1:100 to 1:12,800) at 
1.5 hours post inoculation, the plasma from the S. Typhi carriers exhibited 
significantly greater bactericidal activity than plasma from the acute typhoid patients 
and the cholecystectomy controls (r<0.001, Wilcoxon signed-rank test) (Figure 
7.8). These data indicate that S. Typhi carriage and IgG responses against Vi, 
STY1479, and typhoid toxoid correlate with a functional antibody response, and 
may be an additional marker of carriage associated immunity. Furthermore, samples 
from the plasma bank with an antibody response indicative of carriage exhibited 
substantially greater bactericidal activity than plasma from those with low IgG 
responses against the three informative antigens (r=0.01, Wilcoxon signed-rank 
test). Plasma from the predicted S. Typhi carriers induced greater bactericidal 
activity than the acute typhoid plasma samples yet exhibited comparable activity to 
plasma from the S. Typhi carriers. These data confirm the functionality of antibody 
in those with an IgG profile indicative of carriage, identified by antibody IgG profile 
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against to these three antigens and again imply carriage associated immunity in this 
population.
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Figure 7.8 Antibody-dependent complement mediated bactericidal killing of Salmonella Typhi  
Boxplots (top panel) present killing rates of the assayed plasma samples (across 2-fold serial dilutions, started from 1:100 to 1:12,800), which were collected 
from acute S. Typhi infected patients (blue), cholecystectomy controls (orange), S. Typhi carriage (red), typhoid indicative plasma bank (green) and non-
typhoid indicative plasma bank (grey). Lines (bottom panel) show individual killing rates of the same set of data. 
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7.3 Discussion 
During invasive Salmonella infection, PAMPs (pathogen-associated-molecular-
patterns) and DAMPs (danger- associated molecular-patterns) are recognised by 
PRRs (pattern recognition receptors) 99, which activates the innate immune system 
inducing the recruitment of immune cells such as neutrophils and macrophages and 
the generation of pro-inflammatory cytokines 451 99,230,452–454. Cytokines contribute 
greatly to both pathogenesis and control of systemic Salmonella infections 230,452. 
Elevated production of pro-inflammatory cytokines, which promotes a systemic 
inflammatory response, have been observed in patients with acute S. Typhi 
infections 230,452,455 and interferons (IFNs) are the signatures for immunological 
responses to Salmonella infection 99,192. However, limited data has examined the 
cytokine profile of individuals with chronic typhoid carriers. Aiming to understand 
if typhoid chronic carriages induce a comparable cytokine profile as those with acute 
infections, I investigated a panel of pro-inflammatory cytokines in plasma samples 
from acute typhoid patients and chronic carriers. Using principal component analysis 
to visualise the cytokine profiles obtained from different groups of patients, I was 
able to show that cytokine profiles are different between the various phases of S. 
Typhi infections (acute or chronic) and from controls. The subsequent analysis 
revealed distinguishable cytokines profiles in plasma from different patient groups, 
showing significant lower cytokine concentrations in plasma samples from chronic 
carriages than those from acute typhoid patients. The consistent pattern between all 
examined pro-inflammatory cytokines suggests that S. Typhi does not stimulate as 
strong a systemic pro-inflammatory response during chronic carriage stage as it does 
during an acute infection. Additionally, the level of systemic pro-inflammatory 
cytokines in chronic carriage was found to be significantly lower than those in the 
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cholecystectomy controls. These observations indicate that individuals with S. Typhi 
in their gallbladder had diminished concentrations of pro-inflammatory cytokines. 
Additionally, the ratio INF-γ:IL-10 was significantly lower in the S. Typhi chronic 
carriers in comparison to the acute patients and cholecystectomy controls. IL-10 
inhibits synthesis of the pro-inflammatory cytokines IFN-γ, IL-2, IL-3 and TNFα, 
down regulating the inflammatory response and macrophage activation 456.  These 
data suggest that S. Typhi in the gallbladder is actively suppressing the inflammatory 
response. The Vi capsule is known to be immunomodulatory 173,183 and the anti-
inflammatory effect of IL-10 may facilitate the distinct profile of pro-inflammatory 
cytokines and suppress the development of the febrile disease in chronic carriers. 
 
Salmonella carriage is of public concern as these people are a persistent reservoir of 
infection,  contributing to disease transmission and ultimately to new disease 
episodes in the community 250. Additionally, S. Typhi carriers have a significantly 
increased risks of gallbladder carcinoma as a consequence of the chronic irritation of 
their gallbladder 254,255.  Therefore, the prospective detection of chronic Salmonella 
carriers is essential for eliminating local enteric fever transmission 257 as well as 
being valuable knowledge for those carrying the pathogen or having gallbladder 
abnormalities 254. Yet, detection of enteric chronic carriers is not straight forward 
because they are outwardly asymptomatic.  
 
Serological examination, especially the utility of anti-Vi antibody 200,259,457,458,  is a 
practical approach to identify S. Typhi chronic carriers 250,257,258. However, there are 
drawbacks to the use of anti-Vi antibody in typhoid endemic areas as elevated anti-
Vi antibody in healthy individuals is highly prevalent in these regions 457. 
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Campaigns with Vi vaccine in typhoid endemic areas 459 further compound the 
situation. My data demonstrated that antibody (IgG) against YncE, typhoid toxin, 
and Vi are significantly differential between S. Typhi chronic carriers, acute typhoid 
cases and cholecystectomy controls. I used these IgG profiles to detect S. Typhi 
chronic carriers among individuals of 20≤ aged ≤65 years in a plasma bank in 
Kathmandu, a typhoid endemic area. By combining these antibody profiles, I 
estimated an upper limited prevalence of S. Typhi carriage of 14.1% with the least 
missing cases and a specificity of >0.9. However, in order to not misdiagnose any 
non-S. Typhi carriers, the rate was predicted to be 2.6% with highest specificity (=1). 
This estimation of 2.6% is comparable with the findings from the definite diagnosis 
(culture confirmed) of the organism S. Typhi in gallbladder of  those undergoing 
cholecystectomy reported in this original study (1.7% mixed sex) 15, and previous 
studies (4% for female and 2.9% for male) 460. I then calculated that there were an 
estimated 27,623 (95%CI;13,811-46,748) carriers existing among the population of 
20≤ aged ≤65 in year 2011, in Kathmandu valley, Nepal. This work, for the first time 
in almost 4 decades since the estimation of the number of S. Typhi carriage among 
Chilean population reported by Levine at. al in 1982 461, delivers a method to 
estimate the number and prevalence of S. Typhi chronic carrier in an endemic area.  
 
Due to the anonymous nature of the population plasma bank, the confirmation of S. 
Typhi chronic carriage based on serology was not possible. However, I further found 
an association between the bactericidal activity and IgG profiles in plasma from S. 
Typhi carriers. I additionally found that samples in the plasma bank that had an 
antibody profile indicative of carriage also exhibited a comparable bactericidal 
activity. This observation provides supporting data that these individuals are likely 
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true carriers. Of note, the data presented in Chapter 6 suggested that anti-YncE 
(STY1479) antibody did not induce antibody-dependent complement-mediated 
bactericidal activity. Consequently, anti-YncE antibody was not responsible for the 
high level of bactericidal activity against S. Typhi in plasma of S. Typhi carriers.  
 
Even though the estimated rate of S. Typhi carriers was highly comparable with 
previous studies, the method used to identify S. Typhi carriage was developed on a 
small sample size and may have been under powered. Consequently, I suggest these 
methods are validated in a large sample size and in different endemic settings.  
 
In conclusion, S. Typhi carriers have a unique immunological profile with a distinct 
cytokine pattern and antigen specific antibody profiles in their plasma. My findings 
delivered new insights into methods that can be used for identifying and estimating 
the prevalence of S. Typhi carriage in an endemic typhoid population. 
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Chapter 8 General discussion 
 
As we move into the era of potential typhoid elimination through the use of 
conjugate vaccines we need better tools to determine disease burden. We need better 
point of care tests to attribute appropriate antimicrobial treatment and to measure the 
potential impact of immunization or alternative interventions. Also, the detection of 
typhoid carriers is also essential to ensure the disease is eliminated rapidly and to 
limit sustained transmission from carriers after acute shedding is reduced by 
immunization. My thesis outlines several routes that may contribute to these areas.  
 
The emergence of MDR and XDR isolates of S. Typhi 462 and an increasing 
incidence of S. Paratyphi A are contributing to changing the international dynamics 
of enteric fever 463. These changes add urgency to the demand for more efficient 
enteric fever control campaigns. My investigation into the key factors associated 
with typhoid elimination in Vietnam demonstrated that national economic growth, 
affording improved quality of drinking water, and better sanitation was the greatest 
contribution to disease control. These factors reduce the general exposure of humans 
to typhoid causing organisms. Consequently, Vietnam should be considered as an 
exemplar to other current endemic typhoid areas such as Kathmandu (Nepal) and 
Chittagong (Bangladesh). However, these conditions may not be promptly achieved 
in these areas. Therefore, suitable interim measures are required to better manage the 
disease and measure disease burden, the more accurate diagnosis of acute and 
carriage cases is essential. Various approaches have been investigated to overcome 
the limitations of the available diagnostic tests for acute typhoid. Specifically, most 
approaches have low sensitivity (bacterial culture) or modest specificity (serology 
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tests using somatic and flagellar antigens); therefore, these methods are unlikely to 
impact on the development of simple, rapid diagnostic tests over the coming years. 
My study evaluated a range of S. Typhi specific antigens for the purpose of 
identifying acute typhoid cases amongst other febrile infections and afebrile controls 
in Bangladesh. The generated data signified that the combination of the traditional S. 
Typhi capsular antigen Vi with at least one specific S. Typhi protein antigen may 
provide some serological utility for typhoid diagnostics. These antigens may aid in 
the issue of diagnosing febrile disease of unknown origin and facilitate the use of 
appropriate antimicrobial therapy. Further, my study also aimed to address the 
challenges of prospectively detecting asymptomatic typhoid carriers, which is 
strategic for regional typhoid elimination. My findings delivered unprecedented 
advances for identifying and estimating the prevalence of S. Typhi carriage in 
human populations. Another crucial aim for the rational control of enteric fever is 
widespread immunization campaigns of a new generation of vaccines which are safe 
and confer protection to both variants of typhoidal Salmonella. Correspondingly, my 
study also focused on exploring the longitudinal host immune responses against S. 
Typhi and S. Paratyphi A, which delivered a unique set of data regarding a panel of 
novel immunogenic antigens that are shared between the two organisms during 
natural infection. These findings provide valuable preliminary data that may be 
applied to the development of a new generation of conjugate vaccines against enteric 
fever. Additionally, to control enteric fever in endemic areas where organisms that 
exhibit resistance to the last resort antimicrobials may require alternative treatment 
approaches. My work additionally investigated the antibody response against 
typhoid toxin, specifically regarding the acquisition of antibody during natural S. 
Typhi and S. Paratyphi A infection and toxin neutralisation capability. This 
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informative data provides supportive evidence which may provide a significant step 
towards the development of monoclonal anti-toxin antibody that could be used for 
enteric fever therapy.  
 
During the work in this thesis I was granted a UK patent for the use of various 
protein antigens for the diagnosis of typhoid and we have since licensed these 
antigens to Becton-Dickenson for use in their multi-pathogen tropical febrile disease 
screen (Malaria, dengue, and typhoid fever). I see the development of multi-
pathogen assays the most relevant way forward for diagnosing febrile disease in the 
tropical and the differentiation of bacterial, viral, or parasitic disease should be a 
major advance. A further utility of my antigens could be to measure disease burden 
in areas under consideration for immunization programmes. The only current 
surveillance data arises from Widal test or blood culture, both of which have 
limitations. My data suggests that we can measure sero-conversion on populations 
that have typhoid fever. Consequently, these data may be used to assess where 
typhoid vaccines could have the greatest impact. This would be a hugely beneficial 
tool for GAVI eligible countries and may be supported by the WHO. Furthermore, 
the standardisation of such a test(s) would allow for a comparatively cost-effective 
method to assess the impact of vaccination longitudinally. Again, we do not have 
such tools and my data implies that such approaches have potential.  
 
The findings described in my thesis required further assessment through comparable 
studies in additional cohorts. Additionally, further research is currently being 
conducted in my laboratory and other research groups in Asia to validate the finding 
regarding some of the S. Typhi antigens described in my thesis; specifically, with 
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respect to their ability to induce acute and longitudinal immune responses in 
different patient populations. These studies will be crucial for future development of 
commercial enteric fever diagnostic tests and for conjugate vaccine development. In 
conclusion, my thesis contributes to the data required to assist in rational enteric 
fever control campaigns in endemic areas by providing new fundamental, valuable 
data for the purposes of diagnostics, vaccines and potential new treatments for 
enteric fever. Ultimately, I hope this work can have a direct impact on the future 
policy of typhoid disease control in endemic and nin-endemic regions. 
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Chapter 10 Appendices 
Appendix A Full list of S. Typhi CDSs identified following typhoid plasma challenge of the transposon mutant library in chapter 6 
CDS_name Products Functional classes logFC logCPM p.value q.value Time 
point 
Other 
time 
points 
STY1776 50S ribosomal subunit protein L35 3.A.2 Ribosomal protein synthesis, modification 11.7 6.9 1.3E-55 1.7E-54 D1 M3 
STY3499 RNA polymerase sigma-54 factor (sigma-N) 2. Broad regulatory function 8.6 3.9 1.4E-11 2.5E-11 D1 M1M3 
STY2668 pseudogene 4.A.3 Transport Carbohydes, organic acids and alcohols 8.5 3.9 2.3E-11 4.2E-11 D1 M3 
rpoH RNA polymerase sigma-32 factor 2. Broad regulatory function 8.4 7.0 8.2E-56 1.1E-54 D1   
STY2001 hypothetical protein 5.H Hypothetical protein 7.9 3.3 1.2E-08 2.0E-08 D1   
STY3862 conserved hypothetical protein 5.H Hypothetical protein 7.2 2.8 8.4E-06 1.2E-05 D1   
STY3612 diaminopimelate epimerase 1.D.2 Aspartate Family 6.9 6.4 3.7E-41 2.2E-40 D1   
STY0012 DnaK protein (heat shock protein 70) 4.B Chaperones 6.1 7.6 2.1E-59 3.5E-58 D1 M3 
STY3904 glucose inhibited division protein 3.A.7 DNA replication, repair, restriction, modification 5.9 7.2 1.4E-52 1.5E-51 D1 M1M3 
STY2827 ribonuclease III 3.B.1 Degradation of RNA 5.6 5.7 3.0E-28 9.5E-28 D1   
tufB elongation factor Tu 3.A.8 Protein translation and modification 5.6 8.1 1.1E-65 2.7E-64 D1 D8M1M3 
STY4214 putative low-affinity inorganic phosphate transporter 4.A.5 Transport Anions 5.5 9.4 7.9E-83 5.4E-81 D1 M3 
spiA putative outer membrane secretory protein 4.I Pathogenesis 5.4 5.9 8.3E-30 2.8E-29 D1 M3 
psd phosphatidylserine decarboxylase proenzyme 3.A.11 Phospholipids 5.3 7.9 1.2E-58 1.9E-57 D1   
STY3914 ATP synthase epsilon subunit 1.A Degradation 5.2 5.3 1.3E-22 3.2E-22 D1 D8M3 
STY1006 pseudogene 1.A Degradation 5.2 7.1 1.3E-45 9.4E-45 D1 M1 
STY2958 hypothetical protein 5.H Hypothetical protein 5.1 8.5 6.0E-66 1.5E-64 D1   
yrfD conserved hypothetical protein 5.H Hypothetical protein 5.1 9.4 1.0E-76 5.0E-75 D1   
STY3480 probable GTP-binding protein 5.I Unknown 5.1 7.9 8.1E-57 1.2E-55 D1   
STY0731 ferric uptake regulation protein 2. Broad regulatory function 5.0 5.9 1.5E-28 4.7E-28 D1   
trpS tryptophanyl-tRNA synthetase 3.A.5 Aminoacyl tRNA synthesis, tRNA modification 4.9 8.1 6.2E-59 1.0E-57 D1 D8M1M3 
trkA potassium transport protein 4.A.2 Transport Cations 4.9 6.2 2.1E-31 7.5E-31 D1 M3 
STY3937 thiophene and furan oxidation protein 4.G Detoxification 4.8 6.7 8.1E-38 3.9E-37 D1 M3 
STY1909 peptidyl-tRNA hydrolase 3.A.5 Aminoacyl tRNA synthesis, tRNA modification 4.6 6.8 2.2E-38 1.1E-37 D1   
STY1357 peptide transport system permease protein SapC 4.A.6 Transport Other 4.6 4.3 6.6E-12 1.2E-11 D1 M1M3 
STY2568 phosphate acetyltransferase 1.A.1 Degradation of carbohydrate 4.6 4.3 6.6E-12 1.2E-11 D1 M3 
STY3809 6-phosphofructokinase 1.B.1 Glycolysis 4.6 9.5 1.3E-68 3.6E-67 D1 M1M3 
safA probable lipoprotein 4.I Pathogenesis 4.6 6.4 6.8E-33 2.6E-32 D1   
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wcaE putative glycosyltransferase 3.C.2 Surface polysacchar 4.6 8.1 2.8E-54 3.4E-53 D1   
STY4629 hypothetical protein 4.I Pathogenesis 4.4 4.6 6.7E-14 1.3E-13 D1   
ptsJ putative transcriptional regulator 2. Broad regulatory function 4.4 6.2 3.0E-29 9.8E-29 D1 M1M3 
STY0107 survival protein SurA precursor 3.A.8 Protein translation and modification 4.1 8.7 3.7E-54 4.5E-53 D1 M3 
secG protein-export membrane protein 4.A Transport/binding proteins 4.1 7.5 4.1E-41 2.4E-40 D1   
ssrB putative two-component response regulator 4.I Pathogenesis 4.0 6.6 5.3E-32 2.0E-31 D1   
STY1744 pyruvate kinase 1.B.1 Glycolysis 3.9 5.1 1.5E-16 3.1E-16 D1 M3 
STY4231 putative lipoprotein 3.C.1 Membranes lipoprotein 3.9 10.0 5.1E-58 7.9E-57 D1   
STY0781 succinyl-CoA synthetase beta chain 1.B.3 Tricarboxylic acid cycle 3.8 6.9 2.1E-32 7.9E-32 D1   
STY4681 putative transcriptional regulator 2. Broad regulatory function 3.8 9.2 1.6E-51 1.7E-50 D1   
crcB putative membrane protein 3.C.1 Membranes lipoprotein 3.8 7.3 8.8E-37 4.1E-36 D1 M1M3 
STY0181 aconitate hydratase 2 (citrate hydro-lyase 2) 1.B.3 Tricarboxylic acid cycle 3.8 7.0 1.4E-33 5.6E-33 D1 M3 
STY0599 hypothetical protein 5.I Unknown 3.8 7.2 8.2E-35 3.4E-34 D1 M3 
STY4594 hypothetical protein 4.I Pathogenesis 3.8 10.4 7.4E-56 1.0E-54 D1 D8 
STY0374 possible transmembrane regulator 2. Broad regulatory function 3.7 7.8 7.9E-40 4.2E-39 D1   
STY4808 conserved hypothetical protein 5.H Hypothetical protein 3.7 8.8 2.1E-47 1.7E-46 D1   
STY3911 ATP synthase alpha subunit 1.A Degradation 3.7 5.7 1.6E-20 3.9E-20 D1   
STY3092 hypothetical protein 5.I Unknown 3.7 8.4 4.1E-44 2.8E-43 D1   
STY1378 transcriptional regulatory protein TyrR 2. Broad regulatory function 3.6 8.9 8.4E-46 6.4E-45 D1   
STY4842 probable regulatory protein 4.I Pathogenesis 3.6 7.4 5.8E-35 2.4E-34 D1 D8 
STY3463 polynucleotide phosphorylase 3.A.9 RNA synthesis, modification 3.6 11.4 2.6E-53 2.9E-52 D1 D8M1M3 
STY4615 putative phage baseplate assembly protein 4.I Pathogenesis 3.5 7.7 3.8E-36 1.7E-35 D1   
STY2790 conserved hypothetical protein 5.H Hypothetical protein 3.5 8.2 1.3E-39 6.9E-39 D1 M3 
STY1463 putative membrane protein 3.C.1 Membranes lipoprotein 3.5 7.3 7.1E-33 2.7E-32 D1   
STY4875 putative membrane protein 3.C.1 Membranes lipoprotein 3.4 10.1 4.2E-48 3.6E-47 D1   
STY2622 conserved hypothetical protein 5.H Hypothetical protein 3.4 9.5 9.4E-46 7.0E-45 D1   
STY2532 putative membrane protein 3.C.1 Membranes lipoprotein 3.4 8.3 1.6E-39 8.3E-39 D1   
STY3689 phage baseplate assembly protein 5.A Latterally acquired elements 3.4 8.6 3.4E-41 2.0E-40 D1   
malX pseudogene 4.A.3 Transport Carbohydes, organic acids and alcohols 3.4 6.5 1.7E-25 4.8E-25 D1   
STY1918 hydrogenase-1 operon protein HyaF 1.B.7.a Aerobic Respiration 3.4 8.6 9.6E-41 5.4E-40 D1   
tufA elongation factor Tu 3.A.2 Ribosomal protein synthesis, modification 3.4 6.2 1.5E-22 3.8E-22 D1 M1 
STY3907 ATP synthase A chain 1.A Degradation 3.4 5.0 1.7E-13 3.2E-13 D1   
cI phage immunity repressor protein 5.A Latterally acquired elements 3.4 8.3 2.1E-38 1.1E-37 D1   
STY2829 GTP-binding protein LepA 3.A.8 Protein translation and modification 3.4 8.8 5.7E-41 3.3E-40 D1 D8 
STY1162 PhoH protein (phosphate starvation-inducible protein PsiH) 1.C Central Intermediary metabolism 3.3 9.5 3.8E-44 2.6E-43 D1   
steA pseudogene 3.C.3 Surface structure 3.3 8.8 8.3E-41 4.7E-40 D1 M3 
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STY1099 putative secreted protein 3.C.1 Membranes lipoprotein 3.3 8.8 8.3E-41 4.7E-40 D1   
STY3392 conserved hypothetical protein 5.H Hypothetical protein 3.3 8.9 2.2E-41 1.3E-40 D1   
STY2086 conserved hypothetical protein 5.H Hypothetical protein 3.3 9.0 1.5E-41 8.8E-41 D1   
STY1218 flagellar basal-body rod protein FlgG (distal rod protein) 3.C.3 Surface structure 3.3 9.2 2.3E-42 1.4E-41 D1   
STY0514 putative membrane protein 3.C.1 Membranes lipoprotein 3.3 9.3 2.9E-42 1.8E-41 D1   
STY0103 bis(5'-nucleosyl)-tetraphosphatase 1.F.4 Salvage of nucleosides and nucleotides 3.3 5.1 7.8E-14 1.5E-13 D1 M1M3 
sseB putative pathogenicity island effector effector protein 4.I Pathogenesis 3.3 8.5 4.5E-38 2.2E-37 D1 M3 
STY3460 probable amino acid permease 4.A.1 Transport amino acid and amines 3.2 10.1 6.9E-44 4.7E-43 D1 M3 
STY4438 putative exported protein 3.C.1 Membranes lipoprotein 3.2 9.9 5.2E-43 3.3E-42 D1   
STY3952 Solute binding receptor protein 1.B.7.b Anaerobic Respiration 3.2 8.6 1.1E-37 5.3E-37 D1   
STY3626 
probable UDP-N-acetyl-D-mannosaminuronic acid 
transferase 3.C.2 Surface polysacchar 3.2 8.5 3.0E-37 1.4E-36 D1   
STY1248 conserved hypothetical protein 5.H Hypothetical protein 3.2 9.0 2.0E-39 1.0E-38 D1   
pduV putative propanediol utilization protein PduV 1.A.1 Degradation of carbohydrate 3.2 8.5 1.0E-36 4.7E-36 D1   
STY3778 heat shock protein 3.B.3 Degradation of proteins, peptides, glycoproteins 3.2 9.9 5.7E-42 3.5E-41 D1   
STY1653 fumarate hydratase class II 1.B.3 Tricarboxylic acid cycle 3.2 6.8 5.7E-25 1.6E-24 D1   
STY0192 hypoxanthine phosphoribosyltransferase 1.F.4 Salvage of nucleosides and nucleotides 3.2 8.2 9.9E-35 4.1E-34 D1   
STY0186 putative transcriptional regulator 2. Broad regulatory function 3.1 9.5 3.4E-40 1.9E-39 D1 D8 
STY3547 probable LysR-family transcriptional regulator 2. Broad regulatory function 3.1 9.6 4.4E-40 2.4E-39 D1   
STY1251 NADH dehydrogenase 1.B.7.a Aerobic Respiration 3.1 6.4 8.7E-22 2.2E-21 D1 M1M3 
STY1561 spermidine N1-acetyltransferase 1.E Polyamine synthesis 3.1 9.5 2.7E-39 1.4E-38 D1   
STY3633 
UDP-N-acetylglucosamine epimerase (UDP-GlcNAc-2-
epimerase) 3.C.2 Surface polysacchar 3.1 9.6 2.7E-39 1.4E-38 D1   
STY2878 putative type I secretion protein 4.I Pathogenesis 3.1 10.0 7.3E-40 3.9E-39 D1   
STY2751 GMP synthase (glutamine-hydrolyzing) 1.F.1 Purine ribonucleotide biosynthesis 3.0 5.9 1.2E-17 2.5E-17 D1 M1M3 
STY2836 ATP-dependent RNA helicase SrmB 3.A.9 RNA synthesis, modification 3.0 7.9 3.2E-31 1.1E-30 D1 D8M3 
STY1372 phage shock protein B 5.F Adaptions and atypical conditions 3.0 5.7 2.6E-16 5.3E-16 D1   
STY1602 hypothetical protein 5.I Unknown 3.0 7.1 1.6E-25 4.5E-25 D1   
STY3816 manganese superoxide dismutase 4.G Detoxification 3.0 6.5 7.2E-22 1.8E-21 D1   
STY0447 conserved hypothetical protein 5.H Hypothetical protein 3.0 8.5 1.1E-33 4.3E-33 D1   
menC O-succinylbenzoate-CoA synthase 1.G.11 Menaquinone  3.0 8.7 1.5E-34 6.3E-34 D1   
hyaC2 Ni/Fe-hydrogenase 1 b-type cytochrome subunit HyaC2 1.B.7.a Aerobic Respiration 3.0 8.6 3.1E-34 1.3E-33 D1   
STY2839 conserved hypothetical protein 5.H Hypothetical protein 3.0 8.3 2.8E-32 1.0E-31 D1 D8 
STY4497 alpha-galactosidase 1.A.1 Degradation of carbohydrate 3.0 9.3 1.6E-36 7.4E-36 D1   
STY2739 uracil phosphoribosyltransferase 1.F.4 Salvage of nucleosides and nucleotides 3.0 8.9 4.1E-35 1.7E-34 D1 M3 
STY1937 conserved hypothetical protein 5.H Hypothetical protein 3.0 8.8 4.4E-34 1.8E-33 D1   
STY3507 aerobic respiration control sensor protein 2. Broad regulatory function 2.9 8.2 3.1E-31 1.1E-30 D1   
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STY2689 putative membrane protein 3.C.1 Membranes lipoprotein 2.9 8.8 8.5E-34 3.4E-33 D1   
yjga conserved hypothetical protein 5.H Hypothetical protein 2.9 6.6 2.0E-21 4.9E-21 D1 M1M3 
STY1569 conserved hypothetical protein 5.H Hypothetical protein 2.9 8.1 1.2E-30 4.1E-30 D1   
STY0970 hypothetical protein 5.I Unknown 2.9 5.9 3.0E-17 6.4E-17 D1 M1M3 
STY2145 tyrosine-specific transport protein 4.A.1 Transport amino acid and amines 2.9 7.6 1.2E-27 3.6E-27 D1 D8M3 
STY0893 conserved hypothetical protein 5.H Hypothetical protein 2.9 7.8 8.5E-29 2.8E-28 D1   
STY0516 haemolysin expression modulating protein 2. Broad regulatory function 2.9 5.7 3.2E-15 6.5E-15 D1 M1M3 
STY1608 hypothetical protein 5.I Unknown 2.9 8.5 1.1E-31 3.9E-31 D1 M3 
sigD cell invasion protein 4.I Pathogenesis 2.9 8.7 1.7E-32 6.3E-32 D1   
STY1033 putative bacteriophage protein 5.A Latterally acquired elements 2.9 8.9 8.0E-33 3.1E-32 D1   
STY4410 putative pseudouridine synthase 3.A.3 Ribosomal maturation and modification 2.9 10.2 2.4E-36 1.1E-35 D1   
ttrC tetrathionate reductase subunit C (membrane protein) 4.I Pathogenesis 2.9 8.7 3.0E-32 1.1E-31 D1   
eutS putative ethanolamine utilization protein EutS #N/A 2.9 7.3 3.6E-25 1.0E-24 D1   
STY2681 thiosulphate-binding protein precursor 4.A.5 Transport Anions 2.8 8.2 1.2E-29 4.1E-29 D1   
asrB anaerobic sulfite reductase subunit B 1.B.7.b Anaerobic Respiration 2.8 8.2 5.2E-29 1.7E-28 D1   
STY4121 putative hexulose-6-phosphate synthase 1.C Central Intermediary metabolism   2.8 8.6 1.3E-30 4.6E-30 D1   
STY2504 pseudogene 2. Broad regulatory function 2.8 7.6 4.7E-26 1.4E-25 D1   
STY2851 ftsH suppressor protein SfhB 3.A.2 Ribosomal protein synthesis, modification 2.8 9.9 2.9E-34 1.2E-33 D1 D8M3 
STY3845 putative CopG-family DNA-binding protein 5.I Unknown 2.8 8.0 4.9E-28 1.5E-27 D1   
STY2320 GDP-fucose synthetase 1.C.3 Sugar Nuclotides 2.8 9.4 1.5E-32 5.7E-32 D1   
STY1501 putative secreted protein 3.C.1 Membranes lipoprotein 2.8 8.3 1.0E-28 3.3E-28 D1 D8 
STY1908 putative  membrane protein 3.C.1 Membranes lipoprotein 2.8 8.6 6.3E-30 2.2E-29 D1   
STY0450 hypothetical protein 5.I Unknown 2.7 7.2 5.2E-23 1.3E-22 D1   
bcfA fimbrial subunit 3.C.3 Surface structure 2.7 9.2 1.5E-31 5.4E-31 D1 D8 
gph phosphoglycolate phosphatase 1.A.1 Degradation of carbohydrate 2.7 10.3 6.1E-34 2.5E-33 D1   
STY1262 
spermidine/putrescine-binding periplasmic protein 
precursor 4.A.1 Transport amino acid and amines 2.7 8.8 1.9E-30 6.6E-30 D1   
STY3441 PTS system, galactitol-specific IIA component 4.A.3 Transport Carbohydes, organic acids and alcohols 2.7 8.4 1.3E-28 4.3E-28 D1   
STY1758 conserved hypothetical FAD-binding protein 5.I Unknown 2.7 10.1 2.3E-33 9.1E-33 D1   
stgB fimbrial chaperone protein 3.C.3 Surface structure 2.7 8.5 4.4E-29 1.4E-28 D1   
STY1076 conserved hypothetical protein 5.H Hypothetical protein 2.7 5.7 3.4E-14 6.5E-14 D1   
STY2697 putative membrane protein 3.C.1 Membranes lipoprotein 2.7 8.4 1.8E-28 5.8E-28 D1   
yacK possible multicopper oxidase precursor 5.I Unknown 2.7 10.1 7.2E-33 2.8E-32 D1   
STY1563 pseudogene 5.H Hypothetical protein 2.7 6.8 1.2E-20 3.0E-20 D1   
STY0910 putrescine-binding periplasmic protein precursor 4.A.1 Transport amino acid and amines 2.7 8.6 9.2E-29 3.0E-28 D1   
STY4119 putative sugar isomerase 5.I Unknown 2.7 9.0 6.4E-30 2.2E-29 D1   
STY2728 glycine cleavage system transcriptional repressor 2. Broad regulatory function 2.7 9.2 1.6E-30 5.6E-30 D1   
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STY4481 NrfG protein 3.C.1 Membranes lipoprotein 2.7 9.2 2.9E-30 1.0E-29 D1   
STY0006 putative amino-acid transport protein 4.A Transport/binding proteins 2.7 9.8 1.3E-31 5.0E-31 D1   
STY1573 putative ABC transporter ATP/GTP-binding protein 4.A Transport/binding proteins 2.7 8.1 1.7E-26 5.2E-26 D1   
STY3199 thiol:disulfide interchange protein 3.A.8 Protein translation and modification 2.7 9.1 9.2E-30 3.2E-29 D1 D8 
STY2970 formate hydrogenlyase subunit 6 1.B.8 Fermentation 2.7 7.7 7.7E-25 2.1E-24 D1   
STY0393 probable terminal oxidase subunit II 1.B.7.c Electron Transport 2.7 9.4 2.4E-30 8.5E-30 D1   
STY4018 conserved hypothetical protein 5.H Hypothetical protein 2.7 9.1 9.8E-30 3.3E-29 D1   
STY3665 hypothetical protein 5.I Unknown 2.6 8.2 1.1E-26 3.4E-26 D1   
pduS putative ferredoxin 1.B.7.c Electron Transport 2.6 8.5 1.9E-27 6.0E-27 D1 M3 
ssaL putative secretion system protein 4.I Pathogenesis 2.6 6.1 1.0E-15 2.1E-15 D1   
STY4611 probable phage tail fibre protein 4.I Pathogenesis 2.6 10.3 1.6E-31 5.9E-31 D1   
STY0194 hypothetical ABC transporter ATP-binding protein 4.A Transport/binding proteins 2.6 9.6 7.1E-30 2.5E-29 D1 D8 
trkH trk system potassium uptake protein 1.C.5 Sulphur Metabolism 2.6 7.4 2.3E-22 5.8E-22 D1 D8M3 
STY0865 putative membrane protein 3.C.1 Membranes lipoprotein 2.6 9.6 1.1E-29 3.7E-29 D1 D8 
STY1439 putative membrane protein 3.C.1 Membranes lipoprotein 2.6 9.0 2.4E-28 7.7E-28 D1   
STY1016 exonuclease 5.A Latterally acquired elements 2.6 7.9 2.8E-24 7.6E-24 D1 D8 
sgaH putative hexulose-6-phosphate synthase 1.C Central Intermediary metabolism 2.6 9.0 8.0E-28 2.5E-27 D1   
celB PTS system, cellobiose-specific IIC component 4.A.3 Transport Carbohydes, organic acids and alcohols 2.6 8.7 7.9E-27 2.4E-26 D1   
STY2184 flagellar motor switch protein FliM 3.C.3 Surface structure 2.6 8.6 1.1E-26 3.2E-26 D1   
cysQ cysQ protein 1.C.5 Sulphur Metabolism 2.6 8.3 1.0E-25 2.9E-25 D1   
STY3946 putative membrane transport protein 4.A Transport/binding proteins 2.5 9.8 3.0E-29 1.0E-28 D1   
STY2901 pseudogene 4.A Transport/binding proteins 2.5 10.2 6.1E-30 2.1E-29 D1   
STY1790 conserved hypothetical protein 5.H Hypothetical protein 2.5 8.4 9.4E-26 2.8E-25 D1   
safD putative fimbrial structural subunit 4.I Pathogenesis 2.5 7.2 8.0E-21 1.9E-20 D1   
STY3307 D-mannonate oxidoreductase 1.A.1 Degradation of carbohydrate 2.5 9.4 3.3E-28 1.1E-27 D1 D8 
STY3122 regulatory protein for glycine cleavage pathway 1.C Central Intermediary metabolism 2.5 9.1 2.5E-27 7.8E-27 D1   
STY0395 AraC-family transcriptional regulator 2. Broad regulatory function 2.5 8.9 6.5E-27 2.0E-26 D1 D8 
STY0479 probable secreted protein 3.C.1 Membranes lipoprotein 2.5 6.8 3.7E-18 8.2E-18 D1 M3 
STY0134 probable activator protein in leuABCD operon 1.D.6 Pyruvate Family 2.5 7.3 1.3E-20 3.2E-20 D1 M3 
phnU 
probable membrane component of 2-
aminoethylphosphonate transporter 4.A.1 Transport amino acid and amines 2.5 8.6 1.2E-25 3.6E-25 D1   
STY4755 putative exported protein 3.C.1 Membranes lipoprotein 2.5 10.2 8.9E-29 2.9E-28 D1   
STY0887 hypothetical ABC transporter ATP-binding protein 4.A Transport/binding proteins 2.5 9.3 5.0E-27 1.5E-26 D1   
STY2832 sigma-E factor negative regulatory protein 2. Broad regulatory function 2.5 5.6 2.9E-12 5.4E-12 D1   
STY0982 integration host factor beta-subunit (IHF-beta) 3.A.7 DNA replication, repair, restriction, modification 2.5 9.4 3.3E-27 1.0E-26 D1 D8M3 
STY2595 DedD protein 5.I Unknown 2.5 7.5 4.9E-21 1.2E-20 D1   
STY0007 transaldolase B 1.B.5.b Non-oxydative branch 2.5 9.2 1.8E-26 5.4E-26 D1   
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glpD aerobic glycerol-3-phosphate dehydrogenase 1.B.7.a Aerobic Respiration 2.5 8.5 1.9E-24 5.1E-24 D1   
sipB pathogenicity island 1 effector protein 4.I Pathogenesis 2.5 9.5 6.4E-27 1.9E-26 D1   
STY2937 glycine betaine-binding periplasmic protein precursor 4.A.1 Transport amino acid and amines 2.5 9.8 1.9E-27 6.0E-27 D1   
stpA tyrosine phosphatase (associated with virulence) 3.A.8 Protein translation and modification 2.4 8.2 1.2E-23 3.2E-23 D1   
spak secretory protein (associated with virulence) 4.I Pathogenesis 2.4 7.4 2.1E-20 5.1E-20 D1   
STY1871 putative heat shock protein 4.B Chaperones 2.4 8.8 4.1E-25 1.2E-24 D1   
STY1153 glucose-1-phosphatase precursor (G1Pase), secreted 1.C Central Intermediary metabolism 2.4 9.6 1.4E-26 4.3E-26 D1   
STY3684 putative regulatory protein 5.I Unknown 2.4 8.9 3.1E-25 8.7E-25 D1 D8 
STY0475 hpothetical major facilitator family transport protein 4.A Transport/binding proteins 2.4 8.9 3.4E-25 9.6E-25 D1   
phnS 
probable periplasmic binding component of 2-
aminoethylphosphonate transporter 4.A.1 Transport amino acid and amines 2.4 8.8 9.5E-25 2.6E-24 D1   
STY0383 probable lipoprotein 3.C.1 Membranes lipoprotein 2.4 8.7 1.9E-24 5.1E-24 D1   
STY3491 putative membrane protein 3.C.1 Membranes lipoprotein 2.4 9.4 5.3E-26 1.6E-25 D1   
STY2820 putative transmembrane transport protein 4.A Transport/binding proteins 2.4 6.5 6.9E-16 1.4E-15 D1   
STY0814 molybdate-binding periplasmic protein precursor 4.A.2 Transport Cations 2.4 8.5 6.5E-24 1.8E-23 D1   
STY3905 glucose inhibited division protein 3.A.7 DNA replication, repair, restriction, modification 2.4 9.2 2.0E-25 5.8E-25 D1   
STY3208 hypothetical protein 5.I Unknown 2.4 8.3 3.9E-23 1.0E-22 D1   
sthB putative fimbrial chaperone protein 3.C.3 Surface structure 2.4 9.2 2.5E-25 7.1E-25 D1   
STY2650 nucleoside permease NupC 4.A.6 Transport Other 2.4 9.4 1.0E-25 3.0E-25 D1 D8M3 
STY3384 bacitracin resistance protein (putative undecaprenol kinase) 5.D Drug/Analogue sensitivity 2.4 9.4 1.3E-25 3.8E-25 D1   
STY1091 outer membrane protein A 3.C Cell envelope 2.4 8.0 5.7E-22 1.4E-21 D1   
mtgA 
monofunctional biosynthetic peptidoglycan 
transglycosylase 3.C.4 Murein sacculus and peptidoglycan 2.4 9.2 4.3E-25 1.2E-24 D1 D8 
STY2562 putative oxetanocin A biosynthetic enzyme 5.I Unknown 2.4 8.4 7.3E-23 1.9E-22 D1   
menB naphthoate synthase 1.G.11 Menaquinone  2.4 8.9 3.9E-24 1.0E-23 D1   
STY2367 putative membrane protein 3.C.1 Membranes lipoprotein 2.3 10.0 6.0E-26 1.8E-25 D1 D8 
STY3590 putative membrane protein 3.C.1 Membranes lipoprotein 2.3 9.6 2.8E-25 7.9E-25 D1 D8 
pduT putative propanediol utilization protein PduT 1.A.1 Degradation of carbohydrate 2.3 7.9 6.5E-21 1.6E-20 D1   
STY3804 putative carbohydrate kinase 5.I Unknown 2.3 9.2 2.1E-24 5.7E-24 D1   
STY0909 conserved hypothetical protein 5.H Hypothetical protein 2.3 7.5 2.8E-19 6.4E-19 D1   
STY2971 formate hydrogenlyase subunit 5 1.B.8 Fermentation 2.3 9.4 8.3E-25 2.3E-24 D1   
STY2571 putative transketolase N-terminal section 1.C Central Intermediary metabolism 2.3 8.4 1.7E-22 4.3E-22 D1   
invA possible secretory protein (associated with virulence) 4.I Pathogenesis 2.3 8.9 1.1E-23 3.0E-23 D1 D8 
STY1629 putative bacteriophage protein 5.A Latterally acquired elements 2.3 9.4 2.1E-24 5.8E-24 D1   
STY0211 dosage-dependent dnaK suppressor protein 3.A.7 DNA replication, repair, restriction, modification 2.3 7.6 1.5E-19 3.4E-19 D1 M3 
STY1938 conserved hypothetical protein 5.H Hypothetical protein 2.3 7.5 5.3E-19 1.2E-18 D1   
STY1365 pseudogene 5.I Unknown 2.3 8.1 5.4E-21 1.3E-20 D1   
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STY2613 pseudogene 5.H Hypothetical protein 2.3 8.6 1.6E-22 4.1E-22 D1 D8 
yfbB conserved hypothetical protein 5.H Hypothetical protein 2.3 8.3 1.5E-21 3.8E-21 D1   
STY4415 putative membrane protein 3.C.1 Membranes lipoprotein 2.3 8.9 4.0E-23 1.0E-22 D1   
STY2343 putative two-component system sensor kinase 2. Broad regulatory function 2.3 9.3 6.6E-24 1.8E-23 D1   
STY2811 putative sensor kinase protein 2. Broad regulatory function 2.3 8.6 2.2E-22 5.5E-22 D1   
STY3677 major capsid protein 5.A Latterally acquired elements 2.3 9.9 1.3E-24 3.5E-24 D1   
STY0726 putative lipoprotein 3.C.1 Membranes lipoprotein 2.3 7.1 2.8E-17 6.0E-17 D1   
STY1759 putative membrane protein 3.C.1 Membranes lipoprotein 2.3 8.8 1.2E-22 3.1E-22 D1   
STY2290 6-phosphogluconate dehydrogenase, decarboxylating 1.B.5 Pentose phosphate 2.3 9.4 9.6E-24 2.6E-23 D1 M1 
STY3823 L rhamnose-proton symporter 4.A.3 Transport Carbohydes, organic acids and alcohols 2.3 9.6 6.2E-24 1.7E-23 D1   
STY2128 methyl-accepting chemotaxis protein II 4.D Chemotaxis and mobility 2.3 9.0 6.7E-23 1.7E-22 D1 M3 
ybdQ conserved hypothetical protein 5.H Hypothetical protein 2.3 8.3 4.1E-21 1.0E-20 D1   
STY0653 alkyl hydroperoxide reductase c22 protein 4.G Detoxification 2.3 6.9 2.7E-16 5.6E-16 D1   
nrdI NrdI protein 1.F.5 Miscellaneous 2.3 7.7 4.3E-19 9.8E-19 D1   
STY2977 hydrogenase isoenzymes formation protein HypB 1.B.8 Fermentation 2.3 9.6 1.4E-23 3.7E-23 D1 D8 
STY0321 Rhs-family protein 4.I Pathogenesis 2.3 10.3 2.1E-24 5.8E-24 D1   
STY4203 pseudogene 1.A.2 Degradation of amino acids 2.2 7.8 1.9E-19 4.4E-19 D1 M3 
STY2137 trehalose-6-phosphate synthase 5.F Adaptions and atypical conditions 2.2 9.8 9.7E-24 2.6E-23 D1   
STY3632 glucose-1-phosphate thymidylyltransferase 3.C.2 Surface polysacchar 2.2 9.1 1.7E-22 4.2E-22 D1   
pyrB aspartate carbamoyltransferase catalytic subunit 1.F.2 Pyrimidine ribonucle 2.2 9.2 8.3E-23 2.1E-22 D1   
yjjA putative secreted protein 3.C.1 Membranes lipoprotein 2.2 8.7 1.0E-21 2.6E-21 D1   
STY2021 putative bacteriophage protein 5.A Latterally acquired elements 2.2 8.4 9.2E-21 2.2E-20 D1   
STY3402 conserved hypothetical protein 5.H Hypothetical protein 2.2 8.5 5.4E-21 1.3E-20 D1   
STY4603 hypothetical protein 4.I Pathogenesis 2.2 11.0 1.4E-24 3.8E-24 D1   
STY3707 conserved hypothetical protein 5.H Hypothetical protein 2.2 9.7 5.0E-23 1.3E-22 D1   
STY2583 histidine transport system permease protein 4.A.1 Transport amino acid and amines 2.2 8.2 6.3E-20 1.5E-19 D1   
STY4206 conserved hypothetical protein 5.H Hypothetical protein 2.2 8.6 5.7E-21 1.4E-20 D1 D8 
STY3764 putative serine hydroxymethyltransferase 5.I Unknown 2.2 8.7 3.8E-21 9.4E-21 D1   
STY4127 putative membrane protein 3.C.1 Membranes lipoprotein 2.2 9.0 8.8E-22 2.2E-21 D1   
dmsC putative dimethyl sulfoxide reductase subunit C 1.C.5 Sulphur Metabolism 2.2 8.3 5.9E-20 1.4E-19 D1   
STY3461 ATP-dependent RNA helicase (dead-box protein) 3.A.9 RNA synthesis, modification 2.2 7.4 3.3E-17 7.1E-17 D1   
nikR nickel responsive regulator 2. Broad regulatory function 2.2 8.2 6.7E-20 1.6E-19 D1   
STY3857 pseudogene 5.H Hypothetical protein 2.2 9.4 2.9E-22 7.3E-22 D1   
STY4171 dipeptide transport ATP-binding protein DppD 4.A.6 Transport Other 2.2 9.2 5.6E-22 1.4E-21 D1   
yheS probable ABC transporter ATP-binding protein 4.A Transport/binding proteins 2.2 10.0 7.8E-23 2.0E-22 D1   
STY4909 conserved hypothetical protein 5.H Hypothetical protein 2.2 9.2 1.4E-21 3.3E-21 D1   
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STY3888 hypothetical 20.8 kDa protein in rbsr-rrsc intergenic region 2. Broad regulatory function 2.2 9.7 2.2E-22 5.5E-22 D1   
STY1830 putative outer membrane protein 3.C Cell envelope 2.2 9.0 4.5E-21 1.1E-20 D1   
STY2854 chorismate mutase-P/prephenate dehydratase 1.D.4 Aromatic Amino Acid 2.2 10.0 1.6E-22 4.1E-22 D1   
sscB putative pathogenicity island protein 4.I Pathogenesis 2.2 8.7 2.3E-20 5.3E-20 D1   
STY4628 probable capsid portal protein 4.I Pathogenesis 2.2 9.7 3.7E-22 9.2E-22 D1   
STY0485 cytochrome o ubiquinol oxidase subunit II 1.B.7.a Aerobic Respiration 2.2 9.0 5.8E-21 1.4E-20 D1   
STY1551 putative regulatory protein 2. Broad regulatory function 2.1 8.7 2.2E-20 5.3E-20 D1   
STY3418 conserved hypothetical protein 5.H Hypothetical protein 2.1 8.8 3.1E-20 7.4E-20 D1   
STY0119 L-arabinose isomerase 1.A.1 Degradation of carbohydrate 2.1 8.1 1.4E-18 3.1E-18 D1   
stbE fimbrial chaperone protein 3.C.3 Surface structure 2.1 8.8 3.3E-20 7.9E-20 D1   
STY4086 2-amino-3-ketobutyrate coenzyme A ligase 1.C Central Intermediary metabolism 2.1 9.2 6.0E-21 1.4E-20 D1   
STY3848 conserved hypothetical protein 5.H Hypothetical protein 2.1 9.1 9.9E-21 2.4E-20 D1   
STY4192 conserved hypothetical protein 5.H Hypothetical protein 2.1 8.8 3.4E-20 8.0E-20 D1   
menD menaquinone biosynthesis protein 1.G.11 Menaquinone  2.1 8.9 3.4E-20 8.0E-20 D1   
STY3112 1,2-propanediol oxidoreductase (lactaldehyde reductase) 1.A.1 Degradation of carbohydrate 2.1 8.2 1.3E-18 3.0E-18 D1   
STY3666 hypothetical protein 5.I Unknown 2.1 8.0 3.1E-18 6.9E-18 D1   
pilQ nucleotide-binding protein 4.A Transport/binding proteins 2.1 9.8 2.3E-21 5.6E-21 D1   
STY0484 cytochrome o ubiquinol oxidase subunit I 1.B.7.a Aerobic Respiration 2.1 8.1 1.9E-18 4.1E-18 D1 D8 
arcC carbamate kinase 1.A.1 Degradation of carbohydrate 2.1 8.0 4.5E-18 9.8E-18 D1   
STY4191 2-dehydro-3-deoxygluconokinase 1.A.1 Degradation of carbohydrate 2.1 8.5 3.1E-19 7.0E-19 D1   
STY1565 putative dimethyl sulphoxide reductase subunit 1.A.1 Degradation of carbohydrate 2.1 9.0 4.4E-20 1.0E-19 D1 D8 
STY1104 pseudogene 3.C.1 Membranes lipoprotein 2.1 8.1 4.9E-18 1.1E-17 D1   
STY4046 putative purine permease 4.A.6 Transport Other 2.1 9.7 5.7E-21 1.4E-20 D1   
STY0166 prepilin peptidase dependent protein D precursor 4.A Transport/binding proteins 2.1 7.1 6.0E-15 1.2E-14 D1   
STY1661 conserved hypothetical protein 5.H Hypothetical protein 2.1 7.3 1.7E-15 3.4E-15 D1   
rnr ribonuclease R (RNase R) 3.B.1 Degradation of RNA 2.1 10.1 2.9E-21 7.1E-21 D1   
STY4012 pseudogene 2. Broad regulatory function 2.1 10.7 8.3E-22 2.1E-21 D1   
STY1433 conserved hypothetical protein 5.H Hypothetical protein 2.1 9.0 1.1E-19 2.5E-19 D1   
STY3155 galactose operon repressor 1.A.1 Degradation of carbohydrate 2.1 9.6 2.1E-20 5.0E-20 D1 D8 
STY3771 pseudogene 1.C.5 Sulphur Metabolism 2.1 11.0 1.0E-21 2.5E-21 D1 D8 
ytfH conserved hypothetical protein 5.H Hypothetical protein 2.1 8.2 4.6E-18 1.0E-17 D1   
STY4213 universal stress protein B 5.I Unknown 2.1 8.1 1.4E-17 2.9E-17 D1 D8 
STY3808 periplasmic sulphate binding protein 1.C.5 Sulphur Metabolism 2.1 10.0 1.2E-20 2.8E-20 D1   
STY1311 conserved hypothetical protein 5.H Hypothetical protein 2.1 8.2 8.2E-18 1.8E-17 D1   
STY1312 cardiolipin synthetase 3.A.11 Phospholipids 2.1 9.7 2.7E-20 6.4E-20 D1 D8 
STY2491 ADA regulatory protein 3.A.7 DNA replication, repair, restriction, modification 2.0 6.7 4.2E-13 7.9E-13 D1   
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yjfL putative membrane protein 3.C.1 Membranes lipoprotein 2.0 8.8 6.9E-19 1.6E-18 D1 D8 
STY4782 putative membrane protein 3.C.1 Membranes lipoprotein 2.0 8.3 5.2E-18 1.1E-17 D1 D8 
STY0790 conserved hypothetical protein 5.H Hypothetical protein 2.0 7.0 3.3E-14 6.4E-14 D1   
STY1412 conserved hypothetical protein 5.H Hypothetical protein 2.0 8.8 5.1E-19 1.2E-18 D1   
fimW fimbriae w protein 3.C.3 Surface structure 2.0 7.2 9.3E-15 1.8E-14 D1   
STY3693 conserved hypothetical protein 5.I Unknown 2.0 10.0 2.7E-20 6.5E-20 D1   
STY0328 hypothetical protein 4.I Pathogenesis 2.0 8.3 8.9E-18 1.9E-17 D1   
waaQ lipopolysaccharide core biosynthesis protein 3.C.2 Surface polysacchar 2.0 6.2 2.9E-11 5.1E-11 D1 M3 
STY2825 DNA repair protein RecO 3.A.7 DNA replication, repair, restriction, modification 2.0 8.5 6.7E-18 1.5E-17 D1 D8 
yjfY conserved hypothetical protein 5.H Hypothetical protein 2.0 8.4 1.1E-17 2.4E-17 D1   
STY4429 chorismate lyase 1.G.11 Menaquinone  2.0 9.6 1.4E-19 3.2E-19 D1 D8 
STY0556 outer membrane protein 3.C Cell envelope 2.0 9.4 2.9E-19 6.6E-19 D1   
STY2036 putative bacteriophage protein #N/A 2.0 7.9 2.2E-16 4.6E-16 D1   
STY0085 FixA protein 1.A.1 Degradation of carbohydrate 2.0 9.0 1.2E-18 2.6E-18 D1 D8 
STY3914 ATP synthase epsilon subunit 1.A Degradation 14.5 11.4 8.9E-187 1.4E-185 D8 D1M3 
tufB elongation factor Tu 3.A.8 Protein translation and modification 13.7 13.0 7.1E-235 4.7E-233 D8 D1M1M3 
STY3800 pseudogene 3.A.11 Phospholipids 13.4 13.4 1.4E-246 2.0E-244 D8   
nuoI NADH dehydrogenase I chain I 1.B.7.a Aerobic Respiration 13.3 12.6 4.1E-223 1.6E-221 D8 M3 
trpS tryptophanyl-tRNA synthetase 3.A.5 Aminoacyl tRNA synthesis, tRNA modification 12.6 12.5 3.3E-220 1.1E-218 D8 D1M1M3 
STY1335 conserved hypothetical protein 5.H Hypothetical protein 12.4 13.9 1.6E-263 1.7E-260 D8   
STY3417 conserved hypothetical protein 5.H Hypothetical protein 12.4 12.5 4.5E-222 1.7E-220 D8 M3 
STY3913 ATP synthase beta subunit 1.A Degradation 12.4 11.9 1.5E-203 3.0E-202 D8   
STY4213 universal stress protein B 5.I Unknown 12.4 14.8 6.7E-289 2.8E-285 D8 D1 
STY2839 conserved hypothetical protein 5.H Hypothetical protein 12.4 14.3 9.1E-274 1.9E-270 D8 D1 
STY0483 cytochrome o ubiquinol oxidase subunit III 1.B.7.a Aerobic Respiration 12.0 13.1 4.4E-238 3.6E-236 D8   
STY4910 peptide chain release factor 3 3.A.8 Protein translation and modification 12.0 14.1 7.6E-268 1.1E-264 D8   
STY2145 tyrosine-specific transport protein 4.A.1 Transport amino acid and amines 11.8 13.1 5.2E-239 4.8E-237 D8 D1M3 
STY2836 ATP-dependent RNA helicase SrmB 3.A.9 RNA synthesis, modification 11.8 13.3 5.8E-246 7.6E-244 D8 D1M3 
STY1609 hypothetical protein 5.I Unknown 11.8 13.1 1.8E-239 1.7E-237 D8   
STY3453 conserved hypothetical protein 5.H Hypothetical protein 11.8 13.9 2.7E-263 2.3E-260 D8   
STY4842 probable regulatory protein 4.I Pathogenesis 11.8 12.3 7.8E-214 2.1E-212 D8 D1 
STY1818 putative nitroreductase 5.I Unknown 11.7 13.4 5.0E-247 7.3E-245 D8   
STY4205 glutathione reductase 1.G.10 Thioredoxin 11.7 13.6 1.3E-254 4.0E-252 D8   
STY2546 NADH dehydrogenase I chain N 1.B.7.a Aerobic Respiration 11.7 12.5 1.4E-220 4.8E-219 D8   
STY1578 putative regulatory protein 2. Broad regulatory function 11.6 12.6 3.7E-225 1.6E-223 D8   
STY2918 conserved hypothetical protein 5.H Hypothetical protein 11.5 13.8 3.6E-259 2.1E-256 D8   
 249 
ybaD pseudogene 5.H Hypothetical protein 11.5 13.6 4.5E-254 1.3E-251 D8 M3 
fimI pseudogene 3.C.3 Surface structure 11.5 13.7 5.4E-256 2.2E-253 D8   
STY0777 succinate dehydrogenase flavoprotein subunit 1.B.3 Tricarboxylic acid cycle 11.4 13.1 6.3E-239 5.7E-237 D8   
fliA 
RNA polymerase sigma transcription factor for flagellar 
operon 3.C.3 Surface structure 11.4 13.6 1.3E-254 4.0E-252 D8   
STY2202 putative membrane protein 3.C.1 Membranes lipoprotein 11.4 13.5 2.5E-249 4.2E-247 D8   
glpR glycerol-3-phosphate regulon repressor 1.B.7.b Anaerobic Respiration 11.3 13.1 3.0E-238 2.5E-236 D8 M3 
STY4110 mannitol-1-phosphate dehydrogenase 1.A.1 Degradation of carbohydrate 11.3 12.5 5.4E-222 2.0E-220 D8   
garR 2-hydroxy-3-oxopropionate reductase 1.A.1 Degradation of carbohydrate 11.3 13.7 4.3E-256 2.0E-253 D8   
STY3263 conserved hypothetical protein 5.H Hypothetical protein 11.3 13.7 7.6E-256 2.9E-253 D8   
yafE putative methyltransferase 5.I Unknown 11.2 13.3 7.8E-244 9.6E-242 D8   
spaN 
surface presentation of antigens protein (associated with 
type III secretion and virulence) 4.I Pathogenesis 11.2 12.9 8.7E-232 5.4E-230 D8   
STY4488 conserved hypothetical protein 5.H Hypothetical protein 11.1 13.6 5.3E-252 1.2E-249 D8   
STY1241 conserved hypothetical protein 5.H Hypothetical protein 11.1 13.4 6.1E-249 9.8E-247 D8   
STY3687 putative phage baseplate assembly protein 5.A Latterally acquired elements 11.1 13.8 2.1E-252 5.1E-250 D8   
STY2678 sulphate transport ATP-binding protein CysA 4.A.5 Transport Anions 11.1 11.6 3.6E-192 6.0E-191 D8   
STY2500 putative MR-MLE-family protein 5.I Unknown 11.1 14.4 1.2E-257 6.5E-255 D8   
appC cytochrome bd-II oxidase subunit I (pseudogene) 1.B.7.c Electron Transport 11.1 13.8 3.0E-253 7.9E-251 D8   
STY3199 thiol:disulfide interchange protein 3.A.8 Protein translation and modification 11.1 14.1 3.6E-255 1.3E-252 D8 D1 
torC pseudogene 1.B.7.b Anaerobic Respiration 11.1 14.8 3.8E-260 2.7E-257 D8   
ybiI hypothetical Zinc-finger containing protein 5.I Unknown 11.1 12.8 1.1E-229 5.6E-228 D8   
STY2725 
phosphoribosylaminoimidazole-succinocarboxamide 
synthase 1.F.1 Purine ribonucleotide biosynthesis 11.1 13.2 2.2E-242 2.5E-240 D8   
STY0637 hypothetical membrane protein p43 3.C.1 Membranes lipoprotein 11.1 13.9 2.1E-251 4.6E-249 D8   
STY3535 tartrate dehydratase 1.B.8 Fermentation 11.0 13.8 2.5E-250 5.0E-248 D8   
STY4911 Putative periplasmic protein 5.F Adaptions and atypical conditions 11.0 14.0 4.2E-251 8.8E-249 D8   
STY1859 conserved hypothetical protein 5.H Hypothetical protein 10.9 13.0 6.4E-235 4.3E-233 D8   
ycaM probable transport protein 4.A Transport/binding proteins 10.9 13.8 2.0E-246 2.6E-244 D8   
STY2613 pseudogene 5.H Hypothetical protein 10.9 13.7 1.1E-245 1.4E-243 D8 D1 
STY0721 N-acetylglucosamine-6-phosphate deacetylase 1.C.4 Amino sugars 10.9 11.5 3.0E-189 4.9E-188 D8   
oadG oxaloacetate decarboxylase gamma chain 4.A.2 Transport Cations 10.8 13.9 1.1E-247 1.7E-245 D8   
STY1268 hypothetical protein 5.I Unknown 10.8 14.2 1.8E-249 3.2E-247 D8   
STY2033 putative bacteriophage protein 5.A Latterally acquired elements 10.8 12.6 1.9E-223 7.6E-222 D8   
smg conserved hypothetical protein 5.H Hypothetical protein 10.8 14.3 3.1E-250 5.9E-248 D8   
slyX conserved hypothetical protein 5.H Hypothetical protein 10.8 12.8 1.0E-228 5.1E-227 D8   
STY1331 putative pseudouridine synthase 3.A.3 Ribosomal maturation and modification 10.8 13.2 3.2E-242 3.5E-240 D8   
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STY1565 putative dimethyl sulphoxide reductase subunit 1.A.1 Degradation of carbohydrate 10.8 14.2 4.6E-248 7.1E-246 D8 D1 
STY3875 Two-component system sensory histidine kinase 1.D.1 Glutamate Family 10.8 12.7 1.1E-226 4.9E-225 D8 M3 
STY2829 GTP-binding protein LepA 3.A.8 Protein translation and modification 10.8 12.8 4.3E-230 2.4E-228 D8 D1 
STY1501 putative secreted protein 3.C.1 Membranes lipoprotein 10.7 12.8 7.5E-231 4.4E-229 D8 D1 
STY3819 possible membrane transport protein 4.A Transport/binding proteins 10.7 13.6 4.4E-242 4.7E-240 D8   
STY3262 conserved hypothetical protein 5.H Hypothetical protein 10.7 14.8 4.9E-250 9.0E-248 D8   
STY1539 putative membrane protein 3.C.1 Membranes lipoprotein 10.7 13.6 8.8E-241 9.0E-239 D8 M3 
STY0186 putative transcriptional regulator 2. Broad regulatory function 10.6 13.6 1.8E-240 1.8E-238 D8 D1 
ygaU pseudogene 5.H Hypothetical protein 10.6 12.5 9.5E-222 3.5E-220 D8   
STY0553 hypothetical ABC transporter ATP-binding protein 4.A Transport/binding proteins 10.6 13.4 2.5E-238 2.2E-236 D8   
hslT heat shock protein A 5.F Adaptions and atypical conditions 10.6 14.1 6.0E-243 7.2E-241 D8   
STY1129 putative exported protein 3.C.1 Membranes lipoprotein 10.5 12.3 1.7E-215 4.7E-214 D8   
STY2746 hypothetical protein 5.I Unknown 10.5 13.4 4.1E-236 3.2E-234 D8   
STY1222 flagellar hook-associated protein 1 3.C.3 Surface structure 10.5 13.5 7.2E-236 5.3E-234 D8   
STY2675 putative amidotransferase 5.I Unknown 10.5 12.3 5.5E-216 1.6E-214 D8 M3 
envE putative lipoprotein 3.C.1 Membranes lipoprotein 10.5 11.9 2.1E-202 4.2E-201 D8   
STY2770 conserved hypothetical protein 5.H Hypothetical protein 10.5 13.6 2.3E-236 1.8E-234 D8   
rrmA rRNA guanine-N1-methyltransferase 3.A.9 RNA synthesis, modification 10.5 12.8 9.2E-230 4.9E-228 D8   
STY1173 conserved hypothetical protein 5.H Hypothetical protein 10.4 13.1 9.4E-233 5.9E-231 D8   
STY2565 conserved hypothetical protein 5.H Hypothetical protein 10.4 12.8 5.2E-230 2.8E-228 D8   
spaQ secretory protein (associated with virulence) 4.I Pathogenesis 10.4 10.6 6.9E-163 8.3E-162 D8   
STY2443 sugar efflux transporter 4.A Transport/binding proteins 10.4 13.5 4.4E-235 3.0E-233 D8 M3 
STY2437 putative membrane protein 3.C.1 Membranes lipoprotein 10.4 13.4 5.9E-234 3.8E-232 D8   
STY1945 septum site determining protein 4.C Cell division 10.4 13.7 1.6E-235 1.1E-233 D8   
STY2389 putative two-component system sensor kinase 2. Broad regulatory function 10.4 14.0 2.9E-238 2.4E-236 D8   
STY2779 putative thiosulfate sulfurtransferase 1.D.4 Aromatic Amino Acid 10.4 12.6 1.5E-223 5.9E-222 D8   
STY3376 glycogen synthesis protein GlgS 3.A.10 Polysaccharides (Cytoplasmic) 10.4 11.3 1.0E-183 1.5E-182 D8   
stbC outer membrane fimbrial usher protein 3.C.3 Surface structure 10.4 14.6 2.8E-242 3.2E-240 D8   
STY3847 conserved hypothetical protein 5.H Hypothetical protein 10.4 13.8 4.4E-236 3.4E-234 D8   
STY2472 nitrate/nitrite response regulator protein NarP 1.B.7.b Anaerobic Respiration 10.4 11.9 6.9E-204 1.4E-202 D8   
STY2916 conserved hypothetical protein 5.H Hypothetical protein 10.4 12.8 1.6E-229 8.2E-228 D8   
STY0753 conserved hypothetical protein 5.H Hypothetical protein 10.3 12.9 1.3E-229 6.6E-228 D8   
mdlA putative ABC transporter ATP-binding membrane protein 4.A Transport/binding proteins 10.3 13.9 1.2E-235 9.0E-234 D8   
STY4928 conserved hypothetical ABC transporter 4.A Transport/binding proteins 10.3 14.6 8.6E-241 9.0E-239 D8   
STY2113 conserved hypothetical protein 5.H Hypothetical protein 10.3 14.1 2.3E-237 1.8E-235 D8   
STY4466 putative xanthine/uracil permeases family protein 4.A Transport/binding proteins 10.3 14.3 1.6E-238 1.5E-236 D8   
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STY2082 DNA polymerase III, theta subunit #N/A 10.3 11.5 2.9E-191 4.8E-190 D8   
ygcX probable glucarate dehydratase 1 1.A.1 Degradation of carbohydrate 10.3 14.0 5.5E-236 4.1E-234 D8   
STY4422 putative membrane protein 3.C.1 Membranes lipoprotein 10.3 13.4 6.4E-231 3.8E-229 D8   
STY0220 ferrichrome-binding periplasmic protein precursor 4.A.6 Transport Other 10.3 13.1 6.2E-229 3.1E-227 D8   
STY4668 conserved hypothetical protein 4.I Pathogenesis 10.3 14.8 2.0E-240 2.0E-238 D8   
bcr bicyclomycin resistance protein 5.D Drug/Analogue sensitivity 10.2 13.6 4.1E-231 2.5E-229 D8   
STY3465 
tRNA pseudouridine 55 synthase (psi55 synthase) (p35 
protein) 3.A.5 Aminoacyl tRNA synthesis, tRNA modification 10.2 13.6 5.5E-231 3.3E-229 D8   
bcfA fimbrial subunit 3.C.3 Surface structure 10.2 13.2 2.2E-228 1.0E-226 D8 D1 
STY2928 conserved hypothetical protein 5.H Hypothetical protein 10.2 13.1 7.5E-227 3.5E-225 D8   
STY4439 conserved hypothetical protein 5.H Hypothetical protein 10.2 13.5 5.2E-229 2.6E-227 D8   
STY3312 hypothetical protein 5.I Unknown 10.2 11.8 2.8E-200 5.4E-199 D8   
btuE 
putative glutathione peroxidase/vitamin B12 transport 
periplasmic protein BtuE 4.A.6 Transport Other 10.2 12.0 7.0E-207 1.6E-205 D8   
ybjZ conserved hypothetical ABC transporter 4.A Transport/binding proteins 10.2 14.4 2.7E-235 1.9E-233 D8   
STY2005 conserved hypothetical protein 5.H Hypothetical protein 10.2 13.4 2.6E-228 1.2E-226 D8   
STY3115 L-fucose permease 4.A.3 Transport Carbohydes, organic acids and alcohols 10.1 13.7 4.1E-230 2.3E-228 D8   
STY2414 vancomycin resistance protein 5.D Drug/Analogue sensitivity 10.1 13.6 1.9E-228 9.4E-227 D8   
stbB fimbrial chaperone protein 3.C.3 Surface structure 10.1 12.4 6.1E-217 1.8E-215 D8   
STY3834 hypothetical protein 5.I Unknown 10.1 14.4 1.1E-233 6.8E-232 D8   
STY3463 polynucleotide phosphorylase 3.A.9 RNA synthesis, modification 10.1 14.6 1.1E-234 7.2E-233 D8 D1M1M3 
STY4206 conserved hypothetical protein 5.H Hypothetical protein 10.1 12.9 1.6E-222 6.2E-221 D8 D1 
ygbJ pseudogene 5.I Unknown 10.1 12.6 4.8E-221 1.6E-219 D8   
STY4139 putative membrane protein 3.C.1 Membranes lipoprotein 10.1 14.0 4.7E-230 2.6E-228 D8   
STY2548 NADH dehydrogenase I chain L 1.B.7.a Aerobic Respiration 10.1 10.3 4.5E-154 5.1E-153 D8   
STY2734 putative membrane protein 3.C.1 Membranes lipoprotein 10.1 13.4 8.0E-226 3.5E-224 D8   
STY0881 conserved hypothetical protein 5.H Hypothetical protein 10.0 12.4 5.3E-218 1.6E-216 D8   
STY2809 putative transcriptional regulator 2. Broad regulatory function 10.0 13.3 1.1E-224 4.6E-223 D8   
STY3108 conserved hypothetical protein 5.H Hypothetical protein 10.0 14.1 1.1E-230 6.4E-229 D8   
STY1571 putative ABC transporter periplasmic binding protein 4.A Transport/binding proteins 10.0 12.4 1.2E-218 3.6E-217 D8   
STY1650 conserved hypothetical protein 5.H Hypothetical protein 10.0 13.5 1.8E-226 8.3E-225 D8   
STY3568 putative exported protein 3.C.1 Membranes lipoprotein 10.0 14.0 1.5E-229 7.5E-228 D8   
STY1587 putative membrane protein 3.C.1 Membranes lipoprotein 10.0 12.9 4.8E-221 1.6E-219 D8   
steF fimbrial subunit 3.C.3 Surface structure 10.0 13.7 1.1E-226 5.2E-225 D8   
STY1568 putative dimethyl sulphoxide reductase subunit 1.A.1 Degradation of carbohydrate 10.0 12.0 2.2E-204 4.7E-203 D8   
STY3313 
possible ABC-transport protein, periplasmic-binding 
component 4.A Transport/binding proteins 10.0 12.7 1.6E-218 4.8E-217 D8   
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pipA conserved hypothetical protein 4.I Pathogenesis 10.0 13.6 2.0E-225 8.8E-224 D8   
STY3803 hypothetical protein 5.I Unknown 10.0 13.5 5.1E-224 2.1E-222 D8   
STY0010 conserved hypothetical protein 5.H Hypothetical protein 9.9 13.7 6.3E-225 2.7E-223 D8   
STY4201 gntR family regulatory protein 2. Broad regulatory function 9.9 12.7 2.1E-216 6.2E-215 D8   
ybaV putative exported protein 3.C.1 Membranes lipoprotein 9.9 12.5 6.7E-216 1.9E-214 D8   
STY0124 putative ABC transporter integral membrane protein 4.A Transport/binding proteins 9.9 13.4 1.4E-222 5.5E-221 D8   
STY2398 pseudogene 3.C.4 Murein sacculus and peptidoglycan 9.9 13.1 2.7E-220 8.6E-219 D8   
STY0867 glutamine transport system permease protein GlnP 4.A.1 Transport amino acid and amines 9.9 13.3 6.8E-221 2.3E-219 D8   
STY1252 putative secreted protein 3.C.1 Membranes lipoprotein 9.9 12.0 1.2E-206 2.7E-205 D8   
STY4154 putative DNA-binding protein 5.I Unknown 9.9 13.9 5.8E-226 2.6E-224 D8   
STY2159 putative ABC-transport ATP-binding protein 4.A Transport/binding proteins 9.9 13.6 1.4E-223 5.8E-222 D8   
sugE SugE protein 4.B Chaperones 9.9 13.6 8.7E-223 3.4E-221 D8   
STY2913 GabA permease (4-amino butyrate transport carrier) 4.A.3 Transport Carbohydes, organic acids and alcohols 9.9 13.7 1.6E-223 6.3E-222 D8   
STY4262 putative membrane protein 3.C.1 Membranes lipoprotein 9.9 13.9 3.5E-225 1.5E-223 D8   
ttrA tetrathionate reductase subunit A 4.I Pathogenesis 9.9 13.3 1.5E-220 5.1E-219 D8   
STY3623 uroporphyrinogen III methylase 1.G.12 Heme and porphyrin 9.8 13.2 9.0E-220 2.8E-218 D8   
STY3125 conserved hypothetical protein 5.H Hypothetical protein 9.8 13.5 2.2E-221 8.0E-220 D8   
STY3934 conserved hypothetical protein 5.H Hypothetical protein 9.8 13.5 2.7E-221 9.4E-220 D8   
STY3951 Two-component sensor protein histidine protein kinase. 1.B.7.b Anaerobic Respiration 9.8 14.9 5.6E-230 3.0E-228 D8   
STY0620 oxygen-insensitive NAD(P)H nitroreductase 5.D Drug/Analogue sensitivity 9.8 13.5 3.7E-221 1.3E-219 D8   
STY1549 dipeptidyl carboxypeptidase II 3.B.3 Degradation of proteins, peptides, glycoproteins 9.8 13.5 2.0E-221 7.2E-220 D8   
STY1680 putative HlyD-family protein 5.I Unknown 9.8 13.1 3.4E-217 1.0E-215 D8   
yjfC conserved hypothetical protein 5.H Hypothetical protein 9.8 12.7 4.2E-214 1.1E-212 D8   
fliB pseudogene #N/A 9.8 13.8 1.8E-222 6.7E-221 D8   
STY0927 putative N-acetylmuramoyl-L-alanine amidase 3.C.4 Murein sacculus and peptidoglycan 9.8 12.2 1.9E-211 4.8E-210 D8   
dsbG thiol:disulfide interchange protein DsbG precursor 1.C Central Intermediary metabolism 9.8 12.9 2.8E-215 7.8E-214 D8   
pocR pdu/cob regulatory protein PocR 2. Broad regulatory function 9.7 13.1 5.7E-216 1.6E-214 D8   
STY3989 putative carbohydrate kinase 1.A.1 Degradation of carbohydrate 9.7 14.2 8.7E-224 3.6E-222 D8   
STY4429 chorismate lyase 1.G.11 Menaquinone  9.7 13.8 1.2E-221 4.5E-220 D8 D1 
STY4407 peptidase E 3.B.3 Degradation of proteins, peptides, glycoproteins 9.7 13.6 8.1E-220 2.6E-218 D8   
STY3751 acetylglutamate kinase 1.D.1 Glutamate Family 9.7 13.2 3.0E-216 8.6E-215 D8   
STY0165 protein transport protein HofB 4.A.6 Transport Other 9.7 13.1 7.8E-216 2.2E-214 D8   
STY1796 conserved hypothetical protein 5.H Hypothetical protein 9.7 12.7 2.4E-212 6.3E-211 D8   
ybhL pseudogene 3.C.1 Membranes lipoprotein 9.7 14.1 2.1E-222 7.9E-221 D8   
STY3580 flavin reductase 1.B.7.c Electron Transport 9.7 12.3 1.5E-208 3.6E-207 D8 M3 
STY1160 sodium/proline symporter (proline permease) 4.A.1 Transport amino acid and amines 9.7 13.9 1.6E-220 5.2E-219 D8   
 253 
STY3694 hypothetical protein 5.I Unknown 9.6 14.1 4.0E-221 1.4E-219 D8   
STY3810 putative transmembrane efflux protein 4.A Transport/binding proteins 9.6 14.0 1.6E-220 5.2E-219 D8   
cheM methyl-accepting chemotaxis protein II 4.D Chemotaxis and mobility 9.6 14.1 5.3E-221 1.8E-219 D8   
STY4636 DNA adenine methylase 4.I Pathogenesis 9.6 13.5 4.5E-217 1.3E-215 D8   
STY2932 ribonucleoside-diphosphate reductase 2 alpha chain 1.F.5 Miscellaneous 9.6 14.0 1.9E-220 6.0E-219 D8   
fliT flagellar protein FliT 3.C.3 Surface structure 9.6 11.3 2.0E-183 2.9E-182 D8   
hpaG 
4-hydroxyphenylacetate degradation bifunctional 
isomerase/decarboxylase [includes: 2-hydroxyhepta-2,4-
diene-1,7-dioate isomerase 1.A.1 Degradation of carbohydrate 9.6 12.4 1.3E-208 3.2E-207 D8   
hslS heat shock protein B 5.F Adaptions and atypical conditions 9.6 13.7 1.3E-217 3.9E-216 D8   
ppiA peptidyl-prolyl cis-trans isomerase 3.A.8 Protein translation and modification 9.6 13.2 3.2E-214 8.6E-213 D8   
STY1289 respiratory nitrate reductase 1 beta chain 1.B.7.b Anaerobic Respiration 9.6 13.3 1.4E-214 3.7E-213 D8   
pgtB phosphoglycerate transport system sensor protein PgtB 4.A Transport/binding proteins 9.6 13.7 6.9E-217 2.0E-215 D8   
STY0538 fosmidomycin resistance protein 4.A.6 Transport Other 9.5 13.0 1.3E-211 3.3E-210 D8   
trkH trk system potassium uptake protein 1.C.5 Sulphur Metabolism 9.5 10.9 1.3E-171 1.6E-170 D8 D1M3 
cbiA cobyrinic acid A,C-diamide synthase 1.G.13 Cobalamin 9.5 12.7 8.0E-209 1.9E-207 D8   
STY3636 lipopolysaccharide biosynthesis protein 3.C.2 Surface polysacchar 9.5 13.7 5.6E-216 1.6E-214 D8   
STY2179 flagellar assembly protein FliH 3.C.3 Surface structure 9.5 12.1 2.1E-203 4.4E-202 D8   
STY4447 conserved hypothetical protein 5.H Hypothetical protein 9.5 11.5 1.4E-191 2.4E-190 D8   
gtrA bactoprenol-linked glucose translocase 3.C.2 Surface polysacchar 9.5 13.0 5.4E-210 1.3E-208 D8 M1 
tctE putative two-component system sensor kinase 2. Broad regulatory function 9.5 13.1 1.1E-210 2.7E-209 D8   
nirC putative nitrite transporter 4.A.5 Transport Anions 9.5 14.0 2.4E-216 6.9E-215 D8   
STY4820 pseudogene 5.I Unknown 9.5 13.4 2.1E-212 5.5E-211 D8   
STY1384 periplasmic murein peptide-binding protein MppA 4.A.6 Transport Other 9.5 13.5 7.5E-213 2.0E-211 D8   
STY2646 putative decarboxylase 5.I Unknown 9.4 14.4 6.2E-218 1.9E-216 D8   
STY2004 putative hydrolase 5.I Unknown 9.4 13.5 9.4E-212 2.4E-210 D8   
STY3709 
phosphoribosylaminoimidazolecarboxamide 
formyltransferase and IMP cyclohydrolase (bifunctional 
enzyme) 1.F.1 Purine ribonucleotide biosynthesis 9.4 13.8 7.2E-214 1.9E-212 D8   
mntH manganese transport protein MntH 4.A Transport/binding proteins 9.4 12.8 7.7E-207 1.8E-205 D8   
nlpC putative lipoprotein 3.C.1 Membranes lipoprotein 9.4 13.3 3.3E-210 8.1E-209 D8   
STY4901 conserved hypothetical regulatory protein 2. Broad regulatory function 9.4 13.5 7.6E-212 2.0E-210 D8   
STY1615 conserved hypothetical protein 5.H Hypothetical protein 9.4 13.3 5.4E-210 1.3E-208 D8   
STY2211 AMP nucleosidase 1.F.4 Salvage of nucleosides and nucleotides 9.4 13.5 3.0E-211 7.5E-210 D8   
STY2650 nucleoside permease NupC 4.A.6 Transport Other 9.4 12.9 1.4E-206 3.3E-205 D8 D1M3 
STY3481 putative membrane protein 3.C.1 Membranes lipoprotein 9.4 13.4 1.6E-210 4.1E-209 D8   
STY3133 protease III precursor (pitrilysin) 3.B.3 Degradation of proteins, peptides, glycoproteins 9.4 14.0 7.9E-214 2.1E-212 D8   
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STY0865 putative membrane protein 3.C.1 Membranes lipoprotein 9.3 12.9 4.0E-206 8.9E-205 D8 D1 
citC citrate-sodium symporter 4.A.3 Transport Carbohydes, organic acids and alcohols 9.3 13.2 2.9E-208 6.7E-207 D8   
STY0306 putative membrane protein 4.I Pathogenesis 9.3 12.9 8.6E-206 1.9E-204 D8   
STY0273 putative ABC transporter permease protein 4.A Transport/binding proteins 9.3 12.9 1.6E-205 3.4E-204 D8   
STY1660 putative oxidoreductase 5.I Unknown 9.3 12.6 1.5E-203 3.1E-202 D8   
STY1835 conserved hypothetical protein 5.H Hypothetical protein 9.3 12.2 3.7E-200 7.1E-199 D8   
STY0612 probable pyridine nucleotide-disulfide oxidoreductase 5.I Unknown 9.3 13.0 1.6E-205 3.4E-204 D8   
STY2396 periplasmic beta-glucosidase precursor 1.A.1 Degradation of carbohydrate 9.3 13.6 9.1E-210 2.2E-208 D8   
yheR putative oxidoreductase 5.I Unknown 9.3 12.4 6.9E-201 1.3E-199 D8   
STY4297 putative membrane protein 3.C.1 Membranes lipoprotein 9.3 13.6 4.7E-209 1.1E-207 D8   
gltP proton glutamate symport protein 4.A.1 Transport amino acid and amines 9.3 13.1 1.7E-205 3.7E-204 D8   
STY2966 putative exported protein 3.C.1 Membranes lipoprotein 9.2 12.4 1.7E-200 3.2E-199 D8   
tdcE probable formate acetyltransferase 1.B.7.b Anaerobic Respiration 9.2 13.7 3.4E-209 8.1E-208 D8   
STY0164 protein transport protein HofC 4.A.6 Transport Other 9.2 12.0 7.6E-196 1.3E-194 D8   
hyaB2 pseudogene 1.B.7.a Aerobic Respiration 9.2 12.3 3.7E-199 6.8E-198 D8   
STY4933 right origin-binding protein 3.A.7 DNA replication, repair, restriction, modification 9.2 13.2 4.6E-205 1.0E-203 D8   
STY2530 conserved hypothetical protein 5.H Hypothetical protein 9.2 12.6 4.2E-201 8.1E-200 D8   
STY4593 hypothetical protein 4.I Pathogenesis 9.2 12.3 4.4E-198 8.1E-197 D8   
STY2428 putative esterase 5.I Unknown 9.2 11.7 2.1E-193 3.5E-192 D8   
STY0194 hypothetical ABC transporter ATP-binding protein 4.A Transport/binding proteins 9.2 12.7 2.1E-201 4.2E-200 D8 D1 
STY0215 penicillin-binding protein 1b; peptidoglycan synthetase 3.C.4 Murein sacculus and peptidoglycan 9.2 10.1 4.9E-148 5.2E-147 D8   
STY3617 conserved hypothetical protein 5.H Hypothetical protein 9.2 13.3 5.5E-205 1.2E-203 D8   
STY4406 putative membrane protein 3.C.1 Membranes lipoprotein 9.2 13.6 1.3E-206 3.0E-205 D8   
tviA Vi polysaccharide biosynthesis protein 4.I Pathogenesis 9.2 13.6 3.5E-206 7.9E-205 D8   
ygcY probable glucarate dehydratase 2 1.A.1 Degradation of carbohydrate 9.1 13.3 7.7E-205 1.7E-203 D8   
STY1694 putative integral membrane transport protein 4.A Transport/binding proteins 9.1 12.2 5.9E-196 1.1E-194 D8   
STY3802 putative GntR-family regulatory protein 2. Broad regulatory function 9.1 13.4 1.3E-204 2.8E-203 D8   
glgX glycogen operon protein 3.B.4 Degradations of polysaccharides 9.1 13.9 1.1E-207 2.5E-206 D8   
STY3902 regulatory protein 1.D.2 Aspartate Family 9.1 12.1 6.4E-195 1.1E-193 D8   
STY3947 conserved hypothetical protein 5.H Hypothetical protein 9.1 13.4 3.1E-204 6.6E-203 D8   
STY2598 DedA protein (dsg-1 protein) 5.I Unknown 9.1 12.7 2.0E-199 3.8E-198 D8   
STY4200 cytoplasmic trehalase 1.A.1 Degradation of carbohydrate 9.1 13.4 5.8E-204 1.2E-202 D8   
STY2989 
hypothetical protein found within S. typhi pathogenicity 
island 1 4.I Pathogenesis 9.1 14.0 2.6E-207 6.1E-206 D8   
STY0621 conserved hypothetical protein 5.H Hypothetical protein 9.1 12.3 9.7E-196 1.7E-194 D8   
STY4129 conserved hypothetical protein 5.H Hypothetical protein 9.1 12.1 2.3E-194 3.9E-193 D8   
STY2429 putative DNA-binding protein 5.I Unknown 9.1 10.8 3.1E-168 4.0E-167 D8 M3 
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ybjF hypothetical RNA methyltransferase 5.I Unknown 9.1 13.0 6.6E-200 1.2E-198 D8   
STY1750 putative amintransferase 1.C Central Intermediary metabolism 9.1 12.3 5.0E-195 8.8E-194 D8   
STY2732 pseudogene 5.H Hypothetical protein 9.0 13.3 4.8E-202 9.6E-201 D8   
nrdD anaerobic ribonucleoside-triphosphate reductase 1.F.3 2'-deoxyribonucleotide metabolism 9.0 13.3 7.0E-202 1.4E-200 D8   
STY3590 putative membrane protein 3.C.1 Membranes lipoprotein 9.0 12.8 1.2E-198 2.2E-197 D8 D1 
STY1362 pseudogene 4.I Pathogenesis 9.0 8.0 1.5E-79 1.2E-78 D8   
STY2940 Multi-drug resistance protein A 5.D Drug/Analogue sensitivity 9.0 13.3 1.2E-201 2.4E-200 D8   
STY3479 
Penicillin-binding protein (D-alanyl-D-alanine 
carboxypeptidase) 3.C.4 Murein sacculus and peptidoglycan 9.0 13.4 1.4E-201 2.8E-200 D8   
STY3593 putative regulatory protein 2. Broad regulatory function 9.0 12.6 4.0E-196 7.2E-195 D8   
cII phage regulatory protein 5.A Latterally acquired elements 9.0 11.0 2.6E-176 3.5E-175 D8 M3 
STY0014 putative regulatory protein 2. Broad regulatory function 9.0 14.0 8.5E-205 1.8E-203 D8   
STY1504 putative hydrolase 5.I Unknown 9.0 12.3 3.2E-194 5.4E-193 D8   
STY3320 hydrogenase-2 small subunit 1.B.7.b Anaerobic Respiration 9.0 12.7 3.3E-196 5.9E-195 D8   
citF citrate lyase alpha chain 1.C Central Intermediary metabolism 9.0 12.4 3.5E-194 5.9E-193 D8   
fliZ FliZ protein 5.I Unknown 9.0 10.6 9.4E-163 1.1E-161 D8   
luxS autoinducer-2 production protein LuxS 2. Broad regulatory function 9.0 13.7 1.5E-202 3.1E-201 D8   
STY3306 D-mannonate hydrolase 1.A.1 Degradation of carbohydrate 9.0 12.9 2.6E-197 4.8E-196 D8   
STY4020 conserved hypothetical protein 5.H Hypothetical protein 9.0 12.4 1.4E-193 2.3E-192 D8   
STY2873 conserved hypothetical protein 5.H Hypothetical protein 9.0 6.5 9.5E-35 7.2E-34 D8   
STY2933 ribonucleoside-diphosphate reductase 2 beta chain 1.F.5 Miscellaneous 8.9 13.8 2.9E-202 5.9E-201 D8   
menF isochorismate synthase 1.G.11 Menaquinone  8.9 12.2 2.4E-191 3.9E-190 D8   
STY0680 pseudogene 5.I Unknown 8.9 11.7 7.1E-188 1.1E-186 D8   
relA GTP pyrophosphokinase 2. Broad regulatory function 8.9 13.6 2.3E-201 4.5E-200 D8   
STY4152 putative exported protein 3.C.1 Membranes lipoprotein 8.9 13.8 1.2E-201 2.3E-200 D8   
ggt gamma-glutamyltranspeptidase precursor 1.G.10 Thioredoxin 8.9 12.7 8.7E-195 1.5E-193 D8   
STY4168 periplasmic dipeptide transport protein precursor 4.A.6 Transport Other 8.9 13.5 1.6E-199 3.0E-198 D8   
STY2421 galactoside transport system permease protein MglC 4.A.3 Transport Carbohydes, organic acids and alcohols 8.9 12.0 2.7E-189 4.3E-188 D8   
STY2404 conserved hypothetical protein 5.H Hypothetical protein 8.9 13.0 6.3E-196 1.1E-194 D8   
STY3078   5.H Hypothetical protein 8.9 12.8 1.4E-194 2.4E-193 D8   
dcuR two-component response regulator 2. Broad regulatory function 8.9 13.8 1.8E-200 3.4E-199 D8   
STY1079 dihydroorotate dehydrogenase 1.F.2 Pyrimidine ribonucle 8.8 13.8 2.9E-200 5.5E-199 D8   
kdgR probable global regulatory protein 2. Broad regulatory function 8.8 11.7 8.8E-186 1.3E-184 D8   
mdoB putative phosphoglycerol transferase 5.I Unknown 8.8 14.4 1.4E-201 2.7E-200 D8   
STY3708 possible LysR-family transcriptional regulatory protein 2. Broad regulatory function 8.8 14.2 5.3E-200 1.0E-198 D8   
STY2022 putative exported protein 5.I Unknown 8.8 9.7 6.3E-134 6.3E-133 D8   
mltC membrane-bound lytic murein transglycosylase C 3.C.4 Murein sacculus and peptidoglycan 8.7 13.1 6.4E-194 1.1E-192 D8   
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STY4116 aldehyde dehydrogenase B 1.A.1 Degradation of carbohydrate 8.7 13.3 1.5E-194 2.6E-193 D8   
yhjL pseudogene 3.C.2 Surface polysacchar 8.7 13.7 1.2E-196 2.2E-195 D8   
STY3980 hypothetical protein 5.I Unknown 8.7 12.4 2.4E-188 3.7E-187 D8   
STY1286 nitrate/nitrite sensor protein NarX 1.B.7.b Anaerobic Respiration 8.7 12.7 7.7E-191 1.3E-189 D8   
STY3534 tartrate dehydratase 1.B.8 Fermentation 8.7 13.6 3.6E-196 6.5E-195 D8   
yiaH pseudogene 3.C.1 Membranes lipoprotein 8.7 14.3 3.0E-198 5.5E-197 D8   
STY4193 putative membrane protein 3.C.1 Membranes lipoprotein 8.7 13.3 5.1E-194 8.6E-193 D8   
STY2577 conserved hypothetical protein 5.H Hypothetical protein 8.7 11.3 2.8E-179 4.0E-178 D8   
STY0294 ClpB-like protein 4.I Pathogenesis 8.7 12.6 2.3E-188 3.6E-187 D8   
sgaT putative transport protein SgaT 4.A Transport/binding proteins 8.7 12.4 2.2E-186 3.3E-185 D8   
STY2851 ftsH suppressor protein SfhB 3.A.2 Ribosomal protein synthesis, modification 8.6 12.3 9.0E-186 1.4E-184 D8 D1M3 
STY0641 isochorismatase 1.G.14 Iron uptake and storage 8.6 10.9 1.2E-172 1.6E-171 D8   
STY4573 hypothetical protein 4.I Pathogenesis 8.6 13.8 3.1E-194 5.3E-193 D8   
STY4570 putative exported protein 4.I Pathogenesis 8.6 13.2 6.5E-191 1.1E-189 D8   
yhjJ putative zinc-protease precursor 3.B.3 Degradation of proteins, peptides, glycoproteins 8.6 12.8 4.2E-189 6.6E-188 D8   
STY0489 trigger factor 4.C Cell division 8.6 12.7 2.3E-187 3.6E-186 D8   
STY2944 gamma-glutamylcysteine synthetase 1.G.10 Thioredoxin 8.6 10.5 6.3E-161 7.4E-160 D8 M1 
STY3332 biopolymer transport ExbB protein 4.A Transport/binding proteins 8.6 11.3 2.0E-177 2.7E-176 D8   
STY1649 outer membrane protein 4.A Transport/binding proteins 8.6 13.0 5.4E-189 8.5E-188 D8   
STY4091 
2,3-bisphosphoglycerate-independent phosphoglycerate 
mutase 5.I Unknown 8.6 13.9 3.5E-193 5.8E-192 D8   
STY1097 helicase IV (75 kD helicase) 3.A.7 DNA replication, repair, restriction, modification 8.5 12.8 1.4E-187 2.2E-186 D8   
rhlB putative ATP-dependent RNA helicase 3.A.9 RNA synthesis, modification 8.5 12.6 1.0E-185 1.5E-184 D8   
ompX outer membrane protein x precursor 3.C Cell envelope 8.5 11.8 7.4E-180 1.1E-178 D8   
STY3656 acetolactate synthase large subunit 1.D.6 Pyruvate Family 8.5 13.1 2.6E-188 4.0E-187 D8   
STY0605 putative membrane protein 3.C.1 Membranes lipoprotein 8.5 14.0 1.5E-191 2.5E-190 D8 M1 
STY2455 putative ABC-transporter ATP-binding protein 5.H Hypothetical protein 8.5 11.4 3.6E-174 4.8E-173 D8   
STY3337 probable alcohol dehydrogenase 5.I Unknown 8.4 12.7 5.7E-184 8.5E-183 D8   
STY3754 phosphoenolpyruvate carboxylase 1.B.8 Fermentation 8.4 13.8 6.5E-189 1.0E-187 D8   
dpiA transcriptional regulatory protein dpia 2. Broad regulatory function 8.4 11.0 4.8E-171 6.2E-170 D8   
STY3783 glycerol uptake facilitator protein 4.A.3 Transport Carbohydes, organic acids and alcohols 8.4 12.0 5.3E-178 7.4E-177 D8   
STY1566 putative dimethyl sulphoxide reductase subunit 1.A.1 Degradation of carbohydrate 8.4 12.3 4.8E-180 6.9E-179 D8   
STY4851 conserved hypothetical protein 4.I Pathogenesis 8.4 13.2 3.3E-185 5.0E-184 D8   
STY4059 conserved hypothetical protein 5.H Hypothetical protein 8.4 14.1 9.6E-189 1.5E-187 D8   
mtgA 
monofunctional biosynthetic peptidoglycan 
transglycosylase 3.C.4 Murein sacculus and peptidoglycan 8.4 11.7 2.0E-174 2.7E-173 D8 D1 
STY2602 Div protein 4.C Cell division 8.3 12.2 1.6E-178 2.3E-177 D8   
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STY4821 integrase #N/A 8.3 13.2 1.7E-184 2.5E-183 D8   
STY3692 hypothetical protein 5.I Unknown 8.3 13.1 7.6E-184 1.1E-182 D8   
STY0362 xanthine-guanine phosphoribosyltransferase 1.F.4 Salvage of nucleosides and nucleotides 8.3 11.5 1.8E-172 2.4E-171 D8   
STY1103 conserved hypothetical protein 5.H Hypothetical protein 8.3 11.3 6.1E-171 7.8E-170 D8   
STY1164 putative membrane transporter 4.A Transport/binding proteins 8.3 11.1 2.5E-168 3.1E-167 D8   
ushA pseudogene 1.C.3 Sugar Nuclotides 8.3 12.9 1.8E-181 2.6E-180 D8   
corB putative membrane protein 3.C.1 Membranes lipoprotein 8.3 12.8 1.2E-180 1.8E-179 D8   
STY0631 enterobactin synthetase component F 4.I Pathogenesis 8.3 11.6 2.6E-172 3.4E-171 D8   
STY1534 putative membrane protein 3.C.1 Membranes lipoprotein 8.3 12.5 4.5E-178 6.2E-177 D8   
STY0308 pseudogene 4.I Pathogenesis 8.2 12.8 1.3E-179 1.8E-178 D8   
STY4594 hypothetical protein 4.I Pathogenesis 8.2 11.5 1.5E-170 2.0E-169 D8 D1 
yhjA probable cytochrome c peroxidase 5.I Unknown 8.2 12.9 6.3E-180 9.1E-179 D8   
STY3983 pseudogene 3.C.1 Membranes lipoprotein 8.2 12.4 5.9E-177 8.1E-176 D8   
STY0077 carbamoyl-phosphate synthase large chain 1.F.2 Pyrimidine ribonucle 8.2 12.8 4.9E-179 6.9E-178 D8   
yjeM putative amino acid permease 4.A Transport/binding proteins 8.2 14.1 6.9E-184 1.0E-182 D8   
STY2791 putative RNA methyltransferase 3.A.9 RNA synthesis, modification 8.2 10.9 2.0E-164 2.5E-163 D8   
hutU urocanate hydratase 1.A.2 Degradation of amino acids 8.2 11.5 1.1E-168 1.4E-167 D8   
STY4209 oligopeptidase A 3.B.3 Degradation of proteins, peptides, glycoproteins 8.2 12.7 2.3E-177 3.2E-176 D8   
STY2382 conserved hypothetical protein 5.H Hypothetical protein 8.1 14.2 4.5E-183 6.6E-182 D8   
STY4188 conserved hypothetical protein 5.H Hypothetical protein 8.1 13.5 9.9E-181 1.5E-179 D8   
gpsA glycerol-3-phosphate dehydrogenase 1.B.7.a Aerobic Respiration 8.1 12.0 1.3E-172 1.8E-171 D8   
acT hypothetical transcriptional activator 2. Broad regulatory function 8.1 11.0 5.4E-164 6.5E-163 D8   
mdfA Multi-drug translocase MdfA 4.A.6 Transport Other 8.1 12.3 3.8E-174 5.1E-173 D8   
STY0701 putative hydrolase C-terminus 5.I Unknown 8.1 13.1 2.0E-178 2.8E-177 D8   
STY1193 conserved hypothetical protein 5.H Hypothetical protein 8.1 11.5 4.2E-167 5.3E-166 D8   
STY0678 cold shock-like protein cspE 2. Broad regulatory function 8.1 13.6 1.9E-179 2.6E-178 D8   
STY0231 protease DO precursor; heat shock protein HtrA 3.B.3 Degradation of proteins, peptides, glycoproteins 8.1 13.2 9.5E-178 1.3E-176 D8   
pilO putative pilus assembly protein 4.I Pathogenesis 8.1 12.4 1.5E-173 2.0E-172 D8   
STY2402 putative lipoprotein 3.C.1 Membranes lipoprotein 8.1 11.0 2.8E-163 3.4E-162 D8   
STY0480 conserved hypothetical protein 5.H Hypothetical protein 8.1 12.0 1.1E-170 1.4E-169 D8   
bigA pseudogene 3.C.2 Surface polysacchar 8.1 13.8 1.1E-179 1.6E-178 D8   
orgAb oxygen-regulated invasion protein 4.I Pathogenesis 8.1 13.2 1.6E-177 2.2E-176 D8   
STY2819 putative oxidoreductase 5.I Unknown 8.0 12.9 2.7E-175 3.6E-174 D8   
STY4756 putative exported protein 3.C.1 Membranes lipoprotein 8.0 14.4 1.8E-180 2.7E-179 D8   
STY2849 ClpB protein (heat shock protein f84.1) 3.B.3 Degradation of proteins, peptides, glycoproteins 8.0 13.0 1.0E-175 1.3E-174 D8   
cstA probable carbon starvation protein 4.A Transport/binding proteins 8.0 13.3 8.9E-177 1.2E-175 D8   
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rcsC sensor protein RcsC 2. Broad regulatory function 8.0 13.9 1.6E-178 2.2E-177 D8   
STY3319 probable hydrogenase-2 cytochrome b subunit 1.B.7.b Anaerobic Respiration 8.0 11.9 3.4E-167 4.3E-166 D8   
STY4484 formate dehydrogenase H 1.B.8 Fermentation 8.0 13.3 2.3E-175 3.1E-174 D8   
mgtB Magnesium transport ATPase, P-type 2 4.A Transport/binding proteins 8.0 14.0 3.5E-177 4.8E-176 D8   
STY4568 possible exported protein 4.I Pathogenesis 7.9 12.2 1.8E-168 2.3E-167 D8   
STY4256 sn-Glycerol-3-phosphate transport system permease protein 4.A.3 Transport Carbohydes, organic acids and alcohols 7.9 10.6 2.1E-155 2.4E-154 D8   
STY2367 putative membrane protein 3.C.1 Membranes lipoprotein 7.9 12.1 1.1E-166 1.3E-165 D8 D1 
STY2843 conserved hypothetical protein 5.H Hypothetical protein 7.9 10.1 2.3E-146 2.4E-145 D8   
STY1793 catalase HPII 4.G Detoxification 7.8 12.1 2.9E-166 3.6E-165 D8   
STY2760 putative exported protein 4.I Pathogenesis 7.8 13.6 1.6E-172 2.2E-171 D8   
ybiR putative membrane protein 3.C.1 Membranes lipoprotein 7.8 11.2 1.4E-158 1.7E-157 D8   
STY0112 DNA polymerase II 3.A.7 DNA replication, repair, restriction, modification 7.8 12.5 5.5E-167 6.9E-166 D8   
STY3093 hypothetical protein 5.I Unknown 7.7 13.3 2.2E-169 2.8E-168 D8   
STY1228 conserved hypothetical protein 5.H Hypothetical protein 7.7 12.5 5.5E-166 6.8E-165 D8   
STY1921 probable cytochrome oxidase subunit II 1.B.7.c Electron Transport 7.7 10.5 2.0E-151 2.3E-150 D8   
STY2756 conserved hypothetical protein 4.I Pathogenesis 7.7 11.9 1.6E-162 1.9E-161 D8   
pqaB melittin resistance protein PqaB 5.D Drug/Analogue sensitivity 7.7 11.6 4.5E-160 5.3E-159 D8   
STY1281 putative calcium/proton antiporter 4.A.2 Transport Cations 7.7 12.8 1.8E-166 2.2E-165 D8   
STY4937 inner membrane protein CreD 5.A Laterally acquired elements 7.7 12.3 6.4E-164 7.8E-163 D8   
STY3592 putative hydrolase 5.I Unknown 7.7 10.2 6.1E-148 6.5E-147 D8   
ybhP conserved hypothetical protein 5.H Hypothetical protein 7.7 9.0 3.2E-112 2.8E-111 D8   
STY1346 osmotically inducible lipoprotein B precursor 5.F Adaptions and atypical conditions 7.7 12.9 9.1E-167 1.1E-165 D8   
STY2611 conserved hypothetical protein 5.H Hypothetical protein 7.7 9.3 2.1E-122 2.0E-121 D8   
STY3405 probable membrane transport protein 4.A Transport/binding proteins 7.7 12.0 2.8E-161 3.2E-160 D8   
STY3044 DeoR-family trancriptional regulator 2. Broad regulatory function 7.7 8.6 6.1E-100 5.2E-99 D8   
slrP pseudogene 4.I Pathogenesis 7.7 13.5 1.2E-167 1.5E-166 D8   
STY2124 chemotaxis protein CheZ 4.D Chemotaxis and mobility 7.6 10.0 1.6E-144 1.7E-143 D8   
STY0358 hypothetical protein DinP (DNA damage-inducible protein) 5.I Unknown 7.6 12.5 1.9E-163 2.3E-162 D8   
frdA fumarate reductase, flavoprotein subunit 1.B.7.b Anaerobic Respiration 7.6 12.3 4.2E-162 5.0E-161 D8   
STY3936 putative membrane transport protein 4.A Transport/binding proteins 7.6 11.7 1.8E-158 2.0E-157 D8   
STY2190 colanic acid capsullar biosynthesis activation protein A 3.C.2 Surface polysacchar 7.6 11.9 9.4E-160 1.1E-158 D8   
STY3538 possible GntR-family transcriptional regulator 2. Broad regulatory function 7.6 10.8 4.6E-151 5.1E-150 D8   
STY3549 possible exported protein 3.C.1 Membranes lipoprotein 7.6 12.8 1.3E-163 1.5E-162 D8   
STY0517 conserved hypothetical protein 5.H Hypothetical protein 7.6 13.1 8.9E-165 1.1E-163 D8   
STY2158 cell-division regulatory protein 4.C Cell division 7.5 11.1 5.2E-151 5.8E-150 D8   
ampH penicillin-binding protein AmpH 3.C.4 Murein sacculus and peptidoglycan 7.5 12.8 9.0E-162 1.1E-160 D8   
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STY4562 hypothetical protein 4.I Pathogenesis 7.5 13.6 5.4E-164 6.5E-163 D8   
STY0168 
AmpD protein (anhydro-N-acetylmuramyl-tripeptide 
amidase) 5.I Unknown 7.5 8.9 2.0E-110 1.8E-109 D8   
STY0395 AraC-family transcriptional regulator 2. Broad regulatory function 7.5 10.4 4.6E-145 4.8E-144 D8 D1 
STY1304 periplasmic oligopeptide-binding protein precursor 4.A.6 Transport Other 7.5 13.1 2.6E-161 3.1E-160 D8   
STY4468 lysR family regulatory protein 2. Broad regulatory function 7.4 12.1 4.2E-156 4.8E-155 D8   
STY2804 transcriptional activator cadC 2. Broad regulatory function 7.4 14.8 4.9E-164 6.0E-163 D8   
STY3765 hypothetical protein 5.I Unknown 7.4 12.3 6.4E-157 7.4E-156 D8   
treC trehalose-6-phosphate hydrolase 1.A.1 Degradation of carbohydrate 7.4 11.3 9.2E-150 1.0E-148 D8   
STY3826 rhamnulokinase 1.A.1 Degradation of carbohydrate 7.4 11.1 1.4E-147 1.5E-146 D8   
bisC biotin sulfoxide reductase #N/A 7.4 12.0 8.8E-154 9.9E-153 D8   
STY3246 endonuclease I 3.B.2 Degradation of DNA 7.4 10.5 2.8E-143 2.9E-142 D8   
prgH pathogenicity 1 island effector protein 4.I Pathogenesis 7.3 12.6 1.0E-156 1.2E-155 D8   
pduE diol dehydratase small subunit 1.A.1 Degradation of carbohydrate 7.3 8.4 1.1E-93 8.9E-93 D8   
STY0259 lysine decarboxylase 1.B.2 Pyruvate dehydrogenase 7.3 12.3 1.5E-154 1.7E-153 D8   
STY4136 xylose operon regulatory protein 2. Broad regulatory function 7.3 11.0 2.1E-146 2.2E-145 D8   
sspH2 secreted effector protein 4.I Pathogenesis 7.3 11.8 9.2E-152 1.0E-150 D8   
tcfD putative fimbrail protein 4.I Pathogenesis 7.3 12.4 2.1E-154 2.4E-153 D8   
fimF fimbria-like protein FimF precursor 3.C.3 Surface structure 7.3 9.7 9.4E-135 9.4E-134 D8   
STY1753 conserved hypothetical protein 5.H Hypothetical protein 7.3 10.9 6.4E-145 6.7E-144 D8   
melB melibiose carrier protein 4.A.3 Transport Carbohydes, organic acids and alcohols 7.3 10.9 5.2E-145 5.4E-144 D8   
vexE Vi polysaccharide export protein 4.I Pathogenesis 7.2 13.0 1.3E-154 1.5E-153 D8   
shdA pseudogene 4.I Pathogenesis 7.2 13.5 1.4E-155 1.6E-154 D8   
STY4001 putative carbohydrate kinase 3.A.10 Polysaccharides (Cytoplasmic) 7.2 12.9 8.5E-154 9.6E-153 D8   
STY0303 probable lipoprotein 4.I Pathogenesis 7.2 9.3 2.5E-121 2.3E-120 D8 M3 
STY1276 putative secreted protein 3.C.1 Membranes lipoprotein 7.2 10.1 7.8E-136 7.8E-135 D8   
yliB putative ABC transporter periplasmic binding protein 4.A Transport/binding proteins 7.2 11.8 4.7E-148 5.1E-147 D8   
STY2311 pseudogene 3.C.2 Surface polysacchar 7.2 11.9 1.8E-148 2.0E-147 D8   
STY2035 putative bacteriophage protein #N/A 7.1 9.2 4.8E-118 4.4E-117 D8   
STY3096 sensor protein 2. Broad regulatory function 7.1 14.2 4.3E-155 4.9E-154 D8   
STY1253 putative TetR-family regulatory protein 2. Broad regulatory function 7.1 10.9 1.3E-141 1.3E-140 D8   
STY2494 putative two-component system sensor kinase 2. Broad regulatory function 7.1 12.8 1.2E-151 1.3E-150 D8   
STY3771 pseudogene 1.C.5 Sulphur Metabolism 7.1 12.5 9.0E-150 9.9E-149 D8 D1 
lysR transcriptional activator protein LysR 1.D.2 Aspartate Family 7.1 10.3 2.0E-135 2.0E-134 D8   
scsB 
membrane protein, suppressor for copper-sensitivity B 
precursor 4.G Detoxification 7.1 11.2 2.6E-142 2.7E-141 D8   
 260 
tviE 
Vi polysaccharide biosynthesis protein TviE, Glycosyl 
transferases group 1 4.I Pathogenesis 7.0 13.1 9.1E-150 1.0E-148 D8   
vexA Vi polysaccharide export protein 4.I Pathogenesis 7.0 13.5 7.2E-151 7.9E-150 D8   
STY3671 possible lipoprotein 5.I Unknown 7.0 12.9 4.4E-149 4.8E-148 D8   
waaB lipopolysaccharide 1,6-galactosyltransferase 3.C.2 Surface polysacchar 7.0 13.4 5.0E-150 5.6E-149 D8   
STY2485 probable nitrate reductase 1.B.7.b Anaerobic Respiration 7.0 11.7 2.0E-143 2.1E-142 D8   
STY2875 large repetitive protein 4.I Pathogenesis 7.0 13.6 1.1E-149 1.2E-148 D8   
STY4075 hypothetical protein 5.I Unknown 7.0 11.5 1.1E-141 1.1E-140 D8   
phoN nonspecific acid phosphatase precursor 1.C Central Intermediary metabolism 7.0 11.5 1.8E-141 1.9E-140 D8   
STY0710 
ABC transporter periplasmic binding protein 
(glutamate/aspartate?) 4.A Transport/binding proteins 6.9 9.9 2.0E-128 1.9E-127 D8   
STY4236 putative membrane protein 3.C.1 Membranes lipoprotein 6.9 10.0 3.7E-129 3.6E-128 D8   
STY1186 glucans biosynthesis protein 5.F Adaptions and atypical conditions 6.9 12.6 1.9E-145 2.0E-144 D8   
STY0159 putative lysR-family transcriptional regulator 2. Broad regulatory function 6.9 10.4 4.3E-132 4.3E-131 D8   
STY0439 maltodextrin glucosidase 1.A.1 Degradation of carbohydrate 6.9 10.3 8.0E-132 7.9E-131 D8   
STY4268 gluconate utilization operon repressor 1.B.6 Entner-Doudoroff pathway 6.9 10.3 1.8E-131 1.8E-130 D8   
STY2775 pseudogene 1.B.7.b Anaerobic Respiration 6.9 11.5 1.1E-139 1.1E-138 D8   
tldD TldD protein 5.I Unknown 6.9 11.1 1.2E-136 1.2E-135 D8   
STY0180 putative exported protein 3.C.1 Membranes lipoprotein 6.9 10.8 2.1E-134 2.0E-133 D8   
STY3860 putative membrane permease 4.A Transport/binding proteins 6.9 10.9 5.5E-135 5.5E-134 D8   
STY1496 conserved hypothetical protein 5.H Hypothetical protein 6.8 14.0 1.6E-146 1.7E-145 D8   
STY4824 hypothetical protein 5.H Hypothetical protein 6.8 14.0 2.5E-146 2.7E-145 D8   
STY3721 thiamine biosynthesis protein 1.G.8 Thiamine 6.8 12.8 7.3E-143 7.6E-142 D8   
yifB pseudogene 5.H Hypothetical protein 6.8 16.7 9.1E-147 9.7E-146 D8   
STY3923 conserved hypothetical protein 5.H Hypothetical protein 6.8 13.9 2.0E-144 2.1E-143 D8   
STY3796 putative ABC transporter ATP-binding protein 4.A Transport/binding proteins 6.8 11.5 8.0E-137 8.1E-136 D8   
STY4060 RNase PH 3.B.1 Degradation of RNA 6.8 12.2 8.9E-140 9.1E-139 D8   
STY4785 hypothetical protein 5.I Unknown 6.8 10.3 5.6E-128 5.4E-127 D8   
STY4804 carbamate kinase 1.A.2 Degradation of amino acids 6.7 10.2 3.3E-127 3.2E-126 D8   
STY0616 hypothetical protein 5.H Hypothetical protein 6.7 9.4 8.9E-120 8.3E-119 D8   
STY3594 
5-methyltetrahydropteroyltriglutamate-homocysteine 
methyltransferase 1.D.2 Aspartate Family 6.7 14.8 3.3E-145 3.5E-144 D8   
STY2835 conserved hypothetical protein 5.H Hypothetical protein 6.7 12.1 4.5E-138 4.6E-137 D8   
STY2859 putative membrane protein 3.C.1 Membranes lipoprotein 6.7 12.3 1.6E-138 1.6E-137 D8   
yigL conserved hypothetical protein 5.H Hypothetical protein 6.6 10.5 3.5E-127 3.4E-126 D8   
STY1016 exonuclease 5.A Latterally acquired elements 6.6 8.4 7.9E-95 6.7E-94 D8 D1 
steC periplasmic fimbrial chaperone 3.C.3 Surface structure 6.6 10.0 1.1E-122 1.0E-121 D8   
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STY0384 pseudogene 3.C Cell envelope 6.6 9.6 2.1E-118 1.9E-117 D8   
STY1669 endonuclease III 3.B.2 Degradation of DNA 6.6 8.3 9.1E-89 7.6E-88 D8   
STY3400 conserved hypothetical protein 5.H Hypothetical protein 6.6 10.7 5.4E-128 5.2E-127 D8   
STY0973 formate acetyltransferase 1 1.B.7.b Anaerobic Respiration 6.6 11.3 2.9E-131 2.9E-130 D8   
STY2213 hypothetical protein 5.I Unknown 6.6 9.1 3.7E-113 3.3E-112 D8   
STY0081 probable crotonobetaine/carnitine-CoA ligase 1.A.1 Degradation of carbohydrate 6.6 10.8 7.2E-128 6.9E-127 D8   
STY3443 PTS system, galactitol-specific IIC component 4.A.3 Transport Carbohydes, organic acids and alcohols 6.5 10.0 4.0E-121 3.7E-120 D8   
STY0167 nicotinate-nucleotide pyrophosphorylase 1.G.7 Pyridine nucleotide 6.5 8.9 3.7E-111 3.3E-110 D8   
STY0568 probable metabolite transport protein 4.A Transport/binding proteins 6.5 8.4 1.1E-93 9.6E-93 D8   
STY4459 large repetitive protein 4.I Pathogenesis 6.5 13.2 5.5E-135 5.5E-134 D8   
STY2526 Ais protein 5.I Unknown 6.5 12.0 1.8E-131 1.8E-130 D8   
STY3794 putative ABC transporter, membrane component 4.A Transport/binding proteins 6.4 10.9 3.6E-125 3.4E-124 D8   
STY2397 D-lactate dehydrogenase 1.B.7.a Aerobic Respiration 6.4 10.0 2.2E-118 2.0E-117 D8   
STY3403 possible oxidoreductase 5.I Unknown 6.4 10.1 1.9E-118 1.7E-117 D8   
STY2387 conserved hypothetical protein 5.H Hypothetical protein 6.4 9.9 6.3E-116 5.7E-115 D8   
STY0855 putative ATP-dependent RNA helicase rhlE 5.I Unknown 6.4 10.4 5.4E-121 5.1E-120 D8   
STY2511 
glycerophosphoryl diester phosphodiesterase periplasmic 
precursor 1.C Central Intermediary metabolism 6.3 12.2 5.6E-129 5.4E-128 D8   
STY3406 putative membrane protein 3.C.1 Membranes lipoprotein 6.3 11.1 6.0E-124 5.6E-123 D8   
STY0943 ATP-dependent Clp protease ATP-binding subunit ClpA 3.B.3 Degradation of proteins, peptides, glycoproteins 6.3 11.3 1.7E-125 1.6E-124 D8   
STY3670 possible lipoprotein 5.I Unknown 6.3 11.6 2.9E-126 2.8E-125 D8   
STY3167 probable amino acid transport protein 4.A.1 Transport amino acid and amines 6.3 12.6 4.7E-129 4.6E-128 D8   
cobD putative aminotransferase CobD 1.G.13 Cobalamin 6.3 9.9 2.7E-115 2.4E-114 D8   
STY2625 putative membrane protein 3.C.1 Membranes lipoprotein 6.3 10.3 3.7E-117 3.3E-116 D8   
STY4197 hypothetical luxR-family transcriptional regulator 2. Broad regulatory function 6.2 14.1 6.8E-131 6.7E-130 D8   
STY1312 cardiolipin synthetase 3.A.11 Phospholipids 6.2 10.3 3.4E-116 3.1E-115 D8 D1 
STY3380 adenyl-transferase 3.A.8 Protein translation and modification 6.2 11.1 1.9E-120 1.8E-119 D8   
STY4664 putative DNA helicase 4.I Pathogenesis 6.2 11.7 1.3E-122 1.3E-121 D8   
STY3404 possible drug efflux protein 5.D Drug/Analogue sensitivity 6.2 10.9 6.9E-119 6.4E-118 D8   
STY0426 hypothetical ROK-family protein 5.I Unknown 6.2 8.8 2.8E-100 2.4E-99 D8   
STY3295 possible amino acid transport protein 4.A Transport/binding proteins 6.2 10.0 1.8E-112 1.6E-111 D8   
STY0582 
phosphoribosylaminoimidazole carboxylase catalytic 
subunit 1.F.1 Purine ribonucleotide biosynthesis 6.2 8.4 5.6E-94 4.7E-93 D8   
STY4173 putative amino acid permease 4.A.1 Transport amino acid and amines 6.2 12.5 1.4E-124 1.3E-123 D8   
STY4782 putative membrane protein 3.C.1 Membranes lipoprotein 6.1 8.8 1.3E-100 1.2E-99 D8 D1 
STY1448 putative phosphotransferase enzyme 4.A Transport/binding proteins 6.1 7.6 9.6E-65 7.6E-64 D8   
citF2 citrate lyase alpha chain 1.C Central Intermediary metabolism 6.1 9.2 9.3E-104 8.1E-103 D8   
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STY3435 tagatose-bisphosphate aldolase 1.A.1 Degradation of carbohydrate 6.1 10.6 7.4E-115 6.6E-114 D8   
tviC Vi polysaccharide biosynthesis protein, epimerase 4.I Pathogenesis 6.1 11.6 1.5E-119 1.4E-118 D8   
STY1428 ATP-dependent helicase HrpA 3.A.7 DNA replication, repair, restriction, modification 6.1 11.2 1.4E-117 1.3E-116 D8   
STY4212 universal stress protein A 5.F Adaptions and atypical conditions 6.1 9.7 9.6E-108 8.4E-107 D8   
STY1763 3-deoxy-D-arabinoheptulosonate 7-phosphate synthase 1.D.4 Aromatic Amino Acid 6.0 8.3 1.7E-91 1.4E-90 D8   
STY0111 probable ATP-dependent helicase HepA 3.A.9 RNA synthesis, modification 6.0 10.8 5.4E-114 4.8E-113 D8   
STY1425 putative secreted protein 3.C.1 Membranes lipoprotein 6.0 9.7 1.6E-105 1.4E-104 D8   
STY3837 putative lipoprotein 3.C.1 Membranes lipoprotein 6.0 11.3 4.2E-116 3.8E-115 D8   
ratB pseudogene 4.I Pathogenesis 5.9 11.0 3.8E-113 3.4E-112 D8   
hflC HflC protein 5.I Unknown 5.9 8.6 3.7E-92 3.1E-91 D8   
STY0043 possible sulfatase regulatory protein 1.C.5 Sulphur Metabolism 5.9 13.5 5.2E-118 4.8E-117 D8   
pduG PduG protein 1.A.1 Degradation of carbohydrate 5.8 8.8 2.4E-92 2.0E-91 D8   
dcuS two-component sensor kinase 2. Broad regulatory function 5.8 10.1 3.5E-105 3.0E-104 D8   
tcfA putative fimbrial protein 4.I Pathogenesis 5.8 9.5 3.0E-99 2.5E-98 D8   
STY3066 conserved hypothetical protein 5.H Hypothetical protein 5.8 8.3 1.2E-85 1.0E-84 D8   
pmrB two-component sensor kinase 2. Broad regulatory function 5.7 9.8 8.6E-102 7.5E-101 D8   
allB putative allantoinase 1.B.9 ATP-proton motive factor 5.7 10.4 2.0E-105 1.8E-104 D8   
STY4475 cytochrome c552 precursor 1.B.7.c Electron Transport 5.7 9.7 2.0E-99 1.7E-98 D8   
tviB 
Vi polysaccharide biosynthesis protein, UDP-glucose/GDP-
mannose dehydrogenase 4.I Pathogenesis 5.7 13.2 3.5E-112 3.1E-111 D8   
STY1742 pseudogene 4.I Pathogenesis 5.6 9.7 3.7E-97 3.1E-96 D8   
STY3942 recF protein 3.A.7 DNA replication, repair, restriction, modification 5.6 10.1 2.5E-100 2.2E-99 D8   
STY2977 hydrogenase isoenzymes formation protein HypB 1.B.8 Fermentation 5.6 9.4 2.3E-94 1.9E-93 D8 D1 
samA pseudogene #N/A 5.6 14.6 2.7E-111 2.4E-110 D8   
STY1423 putative exported protein 3.C.1 Membranes lipoprotein 5.6 10.6 1.3E-102 1.1E-101 D8   
STY0131 3-isopropylmalate dehydrogenase 1.D.6 Pyruvate Family 5.5 9.7 8.4E-96 7.2E-95 D8   
STY3223 putative membrane protein 3.C.1 Membranes lipoprotein 5.5 10.4 6.4E-100 5.5E-99 D8   
tsaC outer membrane fimbrial usher protein 4.I Pathogenesis 5.5 10.2 9.3E-99 8.0E-98 D8   
STY2525 conserved hypothetical protein 5.H Hypothetical protein 5.4 9.7 2.7E-94 2.3E-93 D8   
STY2617 conserved hypothetical protein 5.I Unknown 5.4 8.9 1.1E-86 8.8E-86 D8   
STY4043 sodium:galactoside family symporter 4.A.3 Transport Carbohydes, organic acids and alcohols 5.3 8.8 5.0E-83 4.2E-82 D8   
tviD Vi polysaccharide biosynthesis protein 4.I Pathogenesis 5.3 13.1 2.7E-102 2.3E-101 D8   
invA possible secretory protein (associated with virulence) 4.I Pathogenesis 5.3 8.3 1.5E-76 1.2E-75 D8 D1 
STY1315 putative acyl-coA hydrolase 5.I Unknown 5.3 8.7 1.7E-80 1.4E-79 D8   
STY2801 putative 3-phenylpropionate permease 4.A.3 Transport Carbohydes, organic acids and alcohols 5.3 8.5 1.7E-77 1.4E-76 D8   
wzc putative tyrosine-protein kinase 3.A.8 Protein translation and modification 5.2 8.9 2.9E-81 2.4E-80 D8   
dsbA disulfide isomerase 3.A.8 Protein translation and modification 5.1 9.0 6.2E-81 5.1E-80 D8   
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glgB 1,4-alpha-glucan branching enzyme 3.A.10 Polysaccharides (Cytoplasmic) 5.1 10.6 4.8E-91 4.0E-90 D8   
vexB 
Vi polysaccharide export inner-membrane protein (ABC-2 
type transporter) 4.I Pathogenesis 5.1 10.2 8.1E-89 6.8E-88 D8   
STY2216 putative inner membrane protein 3.C.1 Membranes lipoprotein 5.1 8.6 8.5E-75 6.8E-74 D8   
STY4856 conserved hypothetical protein 5.H Hypothetical protein 5.0 9.3 4.0E-81 3.3E-80 D8   
STY3326 putative membrane protein 3.C.1 Membranes lipoprotein 5.0 9.1 7.0E-78 5.7E-77 D8   
mgtC conserved hyopthetical protein 5.H Hypothetical protein 5.0 12.6 3.7E-92 3.1E-91 D8   
STY4222 putative membrane protein 3.C.1 Membranes lipoprotein 4.9 9.9 1.0E-82 8.5E-82 D8   
mrr mrr restriction system protein 3.A.7 DNA replication, repair, restriction, modification 4.9 8.2 2.3E-66 1.8E-65 D8   
hsdR subunit R of type I restriction-modification system 3.A.7 DNA replication, repair, restriction, modification 4.9 9.4 1.3E-78 1.0E-77 D8   
STY2876 putative type I secretion protein 4.I Pathogenesis 4.9 8.3 4.7E-67 3.7E-66 D8   
mgtA Mg(2+) transport ATPase, P-type 4.A.2 Transport Cations 4.9 9.6 8.5E-80 6.9E-79 D8   
STY2171 cytoplasmic alpha-amylase 3.B.4 Degradations of polysaccharides 4.8 13.1 1.1E-90 9.4E-90 D8   
staA putative fimbrial protein 3.C.3 Surface structure 4.8 6.9 2.5E-42 1.9E-41 D8   
STY0085 FixA protein 1.A.1 Degradation of carbohydrate 4.8 8.2 1.6E-64 1.3E-63 D8 D1 
ytfM putative exported protein 3.C.1 Membranes lipoprotein 4.7 9.5 5.3E-75 4.2E-74 D8   
stdB probable outer membrane fimbrial usher protein 3.C.3 Surface structure 4.7 9.6 3.5E-75 2.8E-74 D8   
STY1460 putative peptidase 3.B.3 Degradation of proteins, peptides, glycoproteins 4.6 8.9 6.7E-69 5.4E-68 D8   
STY3451 conserved hypothetical protein 5.H Hypothetical protein 4.6 6.4 4.0E-31 3.0E-30 D8   
STY0057 
probable FkbB-type 16 kD peptidyl-prolyl cis-trans 
isomerase 3.A.8 Protein translation and modification 4.6 5.2 1.1E-18 7.7E-18 D8   
STY1202 conserved hypothetical protein 5.H Hypothetical protein 4.6 7.3 5.3E-46 4.1E-45 D8   
STY2825 DNA repair protein RecO 3.A.7 DNA replication, repair, restriction, modification 4.6 7.3 2.4E-45 1.9E-44 D8 D1 
STY4467 putative sodium/hydrogen exchanger family protein 4.A Transport/binding proteins 4.5 8.3 4.8E-60 3.8E-59 D8   
STY3083 conserved hypothetical protein 5.H Hypothetical protein 4.5 12.0 3.6E-79 2.9E-78 D8   
STY0197 conserved hypothetical protein 5.H Hypothetical protein 4.5 8.4 2.5E-60 2.0E-59 D8   
STY3684 putative regulatory protein 5.I Unknown 4.5 7.3 1.5E-44 1.2E-43 D8 D1 
STY0768 pseudogene 5.H Hypothetical protein 4.4 3.2 4.7E-09 2.9E-08 D8   
slsA conserved hypothetical protein 5.H Hypothetical protein 4.4 8.5 1.8E-61 1.4E-60 D8   
yjfL putative membrane protein 3.C.1 Membranes lipoprotein 4.4 7.4 1.3E-43 9.9E-43 D8 D1 
STY4424 maltose transport inner membrane protein 4.A.3 Transport Carbohydes, organic acids and alcohols 4.3 9.2 8.5E-64 6.7E-63 D8   
STY2981 
transcriptional activator of the formate hydrogenlyase 
system 2. Broad regulatory function 4.2 8.3 3.8E-54 3.0E-53 D8   
STY3307 D-mannonate oxidoreductase 1.A.1 Degradation of carbohydrate 4.1 7.4 1.5E-40 1.2E-39 D8 D1 
STY0050 putative transport protein 4.A Transport/binding proteins 4.1 11.4 7.9E-68 6.3E-67 D8   
STY0319 Rhs-family protein 4.I Pathogenesis 4.1 7.4 8.1E-40 6.1E-39 D8   
STY3129 N-acetylmuramoyl-L-alanine amidase 3.C.4 Murein sacculus and peptidoglycan 4.1 8.4 1.8E-52 1.4E-51 D8   
 264 
STY1933 conserved hypothetical protein 5.H Hypothetical protein 4.1 8.1 1.3E-48 1.0E-47 D8   
STY0473 ApbA 1.F.2 Pyrimidine ribonucle 4.0 6.6 2.4E-28 1.8E-27 D8   
STY2083 conserved hypothetical protein 5.H Hypothetical protein 4.0 9.6 4.0E-60 3.1E-59 D8   
STY1409 putative membrane transport protein 4.A Transport/binding proteins 4.0 6.2 2.1E-23 1.5E-22 D8   
STY0896 
D-alanyl-D-alanine carboxypeptidase (penicillin-binding 
protein 6 precursor) 3.C.4 Murein sacculus and peptidoglycan 3.9 8.7 3.9E-51 3.0E-50 D8   
STY1804 conserved hypothetical protein 5.H Hypothetical protein 3.9 7.6 1.5E-39 1.1E-38 D8   
STY4089 putative exported protein 3.C.1 Membranes lipoprotein 3.9 8.0 7.6E-45 5.9E-44 D8   
STY3494 conserved hypothetical protein 5.H Hypothetical protein 3.9 6.6 8.5E-26 6.2E-25 D8   
STY1593 hypothetical protein 5.I Unknown 3.8 6.2 4.7E-22 3.4E-21 D8   
STY0923 arginine-binding periplasmic protein 1 precursor 4.A.1 Transport amino acid and amines 3.8 7.1 8.2E-33 6.2E-32 D8   
STY0484 cytochrome o ubiquinol oxidase subunit I 1.B.7.a Aerobic Respiration 3.8 5.9 3.1E-19 2.2E-18 D8 D1 
STY3603 conserved hypothetical protein 5.H Hypothetical protein 3.8 5.9 9.7E-20 6.8E-19 D8   
STY3355 probable two-component system sensor histidine kinase 2. Broad regulatory function 3.8 6.7 2.1E-26 1.6E-25 D8   
citG CitG protein 5.I Unknown 3.7 5.6 1.6E-16 1.1E-15 D8   
yrfE putative NUDIX hydrolase 5.I Unknown 3.7 5.8 1.3E-17 8.7E-17 D8   
STY3123 possible lipoprotein 3.C.1 Membranes lipoprotein 3.6 6.0 1.1E-18 7.5E-18 D8   
STY2879 putative reverse transcriptase 4.I Pathogenesis 3.5 7.5 1.5E-32 1.2E-31 D8   
STY2149 putative exported protein 3.C.1 Membranes lipoprotein 3.5 7.2 4.6E-29 3.5E-28 D8   
STY0004 threonine synthase 1.D.2 Aspartate Family 3.5 6.9 5.2E-26 3.8E-25 D8   
STY3248 glutathione synthetase 1.G.10 Thioredoxin 3.5 3.8 1.5E-07 8.9E-07 D8   
misL pseudogene 4.I Pathogenesis 3.5 9.2 4.7E-46 3.7E-45 D8   
STY2513 anaerobic glycerol-3-phosphate dehydrogenase subunit A 1.B.7.b Anaerobic Respiration 3.5 7.0 2.5E-26 1.8E-25 D8   
STY4470 putative membrane protein 3.C.1 Membranes lipoprotein 3.4 4.1 6.0E-08 3.6E-07 D8   
STY0481 cytochrome o ubiquinol oxidase C subunit 1.B.7.a Aerobic Respiration 3.4 4.6 9.6E-10 6.0E-09 D8 M3 
ugd UDP-glucose 6-dehydrogenase 1.C.3 Sugar Nuclotides 3.3 9.0 8.8E-42 6.7E-41 D8   
STY2763a conserved hypothetical protein 5.H Hypothetical protein 3.3 6.5 3.7E-20 2.6E-19 D8   
STY3165 possible regulatory protein 2. Broad regulatory function 3.3 6.6 5.8E-21 4.1E-20 D8   
STY2716 putative exported protein 3.C.1 Membranes lipoprotein 3.3 9.7 5.5E-44 4.3E-43 D8   
STY2771 nucleoside diphosphate kinase (ndk) 1.F.1 Purine ribonucleotide biosynthesis 3.2 4.7 3.8E-09 2.4E-08 D8   
STY2951 conserved hypothetical protein 5.H Hypothetical protein 3.0 5.4 7.0E-11 4.6E-10 D8   
treR trehalose operon repressor 2. Broad regulatory function 2.9 9.0 3.3E-34 2.5E-33 D8   
STY3397 pseudogene 5.I Unknown 2.9 6.8 1.3E-18 9.2E-18 D8   
iroN 
TonB-dependent outer membrane siderophore receptor 
protein 4.I Pathogenesis 2.9 8.1 1.7E-28 1.3E-27 D8   
STY0639 isochorismate synthase EntC 1.G.14 Iron uptake and storage 2.9 4.1 2.3E-06 1.2E-05 D8   
STY1503 putative hydrolase 5.I Unknown 2.9 6.4 8.9E-15 6.0E-14 D8   
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STY1392 hypothetical protein 5.I Unknown 2.8 8.6 2.8E-30 2.1E-29 D8   
STY1666 putative membrane protein 3.C.1 Membranes lipoprotein 2.8 4.8 1.5E-07 8.7E-07 D8   
STY1928 conserved hypothetical protein 5.H Hypothetical protein 2.7 6.8 1.3E-16 8.9E-16 D8   
sthE pseudogene 3.C.3 Surface structure 2.7 6.5 2.7E-14 1.8E-13 D8   
STY1317 putative membrane protein 3.C.1 Membranes lipoprotein 2.7 6.9 7.2E-17 4.9E-16 D8   
STY3268 nucleoside permease 4.A.6 Transport Other 2.7 6.9 1.5E-16 1.0E-15 D8   
prkB phosphoribulokinase 1.C Central Intermediary metabolism 2.7 6.3 1.6E-12 1.1E-11 D8   
STY1458 putative benzoate membrane transport protein 5.I Unknown 2.6 5.3 2.2E-08 1.4E-07 D8   
STY2908 putative membrane protein 3.C.1 Membranes lipoprotein 2.6 4.6 3.4E-06 1.8E-05 D8   
yodD conserved hypothetical protein 5.H Hypothetical protein 2.6 4.8 1.2E-06 6.8E-06 D8   
STY0298 pseudogene 4.I Pathogenesis 2.6 5.6 4.6E-09 2.9E-08 D8   
STY1089 conserved hypothetical protein 5.H Hypothetical protein 2.6 6.7 2.4E-14 1.6E-13 D8   
STY1683 putative oxidoreductase 5.I Unknown 2.6 4.5 8.3E-06 4.2E-05 D8   
STY2268 pseudogene 3.C.4 Murein sacculus and peptidoglycan 2.5 5.4 2.5E-08 1.5E-07 D8   
STY0935 conserved hypothetical protein 5.H Hypothetical protein 2.5 5.9 3.2E-10 2.1E-09 D8   
STY3861 putative membrane permease 4.A Transport/binding proteins 2.5 7.3 5.9E-17 4.1E-16 D8   
STY4000 putative PTS system IIC component 4.A.3 Transport Carbohydes, organic acids and alcohols 2.5 9.9 4.1E-27 3.0E-26 D8   
waaZ lipopolysaccharide core biosynthesis protein RfaZ 3.C.2 Surface polysacchar 2.4 9.5 7.5E-26 5.5E-25 D8   
STY2589 putative amino acid transporter 4.A Transport/binding proteins 2.4 6.6 2.1E-12 1.4E-11 D8   
rpoS RNA polymerase sigma subunit RpoS (sigma-38) 2. Broad regulatory function 2.4 14.7 7.7E-28 5.7E-27 D8   
frdB fumarate reductase, iron-sulfur protein 1.B.7.b Anaerobic Respiration 2.3 5.5 1.7E-07 1.0E-06 D8   
STY1231 fatty acid/phospholipid synthesis protein PlsX 3.A.11 Phospholipids 2.3 6.7 7.0E-12 4.6E-11 D8   
STY0903 putative membrane protein 3.C.1 Membranes lipoprotein 2.3 6.9 1.4E-12 9.5E-12 D8   
STY4148 putative acetyltransferase 5.I Unknown 2.2 9.7 5.7E-22 4.0E-21 D8   
STY4772 hypothetical protein 5.H Hypothetical protein 2.2 6.2 5.9E-09 3.7E-08 D8   
STY2592 amidophosphoribosyltransferase 1.F.1 Purine ribonucleotide biosynthesis 2.1 6.5 1.3E-09 8.5E-09 D8   
STY4009 putative glycosyl hydrolase 5.I Unknown 2.1 6.1 2.3E-08 1.4E-07 D8   
citT citrate carrier 4.A Transport/binding proteins 2.1 5.8 3.2E-07 1.9E-06 D8   
kdgR transcriptional regulator KdgR 2. Broad regulatory function 2.1 5.9 3.6E-07 2.1E-06 D8   
STY0982 integration host factor beta-subunit (IHF-beta) 3.A.7 DNA replication, repair, restriction, modification 2.1 5.4 9.5E-06 4.8E-05 D8 D1M3 
wcaD pseudogene 3.C.2 Surface polysacchar 2.1 6.1 1.1E-07 6.8E-07 D8   
STY3155 galactose operon repressor 1.A.1 Degradation of carbohydrate 2.0 6.0 3.3E-07 1.9E-06 D8 D1 
yjeQ putative membrane protein 3.C.1 Membranes lipoprotein 8.0 3.4 3.4E-08 1.9E-07 M1   
STY3499 RNA polymerase sigma-54 factor (sigma-N) 2. Broad regulatory function 7.3 2.8 4.5E-06 1.8E-05 M1 D1M3 
STY2586 putative decarboxylase 5.I Unknown 4.4 4.1 2.5E-10 1.8E-09 M1 M3 
STY0103 bis(5'-nucleosyl)-tetraphosphatase 1.F.4 Salvage of nucleosides and nucleotides 4.3 6.0 6.1E-27 2.0E-25 M1 D1M3 
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yrfF putative membrane protein 3.C.1 Membranes lipoprotein 4.3 4.9 3.6E-16 5.2E-15 M1   
STY1006 pseudogene 1.A Degradation 4.3 6.3 9.5E-30 4.0E-28 M1 D1 
STY1357 peptide transport system permease protein SapC 4.A.6 Transport Other 4.2 4.0 3.7E-09 2.3E-08 M1 D1M3 
pagC outer membrane invasion protein 4.I Pathogenesis 4.1 4.7 9.2E-14 1.0E-12 M1   
STY3904 glucose inhibited division protein 3.A.7 DNA replication, repair, restriction, modification 4.1 5.5 3.4E-20 6.7E-19 M1 D1M3 
STY2567 acetate kinase 1.A.1 Degradation of carbohydrate 4.0 4.3 2.6E-11 2.2E-10 M1   
tufB elongation factor Tu 3.A.8 Protein translation and modification 4.0 6.6 1.5E-31 6.8E-30 M1 D1D8M3 
STY2002 putative membrane protein 3.C.1 Membranes lipoprotein 4.0 4.6 9.1E-13 9.2E-12 M1   
yscR putative type III secretion protein 4.I Pathogenesis 3.9 4.2 2.2E-10 1.6E-09 M1   
STY1519 membrane transport protein 4.A Transport/binding proteins 3.9 4.9 1.5E-14 1.9E-13 M1   
STY4285 conserved hypothetical protein 5.H Hypothetical protein 3.9 3.7 3.7E-07 1.8E-06 M1 M3 
STY1342 conserved hypothetical protein 5.H Hypothetical protein 3.9 6.6 6.9E-30 2.9E-28 M1   
trpS tryptophanyl-tRNA synthetase 3.A.5 Aminoacyl tRNA synthesis, tRNA modification 3.8 7.1 1.4E-34 8.0E-33 M1 D1D8M3 
STY1038 putative bacteriophage protein 5.A Latterally acquired elements 3.8 6.3 5.6E-26 1.7E-24 M1 M3 
STY3003 doubtful CDS found within S. typhi pathogenicity island 4.I Pathogenesis 3.7 4.0 7.0E-09 4.3E-08 M1   
STY0788 putative membrane protein 3.C.1 Membranes lipoprotein 3.6 5.2 7.7E-16 1.1E-14 M1   
STY3565 Fis DNA-binding protein 3.A.7 DNA replication, repair, restriction, modification 3.5 6.2 1.6E-23 4.0E-22 M1   
STY1230 50S ribosomal protein L32 3.A.2 Ribosomal protein synthesis, modification 3.3 4.1 2.8E-08 1.6E-07 M1 M3 
STY1257 ABC transporter integral membrane subunit 4.A Transport/binding proteins 3.3 5.8 1.2E-18 2.1E-17 M1   
sprB possible AraC-family transcriptional regulator 4.I Pathogenesis 3.2 5.2 1.3E-13 1.5E-12 M1   
STY1251 NADH dehydrogenase 1.B.7.a Aerobic Respiration 3.2 6.5 7.2E-23 1.7E-21 M1 D1M3 
hemK HemK protein, putative protoporphyrinogen oxidase 5.I Unknown 3.1 4.6 1.5E-10 1.1E-09 M1 M3 
yjeT putative membrane protein 3.C.1 Membranes lipoprotein 3.1 5.3 1.7E-14 2.1E-13 M1   
STY2751 GMP synthase (glutamine-hydrolyzing) 1.F.1 Purine ribonucleotide biosynthesis 2.9 5.8 1.9E-16 2.9E-15 M1 D1M3 
STY3703 putative positive regulator of late gene transcription 5.I Unknown 2.9 4.9 4.9E-11 4.0E-10 M1   
STY4585 hypothetical protein 4.I Pathogenesis 2.9 6.2 3.3E-18 5.5E-17 M1 M3 
STY0284 ribonuclease H 3.B.1 Degradation of RNA 2.8 5.1 1.2E-11 1.0E-10 M1   
ptsJ putative transcriptional regulator 2. Broad regulatory function 2.8 4.8 3.5E-10 2.5E-09 M1 D1M3 
STY3639 thioredoxin 1.G.10 Thioredoxin 2.8 5.2 1.2E-11 1.1E-10 M1   
STY1178 assembly/transport component in curli production 3.C.3 Surface structure 2.7 5.4 5.1E-13 5.3E-12 M1   
ptsN nitrogen regulatory IIA protein 2. Broad regulatory function 2.7 6.5 5.0E-19 9.0E-18 M1 M3 
STY2619 phosphohistidine phosphatase 2. Broad regulatory function 2.7 6.6 3.4E-19 6.3E-18 M1 M3 
STY4163 hypothetical protein 5.I Unknown 2.6 6.8 2.3E-19 4.2E-18 M1   
STY2787 conserved hypothetical protein 5.H Hypothetical protein 2.6 6.0 3.3E-15 4.4E-14 M1   
STY1709 putative pathogenicity island protein 4.I Pathogenesis 2.6 4.4 2.2E-07 1.1E-06 M1   
efp elongation factor P 3.A.8 Protein translation and modification 2.5 5.5 8.1E-12 7.3E-11 M1 M3 
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STY0762 pseudogene 3.C.2 Surface polysaccharide and antigen 2.5 4.1 2.4E-06 9.8E-06 M1   
STY0605 putative membrane protein 3.C.1 Membranes lipoprotein 2.5 11.5 8.0E-30 3.3E-28 M1 D8 
STY0516 haemolysin expression modulating protein 2. Broad regulatory function 2.4 5.3 6.7E-11 5.4E-10 M1 D1M3 
STY3564 conserved hypothetical protein 5.H Hypothetical protein 2.4 9.6 1.3E-26 4.2E-25 M1   
STY2368 hypothetical protein 5.I Unknown 2.4 5.9 4.5E-13 4.7E-12 M1   
argR arginine repressor #N/A 2.4 6.1 3.2E-14 3.9E-13 M1 M3 
STY1368 peptide transport system permease protein SapB 4.A.6 Transport Other 2.4 4.5 3.9E-07 1.9E-06 M1 M3 
gtrA bactoprenol-linked glucose translocase 3.C.2 Surface polysacchar 2.4 9.4 1.5E-25 4.4E-24 M1 D8 
STY3906 ATP synthase protein I. 1.A Degradation 2.4 5.1 2.7E-09 1.7E-08 M1   
STY0970 hypothetical protein 5.I Unknown 2.4 5.5 4.6E-11 3.8E-10 M1 D1M3 
yaeP conserved hypothetical protein 5.H Hypothetical protein 2.3 6.5 2.4E-15 3.3E-14 M1   
STY0529 conserved hypothetical protein 5.H Hypothetical protein 2.3 5.3 5.8E-10 4.0E-09 M1   
STY1369 peptide transport periplasmic protein SapA precursor 4.A.6 Transport Other 2.3 7.2 2.1E-18 3.7E-17 M1 M3 
STY3463 polynucleotide phosphorylase 3.A.9 RNA synthesis, modification 2.3 10.3 4.7E-26 1.4E-24 M1 D1D8M3 
STY4041 hypothetical protein 4.I Pathogenesis 2.3 6.7 4.0E-16 5.8E-15 M1   
STY0368 probable secreted protein 3.C.1 Membranes lipoprotein 2.3 6.3 1.8E-14 2.3E-13 M1   
STY2944 gamma-glutamylcysteine synthetase 1.G.10 Thioredoxin 2.3 7.8 2.2E-20 4.4E-19 M1 D8 
ssaV putative type III secretion protein 4.I Pathogenesis 2.3 5.9 2.5E-12 2.3E-11 M1   
STY4246 hypothetical protein 5.I Unknown 2.3 4.8 1.1E-07 5.6E-07 M1 M3 
tufA elongation factor Tu #N/A 2.3 5.3 7.0E-10 4.9E-09 M1 D1 
STY0482 cytochrome o ubiquinol oxidase C subunit 1.B.7.a Aerobic Respiration 2.3 6.6 3.8E-15 5.1E-14 M1   
STY3553 rod shape-determining protein 3.C.4 Murein sacculus and peptidoglycan 2.3 4.9 5.1E-08 2.8E-07 M1   
STY3283 bacteriocin immunity protein 4.I Pathogenesis 2.3 4.4 2.1E-06 8.8E-06 M1   
STY3230 putative membrane protein 3.C.1 Membranes lipoprotein 2.3 7.1 6.7E-17 1.0E-15 M1   
gtrB bactoprenol glucosyl transferase 3.C.2 Surface polysacchar 2.3 10.7 3.8E-25 1.1E-23 M1   
STY0317 hypothetical protein 4.I Pathogenesis 2.2 8.1 3.5E-20 6.9E-19 M1   
STY1982 conserved hypothetical protein 5.H Hypothetical protein 2.2 6.5 3.4E-14 4.0E-13 M1   
STY3809 6-phosphofructokinase 1.B.1 Glycolysis 2.2 7.4 1.5E-17 2.3E-16 M1 D1M3 
STY0755 hypothetical protein 5.I Unknown 2.2 5.4 1.4E-09 9.4E-09 M1 M3 
nrdH putative glutaredoxin 1.G.10 Thioredoxin 2.2 6.5 2.0E-13 2.1E-12 M1   
stbA probable fimbrial protein 3.C.3 Surface structure 2.1 6.3 6.1E-13 6.3E-12 M1   
allD ureidoglycolate dehydrogenase 1.A.1 Degradation of carbohydrate 2.1 6.6 1.5E-13 1.7E-12 M1   
STY2290 6-phosphogluconate dehydrogenase, decarboxylating 1.B.5 Pentose phosphate 2.1 9.3 8.3E-21 1.7E-19 M1 D1 
STY4900 conserved hypothetical regulatory protein 2. Broad regulatory function 2.1 5.7 4.3E-10 3.1E-09 M1   
pduK putative propanediol utilization protein PduK 1.A.1 Degradation of carbohydrate 2.1 7.1 4.6E-15 6.1E-14 M1   
yjga conserved hypothetical protein 5.H Hypothetical protein 2.1 5.9 1.3E-10 9.7E-10 M1 D1M3 
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STY1756 conserved hypothetical protein 5.H Hypothetical protein 2.0 6.5 1.5E-12 1.5E-11 M1   
STY0185 PdxA-like protein 5.I Unknown 2.0 6.8 1.6E-13 1.7E-12 M1   
STY1169 putative transporter 4.A Transport/binding proteins 2.0 5.4 1.9E-08 1.1E-07 M1   
STY2088 conserved hypothetical protein 5.H Hypothetical protein 2.0 6.4 5.6E-12 5.1E-11 M1   
crcB putative membrane protein 3.C.1 Membranes lipoprotein 2.0 5.8 5.5E-10 3.9E-09 M1 D1M3 
STY1776 50S ribosomal subunit protein L35 3.A.2 Ribosomal protein synthesis, modification 10.6 5.8 5.3E-35 4.7E-34 M3 D1 
STY3524 30S ribosomal subunit protein S9 3.A.2 Ribosomal protein synthesis, modification 10.3 5.5 8.1E-29 5.0E-28 M3   
STY3499 RNA polymerase sigma-54 factor (sigma-N) 2. Broad regulatory function 8.7 4.1 7.3E-13 2.1E-12 M3 D1M1 
STY3464 30S ribosomal subunit protein S15 3.A.2 Ribosomal protein synthesis, modification 8.1 3.5 1.2E-08 2.7E-08 M3   
STY1498 haemolysin HlyE 4.H Cell Killing 8.0 3.4 5.9E-08 1.3E-07 M3   
STY2668 pseudogene 4.A.3 Transport Carbohydes, organic acids and alcohols 7.7 3.1 1.6E-06 3.1E-06 M3 D1 
STY2860 50S ribosomal subunit protein L19 3.A.2 Ribosomal protein synthesis, modification 7.4 6.0 6.9E-36 6.4E-35 M3   
STY0954 transport ATP-binding protein CydC 4.A Transport/binding proteins 7.4 2.9 2.5E-06 4.8E-06 M3   
tufB elongation factor Tu 3.A.8 Protein translation and modification 6.6 9.1 1.4E-90 2.4E-88 M3 D1D8M1 
STY3466 ribosome-binding factor A (P15B protein) 3.A.8 Protein translation and modification 6.4 6.5 1.0E-42 1.4E-41 M3   
STY1357 peptide transport system permease protein SapC 4.A.6 Transport Other 6.4 6.0 3.7E-34 3.1E-33 M3 D1M1 
trkA potassium transport protein 4.A.2 Transport Cations 6.4 7.7 2.0E-63 1.1E-61 M3 D1 
STY0786 cytochrome d ubiquinol oxidase subunit I 1.B.7.c Electron Transport 6.4 5.0 2.5E-21 1.0E-20 M3   
STY1299 DNA-binding protein (histone-like protein Hlp-II) 2. Broad regulatory function 6.1 6.6 1.2E-43 1.7E-42 M3   
STY1278 isocitrate dehydrogenase 1.B.3 Tricarboxylic acid cycle 6.1 4.8 3.6E-18 1.4E-17 M3   
STY1744 pyruvate kinase 1.B.1 Glycolysis 5.9 7.0 3.2E-48 6.5E-47 M3 D1 
STY0516 haemolysin expression modulating protein 2. Broad regulatory function 5.9 8.5 7.5E-74 7.2E-72 M3 D1M1 
STY3091 possible secreted protein 3.C.1 Membranes lipoprotein 5.8 4.5 2.5E-15 8.3E-15 M3   
STY2751 GMP synthase (glutamine-hydrolyzing) 1.F.1 Purine ribonucleotide biosynthesis 5.7 8.4 4.2E-70 3.4E-68 M3 D1M1 
STY1356 peptide transport system ATP-binding protein SapD 4.A.6 Transport Other 5.5 5.6 4.5E-27 2.5E-26 M3   
STY1230 50S ribosomal protein L32 3.A.2 Ribosomal protein synthesis, modification 5.3 5.9 6.6E-29 4.1E-28 M3 M1 
STY2568 phosphate acetyltransferase 1.A.1 Degradation of carbohydrate 5.3 4.9 6.7E-19 2.6E-18 M3 D1 
STY3740 pantothenate kinase 1.G.5 Pentothenate 5.3 6.2 4.9E-33 3.8E-32 M3   
STY1368 peptide transport system permease protein SapB 4.A.6 Transport Other 5.3 7.1 1.9E-46 3.4E-45 M3 M1 
STY4070 3-deoxy-D-manno-octulosonic-acid transferase 3.C.2 Surface polysacchar 5.2 5.4 4.8E-23 2.2E-22 M3   
STY0103 bis(5'-nucleosyl)-tetraphosphatase 1.F.4 Salvage of nucleosides and nucleotides 5.1 6.8 2.5E-41 3.1E-40 M3 D1M1 
STY2106 crossover junction endodeoxyribonuclease 3.A.7 DNA replication, repair, restriction, modification 5.1 7.2 9.1E-47 1.7E-45 M3   
STY3914 ATP synthase epsilon subunit 1.A Degradation 5.1 5.3 4.9E-21 2.1E-20 M3 D1D8 
waaQ lipopolysaccharide core biosynthesis protein 3.C.2 Surface polysacchar 5.1 9.0 1.3E-70 1.1E-68 M3 D1 
trkH trk system potassium uptake protein 1.C.5 Sulphur Metabolism 4.9 9.6 2.0E-75 2.1E-73 M3 D1D8 
STY0181 aconitate hydratase 2 (citrate hydro-lyase 2) 1.B.3 Tricarboxylic acid cycle 4.9 8.1 3.8E-57 1.4E-55 M3 D1 
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STY3809 6-phosphofructokinase 1.B.1 Glycolysis 4.8 9.8 1.4E-74 1.4E-72 M3 D1M1 
STY0981 30S ribosomal protein S1 3.A.2 Ribosomal protein synthesis, modification 4.8 4.5 1.6E-13 4.6E-13 M3   
STY3904 glucose inhibited division protein 3.A.7 DNA replication, repair, restriction, modification 4.6 5.9 2.6E-27 1.5E-26 M3 D1M1 
STY4285 conserved hypothetical protein 5.H Hypothetical protein 4.6 4.3 1.7E-11 4.7E-11 M3 M1 
STY0386 hypothetical protein 5.I Unknown 4.5 4.8 1.5E-15 5.0E-15 M3   
hemK HemK protein, putative protoporphyrinogen oxidase 5.I Unknown 4.5 5.8 1.3E-25 6.8E-25 M3 M1 
STY1251 NADH dehydrogenase 1.B.7.a Aerobic Respiration 4.4 7.6 1.1E-46 2.1E-45 M3 D1M1 
STY2586 putative decarboxylase 5.I Unknown 4.3 4.0 1.5E-09 3.6E-09 M3 M1 
STY1355 peptide transport system ATP-binding protein SapF 4.A.6 Transport Other 4.2 7.8 3.4E-45 5.6E-44 M3   
STY0012 DnaK protein (heat shock protein 70) 4.B Chaperones 4.2 5.7 3.6E-23 1.6E-22 M3 D1 
STY2836 ATP-dependent RNA helicase SrmB 3.A.9 RNA synthesis, modification 4.2 9.0 1.8E-56 6.6E-55 M3 D1D8 
spiA putative outer membrane secretory protein 4.I Pathogenesis 4.1 4.8 6.3E-14 1.9E-13 M3 D1 
trpS tryptophanyl-tRNA synthetase 3.A.5 Aminoacyl tRNA synthesis, tRNA modification 4.1 7.3 1.9E-39 2.2E-38 M3 D1D8M1 
STY0956 thioredoxin reductase 1.F.3 2'-deoxyribonucleotide metabolism 4.0 6.9 7.4E-34 6.0E-33 M3   
STY0603 pseudogene 5.A Latterally acquired elements 3.9 6.7 5.8E-31 4.1E-30 M3   
yjga conserved hypothetical protein 5.H Hypothetical protein 3.9 7.5 9.0E-39 1.0E-37 M3 D1M1 
STY1771 integration host factor alpha-subunit 3.A.7 DNA replication, repair, restriction, modification 3.9 9.0 3.2E-51 8.1E-50 M3   
STY1893 putative bacteriophage protein 5.A Latterally acquired elements 3.8 4.2 1.2E-09 3.0E-09 M3   
STY4214 putative low-affinity inorganic phosphate transporter 4.A.5 Transport Anions 3.8 7.8 2.0E-41 2.6E-40 M3 D1 
STY0970 hypothetical protein 5.I Unknown 3.8 6.7 1.3E-30 8.7E-30 M3 D1M1 
STY3937 thiophene and furan oxidation protein 4.G Detoxification 3.7 5.8 2.2E-21 9.6E-21 M3 D1 
STY1226 ribonuclease E 5.A Latterally acquired elements 3.7 7.2 9.8E-35 8.5E-34 M3   
STY2145 tyrosine-specific transport protein 4.A.1 Transport amino acid and amines 3.7 8.3 1.9E-43 2.7E-42 M3 D1D8 
STY3886 molybdopterin-guanine dinucleotide biosynthesis protein A 1.G.4 Molybdopterin 3.7 8.5 1.5E-44 2.4E-43 M3   
STY4246 hypothetical protein 5.I Unknown 3.7 5.9 5.6E-22 2.5E-21 M3 M1 
STY3463 polynucleotide phosphorylase 3.A.9 RNA synthesis, modification 3.6 11.5 1.1E-55 3.8E-54 M3 D1D8M1 
STY1247 putative lipoprotein 3.C.1 Membranes lipoprotein 3.6 6.1 8.1E-24 3.9E-23 M3   
STY3975 conserved hypothetical protein 5.H Hypothetical protein 3.6 8.6 7.5E-44 1.1E-42 M3   
STY2078 hypothetical protein 5.I Unknown 3.6 5.9 1.4E-20 5.8E-20 M3   
STY1416 conserved hypothetical protein 5.H Hypothetical protein 3.5 7.1 4.2E-31 3.0E-30 M3   
STY1415 putative multi-drug transporter 5.D Drug/Analogue sensitivity 3.4 6.9 2.1E-28 1.3E-27 M3   
STY1038 putative bacteriophage protein 5.A Latterally acquired elements 3.4 5.9 6.1E-20 2.5E-19 M3 M1 
STY1849 conserved hypothetical protein 5.H Hypothetical protein 3.4 7.5 8.9E-33 6.8E-32 M3   
STY2542 conserved hypothetical protein 5.H Hypothetical protein 3.4 8.0 3.2E-36 3.0E-35 M3   
STY0096 putative membrane protein 3.C.1 Membranes lipoprotein 3.3 7.4 3.0E-31 2.1E-30 M3   
STY1598 hypothetical protein 5.I Unknown 3.3 7.7 2.2E-33 1.7E-32 M3   
 270 
ompC outer membrane protein C 3.C Cell envelope 3.3 7.6 8.4E-33 6.5E-32 M3   
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Abstract. Typhoid fever, caused by Salmonella enterica serovar Typhi (S. Typhi), is a diminishing public health
problem in Vietnam, and this process may represent a prototype for typhoid elimination in Asia. Here, we review typhoid
epidemiology in Vietnam over 20 years and assess the potential drivers associated with typhoid reduction. In the 1990s,
multidrug resistant S. Typhi were highly prevalent in a sentinel hospital in southern Vietnam. A national typhoid incidence
rate of 14.7/100,000 population per year was estimated around the new millennium. The Vietnamese government rec-
ognized the public health issue of typhoid in the 1990s and initiated vaccine campaigns to protect the most vulnerable
members of the population. At their peak, these campaigns immunized approximately 1,200,000 children in 35 provinces.
Concurrently, Vietnam experienced unprecedented economic development from 1998 to 2014, with the gross national
income per capita increasing from $360 to $1,890 over this period. More recent typhoid incidence data are not available,
but surveillance suggests that the current disease burden is negligible. This trajectory can be considered a major public
health success. However, a paucity of systematic data makes it difﬁcult to disaggregate the roles of immunization and
water, sanitation, and hygiene (WASH) interventions in typhoid reduction in Vietnam. Given the limitations of typhoid
vaccines, we surmise the practical elimination of typhoid was largely driven by economic development and improvement
in general population living standards. Better designedWASH intervention studieswith clinical endpoints and systematic
incidence data are essential to glean a greater understanding of contextual factors that impact typhoid incidence
reduction.
INTRODUCTION
Typhoid fever, the disease caused by Salmonella enterica
serovar Typhi (S. Typhi), is a diminishing public health problem
in Vietnam.1 However, the disease remains an ongoing public
health issue in other parts of South andSoutheast Asia,2–4 and
an enhanced understanding of disease estimates and the in-
ﬂuence of antimicrobial resistance (AMR) on disease pre-
sentation is needed to better control this disease across the
region. Furthermore, insights into the trends of typhoid and
factors that directly impinge on disease incidence are impor-
tant for allocating resources for reducing the burden of dis-
ease.5 Currently, Vietnam represents an exemplar Asian
country that has all but eliminated this once common in-
fection, and there is much to be learnt from the reduction of
typhoid in Vietnam. However, how reduction in typhoid was
precisely achieved is unclear, and providing a roadmap for
typhoid reduction in similar settings is largely dependent on
good historical quantitative data.
Typhoid fever incidence in Vietnam. Typhoid fever has
likely been endemic in Vietnam for some time, although his-
torical incidencedata for this commoncauseof febrile disease
from across Southeast Asia before the reuniﬁcation of Vietnam
in 1975 is scarce. Notiﬁed typhoid fever cases reported to the
pre-reuniﬁcation government of South Vietnam showed a
generally increasing trend from 2.05 cases per 100,000 people
annually in 1957 to 10.02 cases per 100,000 people annually in
1966 (Figure 1).6 Health care provisions, and water and sani-
tation infrastructure in South Vietnam during this time period
were generally poor, which likely contributed to the increasing
rates of typhoid fever and other infectious disease during this
period, which were frequently observed in military personnel
returning back to the United States.7 By contrast, a report
suggests that the pre-reuniﬁcation government in North Viet-
namprioritizedhealth careaccessandbeganmassvaccination
campaigns against typhoid fever and other communicable
diseases as early as 1954, although reliable incidence data
from North Vietnam during this period are not available.8
The best and most accurate recent estimates of typhoid
incidence in Vietnam were calculated during the In-
ternational Vaccine Institute’s Diseases of the Most Impov-
erished (DOMI) program, which was conducted between
1999 and 2003.9 The annual incidence of typhoid fever in
Hue, in central Vietnam, in 2002–2004 was estimated to be
21.3/100,000 person years and 24.2/100,000 person years
in children aged 5–15 in years (Figure 1). This program went
on to conduct various epidemiological investigations and
vaccine studies in the same location.10,11 In addition, the
National Institute of Epidemiology (NIHE) in Hanoi con-
ducted further nationwide surveillance around the same
period of time as the DOMI study. The average number of
typhoid cases in Vietnam across the country in all ages was
estimated to be 11,696, corresponding with an average
national incidence rate of 14.7/100,000 population per
year.12 During this period (1999–2003) two of the 63 prov-
inces of Vietnam (Soc Trang in the south and Dien Bien in the
north) were estimated to have particularly high inci-
dences (> 100/100,000 population per year) (Figure 2); a
further 18 were estimated to have a medium incidence
(> 10 < 100/100,000 population per year). The propensity of
the disease was understood to arise in children, with an
estimated incidence of 36.6/100,000 population aged < 15
years per year.12 Lastly, in 1998, Lin and others.13 estimated
a population incidence of 198/100,000 population in the
Dong Thap province in the Mekong Delta, equating with a
crude incidence of 930/100,000 people (Figure 1).
Typhoid trends in Ho Chi Minh City (HCMC). Routine
blood culture data from the Hospital for Tropical Diseases
*Address correspondence to Stephen Baker, Hospital for Tropical
Diseases, 764 VoVanKiet, Quan 5, HoChiMinhCity, Vietnam. E-mail:
sbaker@oucru.org
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(HTD) in HCMC in the south of Vietnam between 1994 and
2015 highlights a major reduction in the prevalence (and ab-
solute number) of positive blood cultures forS. Typhi over time
(Figure 3).1 Hospital for Tropical Diseases is a sentinel in-
fectious disease hospital that serves as a primary and sec-
ondary facility for the surrounding local population in HCMC
anda tertiary referral center for 17 provinces in the south of the
country, and, therefore, has a catchment population of ap-
proximately 40 million people. The highest rates of positive
blood cultures for S. Typhi at HTD were recorded in 1995 and
1998, when the proportion of positive blood cultures for S.
Typhi was 14.5% and 12.8% (of all blood cultures taken), re-
spectively. In the late 1990s, this ﬁgure began to show an
annual decline; 5% S. Typhi blood culture positivity rate of all
blood cultures taken in 1999. After the turn of the millennium,
the number of culture positive cases of typhoid fever at HTD
continued to decrease annually, with the prevalence of S.
Typhi–positive blood cultures not rising higher than 1% from
2005 onward. Therefore, in the absence of contemporary (and
accurate incidence) data, if we extrapolate these trends we
FIGURE 1. Historic crude estimates of typhoid fever incidence in Vietnam. Histogram showing the estimated crude incidences (on a log scale) of
typhoid fever in Vietnam from government records (GR) and subnational incidence estimates available from Ochiai et al.9 (aggregated estimated
from 2002 to 2004, with 2003 as the midpoint from Hue province in people aged 5–18 years) and Lin et al.13 (aggregated estimated from 1997 to
2000, with 1998 as the midpoint from Dong Thap province).
FIGURE 2. Map of Vietnam showing estimated disease incidences and provinces implemented Vi immunization. (A) North orientated map of
Vietnamshowing the estimated incidenceof typhoid fever in Vietnam fromgovernment data between1999 and 2003. Provinceswith high,medium,
and low incidence are highlighted by shading (see key). (B) North orientatedmap of Vietnam showing the 35 provinces in Vietnam in 2005 that were
incorporated into the national typhoid Vi immunization campaign; blue shading (see key). Maps are reproduced from Cuong N. Typhoid Vaccine
Used in Vietnam and its Impact. In: Consultation on Typhoid Vaccine Introduction and Typhoid Surveillance.12
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can surmise that presently the incidence of enteric fever in
Vietnam isprobablyexceptionally low (<10/100,000population
per year), and there has been a remarkable and sustained de-
cline in the prevalence of S. Typhi–positive blood cultures in
HTD and other health care facilities across the country.
In a pattern similar to those observed in parts of sub-
SaharanAfrica (but not in the samemagnitude), therehasbeen
a replacement of “classical” community-acquired pathogens
in bloodstream infections (such as S. Typhi) with those more
commonly associated with HIV infection and the current in-
ternational epidemic of AMRbacteria.14 Speciﬁcally, assorted
fungal pathogens, multidrug-resistant (MDR) non-Salmonella
Gram-negative bacteria, and non-typhoidal Salmonella
now dominate the bloodstream infection landscape in
Vietnam.1,15,16 Paratyphoid fever, which is associatedwith the
various pathovars of Salmonella Paratyphi (S. Paratyphi A, B,
and C), has been reported to be increasing in prevalence in
parts of Asia.17 This surge is speciﬁcally associated with S.
Paratyphi A; however, the isolation of this organism is rare in
Vietnam (andacrossSoutheastAsia) and is generally limited to
extended sporadic outbreaks, as recently observed in neigh-
boring Cambodia.18 A study conducted at HTD cultured less
than 7 S. Paratyphi A isolates per year between 1998 and
2008, this subsequently declined to zero from 2008.1
However, in 1990, Global Burden of Disease estimated in-
cidence of paratyphoid to be 81/100,000 population; this was
estimated to be 40/100,000 population in 2016.19
Antimicrobial susceptibility. Traditionally, Vietnam has
been a global hotspot for multi-drug resistant (MDR) S. Typhi,
which is deﬁned as resistance against the ﬁrst-line antimicro-
bials, ampicillin, chloramphenicol, and trimethoprim-sulphate.20
These latter day ﬁrst-line regimes were commonly prescribed
in the community and in health care settings for the treatment
of typhoid fever, and many non-speciﬁc febrile diseases, in
Vietnam in the 1980s and early 1990s. The ﬁrst notable spike
of MDR S. Typhi in Vietnam arose in the early 1990s, corre-
lating with a major peak in S. Typhi–positive blood cultures at
HTD in HCMC.21 This MDR phenotype in S. Typhi was asso-
ciated with an incH1 plasmid backbone,22 which has been
consistently identiﬁed within S. Typhi isolated in Vietnam and
coupled with organisms belonging to a speciﬁc phylogenetic
group known as haplotype 58,23 now designated genotype
4.3.1.24 These organisms, with this same MDR phenotype,
were described as still circulating in high numbers in the
MekongDelta region, some150 kmaway fromHCMC, in 2004
and 2005.25
Salmonella enterica serovar Typhi belonging to genotype
4.3.1 are also commonly associatedwith amutation (S83F) in
FIGURE 3. The decline in Salmonella Typhi–positive blood cultures in a sentinel infectious disease hospital in Ho Chi Minh City (HCMC). Plot
showing the proportion of total blood cultures taken fromwhich Salmonella Typhi was isolated between 1993 and 2015 at the Hospital for Tropical
Diseases in HCMC, with a locally weighted scatterplot smoothing curve. The total number of blood cultures taken and the number from which
Salmonella Typhi were isolated are shown at the base of the ﬁgure.
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the DNA gyrase gene gyrA, catalyzing resistance against
naladixic acid and reduced susceptibility against the
second-generation ﬂuoroquinolones, ciproﬂoxacin, and
oﬂoxacin.26,27 Variants with this speciﬁc gyrAmutation began
to emerge in Vietnam in the early 1990s,28 shortly after the
introduction of quinolones for the treatment of non-speciﬁc
febrile diseases when the ﬁrst-line treatments became less
effective at inducing defervescence. The secondary peak in
S. Typhi cases in routine blood culture data from HTD was
associated with the emergence of organisms exhibiting re-
sistance against quinolones and reduced susceptibility
against ﬂuoroquinolones.1,29 These organisms, speciﬁcally
genotype 4.3.1 S. Typhi with an S83F mutation in gyrA, have
since become themost prevalent variant in Vietnam,25 reﬂecting
the pattern of the molecular epidemiology of S. Typhi across
much of Asia.27 Current information regarding the AMR proﬁles
of the extant S. Typhi population in Vietnam are limited, but our
unpublished data suggests that MDR strains have all but dis-
appeared in the southern part of the country and S. Typhi with
an S83F and reduced susceptibility to ﬂuoroquinolones con-
tinue to circulate. Notably, despite the sustained use and
availability of ﬂuoroquinolones in Vietnam for various bacterial
infections, ciproﬂoxacin- and oﬂoxacin-resistant S. Typhi has
yet toemerge,although ithasbeenobservedelsewhere inAsia.30
Vaccination campaigns. The Vietnamese government
recognized the public health issue of typhoid fever in the
1990s and initiated several vaccine campaigns with in-
ternationally manufactured vaccines in an attempt to protect
the most vulnerable groups within the population, most
commonly children.31 Furthermore, NIHE in Hanoi was a pi-
oneer in instigating locally manufactured Vi Polysaccharide
vaccine and distributing it as a control measure through the
public health network. However, despite a Vi conjugate vac-
cine and a neworal attenuated typhoid vaccine being trialed in
Vietnam for the ﬁrst time, these were never introduced as
public health interventions.32,33 All the national typhoid Vi
Polysaccharide vaccine programs conducted between 1997
and 2012 were executed as school-based campaigns, im-
munizing children between the ages of 3 and 10 years.
Between 1997 and 2003, the Vietnamese government im-
munized more than 4,000,000 children aged 3–5 years with
TYPHIMVi polysaccharide,manufactured byAventis Pasteur.
After manufacturing their own Vi polysaccharide vaccine
through the Institute of Vaccines and Medical Biologicals/Da
Lat Pasteur Vaccine Company, the Vietnamese public health
systemadministeredmore than 2,000,000 additional doses to
children aged 5–10 years (2004–2010), and latterly children
aged 3–5 years (2011–2012). At the peak of these Vi vaccine
campaigns in 2005 (1,200,000 doses), children were being
immunized in 35 different provinces across the country
(Figure 2).12 The coverage rate of these campaigns were high,
with > 90% of the target population receiving a Vi vaccine
between1999 and2010. Population baseddata assessing the
direct effect (i.e., without additional sanitation covariates) of
these immunization programs on typhoid incidence are un-
available, but there was a substantial decrease in the in-
cidenceof typhoid fever across the country between 1997 and
2007, most notably in the northwest of the country and the
Mekong River Delta in the South, which were covered exten-
sively by the immunization program (Figure 2).12
Contextual factors that may have inﬂuenced typhoid
fever incidence. Being of low socioeconomic status is a
major risk factor for contracting typhoid fever.34 Vietnam
has been through an unprecedented period of economic
development since the mid-1990s, which has had a sub-
stantial knock-on effect on the reduction of poverty and
poverty-associated communicable diseases.35 Between
1998 and 2014 Vietnam’s gross domestic product in-
creased from $27 billion to $86 billion, and the gross na-
tional income per capita increased from $360 to $1,890 over
the same time period.36 These ﬁgures correlate with a re-
duction in national poverty (poverty headcount ratio at $1.90
adaydeclining from34.8% in1998 to 3.2% in 2012) (Figure 4)
and a waning in typhoid fever incidence, but overlap with the
period of the national immunization campaigns. In addition,
multiple contextual factors are considered to have had an
effect on the incidence of typhoid fever. Typhoid fever is
associated with poor water quality, and evidence of the or-
ganism in water supplies can be measured using molecular
methods.37 Consequently, water, sanitation, and hygiene
(WASH) conditions are one of the major factors in assessing
disease control. Sub-national data on water and sanitation
extracted from Multiple Indicator Cluster Surveys (MICS) in
Vietnam show that the fraction of the population in the
southeast of Vietnam with access to improved sanitation
facilities (means of excreta disposal that decrease human
contact with feces) increased from only 42% in 1995 to
93.6% in 2014.38 Furthermore, the proportion of the south-
eastern population of Vietnam with improved water sources
(as per MICS standards; water piped into homes or yard,
public taps, standpipes, protected wells, or springs) rose
from 93.6% in 2006 to a peak of 98.4% in 2011.38 Corre-
spondingly, data from theWorldBank shows that there was a
steady increase in the proportion of the Vietnamese pop-
ulation with access to improved sources of drinking water
between 1998 (74.5% of the population) and 2014 (96.4% of
the population).39 Similarly, there was an increase in the
proportion of the population with access to improved sani-
tation facilities, including ﬂush and slab latrines, over the
sameperiod; 49.5%of the population in 1998 to 76.3%of the
population in 2012 (urban/rural data shown in Figure 4).39
Knowledgegaps.All available data suggest that the trend
of typhoid fever incidence began to exhibit a steep decline in
Vietnam from 1999 onward. Therefore, the outstanding
questions regarding the dramatic reduction in typhoid fever
in Vietnam are: towhat extent did immunization play a role in
reducing typhoid fever? and how much inﬂuence did eco-
nomic growth have on improving living standards to reduce
all waterborne diseases, including typhoid fever? Given the
paucity of data regarding the longitudinal incidences of ty-
phoid fever (and other waterborne diseases) in Vietnam,
disaggregating the independent effect of these differing
approaches is a major challenge. Furthermore, dissimilar
demographics, disease epidemiology, and disease in-
cidence across the provinces of Vietnammake it impractical
to assess the overall impact of a speciﬁc intervention in any
given location. The data that are available are inconclusive
and limited by disease time trends from a single tertiary
referral hospital in HCMC. As a result, these data do not
provide insight into regional differences in typhoid fever
reduction across Vietnam or characterize the current na-
tional burden. Furthermore, there are no systematic data
regarding intestinal perforation (although this has been
described in the southern provinces of Vietnam40), other
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severe disease presentations,41 or typhoid-associated mor-
tality. As a result, it is impossible to directly assess any trends
associated with these severe outcomes.
Regardless of the precise role of any single intervention,
the reduction and virtual elimination of typhoid fever in
Vietnam, largely driven by strong political will,as evidenced
by sanitation improvements, better health care, and im-
munization campaigns, should be considered a major
public health success. However, this success story does
not quite replicate into a blueprint in how typhoid fever
should be controlled across Asia, that is, what worked in
Vietnam may not work in precisely the same way in other
locations. It is likely that the various vaccination campaigns
that have taken place in Vietnam over the last 15 years have
contributed to the observed decreasing trend in typhoid
fever, but their effect is difﬁcult to assess. However, the
immunization campaigns were conducted in children in
selected provinces, and these individuals received a single
dose of the Vi polysaccharide vaccine. This vaccine only
provides limited efﬁcacy in the ﬁrst year after immunization
and there is a rapid decline in antibody titer 2 years after
receiving the vaccine,42,43 herd protection remains variable.
Therefore, weconclude that economicdevelopment, improved
access to clean water supplies, better sanitation, and a re-
duction in poverty probably played the greatest combined role
in reducing the incidence of typhoid in Vietnam. Quantifying
the precise contribution of these in the reduction of typhoid
incidence isagainproblematic, and therearemultipleadditional
factors that shouldalsobeconsidered thatmayconfound these
interactions. It is, however, worth stating that S. Typhi appears
tobeprofoundly sensitive to improvements in sanitation, which
reduces human exposure to the organism, thus, lessening
disease incidence and person-to-person transmission.
CONCLUSION
The reduction of typhoid fever in Vietnam has been re-
markable, and has been largely driven by economic devel-
opment and improved living standards for the population.
Immunization has probably had some impact on disease re-
duction, but the use of an imperfect vaccine may only provide
limited respite in disease transmission without required im-
provements in WASH. Better designed WASH intervention
studieswith disease endpoints and systematic incidence data
are required to glean a greater understanding of the precise
contextual factors that impact on typhoid fever incidence.
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Summary Objectives: The diagnosis of typhoid fever is a challenge. Aiming to develop a
typhoid diagnostic we measured antibody responses against Salmonella Typhi (S. Typhi) pro-
tein antigens and the Vi polysaccharide in a cohort of Bangladeshi febrile patients.
Methods: IgM against 12 purified antigens and the Vi polysaccharide was measured by ELISA in
plasma from patients with confirmed typhoid fever (n Z 32), other confirmed infections
(n Z 17), and healthy controls (n Z 40). ELISAs with the most specific antigens were per-
formed on plasma from 243 patients with undiagnosed febrile disease.
Results: IgM against the S. Typhi protein antigens correlated with each other (rho > 0.8), but
not against Vi (rho < 0.6). Typhoid patients exhibited higher IgM against 11/12 protein antigens
and Vi than healthy controls and those with other infections. Vi, PilL, and CdtB exhibited the
greatest sensitivity and specificity. Specificity and sensitivity was improved when Vi was com-
bined with a protein antigen, generating sensitivities and specificities of 0.80 and >0.85,
respectively. Applying a dynamic cut-off to patients with undiagnosed febrile disease sug-
gested that 34e58% had an IgM response indicative of typhoid.
Conclusions: We evaluated the diagnostic potential of several S. Typhi antigens; our assays
give good sensitivity and specificity, but require further assessment in differing patient popu-
lations.
ª 2017 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
Introduction
Enteric (typhoid) fever is a systemic infection caused by
Salmonella enterica serovars Typhi (S. Typhi) and Paratyphi
A (S. Paratyphi A).1,2 There are an estimated 12 million
cases of typhoid (S. Typhi only) worldwide annually leading
to approximately 120,000 deaths.3,4 The organisms are
transmitted via the fecal-oral route and the disease re-
mains common in low/middle income countries in South/
Southeast Asia and sub-Saharan Africa.5 Despite S. Paraty-
phi A being an emergent cause of enteric fever in parts of
South and Southeast Asia,6 S. Typhi remains the most
commonly reported etiological agent of enteric fever in
Asia and Africa.
Typhoid occurs only in humans, making it a disease that
can technically be eradicated.7 Indeed, typhoid has all but
been eliminated from several countries in Southeast Asia
where it was the most common cause of hospitalized febrile
disease 20e30 years ago.8,9 Elimination in these areas is
generally attributed to extensive improvements in sanita-
tion rather than widespread immunization schemes. The
lack of data regarding the long-term impact of mass immu-
nization for typhoid and the performance of licensed vac-
cines have hindered immunization as a sustainable
typhoid control and elimination strategy. Future consider-
ations for rational control measures for typhoid will rely
on more accurately assessing disease burden, which re-
quires a reliable diagnostic approach.10
All commonly used typhoid diagnostics perform poorly
and are a roadblock for disease control efforts.11,12
Currently, the only reliable method for the identification
of febrile individuals with typhoid is the culture of a caus-
ative organism from a biological specimen.12,13 However,
this procedure is restricted to laboratories with adequate
equipment and microbiology training, and the method has
a limited sensitivity due to low concentrations of organisms
in the peripheral circulation.14e16 Low bacterial loads have
a similar impact on other methods that rely on detecting
the presence of the infecting organisms, such as antigen
detection or nucleic acid amplification. These methods
are often reported to be highly sensitive, but have unreal-
istic performances; pre-treatment with antimicrobials is
likely to compound this issue further.11,15 New typhoid diag-
nostics are a necessity and various approaches have been
evaluated, including measurement of innate immune re-
sponses,17,18 antibody in lymphocyte supernatants,19,20
and the identification of metabolomic signatures.21 Howev-
er, these advances are still restricted to research labora-
tories and are not yet ready to be developed into simple,
rapid diagnostic tests (RDTs).
We previously exploited a protein microarray to identify
a multitude of immunogenic S. Typhi protein antigens to
which an antibody response was generated during the early
stages of typhoid.22 With the aim of validating antigens that
could be used in a diagnostic assay we expressed and puri-
fied several of these potentially serodiagnostic S. Typhi
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antigens and investigated their diagnostic performance in a
cohort of febrile Bangladeshi patients.
Materials and methods
Ethical approval
The study was conducted according to the principles
expressed in the Declaration of Helsinki. The Bangladesh
National Research Ethical Committee (BMRC/NREC/2010-
2013/1543), the Chittagong Medical College Hospital
Ethical Committee, the Oxford Tropical Research Ethics
Committee (OXTREC 53-09) gave ethical approval for the
study. Informed written or thumbprint consent was taken
from the subject, their parent or caretaker for all
enrollees.
Study site, population and study design
The site and recruitment for this study has been descried
previously.23 Briefly, Chittagong Medical College Hospital is
a 1000-bed hospital serving Chittagong and the surrounding
province. Adults and children (>6 months) consecutively
admitted from January to June 2012 to the adult and pedi-
atric wards at CMCH with an axillary temperature of !38 "C
up to 48 h after admission and history of fever for <2 weeks
were eligible for the study.
Here the gold standards for typhoid diagnosis were and
blood culture and PCR amplification from blood using a
previously described method.15 Blood (5e12 mL for adults
and 1e2 mL for children) was cultured using Bact/Alert-
FA and PF blood culture bottles, bottles were incubated
in the Bact/Alert automated system (Biomerieux, France)
for five days. The patient demographics and diagnostic
testing results for this study are reported elsewhere.23
For the purposes of this investigation plasma samples
from 40 healthy adult control subjects (hospital staff at
the study site), 32 cases of confirmed typhoid (16 cases
confirmed by blood culture, 13 cases confirmed by PCR
and three cases confirmed by both blood culture and
PCR), 17 cases from patients with confirmed febrile dis-
eases other than enteric fever (Staphylococcus aureus (2),
Streptococcus pneumoniae (1), Streptococcus acidomini-
mus (1), Enterococcus gallinarum (1), Escherichia coli (2),
Klebsiella pneumoniae (1), Enterobacter cloacae (2), Aci-
netobacter spp. (1), Burkholderia cepacia (3), dengue (2),
R. typhi (2) and O. tsutsugamushi (1)) and 243 febrile pa-
tients with undiagnosed febrile disease were subjected to
serological assays.
PCR amplification, gene expression and protein
purification
We selected 18 S. Typhi antigens that gave a differential
serodiagnostic signal using protein microarray screening
for further expression and purification (Table S1). The cod-
ing sequences of the selected genes, excluding trans-
membrane domains were PCR amplified from CT18 genomic
DNA and cloned into the 50 NcoI and 30NotI restriction sites
of pET28b(þ) vector (Novagen, UK) for further His-Tag puri-
fication. E. coli DH5a were transformed with the plasmid
constructs for stable storage and E. coli BL21(DE3)pLysS
(Promega, WI, USA) were used for expression and purifica-
tion (Table S1).
For protein expression, the E. coli BL21(DE3)pLysS
strains harboring unique plasmid constructs (pEK90-
pEK109) containing the genes of interest were inoculated
into LB broth containing 100 mg/L kanamycin (Sigma, MO,
USA), and incubated at 37 "C overnight. Overnight cultures
were diluted (1:100) into LB broth and incubated at 37 "C
with agitation until optical density (OD600) of 0.5. Expres-
sion of the exogenous proteins was induced by the addition
of isopropyl-b-D-thiogalactoside (IPTG) (SigmaeAldrich,
UK), to a final concentration of 0.1 mM. Bacterial cells
Table 1 Salmonella Typhi antigens expressed in this study for serological testing.
Gene ID
numbera
Isotype detected
using arrayb
Gene
name
Amino acid
identity S.
Typhi CT18/S.
Paratyphi A
AKU_12601
Annotation
STY0452 IgM yajI 163/165 (98%) Putative lipoprotein e Prokaryotic homolog of protein DJ-1
STY0796 IgM ybgF 260/262 (99%) Putative exported protein e Tol/pal system protein
STY1086 IgM e 187/187 (100%) Putative lipoprotein
STY1372 IgM pspB 74/74 (100%) Phage shock protein B
STY1612 IgM e Absent Putative membrane protein e prophage associated
STY4539 IgM pilL Absent Putative exported protein e type IV pili
STY1522 IgG e 292/296 (99%) Putative secreted protein e Choloylglycine secreted homolog
STY1703 IgG ssaP 123/124 (99%) Putative secreted protein e T3SS
STY1767 IgG nlpC 48/140 (34%) Putative lipoprotein e Endopeptidase
STY1886 IgG cdtB 268/269 (99%) Cytolethal distending toxin subunit B homolog
STY3208 IgG e 277/279 (99%) Hypothetical protein e Unknown function
STY4190 IgG yhjJ 190/192 (99.0%) Putative Zinc-protease
a Parkhill et al. 2001.48
b Liang et al. 2013.22
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were harvested (5000 ! g at 4 "C for 10 min) after 3 h of in-
cubation at 24 "C.
For soluble proteins, bacterial pellets were resuspended
in 50 mM phosphate buffer (pH 8) containing 300 mM NaCl
and 10 mM imidazole. After sonication, cell debris and the
membrane fragment were pelleted by centrifugation at
16,000 ! g at 4 "C for 30 min. Supernatants were filtered
through a 0.45 mm membrane before being rocked at 4 "C
with nickel coated agarose beads (Ni-NTA, Invitrogen) for
2 h. Protein bound Ni-NTA beads were loaded into gravity
flow columns (Qiagen, Germany) and washed with 20 mM
imidazole in phosphate buffer. Proteins were eluted with
250 mM imidazole in phosphate buffer. For insoluble pro-
teins a denaturing protocol was performed by firstly incu-
bating the bacterial cells in an 8 M urea (pH 7.8) solution
containing 20 mM sodium phosphate and 500 mM NaCl. Pro-
teins were eluted with 4 M Urea (pH3) in a solution
containing 20 mM Sodium Phosphate buffer and 500 mM
NaCl. Proteins were renatured after purification in 50 mM
Sodium Phosphate solution and 500 mM NaCl.
ELISAs using S. Typhi protein antigens
ELISAs to detect antigen specific IgM in human plasma
samples were performed as described previously with 12
purified protein antigens and S. Typhi Vi polysaccharide an-
tigen.24,25 Briefly, 96 well flat-bottom ELISA plates (Nunc
2404, Thermo Scientific) were coated overnight with
100 ml per well of the various antigens (final concentrations;
7 mg/ml of protein antigens and 1 mg/ml for the Vi antigen
in 50 mM Carbonate Bicarbonate buffer). Coated plates
were washed and blocked with 5% milk solution in PBS. Af-
ter 2 h of blocking, plates were washed and incubated with
Figure 1 Correlation of IgM measurements between selected Salmonella Typhi antigens. A representative selection of data
showing a correlation in IgM measurements in human plasma for the antigens encoded by STY4539, STY1703, STY1886, and the
Vi antigen. Histograms show the distribution of IgM levels by optical density to the highlighted S. Typhi antigen. The scatterplots
below the histograms plot the IgM measurements of the two antigens on a right angle to the histograms and describe the correlation
between antibody responses to two selected antigens. The numerals above the histograms depict the Spearman correlation coef-
ficient (rho) values of the mirrored scatterplot. All other correlations are shown in Fig. S1.
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Figure 2 IgM responses against Salmonella Typhi antigens in a Bangladeshi cohort of febrile patients and controls. Boxplots
showing IgM measurements (optical density) in plasma from afebrile controls (light gray), febrile patients with an infection other
than typhoid fever (medium gray), and confirmed typhoid patients (dark gray). Dark horizontal lines represent the mean IgM
108 N. Tran Vu Thieu et al.
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100 ml (per well) of a 1:200 dilution of plasma at ambient
temperature for 2 h. Plates were washed again and incu-
bated with 100 ml per well of alkaline phosphatase-
conjugated anti-human IgM at ambient temperature for
1 h. The final ELISA plates were developed using p-Nitro-
phenyl phosphate (SigmaFAST N1891, SigmaeAldrich, UK)
substrate for 30 min at ambient temperature and the final
absorbance were read at dual wavelengths (405 nm and
490 nm) using an automated microplate reader (Biorad).
End point positive absorbance results were defined as opti-
cal densities (OD) greater than the absorbance obtained for
the blank control wells plus four times the standard devia-
tion. Three wells of culture S. Typhi positive plasma were
run as control for every 96-well plate for each antigen.
The results of each ELISA plate were accepted only if the
OD values of the controlled were within their range of their
known values plus/minus two standard deviations of the
blank wells.
Statistical analysis
A geometric mean optical density was calculated to sum-
marize the IgM response to the S. Typhi antigens in each
arm of validation group including the negative reference
population samples (healthy controls and other confirmed
febrile infections) and the positive reference population
(febrile patients with confirmed S. Typhi). The Wilcoxon
signed-rank test was used to test the null hypothesis; no
difference in optical densities between the patient groups.
Spearman’s rho was used to investigate potential correla-
tions between IgM antibody responses against the various
antigens. Receiver operating characteristic (ROC) curves
were used to determine the optimal cut-off and the speci-
ficity and sensitivity of the various antigens. A performance
estimation of more than one antigen combination was eval-
uated using Support Vector Machine (SVM). All analyses
were performed with R software (version 3.3.1; R Founda-
tion for Statistical Computing). All confidence intervals
(CIs) are reported 2-sided at the 95% intervals; all other sig-
nificant testing were performed 2-sided with a significance
level of p < 0.05.
Results
Acute IgM antibody responses against Salmonella
Typhi antigens
Of the 18 protein antigens we targeted to purify, we were
able to express and purify 12 (Table 1).
We firstly performed ELISAs independently employing
the purified protein antigens and the Vi polysaccharide to
detect IgM in the plasma of 40 healthy control subjects, 17
febrile individuals with a confirmed infection other than
measurement, with the box representing the 25th and 75th percentiles, whiskers represent the 5th and 95th percentiles; outliers
are represented by dots. A) Boxplots of antibody responses against (from left to right and upper to lower) STY0452, STY0769,
STY1086, STY1372, STY1612, STY1522, STY1703, STY1767, STY3208, and STY4190. All mean antibody measurements were statisti-
cally significant between the healthy controls and typhoid infections and between other infections and typhoid infections, with the
exception of STY1522 (p < 0.05 Wilcoxon Rank sum). B) Boxplots of antibody responses against (in order) STY4539, STY1886, Vi. All
mean antibody measurements are statistically significant between the healthy controls and typhoid infections and between other
infections and typhoid infections (p < 0.05 Wilcoxon Rank sum).
Figure 3 Assessing the sensitivity and specificity of IgM against Salmonella Typhi antigens for the diagnosis of typhoid fever.
Receiver operating characteristic (ROC) curves summarizing the antibody responses against antigen combinations for the diagnosis
of typhoid. The x-axis displays the false positivity rate (Specificity) and the y-axis displays true positive rate (Sensitivity). The per-
formance of two, three and four antigens are shown by the dashed, gray, and black lines, respectively. A) ROC curve produced
when the positive references are typhoid cases confirmed by blood culture and PCR amplification (nZ 32). B) ROC curve produced
when the positive references are typhoid cases confirmed by blood culture only (n Z 19).
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typhoid, and 32 individuals with either blood culture or PCR
(or both) confirmed typhoid infections (n Z 89 samples).
We measured detectable IgM against all twelve of the
purified S. Typhi proteins and the Vi polysaccharide in all of
the 89 samples subjected to ELISA. We compared the IgM ti-
ters from each of the antigens individually to assess the
performance of the antigens and to identify potential cor-
relations between the serological targets. We found that
early IgM responses against the majority of the novel S. Ty-
phi protein antigens, with the exception of STY1522
(rho < 0.7), were highly correlated with one other
(rho > 0.8). Notably, the IgM response to the protein anti-
gens correlated weakly with those directed against the Vi
polysaccharide (rho < 0.6) (Fig. 1 and Fig. S1).
The diagnostic potential of IgM against Salmonella
Typhi antigens
IgM against all twelve of the protein antigens and the Vi
polysaccharide was significantly elevated in the plasma of
the typhoid patients in comparison with the healthy
controls (p < 0.05) (Fig. 2). Furthermore, there was a sig-
nificant differentiation in the plasma IgM measurements be-
tween the typhoid patients and those with a febrile disease
with an alternative confirmed etiology with all antigens
with the exception of STY1522 (p < 0.05).
By assessing raw antibody measurements, we surmised
that the best performing antigens, with respect to differ-
entiating between the patient groups were STY4539,
STY1886, and Vi (Fig. 2). The mean IgM responses (OD
values) in the afebrile controls, the other confirmed infec-
tions and the typhoid infections were 0.29, 0.27, and 0.42
(against STY4539), 0.17, 0.18, and 0.25 (against STY1886),
and 0.22, 0.21, and 0.35 (against Vi), respectively. This
segregation between the patient groups was highly signifi-
cant, resulting in p-values of 0.0001 and 0.003 for IgM
against STY4539; <0.0001 and 0.004 for IgM against
STY1886; and 0.0001 and 0.0001 for IgM against Vi, between
healthy controls and typhoid infections and between other
febrile diseases and typhoid infections, respectively (Wil-
coxon signed-rank test).
Sensitivity and specificity of the serodiagnostic
antigens
To further assess the IgM responses against the various S.
Typhi antigens for the purposes of diagnostic testing we
calculated sensitivities and specificities using a validation
group incorporating two positive reference groups and a
negative reference group for additional statistical power.
The negative reference group (n Z 57) was the combina-
tion of data from the afebrile controls (n Z 40) and from
those with a confirmed diagnosis other than typhoid
(n Z 17 cases). The assay results were validated indepen-
dently with two sets of positive reference data; these
were a combination of blood culture confirmed S. Typhi
along with those with a positive PCR amplification result
for S. Typhi from blood (n Z 32), and the blood culture
confirmed S. Typhi patients only (n Z 19).
The IgM responses against each of the antigens gener-
ated a continuous data set that was used to generate ROC
curves to optimize the index cut-off value. The defined cut-
off values of the thirteen antigens corresponded with a
range of sensitivities ranging from 0.50 to 0.84 and
specificities between 0.58 and 0.84; areas under the ROC
curve (AUC) ranged from 0.7 to 0.85. When used alone none
of the antigens demonstrated a sensitivity or specificity
>0.8. As predicted, Vi, STY4359, and STY1886 were the
three antigens with the greatest serodiagnostic capacity in
discriminating typhoid cases from afebrile controls and
other infections. The sensitivities and specificities for
identifying typhoid patients by IgM titers were 0.68; 0.8
(Vi), 0.62; 0.82 (STY4539), and 0.62; 0.82 (STY1886),
respectively. Correspondingly, the AUCs were 0.84 (95%CI:
0.71, 0.96), 0.77 (95%CI: 0.61, 0.92), and 0.77 (95%CI: 0.62,
0.91).
We next employed SVM to identify combinations of two
or more antigens across all 13 antigens to increase overall
sensitivity and specificity. Using confirmed S. Typhi infec-
tion by blood culture or PCR as the positive reference
(nZ 32), we found 11 combinations of two to four antigens
that gave sensitivities from 0.81 to 0.84, specificities from
0.81 to 0.86, and AUCs from 0.87 to 0.87 (Fig. 3). We addi-
tionally identified 17 combinations of two to four antigens
when using the positive reference as culture confirmed S.
Typhi only (n Z 19), obtaining sensitivities from 0.84 to
0.89, specificities from 0.88 to 0.94, and AUCs from 0.859
to 0.912 (Fig. 3, Tables 2 and 3).
For the positive reference sets, IgM against Vi contrib-
uted to all of the combinations, while STY1703, STY1886,
and STY4539 were present in more than half of the
combinations. The remaining nine antigens contributed to
at least one combination that gave sensitivities and
specificities >0.8. These results demonstrated that, in the
majority of examples, a combination of up to four antigens
was directly associated with an increased performance of
the IgM serology. However, the best performing antigens for
the identification of typhoid patients by IgM were Vi in
combination with either STY1703 or STY1886 (Tables 2
and 3).
Identifying typhoid cases in patients with
undiagnosed febrile disease
In this Bangladeshi cohort there were 226 patients with
febrile disease without laboratory confirmed etiology and
18 with clinically suspected typhoid that were negative by
blood culture and PCR amplification. We aimed to estimate
the proportion of patients in this population who may have
typhoid by applying the SVM cutoffs and combining the IgM
titers against two S. Typhi antigens. We performed two in-
dependent analyses; the first combined IgM titers against
STY1703 and Vi using a combination of culture confirmed
S. Typhi and positive PCR amplification for S. Typhi from
blood as the positive reference group (Fig. 4 and Table 3).
Using these criteria we found that 142/226 (59%) of the un-
diagnosed febrile patient group and 16/18 (88%) with clini-
cally suspected typhoid had IgM titers indicative of typhoid.
Using more stringent criteria (blood culture confirmed pa-
tients) as the positive reference and a combination of IgM
against Vi and STY1886 we found that 119/226 (52%) febrile
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cases and 15/18 (83%) clinically suspected typhoid, respec-
tively, had a profile indicative of typhoid (Fig. 4).
Discussion
Typhoid is caused by a human restricted pathogen that is
transmitted fecal-orally. Consequently, improving the
quality of drinking water supplies and education in better
hygiene practices are likely the most effective measures to
for typhoid elimination. However, these interventions
cannot be promptly realized in the endemic areas of Africa
and South Asia. Therefore, the short-term control of
typhoid is dependent on large vaccination programmes
and appropriate treatment, both of which, for differing
Table 3 The sensitivity and specificity of multiple antigens for typhoid diagnosis using blood culture positive patients only as
positive reference group (n Z 19).
Antigen combinations STY1886 & Vi STY4190 &
STY1886 & Vi
STY4539 & STY4190 &
STY1886 & Vi
Specificity 0.88 0.89 0.88
Sensitivity 0.84 0.84 0.89
Number with undiagnosed febrile disease
predicted to have typhoid (n Z 226)
119 (52%) 78 (34%) 71 (31%)
Number with clinically suspected typhoid
disease predicted to have typhoid (n Z 18)
15 (83%) 13 (72%) 13 (72%)
AUC (95%CI) 0.859
(0.746, 0.972)
0.891
(0.791, 0.991)
0.912
(0.81, 1.014)
Figure 4 Detecting febrile patients with an IgM profile indicative of typhoid fever. Plots predicting the number of undiagnosed
febrile patients that have an IgM measurement indicative of typhoid fever. The black circles represent the negative controls, which
includes healthy controls and patients other with infections. The white boxes represent typhoid cases confirmed by blood culture or
PCR. The gray circles are febrile patients with an IgM profile indicative of not having typhoid fever, gray boxes are febrile patients
defined as having a typhoid infection using the pre-defined IgM profile. A) Plot where the positive reference was defined as the
typhoid cases confirmed by blood culture or PCR (n Z 32); the selected antigen combination was STY1703 and Vi. B) Plot where
the positive reference was defined as the typhoid cases confirmed by blood culture only (nZ 19); the selected antigen combination
was STY1886 and Vi.
Table 2 The sensitivity and specificity of multiple antigens for typhoid diagnosis using blood culture and PCR positive patients
as positive reference group (n Z 32).
Antigen combinations STY1703 & Vi STY4539 &
STY1703 & Vi
STY4539 & STY1703 &
STY1886 & Vi
Specificity 0.86 0.86 0.86
Sensitivity 0.81 0.84 0.84
Number with undiagnosed febrile disease
predicted to have typhoid (n Z 243)
135 (59%) 134 (59%) 134 (59%)
Number with clinically suspected typhoid
disease predicted to have typhoid (n Z 18)
16 (88%) 16 (88%) 16 (88%)
AUC (95%CI) 0.865
(0.782, 0.947)
0.863
(0.779, 0.947)
0.866
(0.783, 0.949)
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reasons, rely on better case detection. The fact that there
is not currently a typhoid diagnostic assay with a high
degree of sensitivity or specificity limits disease burden
assessments,26,27 and may result in patients being misdiag-
nosed and receiving a sub-optimal therapy.28 Furthermore,
with the global increase in S. Typhi associated with reduced
susceptibility and resistance against the fluoroquinolones
and other antimicrobials,29,30 the demand for typhoid diag-
nostics are now greater than ever.31,32
There is a paucity of data arising from studies on humans
with typhoid that have measured the immunological
response to S. Typhi specific antigens.7 Studies that have
been performed have found significant interferon-g (IFN-
g) responses in cells stimulated with various antigens
including fimbriae and outer membrane proteins using poly-
morphonuclear cells from the blood of typhoid patients.33
Further, when whole blood from typhoid patients is stimu-
lated with S. Typhi lipopolysaccharide, TNFa release is
lower during active typhoid than after antimicrobial treat-
ment, indicating a short immune modulation effect, which
may be induced by the Vi polysaccharide.34 Antigen arrays
and other probing techniques have being used successfully
to interrogate the antibody repertoire during early in-
fection,22,35e37 and have detected antibody responses to
several novel, and potentially organism specific, antigens
that may be able to distinguish typhoid patients from con-
trols.22 Using this “screening data” we rationally selected
several S. Typhi protein antigens and aimed to investigate
if early immunological diagnostic signals could be detected
in the plasma of febrile patients.
Our study focused on a well-defined patient group from
Bangladesh, who were enrolled for the primary focus of
studying typhoid diagnostics. Whilst the patient numbers
with typhoid in this group were relatively modest, the
clinical and laboratory criteria for patients with febrile
disease were consistent and have been previously assessed
with commercial serological tests for typhoid.23 We noted
that the IgM response against the twelve purified S. Typhi
protein antigens were stable and well correlated; the IgM
responses in comparison to Vi correlated less consistently.
These data confirm our original antigen screening data
and suggest that these antigens are immunogenic and
induce an antibody response early in infection. Given the
poor performance of commercial RDTs,38,39 our data signify
that the early detection of IgM against more specific S. Ty-
phi protein antigens may be a more specific and sensitive
approach for developing a RDT for typhoid.
Indistinguishable clinical features and the lack of a
reliable gold standard test complicate typhoid diagnosis.
Here, the IgM response against all 12 antigens was signif-
icantly higher in typhoid patients than both afebrile
controls and patients with febrile diseases other than
typhoid. Furthermore, through inference from the AUC
under the ROC curve we were able to identify the best
three performing antigens, which were encoded by STY4539
(PilL) and STY1886 (CdtB) in combination with the Vi
polysaccharide. PilL is a putative exported protein and a
component of the type IV pili encoded adjacent to the
genes encoding Vi on SPI-7.40,41 The PilL protein is induced
following uptake by human derived macrophages,42 and the
type IV pili to which it is associated facilitates entry into
epithelial cells.43 CdtB, encoded by STY1886, is one of
the two A sub-units of typhoid toxin, an AB type toxin.44
Typhoid toxin is a virulence-associated factor of S. Typhi,
which is thought to be associated with the early symptoms
of typhoid.45 We confirm that this component of typhoid
toxin is immunogenic and may be an important biomarker
of acute typhoid.22,46 Whilst these three virulence factors
(PilL, CdtB, and Vi) were not sufficient in themselves to pro-
duce a reproducibly high (>0.8) degree of sensitivity and
specificity for typhoid diagnosis, we gained additional po-
wer by combining data from >1 antigen using an SVM
model. The IgM responses against Vi in combination with
either PilL or CdtB were found to generate the highest de-
gree of sensitivity and specificity. Seemingly, a combination
of the differing IgM responses against polysaccharide and a
protein compensates for a lower affinity to one of the anti-
gens. Furthermore, we were able to estimate the propor-
tion of the population that may have typhoid by imposing
cut-offs from the typhoid confirmed patients onto the pop-
ulation with undiagnosed febrile diseases. These data did
not generate a precise cut-off, therefore, our data suggest
that typhoid diagnostics are not an exact science and our
data should be interpreted with caution. These methods
warrant further investigation in additional cohorts, but it
suggests a substantial burden of undiagnosed febrile dis-
ease is associated with S. Typhi in this setting.
This study has limitations. The sample size was relatively
small; we aimed to rectify this by including a subset of
patients that appear tohaveS. TyphiDNA in theirbloodstream
but were culture negative.47 Using this combination of
methods as a gold standardwewere able to increase thediag-
nostic power of the assays. A further limitation is that this
study was conducted in a single healthcare location over a
limited time period.Whilst our data provide some confidence
that these serological assays may be of utility for typhoid di-
agnostics, thesemethods should to be validated in additional
cohorts. However, there remains a challenge in identifying
typhoid patients that have a sterile blood culture; a combina-
tion of novel approaches, such as metabolomics and/or func-
tional genomics,17,21 in a febrile disease cohort may add
further insight into this important patient group.
In conclusion, we have investigated the serological
diagnostic potential of S. Typhi protein antigens and the
Vi polysaccharide in a group of patients with febrile dis-
eases in Bangladesh. Our novel data show that serology
may have some utility for typhoid diagnostics and a combi-
nation of antigens improves the diagnostic potential. Our
assays give high levels of sensitivity and specificity, but
require further assessment in differing patient populations.
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